

# A new rating scale for Alzheimer's disease

American Journal of Psychiatry

141, 1356-1364

DOI: [10.1176/ajp.141.11.1356](https://doi.org/10.1176/ajp.141.11.1356)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Rivastigmine in the treatment of dementia associated with Parkinson's disease: a randomized, double-blind, placebo-controlled study. , 0, , 13-26.		1
2	PHYSIOLOGICAL ONTOGENY. Journal of General Physiology, 1925, 9, 1-37.	0.9	48
3	Dementiaâ€”Alzheimer Type. Mayo Clinic Proceedings, 1984, 59, 35-42.	1.4	17
4	Oral physostigmine treatment of patients with Alzheimer's disease. American Journal of Psychiatry, 1985, 142, 28-33.	4.0	221
5	Clinical Studies of the Cholinergic Deficit in Alzheimer's Disease. Journal of the American Geriatrics Society, 1985, 33, 749-757.	1.3	41
6	Development of cholinergic drugs for the treatment of Alzheimer's disease. Drug Development Research, 1985, 5, 77-96.	1.4	47
7	CHOLINERGIC APPROACHES TO THE TREATMENT OF ALZHEIMER'S DISEASE. British Medical Bulletin, 1986, 42, 97-100.	2.7	154
8	CLINICAL AND NEUROPSYCHOLOGICAL ASSESSMENT OF DEMENTIA. British Medical Bulletin, 1986, 42, 11-18.	2.7	74
9	Reliability of the family history method in genetic studies of Alzheimer's disease and related dementias. American Journal of Psychiatry, 1986, 143, 1279-1282.	4.0	209
10	Dementia of the Alzheimer Type. Journal of the American Geriatrics Society, 1986, 34, 12-19.	1.3	98
11	Oral Tetrahydroaminoacridine in the Treatment of Senile Dementia, Alzheimer's Type. New England Journal of Medicine, 1987, 316, 1603-1605.	13.9	39
12	Assessing Dementia. Part II: Clinical, Functional, Neuropsychological and Social Issues. Australian and New Zealand Journal of Psychiatry, 1987, 21, 284-304.	1.3	4
13	L-Deprenyl in Alzheimer's Disease. Archives of General Psychiatry, 1987, 44, 427.	13.8	186
14	Reliability of the family history method in genetic studies of Alzheimer??s disease and related dementias. Alzheimer Disease and Associated Disorders, 1987, 1, 200.	0.6	9
15	A Short Test of Mental Status: Description and Preliminary Results. Mayo Clinic Proceedings, 1987, 62, 281-288.	1.4	332
16	Primate learning tasks reveal strong impairments in patients with presenile or senile dementia of the Alzheimer type. Brain and Cognition, 1987, 6, 429-449.	0.8	46
17	RS 86 in the treatment of alzheimer's disease: Cognitive and biological effects. Biological Psychiatry, 1987, 22, 1067-1078.	0.7	85
18	Lecithin and piracetam in Alzheimer's disease. Biological Psychiatry, 1987, 22, 112-114.	0.7	14

#	ARTICLE	IF	CITATIONS
19	A new hierarchic approach to the measurement of dementia. <i>Psychosomatics</i> , 1987, 28, 298-304.	2.5	98
20	Methuselahâ€™An expert system for diagnosis in geriatric psychiatry. <i>Journal of Biomedical Informatics</i> , 1987, 20, 477-488.	0.7	16
21	Mild senile dementia of the alzheimer type: 2. Longitudinal assessment. <i>Annals of Neurology</i> , 1988, 23, 477-484.	2.8	173
22	Psychosis, behavioral disturbance, and the use of neuroleptics in dementia. <i>Comprehensive Psychiatry</i> , 1988, 29, 387-401.	1.5	56
23	4-Aminopyridine in the treatment of alzheimer's disease. <i>Biological Psychiatry</i> , 1988, 23, 485-490.	0.7	65
24	Memory impairment in schizophrenic patients with tardive dyskinesia. <i>Biological Psychiatry</i> , 1988, 23, 129-135.	0.7	30
25	Pharmacological modulation of cortisol secretion and dexamethasone suppression in alzheimer's disease. <i>Biological Psychiatry</i> , 1988, 23, 13-24.	0.7	13
26	CSF Somatostatin in alzheimer's disease, depressed patients, and control subjects. <i>Biological Psychiatry</i> , 1988, 24, 710-712.	0.7	36
27	Differential responsivity of mood, behavior and cognition to cholinergic agents in elderly neuropsychiatric populations. <i>Brain Research Reviews</i> , 1988, 13, 371-389.	9.1	77
28	The screening of cognitive impairment in the elderly: A critical review of current methods. <i>Journal of Clinical Epidemiology</i> , 1988, 41, 635-643.	2.4	44
29	Memory impairment in amnesia and dementia: Implications for the use of animal models. <i>Neurobiology of Aging</i> , 1988, 9, 465-468.	1.5	6
30	Cognitive and brain imaging measures of Alzheimer's disease. <i>Neurobiology of Aging</i> , 1988, 9, 69-86.	1.5	47
33	A new scale for the assessment of depressed mood in demented patients. <i>American Journal of Psychiatry</i> , 1988, 145, 955-959.	4.0	154
34	Behavioral Disturbance in Dementia of the Alzheimer's Type. <i>Journal of the American Geriatrics Society</i> , 1988, 36, 1-6.	1.3	351
35	Comparison of Two Cognitive Rating Scales in Medically Ill Patients. <i>International Journal of Psychiatry in Medicine</i> , 1988, 17, 193-200.	0.8	21
36	Neuropsychological Assessment of the Severely Impaired Elderly Patient. <i>Clinics in Geriatric Medicine</i> , 1989, 5, 531-543.	1.0	70
37	Assessment of Mood, Affect, and Personality. <i>Clinics in Geriatric Medicine</i> , 1989, 5, 441-459.	1.0	6
38	Drug Treatments of Dementia. <i>British Journal of Psychiatry</i> , 1989, 155, 595-611.	1.7	18

#	ARTICLE	IF	CITATIONS
39	Overview of depression and psychosis in Alzheimer's disease. <i>American Journal of Psychiatry</i> , 1989, 146, 577-587.	4.0	617
40	Lymphocyte subpopulations in depressed elderly women. <i>Biological Psychiatry</i> , 1989, 26, 581-589.	0.7	20
41	The EASI: A Self-Administered Screening Test for Cognitive Impairment in the Elderly. <i>Journal of the American Geriatrics Society</i> , 1989, 37, 848-855.	1.3	14
42	Treatment of Alzheimer's disease with short- and long-term oral THA and lecithin: a double-blind study. <i>American Journal of Psychiatry</i> , 1990, 147, 239-242.	4.0	66
43	Differential Patterns of Memory Loss in Patients with Alzheimer's Disease and Korsakoff's Disease. <i>International Journal of Neuroscience</i> , 1990, 52, 67-77.	0.8	16
44	Brief Screening Tests versus Clinical Staging in Senile Dementia of the Alzheimer Type. <i>Journal of the American Geriatrics Society</i> , 1990, 38, 129-135.	1.3	82
45	Validity and Reliability of the Dementia Behavior Disturbance Scale. <i>Journal of the American Geriatrics Society</i> , 1990, 38, 221-226.	1.3	217
46	Memory deficits in advanced Parkinson's disease. <i>Journal of Neural Transmission Parkinson's Disease and Dementia Section</i> , 1990, 2, 59-70.	1.2	19
47	Effects of metrifonate, a long-acting cholinesterase inhibitor, in alzheimer disease: Report of an open trial. <i>Drug Development Research</i> , 1990, 19, 425-434.	1.4	85
49	Comparison of Seven Psychometric Instruments Used for Evaluation of Treatment Effect in Alzheimer's Dementia. <i>Neuroepidemiology</i> , 1990, 9, 193-207.	1.1	26
50	Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. <i>American Journal of Psychiatry</i> , 1990, 147, 1640-1645.	4.0	97
51	Evaluation of intellectual and memory function among dementia patients who were intellectually superior. <i>Neuropsychology, Development and Cognition Section D: the Clinical Neuropsychologist</i> , 1990, 4, 355-374.	1.4	16
52	The Dialectics of Dementia: With Particular Reference to Alzheimer's Disease. <i>Ageing and Society</i> , 1990, 10, 177-196.	1.2	342
53	Alzheimer's Disease: Clinical and Pathological Characteristics. <i>International Journal of Neuroscience</i> , 1990, 50, 147-168.	0.8	17
54	Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Clinical, neuropsychological, and neuropathological components. <i>Aging Clinical and Experimental Research</i> , 1990, 2, 415-424.	1.4	18
55	Behavior management of the dementias. <i>Clinical Psychology Review</i> , 1990, 10, 611-629.	6.0	31
56	Antidementia drug assessment symposium. <i>Neurobiology of Aging</i> , 1991, 12, 379-382.	1.5	15
57	Development of an "early" detection battery for dementia of the Alzheimer type. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1991, 15, 433-479.	2.5	11

#	ARTICLE	IF	CITATIONS
58	Limb abnormalities and chorion villus sampling. <i>Lancet, The</i> , 1991, 338, 51.	6.3	36
59	Platelet phospholipid synthesis in Alzheimer's disease. <i>Neurobiology of Aging</i> , 1991, 12, 65-69.	1.5	5
60	Tacrine in Alzheimer's disease. <i>Lancet, The</i> , 1991, 338, 50-51.	6.3	12
61	Mefloquine plus sulfadoxine and pyrimethamine. <i>Lancet, The</i> , 1991, 338, 51-52.	6.3	2
62	Tacrine in Alzheimer's disease. <i>Lancet, The</i> , 1991, 337, 989-992.	6.3	334
63	Somatostatin and cognitive functions in Alzheimer's disease – the relationship of cerebrospinal fluid somatostatin increase with clinical response to tetrahydroaminoacridine. <i>Neuroscience Letters</i> , 1991, 130, 46-48.	1.0	24
64	Impaired Insight in Alzheimer's Disease. <i>Topics in Geriatrics</i> , 1991, 4, 189-193.	0.9	104
65	Disruption of classical conditioning in patients with Alzheimer's disease. <i>Neurobiology of Aging</i> , 1991, 12, 283-287.	1.5	92
67	Scales for the Assessment of Alzheimer's Disease. <i>Psychiatric Clinics of North America</i> , 1991, 14, 309-326.	0.7	34
68	Parallel Group Analysis of the Effects of Tacrine versus Placebo in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 1991, 2, 207-211.	0.7	4
69	Potential Clinical Use of an Adrenergic/Cholinergic Agent (HP 128) in the Treatment of Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 1991, 640, 263-267.	1.8	5
70	Evaluation of HP 029 (Velnacrine Maleate) in Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 1991, 640, 253-262.	1.8	44
71	Monitoring Progression in Alzheimer's Disease. <i>Journal of the American Geriatrics Society</i> , 1991, 39, 932-941.	1.3	94
72	Subclinical dementia. Relation to cognition, personality and psychopathology: A nine-year prospective study. <i>International Journal of Geriatric Psychiatry</i> , 1991, 6, 239-247.	1.3	28
73	The kingston standardized cognitive assessment. <i>International Journal of Geriatric Psychiatry</i> , 1991, 6, 867-874.	1.3	6
74	A Pilot Study of Low-Dose L-Deprenyl in Alzheimer's Disease. <i>Topics in Geriatrics</i> , 1991, 4, 143-148.	0.9	46
75	A New Assessment Tool for Neuropsychopharmacologic Research: The Computerized Neuropsychological Test Battery. <i>Topics in Geriatrics</i> , 1991, 4, 211-217.	0.9	33
76	Temporal Adaptation and Performance of Daily Living Activities in Persons with Alzheimer's Disease. <i>Physical and Occupational Therapy in Geriatrics</i> , 1991, 9, 31-51.	0.2	5

#	ARTICLE	IF	CITATIONS
77	Optic Nerve Head and Nerve Fiber Layer in Alzheimer's Disease. <i>JAMA Ophthalmology</i> , 1991, 109, 199.	2.6	143
78	Primary or Depressive Dementia: Mental Status Screening. <i>International Journal of Neuroscience</i> , 1992, 64, 33-67.	0.8	9
79	Agitation and postdexamethasone cortisol levels in Alzheimer's disease. <i>American Journal of Psychiatry</i> , 1992, 149, 546-548.	4.0	31
80	The Nursing Home Behavior Problem Scale. <i>Journal of Gerontology</i> , 1992, 47, M9-M16.	2.0	114
81	Clinical staging of dementia in a population survey: comparison of DSM-III-R and the Washington University Clinical Dementia Rating Scale. <i>Acta Psychiatrica Scandinavica</i> , 1992, 86, 49-54.	2.2	59
82	Establishing the Limits of the Mini-Mental State. <i>Archives of Neurology</i> , 1992, 49, 87.	4.9	153
83	A Theoretical Model of Functional Performance in Persons with Alzheimer Disease. <i>Canadian Journal of Occupational Therapy</i> , 1992, 59, 132-140.	0.8	10
84	A Controlled Trial of Tacrine in Alzheimer's Disease. <i>JAMA - Journal of the American Medical Association</i> , 1992, 268, 2523.	3.8	373
85	A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease. <i>New England Journal of Medicine</i> , 1992, 327, 1253-1259.	13.9	627
86	Psychiatric Phenomena in Dementia of the Alzheimer Type. <i>International Psychogeriatrics</i> , 1992, 4, 43-54.	0.6	33
87	Pentoxifylline in Cerebrovascular Dementia. <i>Journal of the American Geriatrics Society</i> , 1992, 40, 237-244.	1.3	66
88	The Test for Severe Impairment: An Instrument for the Assessment of Patients with Severe Cognitive Dysfunction. <i>Journal of the American Geriatrics Society</i> , 1992, 40, 449-453.	1.3	230
89	Assessment of Cognitive, Psychiatric, and Behavioral Disturbances in Patients with Dementia: The Neurobehavioral Rating Scale. <i>Journal of the American Geriatrics Society</i> , 1992, 40, 549-555.	1.3	99
90	Evaluating the effects of drugs on behavior and quality of life: An alternative strategy for clinical trials.. <i>Journal of Consulting and Clinical Psychology</i> , 1992, 60, 225-239.	1.6	4
91	Neuropsychological correlates of single photon emission computed tomography (SPECT) in Alzheimer's disease.. <i>Neuropsychology</i> , 1992, 6, 159-171.	1.0	11
92	Sundowning and Rate of Decline in Mental Function in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 1992, 3, 335-341.	0.7	9
93	Pharmacologic Treatment of Alzheimer's Disease: A Methodologic Critique Based Upon Current Knowledge of Symptomatology and Relevance for Drug Trials. <i>International Psychogeriatrics</i> , 1992, 4, 9-42.	0.6	25
94	Tacrine in Alzheimer's Disease. <i>British Journal of Psychiatry</i> , 1992, 160, 36-40.	1.7	54

#	ARTICLE	IF	CITATIONS
95	Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 11471-11475.	3.3	89
96	Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 11466-11470.	3.3	87
97	The application of the Screening Cerebral Assessment of Neppe (BROCAS SCAN) to a neuropsychiatric population. Journal of Neuropsychiatry and Clinical Neurosciences, 1992, 4, 85-94.	0.9	2
98	Clinical trials in cognitive impairment in the elderly. Aging Clinical and Experimental Research, 1992, 4, 239-250.	1.4	4
99	Methodological Problems in Assessing Therapeutic Efficacy in Patients with Dementia. Drugs and Aging, 1992, 2, 79-85.	1.3	8
100	Single positron emission tomography (SPECT) correlates of cognitive and behavioral dysfunction in Alzheimer's disease. European Neuropsychopharmacology, 1992, 2, 322.	0.3	0
101	Assessment of dementia in elderly schizophrenics with structured rating scales. Schizophrenia Research, 1992, 7, 85-90.	1.1	51
102	Neuroendocrine dysfunction in Alzheimer's disease: results following TRH stimulation. Biological Psychiatry, 1992, 32, 195-198.	0.7	6
103	A new scale for assessing behavioral agitation in dementia. Psychiatry Research, 1992, 41, 73-88.	1.7	48
104	Differential validity of psychometric tests in dementia of the Alzheimer type. Psychiatry Research, 1992, 44, 93-106.	1.7	123
105	Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms. Neurochemical Research, 1992, 17, 917-922.	1.6	67
106	A critique of research applicable to the care of elders with cognitive or affective disorders. Geriatric Nursing, 1992, 13, 245-248.	0.9	1
107	Diagnosis by specialists: psychological testing. Acta Neurologica Scandinavica, 1992, 85, 32-35.	1.0	37
108	Tacrine in Alzheimer's disease. Acta Neurologica Scandinavica, 1992, 85, 75-80.	1.0	12
109	An observational study of two long-stay psychogeriatric wards. International Journal of Geriatric Psychiatry, 1992, 7, 211-217.	1.3	16
110	A critique of current criteria for early dementia in epidemiological studies. International Journal of Geriatric Psychiatry, 1993, 8, 553-559.	1.3	14
111	Catastrophic reactions and other behaviors of Alzheimer's residents: Special unit compared with traditional units. Archives of Psychiatric Nursing, 1993, 7, 292-299.	0.7	64
112	The effectiveness of amiridin in senile dementia of the Alzheimer's type. Neuroscience and Behavioral Physiology, 1993, 23, 83-89.	0.2	10

#	ARTICLE	IF	CITATIONS
113	Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. <i>Psychopharmacology</i> , 1993, 110, 395-401.	1.5	216
114	The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease. <i>Journal of Neural Transmission Parkinson's Disease and Dementia Section</i> , 1993, 5, 185-192.	1.2	21
115	Delayed matching-to-sample performance during a double-blind trial of tacrine (THA) and lecithin in patients with alzheimer's disease. <i>Life Sciences</i> , 1993, 53, 479-486.	2.0	22
116	Electrophysiological and neuropsychological effects of a central alpha2-antagonist atipamezole in healthy volunteers. <i>Behavioural Brain Research</i> , 1993, 55, 85-91.	1.2	26
117	Response to Combination Cholinergic/Noradrenergic Treatments in a Patient With Alzheimer's Disease. <i>American Journal of Geriatric Psychiatry</i> , 1993, 1, 244-248.	0.6	0
118	Cognitive Performance in a High-Functioning Community-Dwelling Elderly Population. <i>Journal of Gerontology</i> , 1993, 48, M146-M151.	2.0	118
119	High, usual and impaired functioning in community-dwelling older men and women: Findings from the MacArthur Foundation Research Network on successful aging. <i>Journal of Clinical Epidemiology</i> , 1993, 46, 1129-1140.	2.4	472
120	Post-mortem examination of dopaminergic parameters in Alzheimer's disease: Relationship to noncognitive symptoms. <i>Psychiatry Research</i> , 1993, 49, 211-217.	1.7	8
121	An ACTH 4-9 analog (Org 2766) and cognitive performance: High-dose efficacy and safety in dementia of the Alzheimer's type. <i>Biological Psychiatry</i> , 1993, 33, 307-309.	0.7	10
122	Cortisol secretion and Alzheimer's disease progression: A preliminary report. <i>Biological Psychiatry</i> , 1993, 34, 158-161.	0.7	27
123	Factor structure of the Mattis dementia rating scale among patients with probable alzheimer's disease. <i>Neuropsychology, Development and Cognition Section D: the Clinical Neuropsychologist</i> , 1993, 7, 313-318.	1.4	11
124	Preliminary Findings of High-Dose Thiamine in Dementia of Alzheimer's Type. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1993, 6, 222-229.	1.2	70
125	Memory Evaluation in Alzheimer's Disease. <i>Archives of Neurology</i> , 1993, 50, 92.	4.9	127
126	Tacrine in Alzheimer's Disease-Reply. <i>JAMA - Journal of the American Medical Association</i> , 1993, 269, 2849-2850.	3.8	3
127	Single Photon Emission Computed Tomography in Dementia: Relationship of Perfusion to Cognitive Deficits. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1993, 6, 144-151.	1.2	13
128	Self-Efficacy and Cognitive Performance in High-Functioning Older Individuals. <i>Journal of Aging and Health</i> , 1993, 5, 455-474.	0.9	76
129	Telephone-Assessed Mental State. <i>Dementia and Geriatric Cognitive Disorders</i> , 1993, 4, 117-119.	0.7	12
131	Assessment in Severe Dementia: The Guy's Advanced Dementia Schedule. <i>Age and Ageing</i> , 1993, 22, 183-189.	0.7	12



#	ARTICLE	IF	CITATIONS
132	Clinical Features Distinguishing Large Cohorts with Possible AD, Probable AD, and Mixed Dementia. <i>Journal of the American Geriatrics Society</i> , 1993, 41, 31-37.	1.3	66
133	Functional Decline in Alzheimer's Disease: A Longitudinal Study. <i>Journal of the American Geriatrics Society</i> , 1993, 41, 654-661.	1.3	114
134	Geriatric Assessment and Driver Functioning. <i>Clinics in Geriatric Medicine</i> , 1993, 9, 365-375.	1.0	27
135	Neuropsychology and Alzheimer's Disease. <i>Clinics in Geriatric Medicine</i> , 1994, 10, 299-313.	1.0	1
137	Severe Impairment Battery. <i>Archives of Neurology</i> , 1994, 51, 41.	4.9	274
138	Peripheral Markers and Diagnostic Criteria in Alzheimer's Disease: Critical Evaluations. <i>Reviews in the Neurosciences</i> , 1994, 5, 213-25.	1.4	11
139	A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. <i>American Journal of Psychiatry</i> , 1994, 151, 390-396.	4.0	399
140	A neuropsychological instrument adding to the description of patients with suspected cortical dementia: the Milan overall dementia assessment.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1994, 57, 1510-1517.	0.9	148
141	Factor Structure and Reliability of the Alzheimer's Disease Assessment Scale in a Multicenter Trial With Linopirdine. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1994, 7, 74-83.	1.2	21
142	Alzheimer's Residents' Cognitive and Functional Measures. <i>Clinical Nursing Research</i> , 1994, 3, 27-41.	0.7	27
143	A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease. <i>JAMA - Journal of the American Medical Association</i> , 1994, 271, 985.	3.8	720
144	The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. <i>Neurology</i> , 1994, 44, 609-609.	1.5	904
145	The effect of tacrine and lecithin in Alzheimer's disease. <i>European Journal of Clinical Pharmacology</i> , 1994, 47, 17-23.	0.8	35
146	Nicotine and tetrahydroaminoacradine: Evidence for improved attention in patients with dementia of the Alzheimer type. <i>Drug Development Research</i> , 1994, 31, 80-88.	1.4	56
147	A double-blind, placebo controlled, multicentre study of tacrine for alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 1994, 9, 649-654.	1.3	18
148	Vasomotor reactivity in dementia of alzheimer type. <i>International Journal of Geriatric Psychiatry</i> , 1994, 9, 913-918.	1.3	5
149	Neural correlates of dementia: Regional brain metabolism (FDG-PET) and the CERAD neuropsychological battery. <i>Archives of Clinical Neuropsychology</i> , 1994, 9, 395-409.	0.3	9
150	The Italian version of the Alzheimer's Disease Assessment Scale (ADAS): psychometric and normative characteristics from a normal aged population. <i>Archives of Gerontology and Geriatrics</i> , 1994, 19, 21-30.	1.4	31

#	ARTICLE	IF	CITATIONS
151	The spectrum of effects of cholinergic treatment of Alzheimer's disease patients. <i>European Neuropsychopharmacology</i> , 1994, 4, 241-243.	0.3	0
152	The Role of Cholinesterase Inhibitors in Alzheimer's Disease. <i>CNS Drugs</i> , 1994, 1, 146-165.	2.7	33
153	Comparison of Mental Status Tests: Implications for Alzheimer's Patients and Their Caregivers. <i>Journal of Gerontology</i> , 1994, 49, S44-S51.	2.0	33
154	Emerging drugs for Alzheimer's disease: Mechanisms of Action and Prospects for Cognitive Enhancing Medications. <i>Medical Clinics of North America</i> , 1994, 78, 911-934.	1.1	28
155	Clinical symptoms associated with age at onset in Alzheimer's disease. <i>American Journal of Psychiatry</i> , 1994, 151, 1646-1649.	4.0	45
156	A Pilot Study of Clonidine Plus Physostigmine in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 1994, 5, 243-246.	0.7	6
157	Tacrine and other anticholinesterase drugs in dementia. <i>Current Opinion in Psychiatry</i> , 1995, 8, 264-267.	3.1	10
158	Validity and utility of the ADAS-L for measurement of cognitive and functional impairment in geriatric schizophrenic inpatients. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1995, 7, 76-81.	0.9	16
159	Cognitive performance on the Alzheimer's Disease Assessment Scale. <i>Neurology</i> , 1995, 45, 1980-1984.	1.5	36
160	Review: Measures to determine the Outcome of Community Services for People with Dementia. <i>Age and Ageing</i> , 1995, 24, 73-83.	0.7	28
161	Canadian Guidelines for the Development of Antidementia Therapies: a Conceptual Summary. <i>Canadian Journal of Neurological Sciences</i> , 1995, 22, 62-72.	0.3	42
162	Clinical Trials in Cognitively Impaired Older Adults: Home versus Clinic Assessments. <i>Journal of the American Geriatrics Society</i> , 1995, 43, 1127-1130.	1.3	15
163	Aggressive behaviour in dementia and its pharmacologic treatment: A review. <i>Nordic Journal of Psychiatry</i> , 1995, 49, 111-118.	0.7	6
164	Classical conditioning in patients with Alzheimer's disease: A multiday study. <i>Psychology and Aging</i> , 1995, 10, 248-254.	1.4	33
165	Predictors of cognitive change in older persons: MacArthur studies of successful aging. <i>Psychology and Aging</i> , 1995, 10, 578-589.	1.4	457
166	Neuropsychological test performance in African-American* and white patients with Alzheimer's disease. <i>Neurology</i> , 1995, 45, 2207-2211.	1.5	106
167	The P1 component of the middle latency auditory evoked potential predicts a practice effect during clinical trials in Alzheimer's disease. <i>Neurology</i> , 1995, 45, 962-966.	1.5	13
168	Early onset Alzheimer's disease in a South American pedigree from Argentina. <i>Acta Neurologica Scandinavica</i> , 1995, 91, 6-13.	1.0	10

#	ARTICLE	IF	CITATIONS
169	A double-blind, placebo-controlled, enriched population study of tacrine in patients with Alzheimer's disease. <i>European Journal of Neurology</i> , 1995, 2, 229-238.	1.7	22
170	Frontal lobe phosphorus metabolism and neuropsychological function in aging and in Alzheimer's disease. <i>Annals of Neurology</i> , 1995, 38, 194-201.	2.8	40
171	Caregiver time use: An outcome measure in clinical trial research on Alzheimer's disease*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 228-236.	2.3	90
172	The efficacy of cholinergic drugs in patients with Alzheimer's disease—focus on the aminoacridines. <i>Human Psychopharmacology</i> , 1995, 10, 89-96.	0.7	5
173	Assessing response to tacrine using the factor analytic structure of the Alzheimer's disease assessment scale (ADAS)-cognitive subscale. <i>International Journal of Geriatric Psychiatry</i> , 1995, 10, 753-756.	1.3	19
174	Correlation between cognitive brain function and electrical brain activity in dementia of Alzheimer type. <i>Journal of Neural Transmission</i> , 1995, 99, 55-62.	1.4	26
175	The Neurobehavioral Rating Scale: Reliability in patients with dementia. <i>Journal of Psychiatric Research</i> , 1995, 29, 185-191.	1.5	20
176	Temporal Quantification of Alzheimer's Disease Severity: 'Time Index' Model. <i>Dementia and Geriatric Cognitive Disorders</i> , 1995, 6, 269-280.	0.7	23
177	Visual Memory in Alzheimer Patients: Effects of Practice, Retention Interval and Severity of Cognitive Decline. <i>Dementia and Geriatric Cognitive Disorders</i> , 1995, 6, 117-120.	0.7	2
178	Effects of sudden insight on long-term sentence priming in Alzheimer's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 1995, 17, 325-334.	0.8	8
179	Dental Amalgam and Cognitive Function in Older Women: Findings From the Nun Study. <i>Journal of the American Dental Association</i> , 1995, 126, 1495-1501.	0.7	57
180	Cognitive Test Performance in Detecting, Staging, and Tracking Alzheimer's Disease. <i>Archives of Neurology</i> , 1995, 52, 1087-1099.	4.9	212
181	Patterns of Deterioration in Senile Dementia of the Alzheimer Type. <i>Archives of Neurology</i> , 1995, 52, 306-310.	4.9	35
182	Neuroleptic Treatment of Agitation and Psychosis in Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1995, 8, S18-S27.	1.2	57
183	Effectiveness and Safety of Velnacrine for the Treatment of Alzheimer's Disease. <i>Archives of Internal Medicine</i> , 1995, 155, 1766.	4.3	44
184	The Predictive Value of Cerebrospinal Fluid Dynamic Tests in Patients With the Idiopathic Adult Hydrocephalus Syndrome. <i>Archives of Neurology</i> , 1995, 52, 783-789.	4.9	207
185	Interrelationships of Peak Expiratory Flow Rate With Physical and Cognitive Function in the Elderly: MacArthur Foundation Studies of Aging. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 1995, 50A, M317-M323.	1.7	71
187	Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease. <i>Biological Psychiatry</i> , 1995, 38, 185-188.	0.7	31

#	ARTICLE	IF	CITATIONS
188	Lack of association between clinical symptoms and postmortem indices of brain serotonin function in Alzheimer's disease. <i>Biological Psychiatry</i> , 1995, 37, 895-896.	0.7	8
189	Methodological aspects of evaluating effects of AD progression. <i>Neurobiology of Aging</i> , 1995, 16, 867-870.	1.5	2
190	l-Deprenyl and physostigmine for the treatment of Alzheimer's disease. <i>Psychiatry Research</i> , 1995, 58, 181-189.	1.7	29
191	The Role of the Caregiver in the Drug Treatment of Dementia. <i>CNS Drugs</i> , 1995, 4, 58-67.	2.7	6
192	Predicting Response to Cholinesterase Inhibitors in Alzheimer's Disease. <i>CNS Drugs</i> , 1995, 4, 114-124.	2.7	13
193	Tacrine. <i>Lancet</i> , The, 1995, 345, 625-630.	6.3	195
194	Assessing cognitive function in schizophrenics and patients with Alzheimer's disease. <i>Schizophrenia Research</i> , 1995, 17, 115-121.	1.1	9
195	A Scale to Measure Impairment in Severe Dementia and Similar Conditions. <i>American Journal of Geriatric Psychiatry</i> , 1996, 4, 247-251.	0.6	41
196	Cerebellar induced aphasia: case report of cerebellar induced prefrontal aphasic language phenomena supported by SPECT findings. <i>Journal of the Neurological Sciences</i> , 1996, 144, 34-43.	0.3	123
197	Designing dementia treatment studies: Diagnosis, efficacy criteria, and duration. <i>European Psychiatry</i> , 1996, 11, 149-154.	0.1	1
198	Excessive urokinase-type plasminogen activator activity in the euglobulin fraction of patients with Alzheimer-type dementia. <i>Journal of the Neurological Sciences</i> , 1996, 139, 83-88.	0.3	11
199	Topography of the maximum of the amplitude of EEG frequency bands in dementia of the Alzheimer type. <i>Biological Psychiatry</i> , 1996, 39, 319-325.	0.7	44
200	Olfactory identification deficits in relatives of Alzheimer's disease patients. <i>Biological Psychiatry</i> , 1996, 39, 375-377.	0.7	49
201	Apolipoprotein E Genotype and Gender Influence Response to Tacrine Therapy. <i>Annals of the New York Academy of Sciences</i> , 1996, 802, 101-110.	1.8	89
202	Preliminary Evaluation of Besipirdine for the Treatment of Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 1996, 777, 410-414.	1.8	11
203	Double-blind placebo-controlled study of velnacrine in Alzheimer's disease. <i>Life Sciences</i> , 1996, 58, 1823-1832.	2.0	14
204	Functional studies of new drugs for the treatment of Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 1996, 94, 137-144.	1.0	15
205	Self-efficacy beliefs and change in cognitive performance: MacArthur studies on Successful Aging. <i>Psychology and Aging</i> , 1996, 11, 538-551.	1.4	89

#	ARTICLE	IF	CITATIONS
206	Drug Treatment of Alzheimer's Disease. <i>Drugs and Aging</i> , 1996, 8, 47-55.	1.3	24
207	Behavioural Disorders in Demented Elderly Patients. <i>CNS Drugs</i> , 1996, 6, 280-300.	2.7	26
208	Nimodipine in the Treatment of Probable Alzheimer's Disease. <i>Clinical Drug Investigation</i> , 1996, 11, 185-195.	1.1	53
209	Mixed-model analysis of incomplete longitudinal data from a high-dose trial of tacrine (cognex®) in alzheimer's patients. <i>Journal of Biopharmaceutical Statistics</i> , 1996, 6, 59-67.	0.4	13
210	Age, Education, and Changes in the Mini-Mental State Exam Scores of Older Women: Findings from the Nun Study. <i>Journal of the American Geriatrics Society</i> , 1996, 44, 675-681.	1.3	122
211	Long-term tacrine (Cognex) treatment. <i>Neurology</i> , 1996, 47, 166-177.	1.5	340
212	The Hierarchic Dementia Scale: Conceptualization. <i>International Psychogeriatrics</i> , 1996, 8, 205-212.	0.6	8
213	Utility of Clinical Trial Batteries in the Measurement of Alzheimer's and Huntington's Dementia. <i>International Psychogeriatrics</i> , 1996, 8, 397-411.	0.6	36
214	Behavioral Intervention Approaches to the Treatment and Management of Alzheimer's Disease: A Research Agenda. <i>International Psychogeriatrics</i> , 1996, 8, 39-44.	0.6	4
215	Behavioral Intervention Strategies for Sleep-Activity Disruption. <i>International Psychogeriatrics</i> , 1996, 8, 77-86.	0.6	13
216	EFFICACY AND TOLERABILITY OF TACRINE IN NURSING HOME RESIDENTS WITH ALZHEIMER'S DEMENTIA. <i>Journal of the American Geriatrics Society</i> , 1996, 44, 1411-1412.	1.3	1
217	Improved Reliability of the Standardized Alzheimer's Disease Assessment Scale (SADAS) Compared with the Alzheimer's Disease Assessment Scale (ADAS). <i>Journal of the American Geriatrics Society</i> , 1996, 44, 712-716.	1.3	23
218	Chapter 29 Cholinomimetic treatment of Alzheimer's disease. <i>Progress in Brain Research</i> , 1996, 109, 299-309.	0.9	8
219	An Enriched-Population, Double-Blind, Placebo-Controlled, Crossover Study of Tacrine and Lecithin in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 1996, 7, 260-266.	0.7	3
220	Selegiline in Treatment of Behavioral and Cognitive Symptoms of Alzheimer Disease. <i>Annals of Pharmacotherapy</i> , 1996, 30, 1122-1129.	0.9	20
221	Physical Activity and Measures of Cognitive Function in Healthy Older Adults: The MacArthur Study of Successful Aging. <i>Journal of Aging and Physical Activity</i> , 1996, 4, 362-376.	0.5	12
222	A Pilot Study of Prednisone in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 1996, 7, 201-206.	0.7	19
223	Differential Response to the Cholinergic Agonist Arecoline among Different Cognitive Modalities in Alzheimer's Disease. <i>Neuropsychopharmacology</i> , 1996, 15, 163-170.	2.8	35

#	ARTICLE	IF	CITATIONS
224	Velnacrine for the treatment of Alzheimer's disease: A double-blind, placebo-controlled trial. <i>Journal of Neural Transmission</i> , 1996, 103, 1105-1116.	1.4	15
225	Comparison of cerebral atrophy evaluated by MRI in Parkinson's disease and multiple system atrophy. <i>European Journal of Neurology</i> , 1996, 3, 429-437.	1.7	0
226	Neuropsychological assessment of dementia: state of the art. <i>Acta Neurologica Scandinavica</i> , 1996, 94, 45-49.	1.0	80
227	Pharmacological treatment of cognitive dysfunction in dementia disorders. <i>Acta Neurologica Scandinavica</i> , 1996, 94, 87-92.	1.0	29
228	High apolipoprotein E $\epsilon$ 4 allele frequency in Age-related memory decline. <i>Annals of Neurology</i> , 1996, 39, 548-551.	2.8	49
229	Efficacy and safety of idebenone in the long-term treatment of Alzheimer's Disease: a double-blind, placebo controlled multicentre study. <i>Human Psychopharmacology</i> , 1996, 11, 53-65.	0.7	22
230	Searching for a treatment for Alzheimer's Disease? tales from the cutting-room floor. <i>International Journal of Geriatric Psychiatry</i> , 1996, 11, 337-342.	1.3	0
231	THE BEHAVIOR PATHOLOGY IN ALZHEIMER'S DISEASE RATING SCALE (BEHAVE-AD): RELIABILITY AND ANALYSIS OF SYMPTOM CATEGORY SCORES. <i>International Journal of Geriatric Psychiatry</i> , 1996, 11, 819-830.	1.3	83
232	Clinical Evaluation of Global Change in Alzheimer's Disease: Identifying Consensus. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1996, 9, 176-180.	1.2	44
233	Cognitive Test Performance in a Community-Based Nondemented Elderly Sample in Rural India: The Indo-U.S. Cross-National Dementia Epidemiology Study. <i>International Psychogeriatrics</i> , 1996, 8, 507-524.	0.6	163
234	Statistical Issues in the Design and Analysis of Clinical Trials in Alzheimer's Disease. <i>Drug Information Journal</i> , 1996, 30, 339-350.	0.5	2
235	Cardinal Features of Cognitive Dysfunction in Alzheimer's Disease: A Factor-Analytic Study of the Alzheimer's Disease Assessment Scale. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1996, 9, 39-46.	1.2	26
236	Neuropsychiatric aspects of Alzheimer's disease. <i>Neurology</i> , 1996, 47, 876-883.	1.5	290
237	Effect of Tacrine on Behavioral Symptoms in Alzheimer's Disease: An Open-Label Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1996, 9, 1-6.	1.2	185
238	Effects of age, education, and gender on cerad neuropsychological test performance in an african American sample. <i>Clinical Neuropsychologist</i> , 1996, 10, 180-190.	1.5	88
239	The content and properties of the Caregiver Activities Time Survey (CATS): An outcome measure for use in clinical trial research on Alzheimer's disease. , 1996, 11, 3-9.		7
240	A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. <i>Neurology</i> , 1996, 47, 705-711.	1.5	154
241	A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. <i>Neurology</i> , 1996, 47, 1389-1395.	1.5	88

#	ARTICLE	IF	CITATIONS
242	Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. <i>Neurology</i> , 1996, 46, 1580-1584.	1.5	251
243	Stepwise Comparative Status Analysis (STEP): A Tool for Identification of Regional Brain Syndromes in Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1996, 9, 185-199.	1.2	84
244	Intent-to-Treat Analysis for Longitudinal Studies with Drop-Outs. <i>Biometrics</i> , 1996, 52, 1324.	0.8	335
245	Donepezil for Alzheimer's disease?. <i>Drug and Therapeutics Bulletin</i> , 1997, 35, 75-76.	0.3	7
246	Increase in Urinary Cortisol Excretion and Memory Declines: MacArthur Studies of Successful Aging1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 2458-2465.	1.8	284
247	Donepezil (AriceptTM): The caregivers voice and clinical impression. , 1997, 12, 272-279.		5
248	Price of Adaptation—Allostatic Load and Its Health Consequences. <i>Archives of Internal Medicine</i> , 1997, 157, 2259.	4.3	955
249	A Placebo-Controlled, Double-blind, Randomized Trial of an Extract of Ginkgo Biloba for Dementia. <i>JAMA - Journal of the American Medical Association</i> , 1997, 278, 1327.	3.8	679
251	Basal forebrain amnesia. <i>Neurocase</i> , 1997, 3, 405-415.	0.2	6
252	Neuropsychological assessment of Alzheimer's disease. <i>Neurology</i> , 1997, 49, S11-3.	1.5	50
253	Effect of Tacrine on Language, Praxis, and Noncognitive Behavioral Problems in Alzheimer Disease. <i>Archives of Neurology</i> , 1997, 54, 836-840.	4.9	110
254	The search for disease-modifying treatment for Alzheimer's disease. <i>Neurology</i> , 1997, 48, S35-41.	1.5	83
255	Disruptive Behavior and Actigraphic Measures in Home-Dwelling Patients with Alzheimer's Disease: Preliminary Report. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1997, 10, 58-62.	1.2	13
256	Alzheimer's Disease Assessment Scale: The Validation of the Scale in Greece in Elderly Demented Patients and Normal Subjects. <i>Dementia and Geriatric Cognitive Disorders</i> , 1997, 8, 273-280.	0.7	35
257	Noncognitive Disturbances in Alzheimer's Disease: Frequency, Longitudinal Course, and Relationship to Cognitive Symptoms. <i>Journal of the American Geriatrics Society</i> , 1997, 45, 1331-1338.	1.3	89
258	Theories Behind Existing Scales for Rating Behavior in Dementia. <i>International Psychogeriatrics</i> , 1997, 8, 293-300.	0.6	18
259	Risk Factors for Clinically Diagnosed Alzheimer's Disease: A Case-Control Study of a Greek Population. <i>International Psychogeriatrics</i> , 1997, 9, 327-341.	0.6	59
260	The presence of leuko-araiosis in patients with Alzheimer's disease predicts poor tolerance to tacrine, but does not discriminate responders from non-responders. <i>Age and Ageing</i> , 1997, 26, 25-29.	0.7	18

#	ARTICLE	IF	CITATIONS
261	The Alzheimer's disease assessment scale. <i>Neurology</i> , 1997, 48, 1511-1517.	1.5	156
262	The relationship between extrapyramidal signs and cognitive performance in patients with Alzheimer's disease enrolled in the CERAD study. <i>Neurology</i> , 1997, 49, 70-75.	1.5	69
263	Performance of elderly white and African American community residents on the abbreviated CERAD Boston naming test. <i>Journal of Clinical and Experimental Neuropsychology</i> , 1997, 19, 204-210.	0.8	27
264	Can the Sensitivity of the Alzheimer's Disease Assessment Scale Be Increased?. <i>American Journal of Geriatric Psychiatry</i> , 1997, 5, 258-260.	0.6	3
265	The Apolipoprotein E4 Allele Is Associated With Increased Behavioral Disturbance in Alzheimer's Disease. <i>American Journal of Geriatric Psychiatry</i> , 1997, 5, 88-89.	0.6	13
266	A Risk-Benefit Assessment of Tacrine in the Treatment of Alzheimer's Disease. <i>Drug Safety</i> , 1997, 16, 66-77.	1.4	24
267	A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease. <i>New England Journal of Medicine</i> , 1997, 336, 1216-1222.	13.9	2,346
268	Challenges in Vascular Dementia Research. <i>Disease Management and Health Outcomes</i> , 1997, 2, 37-44.	0.3	1
269	Potential Role for Estrogen Replacement in the Treatment of Alzheimer's Dementia. <i>American Journal of Medicine</i> , 1997, 103, 46S-50S.	0.6	27
270	Loss of functional hemispheric asymmetry in Alzheimer's dementia assessed with near-infrared spectroscopy. <i>Cognitive Brain Research</i> , 1997, 6, 67-72.	3.3	128
271	Cortisol Secretion and Alzheimer's Disease Progression. <i>Biological Psychiatry</i> , 1997, 42, 1030-1038.	0.7	108
272	A new MRI ratio method for in-vivo estimation of signal hypointensity in aging and Alzheimer's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1997, 21, 1257-1267.	2.5	2
273	The effects of 5-HT3 receptor antagonists on cognitive performance in aged monkeys. <i>Neurobiology of Aging</i> , 1997, 18, 21-28.	1.5	130
274	Effect of Glucose and Peripheral Glucose Regulation on Memory in the Elderly. <i>Neurobiology of Aging</i> , 1997, 18, 297-304.	1.5	86
276	Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. <i>American Journal of Health-System Pharmacy</i> , 1997, 54, 280S-281S.	0.5	82
277	Focal neurocognitive dysfunctions in abstinence delirium: a case report. <i>Acta Neuropsychiatrica</i> , 1997, 9, 107-115.	1.0	0
278	Psychometric Considerations When Measuring Cognitive Decline in Alzheimer's Disease. <i>Neuroepidemiology</i> , 1997, 16, 185-190.	1.1	9
279	Linopirdine: Pharmacology of a Neurotransmitter Release Enhancer. <i>CNS Neuroscience &amp; Therapeutics</i> , 1997, 3, 103-119.	4.0	10



#	ARTICLE	IF	CITATIONS
280	Tacrine Treatment in Alzheimer's Disease Enhances Cerebral Blood Flow and Mental Status and Decreases Caregiver Suffering. <i>Annals of the New York Academy of Sciences</i> , 1997, 826, 472-474.	1.8	14
281	Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. <i>Journal of Psychiatric Research</i> , 1997, 31, 645-655.	1.5	191
282	Aging and Alzheimer's Disease: Lessons From the Nun Study. <i>Gerontologist</i> , The, 1997, 37, 150-156.	2.3	284
283	Body weight, estrogen and cognitive functioning in Alzheimer's disease: an analysis of the Tacrine study group data. <i>Archives of Gerontology and Geriatrics</i> , 1997, 24, 261-267.	1.4	13
284	Measuring the effects of anti-dementia drugs in patients with Alzheimer's disease. , 1997, 12, 347-359.		2
285	IMPROVEMENT OF PICTURE RECALL BY REPETITION IN PATIENTS WITH DEMENTIA OF ALZHEIMER TYPE. , 1997, 12, 85-92.		12
286	The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer's disease. , 1997, 12, 978-988.		135
287	Inappropriate Sexual Behavior in Dementia: A Review of the Treatment Literature. <i>Sexuality and Disability</i> , 1998, 16, 205-217.	0.4	31
288	Threats to the Validity of Clinical Trials Employing Enrichment Strategies for Sample Selection. <i>Contemporary Clinical Trials</i> , 1998, 19, 178-187.	2.0	99
289	Drama and movement therapy in dementia: a pilot study. <i>Arts in Psychotherapy</i> , 1998, 25, 195-201.	0.6	31
290	Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. <i>Phytomedicine</i> , 1998, 5, 417-424.	2.3	7
291	The validity of psychometric instruments for detection of dementia in the elderly general population. , 1998, 13, 368-380.		116
292	Tacrine efficacy in Lewy body dementia. , 1998, 13, 516-519.		37
293	The economic consequences of Alzheimer's disease in the context of new drug developments. , 1998, 13, 531-543.		29
294	Severity of cognitive impairment in Alzheimer's disease affects list learning using the California verbal learning test (CVLT). , 1998, 13, 544-549.		34
295	Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease. , 1998, 13, 625-630.		127
296	Antiglutamatergic therapy in Alzheimer's disease - effects of lamotrigine. <i>Journal of Neural Transmission</i> , 1998, 105, 295-303.	1.4	64
297	Acetylcholinesterase assay may predict cognitive response of Alzheimer patients to eptastigmine treatment. <i>European Journal of Clinical Pharmacology</i> , 1998, 54, 809-810.	0.8	1

#	ARTICLE	IF	CITATIONS
299	Outcome measures for clinical trials in alzheimer's disease: A review on some open issues. Archives of Gerontology and Geriatrics, 1998, 26, 295-300.	1.4	2
300	The Prevalence and 3-Year Incidence of Dementia in Older Black and White Community Residents. Journal of Clinical Epidemiology, 1998, 51, 587-595.	2.4	159
301	Safety and tolerability of metrifonate in patients with alzheimer's disease: Results of a maximum tolerated dose study. Life Sciences, 1998, 62, 1433-1441.	2.0	25
302	Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. European Neuropsychopharmacology, 1998, 8, 67-75.	0.3	260
303	The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Preliminary Clinical Validity. Journal of Clinical and Experimental Neuropsychology, 1998, 20, 310-319.	0.8	2,009
304	Rivastigmine. Drugs and Aging, 1998, 13, 391-411.	1.3	167
305	Glucocorticoids in Alzheimer's Disease. Drugs and Aging, 1998, 12, 1-6.	1.3	38
306	Idebenone. CNS Drugs, 1998, 9, 403-419.	2.7	6
308	Progression of Alzheimer's disease in black and white patients. Neurology, 1998, 51, 154-158.	1.5	23
309	Cerebral infarcts in patients with autopsy-proven Alzheimer's disease. Neurology, 1998, 51, 159-162.	1.5	219
310	Metrifonate for Alzheimer's disease. Neurology, 1998, 50, 1203-1205.	1.5	23
311	Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology, 1998, 50, 1214-1221.	1.5	159
312	Update on Diagnostic Methods, Natural History and Outcome Variables in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 1998, 9, 2-7.	0.7	10
313	A 7 Minute Neurocognitive Screening Battery Highly Sensitive to Alzheimer's Disease. Archives of Neurology, 1998, 55, 349.	4.9	372
314	Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology, 1998, 50, 1222-1230.	1.5	305
315	Cholinesterase Inhibition for Alzheimer Disease. JAMA - Journal of the American Medical Association, 1998, 280, 1777.	3.8	142
316	Right-side neglect in Alzheimer's disease. Neurology, 1998, 51, 1207-1209.	1.5	43
317	Donepezil Improves Cognition and Global Function in Alzheimer Disease<sub>title>A 15-Week, Double-blind, Placebo-Controlled Study</sub>. Archives of Internal Medicine, 1998, 158, 1021.	4.3	674

#	ARTICLE	IF	CITATIONS
318	Ephemeral New Traces and Evaporated Remote Engrams: A Form of Neocortical Temporal Lobe Amnesia? A Preliminary Case Report. <i>Neurocase</i> , 1998, 4, 447-459.	0.2	38
319	L-deprenyl in Alzheimer's disease. <i>Neurology</i> , 1998, 50, 660-668.	1.5	64
320	Impaired traffic sign recognition in drivers with dementia. , 1998, 13, 131-137.		16
321	Amnestic people with Alzheimer's disease who remembered the Kobe earthquake. <i>British Journal of Psychiatry</i> , 1998, 172, 425-428.	1.7	72
322	Everyday Problem Solving Among Individuals With Alzheimer's Disease. <i>Gerontologist</i> , The, 1998, 38, 569-577.	2.3	81
323	Absence of an Apolipoprotein E $\epsilon$ 4 Allele Is Associated With Increased Parietal Regional Cerebral Blood Flow Asymmetry in Alzheimer Disease. <i>Archives of Neurology</i> , 1998, 55, 1460.	4.9	30
324	Use of Antioxidant Supplements and Its Association with Cognitive Function in a Rural Elderly Cohort: The MoVIES Project. <i>American Journal of Epidemiology</i> , 1998, 148, 38-44.	1.6	82
325	Methodology, results and quality of clinical trials of tacrine in the treatment of Alzheimer's disease: a systematic review of the literature. <i>Age and Ageing</i> , 1998, 27, 161-179.	0.7	26
326	Correlates of Dependent Living 3 Months after Ischemic Stroke. <i>Cerebrovascular Diseases</i> , 1998, 8, 259-266.	0.8	43
327	<i>Ginkgo biloba</i> and Memory: An Overview. <i>Nutritional Neuroscience</i> , 1998, 1, 255-267.	1.5	9
328	Assessing the Impact of Neuropsychiatric Symptoms in Alzheimer's Disease: The Neuropsychiatric Inventory Caregiver Distress Scale. <i>Journal of the American Geriatrics Society</i> , 1998, 46, 210-215.	1.3	489
329	Pharmacokinetics, Pharmacodynamics, and Safety of Metrifonate in Patients with Alzheimer's Disease. <i>Journal of Clinical Pharmacology</i> , 1998, 38, 236-245.	1.0	49
330	The Validity of Informant Reports in Assessing the Severity of Dementia: Evidence from the CAMDEX Interview. <i>Dementia and Geriatric Cognitive Disorders</i> , 1998, 9, 56-62.	0.7	21
331	The Clinical Trial Protocol of the Metrifonate in Alzheimer's Trial (MALT). <i>Dementia and Geriatric Cognitive Disorders</i> , 1998, 9, 2-7.	0.7	46
332	Subcortical Vascular Dementia: Survey of Treatment Patterns and Research Considerations. <i>Canadian Journal of Neurological Sciences</i> , 1998, 25, 320-324.	0.3	14
333	Perspectives in the Management of Alzheimer's Disease: Clinical Profile of Donepezil. <i>Dementia and Geriatric Cognitive Disorders</i> , 1998, 9, 29-42.	0.7	32
334	Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. <i>Neurology</i> , 1998, 50, 669-677.	1.5	202
335	Psychological assessment of older adults.. <i>Professional Psychology: Research and Practice</i> , 1998, 29, 5-14.	0.6	7

#	ARTICLE	IF	CITATIONS
336	The Alzheimer's disease assessment scale. <i>Neurology</i> , 1998, 50, 1516-1516.	1.5	1
337	Global Change Assessments in Anti-Alzheimer Clinical Drug Trials. <i>Dementia and Geriatric Cognitive Disorders</i> , 1998, 9, 8-15.	0.7	23
338	Neuropsychological Assessment of the Elderly. , 1998, , 133-169.		7
339	The Stages of Alzheimer's Disease: A Reappraisal. <i>Dementia and Geriatric Cognitive Disorders</i> , 1998, 9, 299-308.	0.7	38
340	How to appraise an article on therapy. <i>Psychiatric Bulletin</i> , 1998, 22, 342-344.	0.3	1
341	Pharmacology and clinical efficacy of cholinesterase inhibitors. <i>American Journal of Health-System Pharmacy</i> , 1998, 55, S22-S25.	0.5	16
342	Do neurologists have a future in neuroimaging?. <i>Neurology</i> , 1998, 50, 1516-1517.	1.5	3
343	Neurofibrillary Tangles in Nondemented Elderly Subjects and Mild Alzheimer Disease. <i>Archives of Neurology</i> , 1999, 56, 713.	4.9	194
344	Metrifonate: A new agent for the treatment of Alzheimer's disease. <i>American Journal of Health-System Pharmacy</i> , 1999, 56, 427-432.	0.5	10
346	A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. <i>Neurology</i> , 1999, 53, 197-197.	1.5	387
347	Neuropsychological Subgroups of Patients with Alzheimer's Disease: An Examination of the First 10 Years of CERAD Data. <i>Journal of Clinical and Experimental Neuropsychology</i> , 1999, 21, 488-518.	0.8	36
348	Neuropsychometric Tests in Cross Sectional and Longitudinal Studies - A Regression Analysis of ADAS - Cog, SKT and MMSE. <i>Pharmacopsychiatry</i> , 1999, 32, 248-254.	1.7	35
349	Double-Blind, Randomized, Placebo-Controlled Clinical Trial on the Efficacy and Tolerability of a Physostigmine Patch in Patients with Senile Dementia of the Alzheimer Type. <i>Pharmacopsychiatry</i> , 1999, 32, 99-106.	1.7	22
350	Advances in Methodology and Current Prospects for Primary Drug Therapies for Alzheimer's Disease. , 2000, 32, 45-62.		1
351	Strategies for analysing behavioural data in clinical trials involving patients with Alzheimer's disease. <i>International Journal of Neuropsychopharmacology</i> , 1999, 2, 59-66.	1.0	7
352	Cholinergic Markers in Elderly Patients With Early Signs of Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 1999, 281, 1401.	3.8	444
353	The Neurobiology and Pharmacotherapy of Alzheimer's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1999, 11, 19-31.	0.9	50
354	Clinical Profile of Donepezil in the Treatment of Alzheimer's Disease. <i>Gerontology</i> , 1999, 45, 23-32.	1.4	81

#	ARTICLE	IF	CITATIONS
355	Pharmacologic Management of Alzheimer Disease Part III: Nonsteroidal Antiinflammatory Drugs â€” Emerging Protective Evidence?. <i>Annals of Pharmacotherapy</i> , 1999, 33, 840-849.	0.9	31
356	In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimerâ€™s disease. <i>Neurology</i> , 1999, 52, 691-691.	1.5	337
357	Comparison of Lewy body variant of Alzheimerâ€™s disease with pure Alzheimerâ€™s disease. <i>Neurology</i> , 1999, 52, 1839-1839.	1.5	123
358	A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimerâ€™s disease. <i>Neurology</i> , 1999, 52, 1146-1146.	1.5	70
359	Evidence-based psychopharmacology 1. Appraising a single therapeutic trial: what is the evidence for treating early Alzheimer's disease with donepezil?. <i>Journal of Psychopharmacology</i> , 1999, 13, 308-312.	2.0	3
360	The Spectrum of Behavioral Responses to Cholinesterase Inhibitor Therapy in Alzheimer Disease. <i>Archives of Neurology</i> , 1999, 56, 1388.	4.9	237
361	Pharmacologic Management of Alzheimer Disease Part I: Hormonal and Emerging Investigational Drug Therapies. <i>Annals of Pharmacotherapy</i> , 1999, 33, 178-187.	0.9	18
363	Cholinesterase Inhibitors: A Therapeutic Strategy for Alzheimer Disease. <i>Annals of Pharmacotherapy</i> , 1999, 33, 441-450.	0.9	161
364	Challenging the Cholinergic Hypothesis in Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 1999, 281, 1433.	3.8	48
365	Dementia in the severely aphasic: Global aphasia without hemiparesisâ€”A stroke subtype simulating dementia. , 1999, 14, 74-78.		0
366	Pharmacologic Management of Alzheimer Disease Part II: Antioxidants, Antihypertensives, and Ergoloid Derivatives. <i>Annals of Pharmacotherapy</i> , 1999, 33, 188-197.	0.9	34
367	The Effects of Donepezil in Alzheimerâ€™s Disease â€” Results from a Multinational Trial<sup>1</sup>. <i>Dementia and Geriatric Cognitive Disorders</i> , 1999, 10, 237-244.	0.7	540
368	Examining Dementia in Down's Syndrome (DS). <i>Clinical Gerontologist</i> , 1999, 20, 23-44.	1.2	9
369	Treatment of Alzheimer's Disease. <i>New England Journal of Medicine</i> , 1999, 341, 1670-1679.	13.9	300
370	Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial Â Commentary: Another piece of the Alzheimer's jigsaw. <i>BMJ: British Medical Journal</i> , 1999, 318, 633-640.	2.4	782
371	Metrifonate (Trichlorfon): a review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimerâ€™s disease. <i>Expert Opinion on Investigational Drugs</i> , 1999, 8, 463-471.	1.9	21
372	Progressive defective recognition of familiar people. <i>Neurocase</i> , 1999, 5, 407-424.	0.2	64
373	Economic impact of Alzheimer's disease in the United Kingdom. <i>British Journal of Psychiatry</i> , 1999, 174, 51-55.	1.7	94

#	ARTICLE	IF	CITATIONS
374	Acetylcholinesterase inhibitors in Alzheimer's disease. British Journal of Clinical Pharmacology, 1999, 48, 471-480.	1.1	285
375	A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (ExelonR). European Journal of Neurology, 1999, 6, 423-429.	1.7	108
377	Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology, 1999, 143, 158-165.	1.5	249
379	Early diagnosis of dementia: neuropsychology. Journal of Neurology, 1999, 246, 6-15.	1.8	288
380	The impact of behavioral impairment of functional ability in Alzheimer's disease. , 1999, 14, 307-316.		34
381	A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study. International Journal of Geriatric Psychiatry, 1999, 14, 973-982.	1.3	50
382	Measuring Outcomes in Alzheimer's Disease Research. Disease Management and Health Outcomes, 1999, 5, 1-12.	0.3	5
383	Memory Assessment in Studies of Cognition-Enhancing Drugs for Alzheimer's Disease. Drugs and Aging, 1999, 14, 197-230.	1.3	42
385	The cholinergic hypothesis of Alzheimer's disease: a review of progress. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 66, 137-147.	0.9	1,714
386	Nonsteroidal Anti-Inflammatory Drugs and Alzheimer's Disease. CNS Drugs, 1999, 11, 207-224.	2.7	10
387	Donepezil use in managed medicare: Effect on health care costs and utilization. Clinical Therapeutics, 1999, 21, 2173-2185.	1.1	30
388	Rational design of anti-dementia therapy. European Neuropsychopharmacology, 1999, 9, S61-S68.	0.3	0
389	Clinical benefits of a new piperidine-class AChE inhibitor. European Neuropsychopharmacology, 1999, 9, S69-S77.	0.3	19
390	Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biological Psychiatry, 1999, 45, 32-40.	0.7	222
391	Can Caregivers Independently Rate Cognitive and Behavioral Symptoms in Alzheimer's Disease Patients?: A Longitudinal Analysis. American Journal of Geriatric Psychiatry, 1999, 7, 321-330.	0.6	4
392	Tacrine for Alzheimer's disease. The Cochrane Library, 1999, , CD000202.	1.5	35
393	Actigraphic Predictors of Depressed Mood in a Cohort of Non-Psychiatric Adults. Australian and New Zealand Journal of Psychiatry, 1999, 33, 553-558.	1.3	23
394	Neuropeptide Abnormalities in Patients With Early Alzheimer Disease. Archives of General Psychiatry, 1999, 56, 981.	13.8	73

#	ARTICLE	IF	CITATIONS
395	Two-Year Treatment of Alzheimer's Disease with Eptastigmine. <i>Dementia and Geriatric Cognitive Disorders</i> , 1999, 10, 139-147.	0.7	35
396	Validity of Different Linguistic Versions of the Alzheimer's Disease Assessment Scale in an International Multicentre Alzheimer's Disease Trial. <i>Dementia and Geriatric Cognitive Disorders</i> , 1999, 10, 269-277.	0.7	10
397	Neuropsychological Features of Dementia due to Dural Arteriovenous Malformation. <i>Cerebrovascular Diseases</i> , 1999, 9, 91-97.	0.8	17
398	Metrifonate treatment of AD. <i>Neurology</i> , 1999, 53, 2010-2010.	1.5	56
399	NEUROPSI: A brief neuropsychological test battery in Spanish with norms by age and educational level. <i>Journal of the International Neuropsychological Society</i> , 1999, 5, 413-433.	1.2	202
400	The utility of naming tests in the diagnosis of Alzheimer's disease. <i>Irish Journal of Psychological Medicine</i> , 1999, 16, 43-46.	0.7	5
401	Neuropsychological evaluation and the diagnosis and differential diagnosis of dementia. <i>Reviews in Clinical Gerontology</i> , 1999, 9, 65-72.	0.5	7
402	New drugs for Alzheimer's disease. <i>British Journal of Psychiatry</i> , 1999, 174, 476-479.	1.7	39
403	Assessment of Functional Ability of People with Alzheimer's Disease. <i>Scandinavian Journal of Occupational Therapy</i> , 1999, 6, 111-118.	1.1	30
404	MRI Temporal Lobe Volume Measures and Neuropsychologic Function in Alzheimer's Disease. <i>Journal of Neuroimaging</i> , 1999, 9, 2-9.	1.0	49
406	Galantamine: Therapeutic Effects beyond Cognition. <i>Dementia and Geriatric Cognitive Disorders</i> , 2000, 11, 28-34.	0.7	64
407	Vitamin E for Alzheimer's disease and mild cognitive impairment. , 2000, , CD002854.		41
408	A 6-Month, Double-Blind, Placebo-Controlled Trial of Eptastigmine in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2000, 11, 17-24.	0.7	18
409	A Double-Blind, Placebo-Controlled, Multicenter Study of Cerebrolysin for Alzheimer's Disease. <i>Journal of the American Geriatrics Society</i> , 2000, 48, 1566-1571.	1.3	52
410	Measuring the outcomes of care in older people: a non-critical review of patient-based measures. II. Mental status, depression and psychological wellbeing instruments. <i>Reviews in Clinical Gerontology</i> , 2000, 10, 123-132.	0.5	1
411	Behavioural and psychological symptoms of dementia. <i>Reviews in Clinical Gerontology</i> , 2000, 10, 245-260.	0.5	21
412	The Impact of Metrifonate Therapy on Caregivers of Patients with Alzheimer's Disease: Results from the MALT Clinical Trial. <i>Journal of the American Geriatrics Society</i> , 2000, 48, 268-274.	1.3	21
413	Measurement of progression in Alzheimer's disease: a clinician's perspective. , 2000, 19, 1393-1400.		20

#	ARTICLE	IF	CITATIONS
414	Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer's disease. , 2000, 19, 1401-1409.		70
415	Sustained cognitive improvement following treatment of Alzheimer's disease with donepezil. , 2000, 15, 50-53.		45
416	Pushing and pulling with the upper extremities while standing: The effects of mild Alzheimer dementia and Parkinson's disease. <i>Movement Disorders</i> , 2000, 15, 255-268.	2.2	23
417	Treatment for Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2000, 15, 562-565.	1.3	5
418	The sensitivity to change over time of the Bristol activities of daily living scale in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2000, 15, 656-661.	1.3	43
419	The Caregiver Activity Survey (CAS): longitudinal validation of an instrument that measures time spent caregiving for individuals with Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2000, 15, 680-686.	1.3	32
420	Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic. <i>International Journal of Geriatric Psychiatry</i> , 2000, 15, 713-720.	1.3	105
421	An efficacy and safety analysis of ExelonR in Alzheimer's disease patients with concurrent vascular risk factors. <i>European Journal of Neurology</i> , 2000, 7, 159-169.	1.7	156
422	New pharmacological treatments for Alzheimer's disease: implications for dementia care nursing. <i>Journal of Advanced Nursing</i> , 2000, 31, 1183-1188.	1.5	14
423	Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial. <i>Acta Neurologica Scandinavica</i> , 2000, 102, 85-89.	1.0	31
424	Rivastigmine, a New-Generation Cholinesterase Inhibitor for the Treatment of Alzheimer's Disease. <i>Pharmacotherapy</i> , 2000, 20, 1-12.	1.2	183
425	Disturbances of spatial vision and object vision correlate differently with regional cerebral glucose metabolism in Alzheimer's disease. <i>Neuropsychologia</i> , 2000, 38, 1356-1361.	0.7	41
426	Preliminary Assessment of Cognitive Function in Breast Cancer Patients Treated with Tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2000, 64, 165-176.	1.1	218
427	A 5-month, randomized, placebo-controlled trial of galantamine in AD. <i>Neurology</i> , 2000, 54, 2269-2276.	1.5	884
428	Senile dementia associated with amyloid $\beta^2$ protein angiopathy and tau perivascular pathology but not neuritic plaques in patients homozygous for the APOE- $\mu$ 4 allele. <i>Acta Neuropathologica</i> , 2000, 100, 1-12.	3.9	74
429	Features of Regional Cerebral Glucose Metabolism Abnormality in Corticobasal Degeneration. <i>Dementia and Geriatric Cognitive Disorders</i> , 2000, 11, 139-146.	0.7	21
430	Metrifonate Therapy in Alzheimer's Disease: A Pooled Analysis of Four Randomized, Double-Blind, Placebo-Controlled Trials. <i>Dementia and Geriatric Cognitive Disorders</i> , 2000, 11, 202-211.	0.7	31
432	Management of cognition and function: new results from the clinical trials programme of Aricept® (donepezil HCl). <i>International Journal of Neuropsychopharmacology</i> , 2000, 3, 13-20.	1.0	11



#	ARTICLE	IF	CITATIONS
434	Assessing the Benefits of Drug Treatment in Dementia. , 0, , 21-36.		0
435	Cholinesterase Inhibitors: A New Class of Psychotropic Compounds. American Journal of Psychiatry, 2000, 157, 4-15.	4.0	432
437	Galantamine in AD. Neurology, 2000, 54, 2261-2268.	1.5	875
438	Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology, 2000, 55, 684-688.	1.5	160
439	Cholinergic dysfunction in diseases with Lewy bodies. Neurology, 2000, 54, 407-407.	1.5	316
440	Review of Outcome Measurement Instruments in Alzheimer's Disease Drug Trials: Psychometric Properties of Behavior and Mood Scales. Journal of Geriatric Psychiatry and Neurology, 2000, 13, 181-196.	1.2	42
441	Lack of association of the $\epsilon$ 2-macroglobulin locus on chromosome 12 in AD. Neurology, 2000, 54, 433-433.	1.5	47
442	A randomized controlled trial of prednisone in Alzheimer's disease. Neurology, 2000, 55, 1067-1067.	1.5	88
443	Cognitive Function and Apolipoprotein E in Very Old Adults: Findings From the Nun Study. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2000, 55, S69-S75.	2.4	49
444	Extended-Release Physostigmine in Alzheimer Disease. Archives of General Psychiatry, 2000, 57, 157.	13.8	24
445	Fear recognition deficits after focal brain damage. Neurology, 2000, 54, 575-575.	1.5	141
446	$\epsilon$ 2-Macroglobulin polymorphism is not associated with AD or AD-type neuropathology in the Japanese. Neurology, 2000, 54, 443-443.	1.5	26
447	A randomized controlled trial of prednisone in Alzheimer's disease. Neurology, 2000, 54, 588-588.	1.5	474
448	Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Neurology, 2000, 54, 421-421.	1.5	59
449	Prevalence and outcomes of vascular cognitive impairment. Neurology, 2000, 54, 447-447.	1.5	356
450	A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology, 2000, 55, 1613-1620.	1.5	850
451	$\epsilon$ 4 does not predict mortality, cognitive decline, or dementia in the oldest old. Neurology, 2000, 54, 412-412.	1.5	101
453	Early-life risk factors and the development of Alzheimer's disease. Neurology, 2000, 54, 415-415.	1.5	168

#	ARTICLE	IF	CITATIONS
454	Galantamine: Additional Benefits to Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2000, 11, 19-27.	0.7	31
455	Use of Estrogens for the Prevention and Treatment of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2000, 11, 1-10.	0.7	40
456	Corticobasal Degeneration: Evaluation of Cortical Atrophy by Means of Hemispheric Surface Display Generated with MR Images. <i>Radiology</i> , 2000, 216, 31-38.	3.6	45
457	Estrogen for Alzheimer's disease in women. <i>Neurology</i> , 2000, 54, 295-295.	1.5	551
458	Ongoing trials in Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 899-915.	1.9	12
459	Cyclandelate in the Treatment of Patients with Mild to Moderate Primary Degenerative Dementia of the Alzheimer Type or Vascular Dementia: Experience from a Placebo Controlled Multi-center Study. <i>Pharmacopsychiatry</i> , 2000, 33, 89-97.	1.7	9
460	Changes in emotional and behavioral symptoms of Alzheimer's disease. , 2000, 15, 176-179.		2
461	Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented. <i>Neurology</i> , 2000, 55, 1847-1853.	1.5	358
462	Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 1007.	3.8	860
463	APOE and AD concordance in twin pairs as predictors of AD in first-degree relatives. <i>Neurology</i> , 2000, 54, 593-593.	1.5	15
464	A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer's Disease. <i>European Neurology</i> , 2000, 44, 236-241.	0.6	301
465	Î2 Macroglobulin and the risk of Alzheimer's disease. <i>Neurology</i> , 2000, 54, 438-438.	1.5	74
466	Donepezil Therapy in Clinical Practice. <i>Archives of Neurology</i> , 2000, 57, 94.	4.9	175
467	A 26-Week Analysis of a Double-Blind, Placebo-Controlled Trial of the Ginkgo biloba Extract EGb 761 in Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2000, 11, 230-237.	0.7	150
468	Oral Cerebrolysin® enhances brain alpha activity and improves cognitive performance in elderly control subjects. , 2000, 59, 315-328.		16
469	A Comparison of ADAS and EEG in the Discrimination of Patients with Dementia of the Alzheimer Type from Healthy Controls. <i>Neuropsychobiology</i> , 2000, 41, 102-107.	0.9	16
470	Internal carotid artery dissection. <i>Neurology</i> , 2000, 54, 442-442.	1.5	9
471	Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2000, 321, 1445-1445.	2.4	516

#	ARTICLE	IF	CITATIONS
472	Memory and MRI-based hippocampal volumes in aging and AD. <i>Neurology</i> , 2000, 54, 581-581.	1.5	391
473	Alzheimer's Disease: Pharmacological Treatment and Management. <i>Clinical Neuropsychologist</i> , 2000, 14, 93-109.	1.5	7
474	Mini mental state examination. <i>Lancet, The</i> , 2000, 355, 315.	6.3	2
475	Efficacy of naftidrofuryl in patients with vascular or mixed dementia: Results of a multicenter, double-blind trial. <i>Clinical Therapeutics</i> , 2000, 22, 834-844.	1.1	19
476	Computerized measurement of cognitive impairment and associated neuropsychiatric dimensions. <i>Comprehensive Psychiatry</i> , 2000, 41, 326-333.	1.5	39
477	Aphasia following cerebellar damage: fact or fallacy?. <i>Journal of Neurolinguistics</i> , 2000, 13, 145-171.	0.5	67
478	Comparison of the determination of superoxide dismutase and antioxidant capacity in neurological patients using two different procedures. <i>Clinica Chimica Acta</i> , 2000, 301, 87-102.	0.5	15
479	Part VI. Primary drug therapies for alzheimer's disease. <i>Disease-a-Month</i> , 2000, 46, 745-760.	0.4	2
480	Cholinesterase inhibitors: expanding applications. <i>Lancet, The</i> , 2000, 356, 2024-2025.	6.3	34
481	Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease in the Elderly. <i>Drugs and Aging</i> , 2000, 16, 123-138.	1.3	29
482	Evidence for Psychotropic Effects of Acetylcholinesterase Inhibitors. <i>CNS Drugs</i> , 2000, 13, 385-395.	2.7	13
483	Metrifonate. <i>CNS Drugs</i> , 2000, 13, 443-467.	2.7	6
484	Nicergoline in Dementia. <i>CNS Drugs</i> , 2000, 14, 267-287.	2.7	21
485	NEUROBEHAVIORAL AND NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER'S DISEASE. <i>Neurologic Clinics</i> , 2000, 18, 829-846.	0.8	148
486	TREATMENT OF ALZHEIMER'S DISEASE. <i>Neurologic Clinics</i> , 2000, 18, 807-827.	0.8	34
487	Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. <i>European Neuropsychopharmacology</i> , 2000, 10, 195-203.	0.3	236
488	Galantamine. <i>Drugs</i> , 2000, 60, 1095-1122.	4.9	309
489	Problems Arising from the Generalising of Treatment Efficacy from Clinical Trials in Alzheimer's Disease. <i>Clinical Drug Investigation</i> , 2000, 19, 33-41.	1.1	13

#	ARTICLE	IF	CITATIONS
490	Nicergoline in the Treatment of Mild-to-Moderate Alzheimer's Disease. <i>Clinical Drug Investigation</i> , 2001, 21, 621-632.	1.1	19
491	The use of ginkgo biloba in the treatment of dementia. <i>Psychiatric Bulletin</i> , 2001, 25, 353-356.	0.3	7
492	Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. <i>Biological Psychiatry</i> , 2001, 49, 289-299.	0.7	318
493	ALZHEIMER'S DISEASE AND RELATED DISORDERS. <i>Medical Clinics of North America</i> , 2001, 85, 803-817.	1.1	43
494	Current Concepts in Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2001, 58, 1985.	4.9	4,117
495	Nicotine for Alzheimer's disease. <i>The Cochrane Library</i> , 2001, , .	1.5	16
496	Alzheimer's disease: current and future therapeutic perspectives. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2001, 25, 73-89.	2.5	25
497	Alcohol dementia: "cortical" or "subcortical" dementia?. <i>Archives of Clinical Neuropsychology</i> , 2001, 16, 523-533.	0.3	3
498	Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. <i>Lancet</i> , 2001, 358, 455-460.	6.3	212
499	Cognitive screening and neuropsychological assessment in early Alzheimer's disease. <i>Clinics in Geriatric Medicine</i> , 2001, 17, 229-254.	1.0	32
500	Pharmacodynamic-Tolerability Relationships of Cholinesterase Inhibitors for Alzheimer's Disease. <i>CNS Drugs</i> , 2001, 15, 375-390.	2.7	109
501	Current status and new developments with galantamine in the treatment of Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 2027-2049.	0.9	31
502	Thiamine for Alzheimer's disease. <i>The Cochrane Library</i> , 2001, , CD001498.	1.5	33
503	Neuropsychological tests in Alzheimer's disease. <i>Aging Clinical and Experimental Research</i> , 2001, 13, 210-220.	1.4	6
504	The cognitive subscale of the "Alzheimer's Disease Assessment Scale" in a Brazilian sample. <i>Brazilian Journal of Medical and Biological Research</i> , 2001, 34, 1295-1302.	0.7	63
505	Memory Changes with Aging and Dementia. , 2001, , 53-63.		9
506	Alzheimer's Disease: Antidementive Drugs. , 2001, , 418-423.		2
507	The Use of Medications for Cognitive Enhancement. <i>Canadian Journal of Neurological Sciences</i> , 2001, 28, S108-S114.	0.3	8

#	ARTICLE	IF	CITATIONS
508	Assessing Outcomes in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2001, 15, S8-S18.	0.6	27
509	Maintaining Cognitive Function in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2001, 15, S26-S33.	0.6	22
510	Brief Review: Rivastigmine, A Second Cholinesterase Inhibitor. <i>Canadian Journal of Neurological Sciences</i> , 2001, 28, S122-S123.	0.3	1
511	Evaluation of Various Methods of Assessing Symptoms of Cognitive Impairment and Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2001, 15, 184-193.	0.6	5
512	Performance of elderly African American and White community residents on the CERAD Neuropsychological Battery. <i>Journal of the International Neuropsychological Society</i> , 2001, 7, 502-509.	1.2	72
513	An Open-Label, 24-Week Pilot Study of the Methyl Donor Betaine in Alzheimer Disease Patients. <i>Alzheimer Disease and Associated Disorders</i> , 2001, 15, 162-165.	0.6	30
514	Donepezil, Rivastigmine, and Vitamin E in Alzheimer Disease: A Combined P300 Event-related Potentials/Neuropsychologic Evaluation over 6 Months. <i>Clinical Neuropharmacology</i> , 2001, 24, 31-42.	0.2	77
515	Information and Competency for Consent to Pharmacologic Clinical Trials in Alzheimer Disease: An Empirical Analysis in Patients and Family Caregivers. <i>Alzheimer Disease and Associated Disorders</i> , 2001, 15, 146-154.	0.6	35
516	Maintaining Functional and Behavioral Abilities in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2001, 15, S34-S40.	0.6	9
517	The Alzheimer's Disease Assessment Scale: Evaluation of Psychometric Properties and Patterns of Cognitive Decline in Multicenter Clinical Trials of Mild to Moderate Alzheimer's Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2001, 15, 174-183.	0.6	94
518	Asia Regional Meeting of the International Working Group for the Harmonization of Dementia Drug Guidelines: Meeting Report. <i>Alzheimer Disease and Associated Disorders</i> , 2001, 15, 66-68.	0.6	5
519	A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. <i>International Clinical Psychopharmacology</i> , 2001, 16, 253-263.	0.9	54
520	Alzheimer's Disease: Stage-Related Interventions. <i>Lippincott's Case Management: Managing the Process of Patient Care</i> , 2001, 6, 48-60.	0.2	5
521	Social relationships, social support, and patterns of cognitive aging in healthy, high-functioning older adults: MacArthur Studies of Successful Aging. <i>Health Psychology</i> , 2001, 20, 243-255.	1.3	643
522	The neuropsychological diagnosis of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2001, 3, 261-285.	1.2	31
523	Chapter 8 Dementia. <i>Blue Books of Practical Neurology</i> , 2001, 25, 147-172.	0.1	0
524	Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2001, 15, S3-S7.	0.6	29
525	Relationship between Blood Flow Kinetics and Severity of Alzheimer's Disease: Assessment of Severity Using a Questionnaire-Type Examination, Alzheimer's Disease Assessment Scale, Cognitive Sub-Scale (ADAS-cog). <i>Dementia and Geriatric Cognitive Disorders</i> , 2001, 12, 318-325.	0.7	13

#	ARTICLE	IF	CITATIONS
527	Pharmacotherapy for Alzheimer's disease. <i>Current Neurology and Neuroscience Reports</i> , 2001, 1, 428-434.	2.0	20
528	Neuroimaging in Alzheimer's disease: Relevance for treatment. <i>Current Psychiatry Reports</i> , 2001, 3, 13-19.	2.1	7
529	The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. <i>Journal of Neural Transmission</i> , 2001, 108, 1319-1325.	1.4	93
530	Parkinson's disease is associated with oxidative stress: comparison of peripheral antioxidant profiles in living Parkinson's, Alzheimer's and vascular dementia patients. <i>Journal of Neural Transmission</i> , 2001, 108, 1135-1148.	1.4	105
531	Cyclooxygenase and Alzheimer's disease: implications for preventive initiatives to slow the progression of clinical dementia. <i>Archives of Gerontology and Geriatrics</i> , 2001, 33, 13-28.	1.4	62
532	Alpha-lipoic acid as a new treatment option for Alzheimer type dementia. <i>Archives of Gerontology and Geriatrics</i> , 2001, 32, 275-282.	1.4	158
533	Process and organizational characteristics of memory clinics in Israel: a national survey. <i>Archives of Gerontology and Geriatrics</i> , 2001, 33, 191-201.	1.4	5
534	The many faces of crossed aphasia in dextrals: report of nine cases and review of the literature. <i>European Journal of Neurology</i> , 2001, 8, 643-658.	1.7	52
535	Memory rehabilitation in Alzheimer's disease: a review of progress. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 794-809.	1.3	206
536	Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 653-666.	1.3	110
537	Naftidrofuryl in the treatment of vascular dementia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2001, 251, 247-254.	1.8	13
538	Temporal Changes in Brain Volume and Cognition in a Randomized Treatment Trial of Vascular Dementia. <i>Journal of Neuroimaging</i> , 2001, 11, 6-12.	1.0	11
539	Behaviour rating scales for older people with dementia: Which is the best for use by nurses?. <i>Australasian Journal on Ageing</i> , 2001, 20, 166-172.	0.4	14
540	Geriatric Neuropsychopharmacology: Unmet Needs. <i>Psychogeriatrics</i> , 2001, 1, 14-26.	0.6	0
541	SPECT and neuropsychological performance in severe depression treated with ECT. <i>Journal of Affective Disorders</i> , 2001, 66, 47-58.	2.0	63
542	Phonological agraphia following a focal anterior insulo-opercular infarction. <i>Neuropsychologia</i> , 2001, 39, 845-855.	0.7	50
543	Clinical validity of the "mini-mental state" for Spanish speaking communities. <i>Neuropsychologia</i> , 2001, 39, 1150-1157.	0.7	347
544	Patterns of Cognitive Decline in Presymptomatic Alzheimer Disease. <i>Archives of General Psychiatry</i> , 2001, 58, 853.	13.8	329

#	ARTICLE	IF	CITATIONS
545	Brain Donation in Normal Aging. <i>Gerontologist, The</i> , 2001, 41, 716-722.	2.3	83
546	Alcohol dementia: "cortical" or "subcortical" dementia?. <i>Archives of Clinical Neuropsychology</i> , 2001, 16, 523-533.	0.3	11
547	Memory Testing in Dementia: How Much Is Enough?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2001, 14, 1-6.	1.2	22
548	A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. <i>Neurology</i> , 2001, 57, 489-495.	1.5	716
549	In-Home Assessment of Dementia by Nurses. <i>Gerontologist, The</i> , 2001, 41, 406-409.	2.3	7
550	<i>APOE</i> Genotype: No Influence on Galantamine Treatment Efficacy Nor on Rate of Decline in Alzheimerâ€™s Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2001, 12, 69-77.	0.7	91
551	Early Detection and Differential Diagnosis of Alzheimerâ€™s Disease and Depression with Neuropsychological Tasks. <i>Dementia and Geriatric Cognitive Disorders</i> , 2001, 12, 265-280.	0.7	328
552	Assessment of health economics in Alzheimerâ€™s disease (AHEAD). <i>Neurology</i> , 2001, 57, 972-978.	1.5	78
553	Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 71, 589-595.	0.9	230
554	Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. <i>Neurology</i> , 2001, 56, 408-410.	1.5	99
555	Open-Label, Multicenter, Phase 3 Extension Study of the Safety and Efficacy of Donepezil in Patients With Alzheimer Disease. <i>Archives of Neurology</i> , 2001, 58, 427.	4.9	362
556	Response of Patients With Alzheimer Disease to Rivastigmine Treatment Is Predicted by the Rate of Disease Progression. <i>Archives of Neurology</i> , 2001, 58, 417-22.	4.9	86
557	Donepezil in the treatment of patients with Alzheimerâ€™s disease. <i>Expert Review of Neurotherapeutics</i> , 2001, 1, 11-19.	1.4	7
558	Can reality orientation be rehabilitated? Development and piloting of an evidence-based programme of cognition-based therapies for people with dementia. <i>Neuropsychological Rehabilitation</i> , 2001, 11, 377-397.	1.0	148
559	Correlates of Change in Functional Status of Institutionalized Geriatric Schizophrenic Patients: Focus on Medical Comorbidity. <i>American Journal of Psychiatry</i> , 2002, 159, 1388-1394.	4.0	69
560	A study of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) in an Icelandic elderly population. <i>Nordic Journal of Psychiatry</i> , 2002, 56, 201-206.	0.7	19
561	Influence of the Severity of Cognitive Impairment on the Effect of the <i>Ginkgo biloba</i> Extract EGb 761<sup>Â®</sup> in Alzheimerâ€™s Disease. <i>Neuropsychobiology</i> , 2002, 45, 19-26.	0.9	119
562	Regional N-Acetylaspartate Reduction in the Hippocampus Detected With Fast Proton Magnetic Resonance Spectroscopic Imaging in Patients With Alzheimer Disease. <i>Archives of Neurology</i> , 2002, 59, 828-34.	4.9	60

#	ARTICLE	IF	CITATIONS
563	Development of a Tool for Assessment and Care Planning for Dementia-Related Problem Behaviors in Home and Community-Based Services Programs: The Problem Behavior Inventory. Home Health Care Services Quarterly, 2002, 21, 29-46.	0.3	5
564	Economic Analysis of Galantamine, a Cholinesterase Inhibitor, in the Treatment of Patients with Mild to Moderate Alzheimer's Disease in The Netherlands. Dementia and Geriatric Cognitive Disorders, 2002, 14, 84-89.	0.7	50
565	Safety and Efficacy of Idebenone versus Tacrine in Patients with Alzheimer's Disease: Results of a Randomized, Double-Blind, Parallel-Group Multicenter Study. Pharmacopsychiatry, 2002, 35, 12-18.	1.7	81
566	Cognitive decline in AD and mild cognitive impairment is associated with global brain damage. Neurology, 2002, 59, 874-879.	1.5	62
570	The Alzheimer's Disease Assessment Scale: Findings from a Low-Education Population. Dementia and Geriatric Cognitive Disorders, 2002, 13, 21-26.	0.7	48
571	Abnormalities in the Pattern of Platelet Amyloid Precursor Protein Forms in Patients With Mild Cognitive Impairment and Alzheimer Disease. Archives of Neurology, 2002, 59, 71.	4.9	92
572	Interleukin-6 and risk of cognitive decline. Neurology, 2002, 59, 371-378.	1.5	482
573	Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. American Journal of Psychiatry, 2002, 159, 738-745.	4.0	437
574	Mifepristone (RU 486) for Alzheimer's disease. Neurology, 2002, 58, 1436-1436.	1.5	52
575	Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology, 2002, 58, 1050-1054.	1.5	173
576	The Relationship Between Cognitive and Physical Performance: MacArthur Studies of Successful Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2002, 57, M228-M235.	1.7	173
577	Guillain-Barré syndrome presenting with loss of taste. Neurology, 2002, 58, 1437-1438.	1.5	26
578	Special characteristics affecting the neuropsychologic assessment of the elderly in Greece. American Journal of Alzheimer's Disease and Other Dementias, 2002, 17, 273-276.	0.9	6
579	Goal setting and attainment in Alzheimer's disease patients treated with donepezil. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 500-507.	0.9	99
580	Use of a false recognition paradigm in an Alzheimer's disease clinical trial: A pilot study. American Journal of Alzheimer's Disease and Other Dementias, 2002, 17, 93-100.	0.9	6
581	Rating scales in old age psychiatry. British Journal of Psychiatry, 2002, 180, 161-167.	1.7	106
582	Cognitive assessment of geriatric schizophrenic patients with severe impairment. Archives of Clinical Neuropsychology, 2002, 17, 611-623.	0.3	21
583	Nimodipine for primary degenerative, mixed and vascular dementia. The Cochrane Library, 2002, , .	1.5	91



#	ARTICLE	IF	CITATIONS
584	Correlation of Regional Proton Magnetic Resonance Spectroscopic Metabolic Changes With Cognitive Deficits in Mild Alzheimer Disease. <i>Archives of Neurology</i> , 2002, 59, 955.	4.9	84
586	On Disentangling States Versus Traits: Demonstration of a New Technique Using the Alzheimer's Disease Assessment Scale. <i>Alzheimer Disease and Associated Disorders</i> , 2002, 16, 254-260.	0.6	2
587	Diagnose and Treat Mild to Moderate Alzheimer's Disease. <i>Nurse Practitioner</i> , 2002, 27, 13-25.	0.2	5
588	Psychometric Identification of Early Alzheimer Disease in an Elderly Chinese Population with Differing Educational Levels. <i>Alzheimer Disease and Associated Disorders</i> , 2002, 16, 65-72.	0.6	28
589	Profiles of Cognitive Decline in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2002, 16, 123-127.	0.6	6
590	Donepezil Versus Vitamin E in Alzheimer's Disease Part 2: Mild Versus Moderate to Severe Alzheimer's Disease. <i>Clinical Neuropharmacology</i> , 2002, 25, 207-215.	0.2	50
591	Indomethacin for Alzheimer's disease. <i>The Cochrane Library</i> , 2002, , CD003673.	1.5	36
592	Cognitive Pharmacotherapy of Alzheimer's Disease and other Dementias. <i>Canadian Journal of Psychiatry</i> , 2002, 47, 715-722.	0.9	14
593	Performance on the Cognitive Abilities Screening Instrument at Different Stages of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2002, 13, 244-248.	0.7	38
594	A videotaped CIBIC for dementia patients. <i>Neurology</i> , 2002, 58, 433-437.	1.5	44
595	New Approaches to Clinical Trials in Vascular Dementia: Memantine in Small Vessel Disease. <i>Cerebrovascular Diseases</i> , 2002, 13, 61-66.	0.8	36
596	Relevant clinical outcomes in probable vascular dementia and Alzheimer's disease with cerebrovascular disease. <i>Journal of the Neurological Sciences</i> , 2002, 203-204, 41-48.	0.3	7
597	Treatment options. <i>Journal of the Neurological Sciences</i> , 2002, 203-204, 125-130.	0.3	20
598	Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors. <i>Clinical Pharmacokinetics</i> , 2002, 41, 719-739.	1.6	303
599	Assessment, Measures and Approaches to Easing Caregiver Burden in Alzheimer's Disease. <i>Drugs and Aging</i> , 2002, 19, 203-215.	1.3	30
600	The diagnosis and differential diagnosis of dementia. <i>Medical Clinics of North America</i> , 2002, 86, 455-476.	1.1	24
601	Assessment of Health Economics in Alzheimer's Disease (AHEAD). <i>Pharmacoeconomics</i> , 2002, 20, 629-637.	1.7	39
602	Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. <i>Lancet, The</i> , 2002, 359, 1283-1290.	6.3	712

#	ARTICLE	IF	CITATIONS
603	Cognitive assessment of geriatric schizophrenic patients with severe impairment. Archives of Clinical Neuropsychology, 2002, 17, 611-623.	0.3	11
604	Allostatic load as a predictor of functional decline. Journal of Clinical Epidemiology, 2002, 55, 696-710.	2.4	404
605	The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiology of Aging, 2002, 23, 383-388.	1.5	165
606	Biochemical markers of Alzheimer's disease: wish and reality. Neurobiology of Aging, 2002, 23, 513-514.	1.5	13
607	Donepezil in the treatment of Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 369-373.	2.5	22
608	Long-term effects of rivastigmine in moderately severe Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 705-712.	2.5	91
609	The CNS effects of Ginkgo biloba extracts and ginkgolide B. Progress in Neurobiology, 2002, 67, 235-257.	2.8	267
610	Pharmacologic treatments of dementia. Medical Clinics of North America, 2002, 86, 657-674.	1.1	216
611	Brain Proton Magnetic Resonance Spectroscopy in Alzheimer Disease: Changes After Treatment With Xanomeline. American Journal of Geriatric Psychiatry, 2002, 10, 81-88.	0.6	35
612	Pharmacological Treatment of Dementia: A Review. , 2002, , 199-271.		3
613	Pharmacological Treatment of Dementia, with the Emphasis on Dementia of the Alzheimer Type. , 0, , 393-400.		0
614	Patterns of cognitive impairment in Alzheimer's disease: assessment and differential diagnosis. Frontiers in Bioscience - Landmark, 2002, 7, e155.	3.0	32
615	Maladie d'Alzheimer : vision d'ensemble, aspects cliniques, facteurs de risque et prévention. Médecine/Sciences, 2002, 18, 689-696.	0.0	0
616	Use of cholinesterase inhibitors in dementia. Advances in Psychiatric Treatment, 2002, 8, 89-96.	0.6	39
617	D-cycloserine for Alzheimer's disease. The Cochrane Library, 2002, , CD003153.	1.5	41
618	To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers?. BMC Neurology, 2002, 2, 6.	0.8	36
619	The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurology, The, 2002, 1, 279-284.	4.9	188
620	Evaluation of Selective COX-2 Inhibitors for the Treatment of Alzheimer's Disease. Journal of Pain and Symptom Management, 2002, 23, S35-S40.	0.6	61

#	ARTICLE	IF	CITATIONS
621	Routine cognitive testing for all drugs?. Drug Discovery Today, 2002, 7, 101-102.	3.2	2
622	Supplementation and the elderly: dramatic results?. Nutrition, 2002, 18, 364.	1.1	11
624	Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Annals of Neurology, 2002, 51, 145-155.	2.8	639
625	Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: Findings from the Nun Study. Annals of Neurology, 2002, 51, 567-577.	2.8	367
626	The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials. International Journal of Geriatric Psychiatry, 2002, 17, 175-183.	1.3	58
627	Clock drawing test in mild and moderate dementia of the Alzheimer's type: a comparative and correlation study. International Journal of Geriatric Psychiatry, 2002, 17, 480-485.	1.3	24
628	Negative symptoms, depression and Alzheimer's disease. International Journal of Geriatric Psychiatry, 2002, 17, 383-387.	1.3	16
629	Development of the Korean version of Alzheimer's Disease Assessment Scale (ADAS-K). International Journal of Geriatric Psychiatry, 2002, 17, 797-803.	1.3	38
630	Development of antiinflammatory therapy for Alzheimer's disease. Drug Development Research, 2002, 56, 421-427.	1.4	6
631	Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. Journal of Molecular Neuroscience, 2002, 19, 23-27.	1.1	135
632	Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone. Journal of Molecular Neuroscience, 2002, 19, 201-206.	1.1	60
633	Cholinesterase inhibitors in dementia. Current Neurology and Neuroscience Reports, 2002, 2, 389-390.	2.0	4
634	Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent. Journal of Neural Transmission, 2002, 109, 1089-1104.	1.4	58
635	Sensitivity and Specificity of Cognitive and Functional Screening Instruments for Dementia: The Indo-U.S. Dementia Epidemiology Study. Journal of the American Geriatrics Society, 2002, 50, 554-561.	1.3	60
636	Use of Artificial Networks in Clinical Trials: A Pilot Study to Predict Responsiveness to Donepezil in Alzheimer's Disease. Journal of the American Geriatrics Society, 2002, 50, 1857-1860.	1.3	24
637	Development of a short neuropsychological battery to screen early dementia in the elderly. Geriatrics and Gerontology International, 2002, 2, 179-186.	0.7	11
638	Successful Treatment of Behavioural Problems in Dementia Using a Cholinesterase Inhibitor: The Ethical Questions. Australian and New Zealand Journal of Psychiatry, 2002, 36, 259-262.	1.3	10
639	Donepezil-treated Patients with Probable Vascular Dementia Demonstrate Cognitive Benefits. Annals of the New York Academy of Sciences, 2002, 977, 513-522.	1.8	54

#	ARTICLE	IF	CITATIONS
640	Value of 99mTc-ECD SPET for the diagnosis of dementia with Lewy bodies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 1342-1348.	3.3	94
641	Hippocampal Volume Is Associated with Memory but not Nonmemory Cognitive Performance in Patients with Mild Cognitive Impairment. <i>Journal of Molecular Neuroscience</i> , 2003, 20, 241-248.	1.1	67
642	Pflanzliche Arzneimittel und evidenzbasierte Medizin. <i>Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz</i> , 2003, 46, 1080-1085.	7.2	1
643	The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients. <i>Journal of Neural Transmission</i> , 2003, 110, 659-669.	1.4	39
644	The treatment of Alzheimer's disease: success short of cure. <i>Lancet Neurology</i> , The, 2003, 2, 630-633.	4.9	27
645	Steroid-induced elevation of glucose in Alzheimer's disease: relationship to gender, apolipoprotein E genotype and cognition. <i>Psychoneuroendocrinology</i> , 2003, 28, 113-120.	1.3	12
646	Factors associated with nutritional status in a group of people in an early stage of dementia. <i>Clinical Nutrition</i> , 2003, 22, 385-389.	2.3	55
647	Surface dyslexia in a Japanese patient with semantic dementia: evidence for similarity-based orthography-to-phonology translation. <i>Neuropsychologia</i> , 2003, 41, 1644-1658.	0.7	50
648	Anomia for people names in DAT's evidence for semantic and post-semantic impairments. <i>Neuropsychologia</i> , 2003, 41, 1593-1598.	0.7	48
649	The effects of galantamine treatment on caregiver time in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2003, 18, 942-950.	1.3	54
650	Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. <i>International Journal of Geriatric Psychiatry</i> , 2003, 18, 740-747.	1.3	48
651	Clinical predictors of response to acetyl cholinesterase inhibitors: experience from routine clinical use in Newcastle. <i>International Journal of Geriatric Psychiatry</i> , 2003, 18, 879-886.	1.3	40
652	Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. <i>Acta Neurologica Scandinavica</i> , 2003, 107, 252-255.	1.0	44
653	Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2003, 108, 368-373.	1.0	76
654	Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis. <i>BMC Geriatrics</i> , 2003, 3, 6.	1.1	11
655	Current pharmacologic options for patients with Alzheimer's disease. , 2003, 2, 1.		48
656	Clinical pharmacology of anti-Alzheimer drugs. <i>Fundamental and Clinical Pharmacology</i> , 2003, 17, 659-672.	1.0	18
657	Cognitive Assessment and Reference Diagnosis System: development of a neuropsychological and clinical examination for clinic and population use. <i>Psychogeriatrics</i> , 2003, 3, 54-62.	0.6	11

#	ARTICLE	IF	CITATIONS
658	Psychiatric Morbidity in a Neurology-Based Memory Clinic: The Effect of Systematic Psychiatric Evaluation. <i>Journal of the American Geriatrics Society</i> , 2003, 51, 1773-1778.	1.3	15
659	Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. <i>European Journal of Neurology</i> , 2003, 10, 633-640.	1.7	47
660	The Sleep Disorders Inventory: an instrument for studies of sleep disturbance in persons with Alzheimer's disease. <i>Journal of Sleep Research</i> , 2003, 12, 331-337.	1.7	140
661	Accuracy of Collateral Source Reports in Very Mild to Mild Dementia of the Alzheimer Type. <i>Journal of the American Geriatrics Society</i> , 2003, 51, 819-823.	1.3	78
662	Mild cognitive impairment clinical trials. <i>Nature Reviews Drug Discovery</i> , 2003, 2, 646-653.	21.5	155
663	Impact of Study Design and Patient Population on Outcomes From Cholinesterase Inhibitor Trials. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 160-168.	0.6	18
664	Donepezil HCl (E2020) Maintains Functional Brain Activity in Patients With Alzheimer Disease: Results of a 24-Week, Double-Blind, Placebo-Controlled Study. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 169-177.	0.6	103
665	Diagnosing Dementia in Long-Term Care Facilities. <i>Journal of the American Medical Directors Association</i> , 2003, 4, S134-S140.	1.2	16
666	Imaging-Based Measures of Disease Progression in Clinical Trials of Disease-Modifying Drugs for Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 146-159.	0.6	26
669	Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based Recommendations. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 131-145.	0.6	148
670	Folic acid with or without vitamin B12 for cognition and dementia. , 2003, , CD004514.		131
671	Alzheimer's disease and total plasma aminothiols. <i>Biological Psychiatry</i> , 2003, 53, 254-260.	0.7	77
672	Ginkgo extract or cholinesterase inhibitors in patients with dementia: What clinical trials and guidelines fail to consider. <i>Phytomedicine</i> , 2003, 10, 74-79.	2.3	150
673	A Pilot Study of Vitamins to Lower Plasma Homocysteine Levels in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 246-249.	0.6	53
674	Vitamin B12 for cognition. <i>The Cochrane Library</i> , 2003, , CD004394.	1.5	86
675	Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:. <i>Current Therapeutic Research</i> , 2003, 64, 216-235.	0.5	232
676	Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2003, 24, 903-907.	1.5	144
680	A review of rivastigmine: A reversible cholinesterase inhibitor. <i>Clinical Therapeutics</i> , 2003, 25, 1634-1653.	1.1	105

#	ARTICLE	IF	CITATIONS
681	An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. <i>Clinical Therapeutics</i> , 2003, 25, 1765-1782.	1.1	73
682	Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. <i>Clinical Therapeutics</i> , 2003, 25, 1806-1825.	1.1	48
683	Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: A multicenter, double-blind, randomized, placebo-controlled trial. <i>Clinical Therapeutics</i> , 2003, 25, 178-193.	1.1	137
684	Antibodies against $\beta$ -Amyloid Slow Cognitive Decline in Alzheimer's Disease. <i>Neuron</i> , 2003, 38, 547-554.	3.8	779
685	Challenges in the Management of Psychotic Symptoms in Long-Term Care. <i>Journal of the American Medical Directors Association</i> , 2003, 4, H17-H20.	1.2	0
686	Selegiline for Alzheimer's disease. <i>The Cochrane Library</i> , 2003, , CD000442.	1.5	83
687	A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer's Disease. <i>Drugs and Aging</i> , 2003, 20, 777-789.	1.3	178
688	A Study of the Criterion Validity of the Mattis Dementia Rating Scale. <i>International Journal of Testing</i> , 2003, 3, 49-58.	0.2	8
689	Pharmacotherapy of dementia with Lewy bodies. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 2027-2037.	0.9	38
690	Galantamine in the Treatment of Cognitive Decline in Patients with Vascular Dementia or Alzheimer's Disease with Cerebrovascular Disease. <i>CNS Drugs</i> , 2003, 17, 905-914.	2.7	31
691	DHEA treatment of Alzheimer's disease. <i>Neurology</i> , 2003, 60, 1071-1076.	1.5	96
692	Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 2651.	3.8	1,843
693	Predictors of institutionalisation in people with dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 1315-1316.	0.9	120
694	Lack of Influence of the Apolipoprotein E Genotype on the Outcome of Selegiline Treatment in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 16, 31-34.	0.7	4
695	The effects of improving hearing in dementia. <i>Age and Ageing</i> , 2003, 32, 189-193.	0.7	116
696	Everyday numerical abilities in Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2003, 9, 871-878.	1.2	25
697	Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer's Disease. <i>American Journal of Psychiatry</i> , 2003, 160, 2003-2011.	4.0	271
698	Defining 'early dementia' and monitoring intervention: What measures are useful in family caregiving?. <i>Aging and Mental Health</i> , 2003, 7, 7-14.	1.5	15

#	ARTICLE	IF	CITATIONS
699	Platelet Amyloid Precursor Protein Abnormalities in Mild Cognitive Impairment Predict Conversion to Dementia of Alzheimer Type. <i>Archives of Neurology</i> , 2003, 60, 1740.	4.9	63
700	Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. <i>Age and Ageing</i> , 2003, 32, 200-204.	0.7	71
701	Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 2819.	3.8	862
702	Are the Clock-Drawing Test and the MMSE Combined Interchangeable with CAMCOG as a Dementia Evaluation Instrument in a Specialized Outpatient Setting?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2003, 16, 74-79.	1.2	58
703	Estrogen Levels Do Not Correlate With Improvement in Cognition. <i>Archives of Neurology</i> , 2003, 60, 209.	4.9	49
704	Donepezil in vascular dementia. <i>Neurology</i> , 2003, 61, 479-486.	1.5	365
705	Analysis of Outcome in Retrieved Dropout Patients in a Rivastigmine vs Placebo, 26-Week, Alzheimer Disease Trial. <i>Archives of Neurology</i> , 2003, 60, 843.	4.9	71
706	Efficacy and Tolerability of Donepezil in Vascular Dementia. <i>Stroke</i> , 2003, 34, 2323-2330.	1.0	352
708	Short-term Effects of Acetylcholinesterase Inhibitor Treatment on EEG and Memory Performance in Alzheimer Patients: an Open, Controlled Trial. <i>Pharmacopsychiatry</i> , 2003, 36, 304-308.	1.7	61
709	Behavioural and Psychological Symptoms of Dementia (BPSD): Effects of EGb 761Â®. <i>Pharmacopsychiatry Supplement</i> , 2003, 36, 56-61.	0.8	21
710	Response Patterns of EGb 761Â® in Alzheimerâ€™s Disease: Influence of Neuropsychological Profiles. <i>Pharmacopsychiatry Supplement</i> , 2003, 36, 50-55.	0.8	12
711	Cognitive and Psychosocial Predictors of Subjective Well-Being in Urban Older Adults. <i>Clinical Neuropsychologist</i> , 2003, 17, 3-18.	1.5	86
712	A LRPAP1 Intronic Insertion/Deletion Polymorphism and Phenotypic Variability in Alzheimer Disease. <i>Research and Theory for Nursing Practice</i> , 2003, 17, 301-319.	0.2	16
713	The Cholinesterase Inhibitors. <i>Journal of Psychiatric Practice</i> , 2003, 9, 422-430.	0.3	4
714	Pharmacotherapy for Alzheimer's Disease: 2002. <i>Clinical Neuropharmacology</i> , 2003, 26, 93-101.	0.2	16
715	THE VALUE OF THE MANAGED ENTRY OF NEW DRUGS. <i>International Journal of Technology Assessment in Health Care</i> , 2003, 19, 114-128.	0.2	3
716	The Effects of a Cholinesterase Inhibitor Are Prominent in Patients With Fluctuating Cognition: A Part 3 Study of the Main Mechanism of Cholinesterase Inhibitors in Dementia. <i>Clinical Neuropharmacology</i> , 2003, 26, 239-251.	0.2	70
717	Differential Diagnosis and Clinical Assessment of Patients With Severe Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2003, 17, S92-S95.	0.6	12

#	ARTICLE	IF	CITATIONS
719	Realistic Expectations: The Management of Severe Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2003, 17, S80-S85.	0.6	45
720	A Three-Factor Model of Cognition in Alzheimer Disease. <i>Cognitive and Behavioral Neurology</i> , 2003, 16, 110-117.	0.5	5
721	Inhibition of Human Cholinesterases by Drugs Used to Treat Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2003, 17, 117-126.	0.6	134
722	Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia. <i>British Journal of Psychiatry</i> , 2003, 183, 248-254.	1.7	681
723	Donepezil for dementia due to Alzheimer's disease. , 2003, , CD001190.		85
724	Update on Rivastigmine. <i>Neurologist</i> , 2003, 9, 230-234.	0.4	25
725	Update on Alzheimer Drugs (Galantamine). <i>Neurologist</i> , 2003, 9, 235-240.	0.4	21
726	Editorial Commentâ€”How to Treat Vascular Dementia?. <i>Stroke</i> , 2003, 34, 2331-2332.	1.0	5
727	The Utility of Mandatory Depression Screening of Dementia Patients in Nursing Homes. <i>American Journal of Psychiatry</i> , 2003, 160, 2012-2017.	4.0	51
728	Alzheimer Disease: Current Concepts and Emerging Diagnostic and Therapeutic Strategies. <i>Annals of Internal Medicine</i> , 2003, 138, 400.	2.0	119
729	The role of $\epsilon$ -APOE $\epsilon$ 4 in longitudinal cognitive decline. <i>Neurology</i> , 2003, 60, 1077-1081.	1.5	242
730	Prediction of the Rate of Decline in Cognitive Function in Alzheimerâ€™s Disease: A Model Based on Simple Demographic Data and Widely Used Rating Scales. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 16, 276-282.	0.7	6
731	The Course of Functional Decline in Geriatric Patients With Schizophrenia. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 610-619.	0.6	2
732	A Multicenter, Placebo-controlled Trial of Melatonin for Sleep Disturbance in Alzheimer's Disease. <i>Sleep</i> , 2003, 26, 893-901.	0.6	368
733	Accounting for changes in social support among married older adults: Insights from the MacArthur Studies of Successful Aging.. <i>Psychology and Aging</i> , 2003, 18, 487-496.	1.4	167
734	Galantamine Provides Sustained Benefits in Patients with â€”Advanced Moderateâ€” Alzheimerâ€™s Disease for at Least 12 Months. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 15, 79-87.	0.7	57
735	Demenz. , 2003, , 882-940.		0
736	23 Antidementive Therapie. , 2003, , .		0



#	ARTICLE	IF	CITATIONS
738	Advances in early diagnosis and differentiation of the dementias. , 2003, , 262-288.		0
739	Pharmacological Treatment of Dementia: A Review. , 2003, , 199-278.		1
740	Double Blind Study of Melatonin Effects on the Sleep-wake Rhythm, Cognitive and Non-cognitive Functions in Alzheimer Type Dementia. Journal of Nippon Medical School, 2003, 70, 334-341.	0.3	203
741	Nightmares without atonia as an early symptom of diffuse Lewy bodies disease. Arquivos De Neuro-Psiquiatria, 2003, 61, 936-941.	0.3	10
742	Galantamine hydrobromide: An agent for Alzheimer's disease. American Journal of Health-System Pharmacy, 2003, 60, 446-452.	0.5	115
743	NSAIDs in the Treatment of Alzheimer's Disease. , 0, , 487-491.		0
744	Homocysteine, Alzheimer genes and proteins, and measures of cognition and depression in older men. Journal of Alzheimer's Disease, 2004, 6, 329-336.	1.2	31
745	Multiple Rapid Automatic Naming Measures of Cognition: Normal Performance and Effects of Aging. Perceptual and Motor Skills, 2004, 98, 739-753.	0.6	41
746	Donepezil (Aricept®) for treatment of Alzheimer's disease and other dementing conditions. Expert Review of Neurotherapeutics, 2004, 4, 5-16.	1.4	36
747	The Cognitive Benefits of Galantamine Are Sustained for at Least 36 Months. Archives of Neurology, 2004, 61, 252.	4.9	157
748	Management of Patients with Alzheimer's Disease plus Cerebrovascular Disease: 12-Month Treatment with Galantamine. Dementia and Geriatric Cognitive Disorders, 2004, 17, 29-34.	0.7	46
749	Effects of galantamine in patients with mild Alzheimer's disease. Current Medical Research and Opinion, 2004, 20, 1815-1820.	0.9	18
751	Donepezil: a clinical review of current and emerging indications. Expert Opinion on Pharmacotherapy, 2004, 5, 161-180.	0.9	40
753	Neuropsychological Test Performance in Healthy Volunteers Before and After Donepezil Administration. Journal of Psychopharmacology, 2004, 18, 102-108.	2.0	53
754	Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease. Neurology, 2004, 63, 2348-2353.	1.5	261
755	Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease. Archives of Neurology, 2004, 61, 1044-53.	4.9	446
756	Reduction of Behavioral Disturbances and Caregiver Distress by Galantamine in Patients With Alzheimer's Disease. American Journal of Psychiatry, 2004, 161, 532-538.	4.0	155
757	Effects of Cholinergic Drugs and Cognitive Training on Dementia. Dementia and Geriatric Cognitive Disorders, 2004, 18, 50-54.	0.7	60

#	ARTICLE	IF	CITATIONS
758	Five-Year Outcome of Cholinergic Treatment of Alzheimer's Disease: Early Response Predicts Prolonged Time until Nursing Home Placement, but Does Not Alter Life Expectancy. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 18, 197-206.	0.7	38
759	Executive Function: The Core Feature of Dementia?. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 18, 207-216.	0.7	48
760	<i>Ginkgo biloba</i> Compared with Cholinesterase Inhibitors in the Treatment of Dementia: A Review Based on Meta-Analyses by the Cochrane Collaboration. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 18, 217-226.	0.7	45
761	Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 677-685.	0.9	120
762	Impact of APOE in mild cognitive impairment. <i>Neurology</i> , 2004, 63, 1898-1901.	1.5	186
763	Regional Distribution of White Matter Hyperintensities in Vascular Dementia, Alzheimer's Disease and Healthy Aging. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 18, 180-188.	0.7	144
764	Efficacy and Safety of Galantamine in Patients with Dementia with Lewy Bodies: A 12-Week Interim Analysis. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 17, 40-48.	0.7	57
765	Donepezil for the Treatment of Mild to Moderate Alzheimer's Disease in France: The Economic Implications. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 17, 5-13.	0.7	27
766	Detecting Dementia: Novel Neuropsychological Markers of Preclinical Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 17, 42-48.	0.7	291
767	Pharmacologic Management of Agitation in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 17, 65-77.	0.7	32
769	Complementary and alternative medical approaches to treating adult neurogenic communication disorders: a review. <i>Disability and Rehabilitation</i> , 2004, 26, 315-325.	0.9	18
770	Efficacy of flupirtine on cognitive function in patients with CJD. <i>Neurology</i> , 2004, 62, 714-718.	1.5	186
771	Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study. <i>Current Medical Research and Opinion</i> , 2004, 20, 1605-1612.	0.9	48
772	Rofecoxib. <i>Neurology</i> , 2004, 62, 66-71.	1.5	382
773	Executive dysfunction can explain word-list learning disability in very mild Alzheimer's disease: The Tajiri Project. <i>Psychiatry and Clinical Neurosciences</i> , 2004, 58, 54-60.	1.0	23
774	Absence of macrocytic anaemia in Alzheimer's disease. <i>International Journal of Laboratory Hematology</i> , 2004, 26, 259-263.	0.2	12
775	Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. <i>European Journal of Neurology</i> , 2004, 11, 734-741.	1.7	75
776	Galantamine Maintains Ability to Perform Activities of Daily Living in Patients with Alzheimer's Disease. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 1070-1076.	1.3	60

#	ARTICLE	IF	CITATIONS
777	Weight change and cognitive performance. <i>International Journal of Obesity</i> , 2004, 28, 1163-1167.	1.6	37
778	Human-computer interaction in the administration and analysis of neuropsychological tests. <i>Computer Methods and Programs in Biomedicine</i> , 2004, 73, 43-53.	2.6	21
779	Value of CSF $\beta$ -amyloid $_{1-42}$ and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. <i>Molecular Psychiatry</i> , 2004, 9, 705-710.	4.1	280
780	The cognitive pattern of vascular dementia and its assessment. <i>Seminars in Cerebrovascular Diseases and Stroke</i> , 2004, 4, 79-86.	0.1	5
781	Galantamine: use in Alzheimer's disease and related disorders. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 153-163.	1.4	19
782	Parkin mutation associated parkinsonism and cognitive decline, comparison to early onset Parkinson's disease. <i>Journal of Neural Transmission</i> , 2004, 111, 47-57.	1.4	31
783	Heterogeneity of cerebral blood flow in frontotemporal lobar degeneration and Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 162-168.	3.3	40
784	The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. <i>Statistics in Medicine</i> , 2004, 23, 305-314.	0.8	62
785	Cross-national comparison and validation of the Alzheimer's Disease Assessment Scale: results from the European Harmonization Project for Instruments in Dementia(EURO-HARPID). <i>International Journal of Geriatric Psychiatry</i> , 2004, 19, 41-50.	1.3	46
786	A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2004, 19, 58-67.	1.3	102
787	Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2004, 19, 243-249.	1.3	51
788	Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. <i>International Journal of Geriatric Psychiatry</i> , 2004, 19, 624-633.	1.3	158
789	EEG and the Test for the Early Detection of Dementia with Discrimination from Depression(TE4D): a validation study. <i>International Journal of Geriatric Psychiatry</i> , 2004, 19, 749-753.	1.3	24
790	Potential treatment effects of donepezil not detected in Alzheimer's disease clinical trials: a physician survey. <i>International Journal of Geriatric Psychiatry</i> , 2004, 19, 954-960.	1.3	39
791	A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. <i>International Journal of Geriatric Psychiatry</i> , 2004, 19, 9-18.	1.3	134
792	ADAS-COG and mental deterioration battery: different instruments for different aspects of cognitive decline in Alzheimer's disease. <i>Neuroscience Research Communications</i> , 2004, 35, 184-192.	0.2	2
793	Correlation between the CAMCOG, the MMSE, and three clock drawing tests in a specialized outpatient psychogeriatric service. <i>Archives of Gerontology and Geriatrics</i> , 2004, 38, 77-84.	1.4	30
794	Cholinesterase Inhibitors and Vascular Dementia. <i>CNS Drugs</i> , 2004, 18, 79-92.	2.7	21

#	ARTICLE	IF	CITATIONS
795	Long-Term Cholinesterase Inhibitor Treatment of Alzheimer's Disease. <i>CNS Drugs</i> , 2004, 18, 757-768.	2.7	53
796	Vascular Cognitive Impairment. <i>Stroke</i> , 2004, 35, 386-388.	1.0	29
797	A Pharmacokinetic, Pharmacodynamic and Safety Study of Celecoxib in Subjects with Probable Alzheimer's Disease. <i>Clinical Research and Regulatory Affairs</i> , 2004, 21, 49-66.	2.1	5
798	Long-Term Outcomes of Galantamine Treatment in Patients With Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2004, 12, 473-482.	0.6	37
799	Increased homocysteine and decreased adenosine formation in Alzheimer's disease. <i>Neurological Research</i> , 2004, 26, 554-557.	0.6	18
800	An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. <i>Current Medical Research and Opinion</i> , 2004, 20, 1747-1752.	0.9	44
801	Metaanalysis of Randomized Trials of the Efficacy and Safety of Donepezil, Galantamine, and Rivastigmine for the Treatment of Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2004, 12, 358-369.	0.6	119
802	The Use, Benefits, and Costs of Cholinesterase Inhibitors for Alzheimer's Dementia in Long-Term Care: Are the Data Relevant and Available?. <i>Journal of the American Medical Directors Association</i> , 2004, 5, 249-255.	1.2	10
803	Alzheimer Disease With Psychosis: Excess Cognitive Impairment Is Restricted to the Misidentification Subtype. <i>American Journal of Geriatric Psychiatry</i> , 2004, 12, 449-456.	0.6	27
804	Rivastigmine in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2004, 12, 420-431.	0.6	15
805	Measuring Progression in Alzheimer's Disease using Serial MRI: 4D MRI. , 2004, , 61-74.		0
806	The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. <i>Schizophrenia Research</i> , 2004, 68, 283-297.	1.1	1,209
807	Donepezil for vascular cognitive impairment. <i>The Cochrane Library</i> , 2004, , CD004395.	1.5	115
808	Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2004, 351, 56-67.	13.9	1,221
809	A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population. <i>Clinical Therapeutics</i> , 2004, 26, 1608-1618.	1.1	29
810	Ethyl-EPA in Alzheimer's disease—a pilot study. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2004, 71, 341-346.	1.0	78
811	Prepulse inhibition in patients with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2004, 25, 1045-1050.	1.5	50
812	Galanthamine from snowdrop—the development of a modern drug against Alzheimer's disease from local Caucasian knowledge. <i>Journal of Ethnopharmacology</i> , 2004, 92, 147-162.	2.0	449

#	ARTICLE	IF	CITATIONS
813	Investigation of profile difference between Alzheimer's disease patients declining at different rates: examination of baseline neuropsychological data. <i>Archives of Clinical Neuropsychology</i> , 2004, 19, 1007-1015.	0.3	22
814	Rivastigmine for Dementia Associated with Parkinson's Disease. <i>New England Journal of Medicine</i> , 2004, 351, 2509-2518.	13.9	1,111
815	Evidence-based pharmacotherapy of Alzheimer's disease. <i>International Journal of Neuropsychopharmacology</i> , 2004, 7, 351-369.	1.0	70
816	Colostrinin1 (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2004, 6, 17-26.	1.2	105
817	Noncognitive Symptoms and Long-Term Treatment Expectations for Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2004, 18, S9-S16.	0.6	9
818	Diagnostic Utility of Neuropsychological Performance and Quantitative MRI-based Measurement in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2004, 18, 163-170.	0.6	19
819	Long-Term Treatment of Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2004, 18, S2-S8.	0.6	70
820	Dementia with Lewy Bodies. <i>Clinical Neuropharmacology</i> , 2004, 27, 281-292.	0.2	9
821	Dementia Deficits Scale. <i>Alzheimer Disease and Associated Disorders</i> , 2004, 18, 22-31.	0.6	36
822	The Psychiatric Interview of Older Adults. <i>Focus (American Psychiatric Publishing)</i> , 2004, 2, 224-235.	0.4	4
823	Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based Recommendations. <i>Focus (American Psychiatric Publishing)</i> , 2004, 2, 239-252.	0.4	1
824	A Guide to Diagnosis of Alzheimer's Disease. <i>CNS Spectrums</i> , 2004, 9, 16-19, 28.	0.7	12
826	Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer's disease: randomised controlled trial. <i>British Journal of Psychiatry</i> , 2005, 187, 450-455.	1.7	135
827	Cognition, Function, and Caregiving Time Patterns in Patients With Mild-to-Moderate Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2005, 19, 29-36.	0.6	94
828	Donepezil in the treatment of dementia. <i>Aging Health</i> , 2005, 1, 7-17.	0.3	3
829	The Validation of a Caregiver Assessment of Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2005, 19, 186-194.	0.6	15
830	A Comparison of the Addenbrooke's Cognitive Examination (ACE), Conventional Neuropsychological Assessment, and Simple MRI-Based Medial Temporal Lobe Evaluation in the Early Diagnosis of Alzheimer's Disease. <i>Cognitive and Behavioral Neurology</i> , 2005, 18, 144-150.	0.5	48
831	Learning potential: a new method for assessing cognitive impairment. <i>International Psychogeriatrics</i> , 2005, 17, 119-128.	0.6	55

#	ARTICLE	IF	CITATIONS
832	Performance on the CERAD neuropsychology battery of two samples of Japanese-American elders: Norms for persons with and without dementia. <i>Journal of the International Neuropsychological Society</i> , 2005, 11, 192-201.	1.2	24
833	Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2005, 11, 446-453.	1.2	135
834	Assessing Mental Status in Dementia: The Behavioral Neurology Assessment - Right time? Right place?. <i>Canadian Journal of Neurological Sciences</i> , 2005, 32, 138-139.	0.3	0
835	Progress in Clinical Neurosciences: Cognitive Markers of Progression in Alzheimer's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2005, 32, 140-151.	0.3	42
836	Screening for Mild Cognitive Impairment: Comparing the SMMSE and the ABCS. <i>Canadian Journal of Psychiatry</i> , 2005, 50, 52-58.	0.9	43
837	Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A 4-Year Randomized Controlled Trial—Correction. <i>Archives of Neurology</i> , 2005, 62, 430.	4.9	3
838	Depression in Long-Term Care.. <i>Clinical Psychology: Science and Practice</i> , 2005, 12, 280-299.	0.6	28
839	Fall-related brain injuries and the risk of dementia in elderly people: a population-based study. <i>European Journal of Neurology</i> , 2005, 12, 86-92.	1.7	54
840	Dementia with cerebrovascular disease: the benefits of early treatment. <i>European Journal of Neurology</i> , 2005, 12, 17-21.	1.7	20
841	Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. <i>Journal of Neurochemistry</i> , 2005, 92, 255-263.	2.1	199
842	A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. <i>Nature Medicine</i> , 2005, 11, 551-555.	15.2	979
843	Accuracy of Self-Reported Depression in Persons with Dementia. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 389-396.	1.3	64
844	Design and Implementation of a Multicenter Trial of Vitamin E in Aging Individuals with Down Syndrome. <i>Journal of Policy and Practice in Intellectual Disabilities</i> , 2005, 2, 86-93.	1.7	8
845	The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials. <i>Genes, Brain and Behavior</i> , 2005, 4, 129-133.	1.1	16
846	A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia. <i>Acta Psychiatrica Scandinavica</i> , 2005, 111, 403-409.	2.2	15
847	Self-reported awareness of performance in dementia. <i>Cognitive Brain Research</i> , 2005, 25, 144-152.	3.3	61
848	Increase in epinephrine excretion is associated with cognitive decline in elderly men: MacArthur studies of successful aging. <i>Psychoneuroendocrinology</i> , 2005, 30, 453-460.	1.3	39
849	Preliminary communication: Urodynamic assessment of donepezil hydrochloride in patients with Alzheimer's disease. <i>Neurourology and Urodynamics</i> , 2005, 24, 273-275.	0.8	19

#	ARTICLE	IF	CITATIONS
850	The Brief Kingston Standardized Cognitive Assessment?Revised. International Journal of Geriatric Psychiatry, 2005, 20, 227-231.	1.3	9
851	A pilot study examining the effectiveness of maintenance Cognitive Stimulation Therapy (MCST) for people with dementia. International Journal of Geriatric Psychiatry, 2005, 20, 446-451.	1.3	99
852	Depressive symptom quality and neuropsychological performance in dementia. International Journal of Geriatric Psychiatry, 2005, 20, 479-484.	1.3	16
853	Detecting effects of donepezil on visual selective attention using signal detection parameters in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2005, 20, 485-488.	1.3	47
854	The need for a consensus in the use of assessment tools for Alzheimer's disease: the Feasibility Study (assessment tools for dementia in Alzheimer Centres across Europe), a European Alzheimer's Disease Consortium's (EADC) survey. International Journal of Geriatric Psychiatry, 2005, 20, 744-748.	1.3	40
855	Subjective memory complaints in Chinese subjects with mild cognitive impairment and early Alzheimer's disease. International Journal of Geriatric Psychiatry, 2005, 20, 876-882.	1.3	109
856	Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. International Journal of Geriatric Psychiatry, 2005, 20, 1020-1027.	1.3	35
857	Cerebral metabolic correlates of four dementia scales in Alzheimer's disease. Journal of Neurology, 2005, 252, 283-290.	1.8	50
858	Psychotic symptoms in Parkinson's disease. Journal of Neurology, 2005, 252, 753-764.	1.8	110
859	A Foreign Speech Accent in a Case of Conversion Disorder. Behavioural Neurology, 2005, 16, 225-232.	1.1	46
860	Diagnosis of Alzheimer's disease: Two-decades of progress. Journal of Alzheimer's Disease, 2005, 9, 409-415.	1.2	29
861	4.4 Rechtliche Probleme und forensische Beurteilungsfragen. , 2005, , .		0
863	Treatment of dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, v53-v59.	0.9	39
864	Evaluation of the safety and immunogenicity of synthetic A $\beta$ 42 (AN1792) in patients with AD. Neurology, 2005, 64, 94-101.	1.5	346
865	ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF WERNICKE'S "KORSAKOFF SYNDROME"~THREE FURTHER CASES SHOW RESPONSE TO DONEPEZIL. Alcohol and Alcoholism, 2005, 40, 151-154.	0.9	39
866	Metabolic Patterns Associated With the Clinical Response to Galantamine Therapy. Archives of Neurology, 2005, 62, 721.	4.9	109
867	Alcohol consumption and cognitive function in late life: A longitudinal community study. Neurology, 2005, 65, 1210-1217.	1.5	160
868	Clinical effects of A $\beta$ immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 2005, 64, 1553-1562.	1.5	1,258

#	ARTICLE	IF	CITATIONS
869	Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease. Archives of Neurology, 2005, 62, 753.	4.9	385
871	Prodromal cognitive signs of dementia in 85-year-olds using four sources of information. Neurology, 2005, 65, 1894-1900.	1.5	34
872	Reduction of Choline Acetyltransferase Activity in Primary Visual Cortex in Mild to Moderate Alzheimer's Disease. Archives of Neurology, 2005, 62, 425.	4.9	70
873	Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial. Clinical Trials, 2005, 2, 387-393.	0.7	39
874	Non-cognitive symptoms in mild cognitive impairment subjects. Neurocase, 2005, 11, 65-71.	0.2	84
875	Galantamine Prolonged-Release Formulation in the Treatment of Mild to Moderate Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2005, 20, 120-132.	0.7	107
876	Efficacy of Rivastigmine in Alzheimer's Disease Patients with Rapid Disease Progression: Results of a Meta-Analysis. Dementia and Geriatric Cognitive Disorders, 2005, 20, 192-197.	0.7	46
877	Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ: British Medical Journal, 2005, 331, 321-327.	2.4	424
878	A total score for the CERAD neuropsychological battery. Neurology, 2005, 65, 102-106.	1.5	314
879	Extending Neuropsychological Assessments into the Primary Mental Ability Space. Aging, Neuropsychology, and Cognition, 2005, 12, 245-277.	0.7	20
880	Diagnostic Accuracy of Mini-Mental Status Examination and Revised Hasegawa Dementia Scale for Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2005, 19, 324-330.	0.7	133
881	A 12-Month Study of the Efficacy of Rivastigmine in Patients with Advanced Moderate Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2005, 19, 51-56.	0.7	53
882	Medial Temporal Lobe Atrophy and APOE Genotype Do Not Predict Cognitive Improvement upon Treatment with Rivastigmine in Alzheimer's Disease Patients. Dementia and Geriatric Cognitive Disorders, 2005, 19, 126-133.	0.7	28
883	Cholinesterase Inhibitor Affects the Amyloid Precursor Protein Isoforms in Patients with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2005, 19, 345-348.	0.7	17
884	Changing Patient Characteristics and Survival Experience in an Alzheimer's Center Patient Cohort. Dementia and Geriatric Cognitive Disorders, 2005, 20, 198-208.	0.7	52
885	Screening for Cognitive Impairment: A Triage for Outpatient Care. Dementia and Geriatric Cognitive Disorders, 2005, 20, 278-285.	0.7	52
886	Education and APOE-e4 in Longitudinal Cognitive Decline: MacArthur Studies of Successful Aging. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2005, 60, P74-P83.	2.4	69
887	Executive Function Impairment in Community Elderly Subjects with Questionable Dementia. Dementia and Geriatric Cognitive Disorders, 2005, 19, 86-90.	0.7	20



#	ARTICLE	IF	CITATIONS
888	Factors Affecting Deficit Awareness in Persons with Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 20, 133-139.	0.7	19
889	Small Vessel Disease and General Cognitive Function in Nondisabled Elderly. <i>Stroke</i> , 2005, 36, 2116-2120.	1.0	311
890	Diagnosis of Alzheimer's disease: Two decades of progress. , 2005, 1, 93-98.		16
891	Rivastigmine for Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 563-580.	1.4	35
892	Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: A 26-week, multicenter, open-label study. <i>American Journal of Geriatric Pharmacotherapy</i> , 2005, 3, 137-148.	3.0	84
893	Inhibitory control of saccadic eye movements and cognitive impairment in Alzheimer's disease. <i>Biological Psychiatry</i> , 2005, 57, 1052-1060.	0.7	157
894	Tratamiento de la demencia. <i>EMC - Tratado De Medicina</i> , 2005, 9, 1-5.	0.0	0
895	The Use of the Occupational Disruptiveness Scale of the Neuropsychiatric Inventory-Nursing Home Version to Measure the Impact of Rivastigmine on the Disruptive Behavior of Nursing Home Residents With Alzheimer's Disease. <i>Journal of the American Medical Directors Association</i> , 2005, 6, 238-245.	1.2	17
896	Subjective Memory Complaints, White-Matter Lesions, Depressive Symptoms, and Cognition in Elderly Patients. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 665-671.	0.6	110
897	Donepezil: a review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2005, 1, 527-536.	1.5	90
898	Early life linguistic ability, late life cognitive function, and neuropathology: findings from the Nun Study. <i>Neurobiology of Aging</i> , 2005, 26, 341-347.	1.5	231
899	Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging. <i>American Journal of Medicine</i> , 2005, 118, 161-167.	0.6	248
900	Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. <i>NeuroRx</i> , 2005, 2, 348-360.	6.0	138
901	Issues for Clinical Drug Development in Neurodegenerative Diseases. <i>Drugs</i> , 2005, 65, 2463-2479.	4.9	2
902	Donepezil in Vascular Dementia. <i>Clinical Drug Investigation</i> , 2005, 25, 271-276.	1.1	1
903	Prise en charge thérapeutique de la démence. <i>EMC - Medecine</i> , 2005, 2, 145-151.	0.0	1
904	Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials. <i>Journal of the Neurological Sciences</i> , 2005, 229-230, 141-146.	0.3	26
905	A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment. <i>Neuropsychopharmacology</i> , 2005, 30, 1204-1215.	2.8	380

#	ARTICLE	IF	CITATIONS
906	Donepezil in Vascular Dementia: Combined Analysis of Two Large-Scale Clinical Trials. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 20, 338-344.	0.7	98
907	Galantamine for Alzheimer's disease and mild cognitive impairment. <i>The Cochrane Library</i> , 2006, , CD001747.	1.5	191
908	Improved quality of life and cognitive stimulation therapy in dementia. <i>Aging and Mental Health</i> , 2006, 10, 219-226.	1.5	133
909	Effects of Cholinesterase Inhibitors on Behavioural Disturbances in Alzheimer's Disease. <i>Drugs and Aging</i> , 2006, 23, 957-967.	1.3	19
910	A Pilot Study Evaluating the Efficacy and Safety of Rivastigmine in Patients with Mixed Dementia. <i>Drugs and Aging</i> , 2006, 23, 241-249.	1.3	14
911	Effects of Donepezil on Neuropsychiatric Symptoms in Patients With Dementia and Severe Behavioral Disorders. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 605-612.	0.6	135
912	Galantamine for vascular cognitive impairment. <i>The Cochrane Library</i> , 2006, , .	1.5	71
913	Assessing Therapeutic Efficacy in a Progressive Disease. <i>CNS Drugs</i> , 2006, 20, 311-325.	2.7	57
914	Diversity, dispersion and inconsistency of reaction time measures: effects of age and task complexity. <i>Aging Clinical and Experimental Research</i> , 2006, 18, 407-417.	1.4	27
915	Vascular dementia may be easier to treat than diagnose. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 123-127.	1.4	0
916	A Naturalistic Study of Galantamine for Alzheimer's Disease. <i>CNS Drugs</i> , 2006, 20, 935-943.	2.7	25
917	Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease. , 2006, 2, 131-139.		29
918	Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. , 2006, 2, 263-271.		43
919	Independent contributions of neural and "higher-order" deficits to symptoms in Alzheimer's disease: A latent variable modeling approach. , 2006, 2, 303-313.		13
920	Commentary on "Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials", 2006, 2, 272-274.		8
921	Use of Antidementia Agents in Vascular Dementia: Beyond Alzheimer Disease. <i>Mayo Clinic Proceedings</i> , 2006, 81, 1350-1358.	1.4	23
922	Homocysteine and cognitive impairment; a case series in a General Practice setting. <i>Nutrition Journal</i> , 2006, 5, 6.	1.5	28
923	Donepezil for dementia due to Alzheimer's disease. <i>The Cochrane Library</i> , 2006, , CD001190.	1.5	214

#	ARTICLE	IF	CITATIONS
924	Memantine Treatment in Mild to Moderate Alzheimer Disease: A 24-Week Randomized, Controlled Trial. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 704-715.	0.6	260
925	Current Pharmacotherapy for Alzheimer's Disease. <i>Annual Review of Medicine</i> , 2006, 57, 513-533.	5.0	285
926	Cognitive Dysfunction, Hippocampal Atrophy and Glucocorticoid Feedback in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2006, 59, 155-161.	0.7	133
927	Effects of donepezil on memory and cognition in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2006, 245, 127-136.	0.3	87
928	Non-dopaminergic treatment of cognitive impairment and dementia in Parkinson's disease: A review. <i>Journal of the Neurological Sciences</i> , 2006, 248, 104-114.	0.3	30
929	Parkinson's disease and arithmetics: The role of executive functions. <i>Journal of the Neurological Sciences</i> , 2006, 248, 124-130.	0.3	32
930	Long-term outcomes in chronically hospitalized geriatric patients with schizophrenia: Retrospective comparison of first generation and second generation antipsychotics. <i>Schizophrenia Research</i> , 2006, 88, 127-134.	1.1	18
931	Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. <i>Cmaj</i> , 2006, 174, 1099-1105.	0.9	141
932	The Ginkgo Evaluation of Memory (GEM) study: Design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. <i>Contemporary Clinical Trials</i> , 2006, 27, 238-253.	0.8	164
933	Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: A retrospective study. <i>Clinical Therapeutics</i> , 2006, 28, 1695-1700.	1.1	13
935	Cortical rhythms reactivity in AD, LBD and normal subjects: A quantitative MEG study. <i>Neurobiology of Aging</i> , 2006, 27, 1100-1109.	1.5	80
936	Apolipoprotein E epsilon4 is associated with atrophy of the amygdala in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 1416-1424.	1.5	40
938	Relationship of cognitive measures and gray and white matter in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2006, 9, 253-260.	1.2	73
939	Evidence-Based Research in Complementary and Alternative Medicine III: Treatment of Patients with Alzheimer's Disease. <i>Evidence-based Complementary and Alternative Medicine</i> , 2006, 3, 411-424.	0.5	31
940	Inequalities in dementia care and the impact of the draft NICE guidelines on diagnosis. <i>British Journal of Neuroscience Nursing</i> , 2006, 2, 171-175.	0.1	0
941	Cholinesterase inhibitors for Parkinson's disease dementia. <i>The Cochrane Library</i> , 2006, , CD004747.	1.5	63
942	Melatonin for the treatment of dementia. <i>The Cochrane Library</i> , 2006, , CD003802.	1.5	32
943	Overdependence on degraded gist memory in Alzheimer's disease.. <i>Neuropsychology</i> , 2006, 20, 625-632.	1.0	3,179

#	ARTICLE	IF	CITATIONS
944	The Primary Care of Alzheimer Disease. American Journal of the Medical Sciences, 2006, 332, 314-333.	0.4	9
947	PROGRESS IN CLINICAL NEUROSCIENCES: Canadian Guidelines for the Development of Antidementia Therapies: A Conceptual Summary. Canadian Journal of Neurological Sciences, 2006, 33, 6-26.	0.3	17
948	Rivastigmine in the Treatment of Dementia Associated with Parkinson's Disease: A Randomized, Double-blind, Placebo-controlled Study. Progress in Neurotherapeutics and Neuropsychopharmacology, 2006, 1, 13-25.	0.0	3
949	A Phase 2 Study of Tramiprosate for Cerebral Amyloid Angiopathy. Alzheimer Disease and Associated Disorders, 2006, 20, 269-274.	0.6	37
950	Cognitive Response to Memantine in Moderate to Severe Alzheimer Disease Patients Already Receiving Donepezil. Alzheimer Disease and Associated Disorders, 2006, 20, 255-262.	0.6	60
951	Cognitive stimulation therapy for people with dementia: cost-effectiveness analysis. British Journal of Psychiatry, 2006, 188, 574-580.	1.7	197
952	A note on the power of Fisher's least significant difference procedure. Pharmaceutical Statistics, 2006, 5, 253-263.	0.7	143
953	Donepezil for Alzheimer's Disease: Pharmacodynamic, Pharmacokinetic, and Clinical Profiles. CNS Neuroscience & Therapeutics, 2001, 7, 353-368.	4.0	69
954	Galantamine â€” a Novel Cholinergic Drug with a Unique Dual Mode of Action for the Treatment of Patients with Alzheimer's Disease. CNS Neuroscience & Therapeutics, 2002, 8, 159-176.	4.0	236
955	Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies. Nature Reviews Drug Discovery, 2006, 5, 64-74.	21.5	39
956	Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics Journal, 2006, 6, 246-254.	0.9	649
957	Cholinesterase inhibitors for Alzheimer's disease. , 2006, , CD005593.		1,156
958	Application of Clinical Trial Simulation to Compare Proof-of-Concept Study Designs for Drugs with a Slow Onset of Effect; An Example in Alzheimer's Disease. Pharmaceutical Research, 2006, 23, 2050-2059.	1.7	47
959	Alzheimer 100 â€” highlights in the history of Alzheimer research. Journal of Neural Transmission, 2006, 113, 1603-1623.	1.4	108
960	Homocysteine and cognitive function in institutionalised elderly. European Journal of Nutrition, 2006, 45, 70-78.	1.8	7
961	P300 auditory event-related potentials and neuropsychological study during donepezil treatment in vascular dementia. Neurological Sciences, 2006, 26, 435-437.	0.9	15
962	Current treatment of mild cognitive impairment and alzheimerâ€™s disease. Current Neurology and Neuroscience Reports, 2006, 6, 365-371.	2.0	32
963	Coping strategies and anxiety in caregivers of people with Alzheimer's disease: The LASER-AD study. Journal of Affective Disorders, 2006, 90, 15-20.	2.0	158

#	ARTICLE	IF	CITATIONS
964	Self-referential tags in the discourse of people with Alzheimer's disease. <i>Brain and Language</i> , 2006, 97, 41-52.	0.8	16
965	Impairment of syntax and lexical semantics in a patient with bilateral paramedian thalamic infarction. <i>Brain and Language</i> , 2006, 96, 69-77.	0.8	27
966	Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE $\epsilon$ 4 allele, in relation to cognitive function and cerebral glucose metabolism. <i>Neurobiology of Disease</i> , 2006, 24, 326-333.	2.1	47
967	Number processing in posterior cortical atrophy: A neuropsychological case study. <i>Neuropsychologia</i> , 2006, 44, 36-51.	0.7	105
968	Knowing 7-8, but not the meaning of "elephant": Evidence for the dissociation between numerical and non-numerical semantic knowledge. <i>Neuropsychologia</i> , 2006, 44, 1708-1723.	0.7	37
969	Volumetry of amygdala and hippocampus and memory performance in Alzheimer's disease. <i>Psychiatry Research - Neuroimaging</i> , 2006, 146, 251-261.	0.9	122
970	The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 259-265.	1.3	28
971	Verbal repetition in patients with Alzheimer's disease who receive donepezil. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 426-431.	1.3	27
972	The Nutrition, Aging, and Memory in Elders (NAME) study: design and methods for a study of micronutrients and cognitive function in a homebound elderly population. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 519-528.	1.3	66
973	Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study. <i>Movement Disorders</i> , 2006, 21, 456-461.	2.2	109
974	Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia. <i>Movement Disorders</i> , 2006, 21, 1663-1666.	2.2	31
975	Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 1899-1907.	2.2	290
976	Cognitive Domains and Trajectories of Functional Independence in Nondemented Elderly Persons. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2006, 61, 1330-1337.	1.7	93
977	Change in circulating C-reactive protein is not associated with atorvastatin treatment in Alzheimer's disease. <i>Neurological Research</i> , 2006, 28, 621-624.	0.6	10
978	A review of the use of cognitive stimulation therapy in dementia management. <i>British Journal of Neuroscience Nursing</i> , 2006, 2, 381-385.	0.1	7
979	Effects of Testosterone on Cognition and Mood in Male Patients With Mild Alzheimer Disease and Healthy Elderly Men. <i>Archives of Neurology</i> , 2006, 63, 177.	4.9	171
980	Development of a Neuropsychological Battery for the Leukoaraiosis and Disability in the Elderly Study (LADIS): Experience and Baseline Data. <i>Neuroepidemiology</i> , 2006, 27, 101-116.	1.1	67
981	Infratentorial Abnormalities in Vascular Dementia. <i>Stroke</i> , 2006, 37, 105-110.	1.0	31

#	ARTICLE	IF	CITATIONS
982	Current and future therapies for Alzheimer's disease and related disorders. <i>Future Neurology</i> , 2006, 1, 741-745.	0.9	0
983	Depressive Symptoms and Cognitive Decline in Late Life. <i>Archives of General Psychiatry</i> , 2006, 63, 153.	13.8	278
984	A Phase II study targeting amyloid- $\beta$ with 3APS in mild-to-moderate Alzheimer disease. <i>Neurology</i> , 2006, 67, 1757-1763.	1.5	194
985	Correlations Between the Functional-Cognitive Assessment Scale and the Alzheimer's Disease Assessment Scale When Administered to Patients With Dementia Residing in Long-term Care. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2006, 21, 274-280.	0.9	0
986	Attentional deficits affect activities of daily living in dementia-associated with Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 1136-1142.	0.9	141
987	The Cambridge Behavioral Inventory: Validation and Application in a Memory Clinic. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2006, 19, 220-225.	1.2	37
988	Therapeutic Uses of Cholinesterase Inhibitors in Neurodegenerative Diseases. , 2006, , 25-33.		3
989	Family history of dementia does not influence the progression of Alzheimer's disease at two years: Results from the REAL.FR Study. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2006, 21, 131-136.	0.9	6
990	The "Protocole de l'Examen Cognitif de la Personne Agée" Lausanne" (PECPA-L): A Cognitive Assessment Tool for the French-Speaking Elderly in Switzerland. <i>European Neurology</i> , 2006, 55, 22-30.	0.6	5
991	Apolipoprotein E $\epsilon$ 4 Allele Is Unrelated to Cognitive or Functional Decline in Alzheimer's Disease: Retrospective and Prospective Analysis. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 22, 73-82.	0.7	67
992	Effects of Cholinergic Drugs and Cognitive Training on Dementia: 2-Year Follow-Up. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 22, 339-345.	0.7	63
993	Validation of the Addenbrooke's Cognitive Examination for Detecting Early Alzheimer's Disease and Mild Vascular Dementia in a German Population. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 22, 385-391.	0.7	32
994	A randomised pilot study to assess the efficacy of an interactive, multimedia tool of cognitive stimulation in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 1116-1121.	0.9	175
995	Effect of the Apolipoprotein E $\epsilon$ 4 Allele on the Efficacy and Tolerability of Galantamine in the Treatment of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 21, 33-39.	0.7	25
996	Cognitive Impairment in Patients with Idiopathic Normal Pressure Hydrocephalus. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 21, 113-119.	0.7	97
997	CSF Biomarkers for Alzheimer's Disease: Levels of $\beta$ -Amyloid, Tau, Phosphorylated Tau Relate to Clinical Symptoms and Survival. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 21, 131-138.	0.7	99
998	Influence of Premorbid IQ and Education on Progression of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 22, 367-377.	0.7	54
999	Long-term cognitive treatment of Alzheimer's disease: A single case study. <i>Neuropsychological Rehabilitation</i> , 2006, 16, 96-109.	1.0	22

#	ARTICLE	IF	CITATIONS
1000	Investigational treatment for vascular cognitive impairment. Expert Opinion on Investigational Drugs, 2007, 16, 647-658.	1.9	8
1001	National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimers Disease (CATIE-AD): Baseline Characteristics. Current Alzheimer Research, 2007, 4, 325-335.	0.7	12
1002	Effect of galantamine on verbal repetition in AD: A secondary analysis of the VISTA trial. Neurology, 2007, 68, 1116-1121.	1.5	50
1003	Alzhemed: A Potential Treatment for Alzheimers Disease. Current Alzheimer Research, 2007, 4, 473-478.	0.7	97
1004	Use of computer assisted and interactive cognitive training programmes with moderate to severely demented individuals: A preliminary study. Aging and Mental Health, 2007, 11, 485-495.	1.5	17
1005	Do extrapyramidal features in Alzheimer patients treated with acetylcholinesterase inhibitors predict disease progression?. Aging and Mental Health, 2007, 11, 451-456.	1.5	6
1006	Current Therapeutic Options for Alzheimers Disease. Current Genomics, 2007, 8, 550-558.	0.7	63
1007	Risk of Rapid Global Functional Decline in Elderly Patients With Severe Cerebral Age-Related White Matter Changes. Archives of Internal Medicine, 2007, 167, 81.	4.3	187
1008	EFFECT OF GALANTAMINE ON VERBAL REPETITION IN AD: A SECONDARY ANALYSIS OF THE VISTA TRIAL. Neurology, 2007, 69, 809-810.	1.5	15
1009	Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. Neurology, 2007, 69, 1491-1497.	1.5	77
1010	IDEAL. Neurology, 2007, 69, S14-22.	1.5	167
1011	The Contribution of Medial Temporal Lobe Atrophy and Vascular Pathology to Cognitive Impairment in Vascular Dementia. Stroke, 2007, 38, 3182-3185.	1.0	107
1012	The ICTUS Study: A Prospective Longitudinal Observational Study of 1,380 AD Patients in Europe. Neuroepidemiology, 2007, 29, 29-38.	1.1	51
1013	Clinical Prediction of Alzheimer Disease Dementia Across the Spectrum of Mild Cognitive Impairment. Archives of General Psychiatry, 2007, 64, 1443.	13.8	148
1014	A Cross-Sectional Study of the Effects of Age, Education, and Gender on the Boston Naming Test. Clinical Neuropsychologist, 2007, 21, 587-616.	1.5	64
1015	Improving Sensitivity of the Recognition Task in the Alzheimer's Disease Assessment Scale. Psychological Reports, 2007, 100, 420-426.	0.9	4
1017	Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study. Neurology, 2007, 68, 501-508.	1.5	470
1018	Interviewing cognitively impaired older adults: How useful is a Cognitive Interview?. Memory, 2007, 15, 17-33.	0.9	27

#	ARTICLE	IF	CITATIONS
1019	Blood Pressure Treatment and Cognition in the Elderly. <i>The American Journal of Geriatric Cardiology</i> , 2007, 16, 150-157.	0.7	4
1020	Vitamin B6, B12, and Folic Acid Supplementation and Cognitive Function. <i>Archives of Internal Medicine</i> , 2007, 167, 21.	4.3	181
1021	Magnetic Resonance Imaging Predictors of Cognition in Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2007, 64, 1023.	4.9	67
1022	Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 25-29.	0.9	38
1023	Clinical Trials in Dementia. <i>Progress in Neurotherapeutics and Neuropsychopharmacology</i> , 2007, 2, 39-78.	0.0	0
1024	Chapter 2 Alzheimer's Disease. <i>Blue Books of Neurology</i> , 2007, , 33-58.	0.1	2
1025	Depressed Mood in Informal Caregivers of Individuals With Mild Cognitive Impairment. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2007, 22, 273-285.	0.9	45
1026	Treatment of Cognitive Decline and Psychiatric Disturbances Associated With Alzheimer's Dementia. <i>Journal of Pharmacy Practice</i> , 2007, 20, 13-28.	0.5	2
1027	Analysis of the Effect of Memantine in Reducing the Worsening of Clinical Symptoms in Patients with Moderate to Severe Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 138-145.	0.7	72
1028	Comparison of the Alzheimer's Disease Assessment Scale Cognitive Subscale and the Vascular Dementia Assessment Scale in Differentiating Elderly Individuals with Different Degrees of White Matter Changes. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 73-81.	0.7	45
1029	Reduced Hippocampal Functional Connectivity in Alzheimer Disease. <i>Archives of Neurology</i> , 2007, 64, 1482.	4.9	314
1030	Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1064-1068.	0.9	81
1031	Memantine in Moderate to Severe Alzheimer's Disease: a Meta-Analysis of Randomised Clinical Trials. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 20-27.	0.7	203
1032	Cognitive Predictors of Donepezil Therapy Response in Alzheimer Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 28-35.	0.7	22
1033	Is Functional Decline Necessary for a Diagnosis of Alzheimer's Disease?. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 375-379.	0.7	23
1034	Importance of Subtle Amnesic and Nonamnesic Deficits in Mild Cognitive Impairment: Prognosis and Conversion to Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 476-482.	0.7	75
1035	Atlas of Alzheimer's Disease. , 0, , .		7
1036	Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1056-1063.	0.9	81



#	ARTICLE	IF	CITATIONS
1037	Galantamine treatment of vascular dementia. <i>Neurology</i> , 2007, 69, 448-458.	1.5	167
1038	Long-Term Efficacy and Safety of Celecoxib in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 8-21.	0.7	119
1039	Preliminary Assessment of Cognitive Function in Older Adults by Clock Drawing, Box Copying and Narrative Writing. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 74-81.	0.7	12
1040	Donepezil in Alzheimer's Disease: What to Expect after 3 Years of Treatment in a Routine Clinical Setting. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 150-160.	0.7	75
1041	Predictive Value of 6-Month Decline in ADAS-cog for Survival without Severe Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 168-174.	0.7	14
1042	Efficacy and Safety of Galantamine in Patients with Dementia with Lewy Bodies: A 24-Week Open-Label Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 401-405.	0.7	82
1043	Cerebrospinal Fluid Biomarkers Predict Decline in Subjective Cognitive Function over 3 Years in Healthy Elderly. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 118-124.	0.7	148
1044	A Normative Study of the Revised Hasegawa Dementia Scale: Comparison of Demographic Influences between the Revised Hasegawa Dementia Scale and the Mini-Mental Status Examination. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 288-293.	0.7	70
1045	Is the degree of cognitive impairment in patients with Alzheimer's disease related to their capacity to appoint an enduring power of attorney?. <i>Age and Ageing</i> , 2007, 36, 527-531.	0.7	29
1046	Relevance of outcome measures in different cultural groups "does one size fit all?". <i>International Psychogeriatrics</i> , 2007, 19, 457-466.	0.6	27
1047	Memantine Treatment in Patients with Mild to Moderate Alzheimer's Disease: Results of a Randomised, Double-Blind, Placebo-Controlled 6-Month Study. <i>Journal of Alzheimer's Disease</i> , 2007, 11, 471-479.	1.2	80
1048	Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: An alternate hypothesis to global cognitive enhancement.. <i>Experimental and Clinical Psychopharmacology</i> , 2007, 15, 546-554.	1.3	28
1049	Pharmacotherapy of Alzheimer Disease. <i>Canadian Journal of Psychiatry</i> , 2007, 52, 620-629.	0.9	30
1050	Memantine Treatment of Cognitive Symptoms in Mild to Moderate Alzheimer Disease: Secondary Analyses From a Placebo-controlled Randomized Trial. <i>Alzheimer Disease and Associated Disorders</i> , 2007, 21, 60-64.	0.6	34
1051	Telephonic Remote Evaluation of Neuropsychological Deficits (TREND): Longitudinal Monitoring of Elderly Community-dwelling Volunteers Using Touch-tone Telephones. <i>Alzheimer Disease and Associated Disorders</i> , 2007, 21, 218-224.	0.6	19
1052	Longitudinal Tracking of FTL. <i>Alzheimer Disease and Associated Disorders</i> , 2007, 21, S58-S63.	0.6	15
1053	Ginkgo biloba for cognitive impairment and dementia. , 2007, , CD003120.		85
1054	Acetylcholinesterase inhibitors for Alzheimer's disease. <i>Aging Health</i> , 2007, 3, 483-494.	0.3	4

#	ARTICLE	IF	CITATIONS
1055	Outcomes for Assessment of Symptomatic and Stabilization/Disease Modifying Drugs. Canadian Journal of Neurological Sciences, 2007, 34, S23-S26.	0.3	1
1056	Target Symptoms and Outcome Measures: Cognition. Canadian Journal of Neurological Sciences, 2007, 34, S42-S46.	0.3	7
1057	Assessment of Behavioural and Psychological Symptoms Associated with Dementia. Canadian Journal of Neurological Sciences, 2007, 34, S67-S71.	0.3	53
1058	Treatment of Moderate to Severe Alzheimer's Disease: Rationale and Trial Design. Canadian Journal of Neurological Sciences, 2007, 34, S103-S108.	0.3	9
1059	Global measures: utility in defining and measuring treatment response in dementia. International Psychogeriatrics, 2007, 19, 421-456.	0.6	93
1060	Antioxidants and Alzheimer's disease: time to stop feeding vitamin E to dementia patients?. International Psychogeriatrics, 2007, 19, 1.	0.6	21
1061	Clinical and economic outcomes – friend or foe?. International Psychogeriatrics, 2007, 19, 497-507.	0.6	13
1062	The measuring, meaning and importance of activities of daily living (ADLs) as an outcome. International Psychogeriatrics, 2007, 19, 467-482.	0.6	29
1064	Midlife respiratory function and Incidence of Alzheimer's disease: A 29-year longitudinal study in women. Neurobiology of Aging, 2007, 28, 343-350.	1.5	86
1065	A metabolic link between S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in Alzheimer's disease. Neurobiology of Aging, 2007, 28, 1834-1839.	1.5	98
1066	Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology, 2007, 53, 699-723.	2.0	593
1067	Efficacy of Multivitamin Supplementation Containing Vitamins B6 and B12 and Folic Acid as Adjunctive Treatment with a Cholinesterase Inhibitor in Alzheimer's Disease: A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study in Taiwanese Patients. Clinical Therapeutics, 2007, 29, 2204-2214.	1.1	106
1068	Theta power is reduced in healthy cognitive aging. International Journal of Psychophysiology, 2007, 66, 10-17.	0.5	120
1069	Meta-analysis of six-month memantine trials in Alzheimer's disease. , 2007, 3, 7-17.		88
1070	A chapter in the development of Alzheimer's disease research: A case study of public policies on the development and funding of research programs. , 2007, 3, 243-258.		19
1071	Management of mild to moderate Alzheimer's disease and dementia. Alzheimer's and Dementia, 2007, 3, 355-384.	0.4	67
1073	Comparison of Performance on the CERAD Neuropsychological Battery of Hispanic Patients and Cognitively Normal Controls at Two Sites. Clinical Gerontologist, 2007, 30, 1-22.	1.2	12
1074	Is Long-Term Treatment of Alzheimer's Disease with Cholinesterase Inhibitor Therapy Justified?. Drugs and Aging, 2007, 24, 881-890.	1.3	29

#	ARTICLE	IF	CITATIONS
1075	Quantitative analysis of amyloid- $\beta$ peptides in cerebrospinal fluid using immunoprecipitation and MALDI-ToF mass spectrometry. <i>Briefings in Functional Genomics &amp; Proteomics</i> , 2007, 6, 149-158.	3.8	38
1076	Dementia syndromes: evaluation and treatment. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 407-422.	1.4	82
1077	The effect of two physiotherapy approaches on physical and cognitive functions and independent coping at home in stroke rehabilitation. A preliminary follow-up study. <i>Disability and Rehabilitation</i> , 2007, 29, 503-511.	0.9	47
1078	Donepezil: an update. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1011-1023.	0.9	235
1079	Clinical predictors of progression to Alzheimer disease in amnesic mild cognitive impairment. <i>Neurology</i> , 2007, 68, 1588-1595.	1.5	192
1080	Diagnostic Criteria Influence Dementia Prevalence. <i>American Journal of Geriatric Psychiatry</i> , 2007, 15, 1034-1045.	0.6	53
1081	Depressive Symptoms as a Predictor of Cognitive Decline: MacArthur Studies of Successful Aging. <i>American Journal of Geriatric Psychiatry</i> , 2007, 15, 406-415.	0.6	132
1083	Alzheimer's disease and mild cognitive impairment: Effects of shifting and interference in simple arithmetic. <i>Journal of the Neurological Sciences</i> , 2007, 263, 79-88.	0.3	29
1084	NEUROPSI ATTENTION AND MEMORY: A Neuropsychological Test Battery in Spanish with Norms by Age and Educational Level. <i>Applied Neuropsychology</i> , 2007, 14, 156-170.	1.5	80
1085	Asymptomatic Spontaneous Cerebral Emboli Predict Cognitive and Functional Decline in Dementia. <i>Biological Psychiatry</i> , 2007, 62, 339-344.	0.7	46
1086	Cortical Plasticity in Alzheimer's Disease in Humans and Rodents. <i>Biological Psychiatry</i> , 2007, 62, 1405-1412.	0.7	155
1087	The delayed word recall task using ADAS-Jcog word booklet effectively divides patients with mild cognitive impairment from normal elderly people. <i>Japanese Journal of Geriatrics</i> , 2007, 44, 490-496.	0.0	1
1088	Brazilian adaptation of the Addenbrooke's Cognitive Examination-Revised (ACE-R). <i>Dementia E Neuropsychologia</i> , 2007, 1, 212-216.	0.3	93
1089	Performance of elderly on the three words-three shapes test: A Brazilian study. <i>Dementia E Neuropsychologia</i> , 2007, 1, 396-401.	0.3	1
1091	Disorders of ageing across cultures. , 2007, , 323-344.		24
1092	Specific symptomatic changes following donepezil treatment of Alzheimer's disease: a multi-centre, primary care, open-label study. <i>International Journal of Geriatric Psychiatry</i> , 2007, 22, 312-319.	1.3	20
1093	A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease—rivastigmine patch versus capsule. <i>International Journal of Geriatric Psychiatry</i> , 2007, 22, 456-467.	1.3	273
1094	Determination of malondialdehyde, reduced glutathione levels and APOE4 allele frequency in late-onset Alzheimer's disease in Denizli, Turkey. <i>Clinical Biochemistry</i> , 2007, 40, 172-176.	0.8	41

#	ARTICLE	IF	CITATIONS
1095	Validity of the postural control and balance for stroke test. <i>Physiotherapy Research International</i> , 2007, 12, 162-174.	0.7	7
1096	Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 36-48.	1.1	20
1097	The Category Cued Recall test in very mild Alzheimer's disease: discriminative validity and correlation with semantic memory functions. <i>European Journal of Neurology</i> , 2007, 14, 102-108.	1.7	33
1098	<sup>99m</sup> Tc-ethyl cysteinyl dimer brain SPECT findings in early stage of dementia with Lewy bodies and Parkinson's disease patients: a correlation with neuropsychological tests. <i>European Journal of Neurology</i> , 2007, 15, 071203214007005-???	1.7	29
1099	A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong. <i>International Journal of Clinical Practice</i> , 2007, 61, 403-410.	0.8	10
1100	The Hawthorne Effect: a randomised, controlled trial. <i>BMC Medical Research Methodology</i> , 2007, 7, 30.	1.4	1,180
1101	The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. <i>BMC Neurology</i> , 2007, 7, 26.	0.8	90
1102	Effects of age and mild cognitive impairment on direct and indirect access to arithmetic knowledge. <i>Neuropsychologia</i> , 2007, 45, 1511-1521.	0.7	39
1103	Disease-modifying trials in Alzheimer's disease: a European task force consensus. <i>Lancet Neurology</i> , The, 2007, 6, 56-62.	4.9	142
1104	Healthy ageing in the Nun Study: definition and neuropathologic correlates. <i>Age and Ageing</i> , 2007, 36, 650-655.	0.7	81
1105	Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. <i>Journal of Neurology</i> , 2007, 254, 351-358.	1.8	34
1106	Alzheimer's Disease. <i>Comprehensive Therapy</i> , 2007, 33, 58-64.	0.2	11
1107	Effectiveness of treatment with donepezil hydrochloride and changes in regional cerebral blood flow in patients with Alzheimer's disease. <i>Annals of Nuclear Medicine</i> , 2007, 21, 257-265.	1.2	36
1108	Comparison of the design differences between the Ginkgo Evaluation of Memory study and the Guidage study. <i>Journal of Nutrition, Health and Aging</i> , 2008, 12, S73-S79.	1.5	6
1109	Increased EEG gamma band activity in Alzheimer's disease and mild cognitive impairment. <i>Journal of Neural Transmission</i> , 2008, 115, 1301-1311.	1.4	133
1110	Volumetric MRI and cognitive measures in Alzheimer disease. <i>Journal of Neurology</i> , 2008, 255, 567-574.	1.8	121
1111	The accuracy of the MMSE in detecting cognitive impairment when administered by general practitioners: A prospective observational study. <i>BMC Family Practice</i> , 2008, 9, 29.	2.9	103
1112	Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. <i>Movement Disorders</i> , 2008, 23, 1532-1540.	2.2	33

#	ARTICLE	IF	CITATIONS
1113	Apathy and depression in Alzheimer's disease are associated with functional deficit and psychotropic prescription. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 409-414.	1.3	74
1114	A feasibility and tolerability study of lithium in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 704-711.	1.3	140
1115	Coping strategies, anxiety and depression in caregivers of people with Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 929-936.	1.3	223
1116	Quantitative EEG in progressing <i>vs</i> stable mild cognitive impairment (MCI): results of a 1-year follow-up study. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 1148-1155.	1.3	79
1117	Evaluation of effect of cognitive intervention programs for the community-dwelling elderly with subjective memory complaints. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 1172-1174.	1.3	30
1118	Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 1222-1230.	1.3	70
1119	Risk of dementia associated with the ApoE $\epsilon$ 4 allele and falls causing head injury without explicit traumatic brain injury. <i>Acta Neurologica Scandinavica</i> , 2008, 118, 153-158.	1.0	10
1120	The Art of Prescribing. <i>Perspectives in Psychiatric Care</i> , 2008, 39, 83-85.	0.9	0
1121	CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer's disease. <i>European Journal of Neurology</i> , 2008, 15, 1155-1162.	1.7	47
1122	Does taking vitamin, mineral and fatty acid supplements prevent cognitive decline? A systematic review of randomized controlled trials. <i>Journal of Human Nutrition and Dietetics</i> , 2008, 21, 317-336.	1.3	43
1123	Metaphor comprehension in Alzheimer's disease: Novelty matters. <i>Brain and Language</i> , 2008, 107, 1-10.	0.8	97
1124	Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. <i>Lancet Neurology</i> , The, 2008, 7, 310-318.	4.9	229
1125	Endpoints for trials in Alzheimer's disease: a European task force consensus. <i>Lancet Neurology</i> , The, 2008, 7, 436-450.	4.9	146
1126	Safety, efficacy, and biomarker findings of PBT2 in targeting A $\beta$ 2 as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2008, 7, 779-786.	4.9	657
1127	Pattern of brain atrophy in elderly patients with depression revealed by voxel-based morphometry. <i>Psychiatry Research - Neuroimaging</i> , 2008, 164, 237-244.	0.9	92
1128	Demencia. , 2008, , 111-142.		0
1129	Review of Normative Data For Common Screening Measures Used to Evaluate Cognitive Functioning in Elderly Individuals. <i>Clinical Neuropsychologist</i> , 2008, 22, 620-650.	1.5	31
1130	Therapeutic Use of Nicergoline. <i>Clinical Drug Investigation</i> , 2008, 28, 533-552.	1.1	67

#	ARTICLE	IF	CITATIONS
1131	Cognitive stimulation for the treatment of Alzheimer's disease. Expert Review of Neurotherapeutics, 2008, 8, 751-757.	1.4	87
1132	Vitamin E for Alzheimer's disease and mild cognitive impairment. , 2008, , CD002854.		94
1133	Symptomatic Therapeutic Aspects in Alzheimer's Disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 269-271.	1.0	0
1134	Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Current Medical Research and Opinion, 2008, 24, 2561-2574.	0.9	124
1136	Development of a cell phone-based video streaming system for persons with early stage Alzheimer's disease. , 2008, 2008, 5330-3.		15
1137	Development, Optimization and Use of Preclinical Behavioral Models to Maximize the Productivity of Drug Discovery for Alzheimer's Disease. , 2008, , 93-157.		10
1139	Theta oscillations are affected by amnesic mild cognitive impairment and cognitive load. International Journal of Psychophysiology, 2008, 70, 75-81.	0.5	56
1140	Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. Neurobiology of Aging, 2008, 29, 168-184.	1.5	61
1141	Enhanced soluble CD40 ligand and Alzheimer's disease: Evidence of a possible pathogenetic role. Neurobiology of Aging, 2008, 29, 348-356.	1.5	35
1142	High field 1H MRS of the hippocampus after donepezil treatment in Alzheimer disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 786-793.	2.5	43
1143	The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: A preliminary randomized double-blind placebo-controlled study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1538-1544.	2.5	313
1144	Ageing and Mental Handicap. Developmental Medicine and Child Neurology, 1986, 28, 519-522.	1.1	2
1145	Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurology, The, 2008, 7, 483-493.	4.9	247
1146	Growth hormone secretagogue MK-677. Neurology, 2008, 71, 1702-1708.	1.5	82
1147	Prognosis of Alzheimer's disease today: A two-year prospective study in 686 patients from the REAL.FR Study. Alzheimer's and Dementia, 2008, 4, 22-29.	0.4	84
1148	Prevention therapeutics of dementia. Alzheimer's and Dementia, 2008, 4, S122-30.	0.4	18
1149	Disease-modifying approaches to Alzheimer's disease: Challenges and opportunities"Lessons from donepezil therapy. Alzheimer's and Dementia, 2008, 4, S109-18.	0.4	12
1150	Leon Thal and the therapeutic age of Alzheimer's disease. , 2008, 4, S4-S6.		1

#	ARTICLE	IF	CITATIONS
1151	The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics. <i>Alzheimer's and Dementia</i> , 2008, 4, 145-153.	0.4	56
1152	Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. <i>Lancet, The</i> , 2008, 372, 207-215.	6.3	440
1153	Long-term effects of A $\beta$ 242 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. <i>Lancet, The</i> , 2008, 372, 216-223.	6.3	1,333
1154	Dementia of the Alzheimer Type. <i>Epidemiologic Reviews</i> , 2008, 30, 15-34.	1.3	126
1155	Self-perceived memory impairment and cognitive performance in an elderly independent population with age-related white matter changes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 869-873.	0.9	42
1156	Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. <i>The Cochrane Library</i> , 2008, , CD004514.	1.5	174
1157	A Three-Country Randomized Controlled Trial of a Psychosocial Intervention for Caregivers Combined With Pharmacological Treatment for Patients With Alzheimer Disease: Effects on Caregiver Depression. <i>American Journal of Geriatric Psychiatry</i> , 2008, 16, 893-904.	0.6	107
1158	Expressive art for the social and community integration of adolescents with acquired brain injuries: a systematic review. <i>Research in Drama Education</i> , 2008, 13, 337-352.	0.2	7
1159	Measuring the mind: assessing cognitive change in clinical drug trials. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 471-473.	1.3	18
1160	Treatment of Cognitive Impairment in??Multiple Sclerosis. <i>CNS Drugs</i> , 2008, 22, 87-97.	2.7	37
1161	Preventing Alzheimer's Disease. <i>CNS Drugs</i> , 2008, 22, 887-902.	2.7	16
1162	A Multicriteria Model Applied in the Diagnosis of Alzheimer's Disease: A Bayesian Network. , 2008, , .		26
1163	Neuropsychological examination in dementia. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008, 89, 15-33.	1.0	3
1164	Mild cognitive impairment (MCI): a historical perspective. <i>International Psychogeriatrics</i> , 2008, 20, 18-31.	0.6	93
1165	Effect of Physical Activity on Cognitive Function in Older Adults at Risk for Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 1027.	3.8	1,331
1166	Predictive Factors of Attrition in a Cohort of Alzheimer Disease Patients. <i>Neuroepidemiology</i> , 2008, 31, 69-79.	1.1	47
1167	The Cerebrovascular Pathology in Alzheimer's Disease and Its Influence on Clinical Variables. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2008, 23, 91-96.	0.9	15
1168	Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6). <i>Journal of Psychopharmacology</i> , 2008, 22, 761-768.	2.0	26

#	ARTICLE	IF	CITATIONS
1169	Neuroanatomical Correlates of Unawareness of Memory Deficits in Early Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 347-353.	0.7	39
1170	Effect of ApoE Genotype on Response to Donepezil in Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 445-450.	0.7	73
1171	Predicting Long-Term Cognitive Outcome with New Regression Models in Donepezil-Treated Alzheimer Patients in a Naturalistic Setting. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 203-211.	0.7	19
1172	The Role of the Uncinate Fasciculus in Memory and Emotional Recognition in Amnesic Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 432-439.	0.7	115
1173	Cube Copying Test in Combination with rCBF or CSF A $\beta$ Predicts Development of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 544-552.	0.7	20
1174	Multi-Center Comparison of Medial Temporal Atrophy in Patients with Alzheimer's Disease &ndash; Data from the ICTUS Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 314-322.	0.7	8
1175	Healthy Cognitive Aging and Leisure Activities Among the Oldest Old in Japan: Takashima Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2008, 63, 1193-1200.	1.7	60
1176	EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. <i>Brain</i> , 2008, 131, 690-705.	3.7	292
1177	Review of Goal Attainment Scaling as a Useful Outcome Measure in Psychogeriatric Patients with Cognitive Disorders. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 528-540.	0.7	48
1178	Participation in dementia research: rates and correlates of capacity to give informed consent. <i>Journal of Medical Ethics</i> , 2008, 34, 167-170.	1.0	66
1179	Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. <i>Neurology</i> , 2008, 70, 191-199.	1.5	171
1180	Panax Ginseng Enhances Cognitive Performance in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2008, 22, 222-226.	0.6	195
1181	Cognitive impairment in spinocerebellar ataxia type 6. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 496-499.	0.9	68
1182	Memantine Treatment in Patients with Mild to Moderate Alzheimers Disease Already Receiving a Cholinesterase Inhibitor: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Current Alzheimer Research</i> , 2008, 5, 83-89.	0.7	244
1183	Toxic dementias. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 851-862.	1.0	0
1184	Controversies in Alzheimer's disease drug development. <i>International Review of Psychiatry</i> , 2008, 20, 389-395.	1.4	23
1185	Economical Aspects of Dementia. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 137-146.	1.0	5
1186	Issues in Design and Conduct of Clinical Trials for Cognitive-Enhancing Drugs. , 2008, , 21-76.		8



#	ARTICLE	IF	CITATIONS
1187	No Effect of One-Year Treatment with Indomethacin on Alzheimer's Disease Progression: A Randomized Controlled Trial. PLoS ONE, 2008, 3, e1475.	1.1	123
1188	The Clinical Significance of Plasmatic Amyloid A $\beta$ -40 Peptide Levels in Alzheimer's Disease Patients Treated With Galantamine. American Journal of Alzheimer's Disease and Other Dementias, 2008, 23, 286-290.	0.9	4
1189	Decreased initiation of usual activities in people with mild-to-moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial. International Psychogeriatrics, 2008, 20, 952-63.	0.6	28
1190	Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. Cmaj, 2008, 179, 1019-1026.	0.9	130
1191	Facilitating Regulation: The Dance of Statistical Significance and Clinical Meaningfulness in Standardizing Technologies for Dementia. BioSocieties, 2008, 3, 241-263.	0.8	12
1192	The Usefulness of Cube Copying for Evaluating Treatment of Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2008, 23, 439-446.	0.9	11
1193	Development of Screening Guidelines and Clinical Criteria for Predementia Alzheimer's Disease. Neuroepidemiology, 2008, 30, 254-265.	1.1	86
1194	Annualized functional change in alzheimer's disease participants and normal controls. Clinical Neuropsychologist, 2008, 22, 801-806.	1.5	4
1195	Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer's Disease: Phase 1 Outcomes From the CATIE-AD Effectiveness Trial. American Journal of Psychiatry, 2008, 165, 844-854.	4.0	274
1196	Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology, 2008, 70, 2024-2035.	1.5	235
1197	Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. Brain, 2008, 131, 2443-2454.	3.7	393
1198	High-Dose B Vitamin Supplementation and Cognitive Decline in Alzheimer Disease. JAMA - Journal of the American Medical Association, 2008, 300, 1774.	3.8	473
1199	Transcranial direct current stimulation improves recognition memory in Alzheimer disease. Neurology, 2008, 71, 493-498.	1.5	378
1200	Galantamine in Alzheimer's disease. Expert Review of Neurotherapeutics, 2008, 8, 9-17.	1.4	60
1202	Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies. International Psychogeriatrics, 2008, 20, 871-89.	0.6	18
1203	Inflammation and Rate of Cognitive Change in High-Functioning Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2008, 63, 50-55.	1.7	106
1204	Role of cerebral microemboli in the causation of Alzheimer's disease and vascular dementia. Future Neurology, 2008, 3, 391-397.	0.9	0
1205	Screening for memory disorders, dementia and Alzheimer's disease. Aging Health, 2008, 4, 399-432.	0.3	73

#	ARTICLE	IF	CITATIONS
1206	Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline. <i>Annals of Internal Medicine</i> , 2008, 148, 379.	2.0	655
1208	Pooled Analyses on Cognitive Effects of Memantine in Patients with Moderate to Severe Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2008, 14, 193-199.	1.2	50
1209	Decreased Plasma and Cerebrospinal Fluid Levels of Stem Cell Factor in Patients with Early Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2008, 15, 451-460.	1.2	47
1210	Peripheral Oxidative Damage in Mild Cognitive Impairment and Mild Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2008, 15, 117-128.	1.2	133
1211	Predictors of Placebo Group Decline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in 24 Week Clinical Trials of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2008, 14, 301-311.	1.2	28
1212	Memantine Treatment in Patients with Mild to Moderate Alzheimer's Disease: Results of a Randomised, Double-Blind, Placebo-Controlled 6-Month Study. <i>Journal of Alzheimer's Disease</i> , 2008, 13, 97-107.	1.2	93
1213	Dementia: pharmacological and non-pharmacological treatments and guideline review. , 0, , 217-243.		2
1214	Cognitive function, neuropsychological evaluation, and syndromes of cognitive impairment. , 2008, , 6-38.		1
1215	A Randomized, Double-blind, Placebo Controlled-trial of Triflusal in Mild Cognitive Impairment. <i>Alzheimer Disease and Associated Disorders</i> , 2008, 22, 21-29.	0.6	55
1216	Effects of Hypertension and Hypercholesterolemia on Cognitive Functioning in Patients With Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2008, 22, 336-342.	0.6	52
1217	Clinical Trial Design Issues in Mild to Moderate Alzheimer Disease. <i>Cognitive and Behavioral Neurology</i> , 2008, 21, 197-201.	0.5	34
1218	Revising the ADAS-cog for a More Accurate Assessment of Cognitive Impairment. <i>Alzheimer Disease and Associated Disorders</i> , 2008, 22, 236-244.	0.6	28
1219	Nutritional Status is Associated With Disease Progression in Very Mild Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2008, 22, 66-71.	0.6	59
1220	Use of Clinical Dementia Rating in Detecting Early Cognitive Deficits in a Community-based Sample of Chinese Older Persons in Hong Kong. <i>Alzheimer Disease and Associated Disorders</i> , 2008, 22, 153-157.	0.6	24
1221	Validation of ASHA FACSâ€“Functional Assessment of Communication Skills for Alzheimer Disease Population. <i>Alzheimer Disease and Associated Disorders</i> , 2008, 22, 375-381.	0.6	30
1222	Ginkgo Biloba. , 2008, , 176-187.		0
1223	Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease. <i>Drug Design, Development and Therapy</i> , 2008, 2, 245.	2.0	11
1224	Neuropsychological rehabilitation program and behavioral disturbances in early-stage Alzheimer patients. <i>Dementia E Neuropsychologia</i> , 2008, 2, 146-150.	0.3	0

#	ARTICLE	IF	CITATIONS
1225	Geriatric neuropsychology: Implications for front line clinicians. <i>NeuroRehabilitation</i> , 2008, 23, 381-394.	0.5	6
1226	Cognitive Assessment in Traumatic Brain Injury. <i>Brain &amp; Neurorehabilitation</i> , 2008, 1, 148.	0.4	3
1227	Administration and Scoring Variance on the ADAS-Cog. <i>Journal of Alzheimer's Disease</i> , 2008, 15, 461-464.	1.2	66
1228	Economic and Clinical Benefits of Galantamine in the Treatment of Mild to Moderate Alzheimer's Disease in a Korean Population: A 52-Week Prospective Study. <i>Journal of Korean Medical Science</i> , 2008, 23, 10.	1.1	19
1229	Disease Modifying Trials in Alzheimer's Disease: Perspectives for the Future. <i>Journal of Alzheimer's Disease</i> , 2008, 15, 289-301.	1.2	15
1230	PREFACE: What Do You Mean by "Translational Research"? An Enquiry Through Animal and Translational Models for CNS Drug Discovery: <i>Neurological Disorders.</i> , 2008, , xv-xlii.		0
1232	Vascular cognitive impairment: definitions and clinical diagnosis. , 0, , 362-371.		0
1233	Treatment of cognitive changes. , 0, , 195-199.		1
1234	Update on the use of memantine in Alzheimer's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2009, 5, 237.	1.0	92
1235	Methodological Issues in Primary Prevention Trials for Neurodegenerative Dementia. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 235-270.	1.2	42
1236	Applications of Neuroimaging to Disease-Modification Trials in Alzheimer's Disease. <i>Behavioural Neurology</i> , 2009, 21, 129-136.	1.1	17
1237	Ascorbic Acid and Rates of Cognitive Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 93-98.	1.2	75
1238	Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease. <i>Clinical Interventions in Aging</i> , 0, , 1.	1.3	10
1239	Location of lacunar infarcts correlates with cognition in a sample of non-disabled subjects with age-related white-matter changes: the LADIS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 478-483.	0.9	102
1240	Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 7619-7623.	3.3	63
1241	Diagnostic Evaluation of Dementia in the Secondary Health Care Sector. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 534-542.	0.7	30
1242	How Well Do the ADAS-cog and its Subscales Measure Cognitive Dysfunction in Alzheimer's Disease?. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 28, 63-69.	0.7	51
1243	Neuropsychological Assessment in the Diagnosis of Alzheimer's Disease. <i>Current Protocols in Neuroscience</i> , 2009, 49, Unit10.3.	2.6	11

#	ARTICLE	IF	CITATIONS
1244	A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. <i>Neurology</i> , 2009, 73, 2061-2070.	1.5	677
1245	Review: Therapy for Alzheimer's disease: how effective are current treatments?. <i>Therapeutic Advances in Neurological Disorders</i> , 2009, 2, 163-180.	1.5	95
1246	Cardiovascular Disease Risk Factors and Progression of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 240-246.	0.7	26
1247	Agreement in Cognitive and Clinical Assessments in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 344-352.	0.7	10
1248	Effectiveness of Donepezil in Reducing Clinical Worsening in Patients with Mild-to-Moderate Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 28, 244-251.	0.7	44
1249	DONEPEZIL TREATMENT OF PATIENTS WITH MCI: A 48-WEEK RANDOMIZED, PLACEBO- CONTROLLED TRIAL. <i>Neurology</i> , 2009, 73, 1514-1516.	1.5	88
1250	Damage of White Matter Tract Correlated with Neuropsychological Deficits in Carbon Monoxide Intoxication after Hyperbaric Oxygen Therapy. <i>Journal of Neurotrauma</i> , 2009, 26, 1263-1270.	1.7	39
1251	Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve. <i>Brain</i> , 2009, 132, 2036-2047.	3.7	376
1252	Galantamine for the Treatment of BPSD in Thai Patients With Possible Alzheimer's Disease With or Without Cerebrovascular Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2009, 23, 593-601.	0.9	7
1253	Donepezil treatment of patients with MCI. <i>Neurology</i> , 2009, 72, 1555-1561.	1.5	207
1254	Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease<sub>A Randomized Controlled Trial</sub>. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 2557.	3.8	542
1255	Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. <i>Brain</i> , 2009, 132, 392-401.	3.7	33
1256	Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders. <i>Current Alzheimer Research</i> , 2009, 6, 144-151.	0.7	236
1257	Misplacing objects in mild to moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 960-965.	0.9	16
1258	Effect of a <i>CYP2D6</i> polymorphism on the efficacy of donepezil in patients with Alzheimer disease. <i>Neurology</i> , 2009, 73, 761-767.	1.5	102
1259	Systemic inflammation and disease progression in Alzheimer disease. <i>Neurology</i> , 2009, 73, 768-774.	1.5	947
1260	Treatment of Alzheimer's disease in the long-term-care setting. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 899-907.	0.5	31
1261	Functional and cognitive criteria produce different rates of mild cognitive impairment and conversion to dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 737-743.	0.9	95

#	ARTICLE	IF	CITATIONS
1262	Within-person changes in inspection time predict memory. <i>Personality and Individual Differences</i> , 2009, 46, 741-743.	1.6	4
1263	Inspection time and everyday functioning: A longitudinal study. <i>Personality and Individual Differences</i> , 2009, 47, 999-1002.	1.6	1
1264	The neural basis of visuospatial perception in Alzheimer's disease and healthy elderly comparison subjects: An fMRI study. <i>Psychiatry Research - Neuroimaging</i> , 2009, 172, 109-116.	0.9	76
1265	Neuropsychological functioning in health and mood disorder: Modulation by glucocorticoids and their receptors. <i>Psychoneuroendocrinology</i> , 2009, 34, S196-S207.	1.3	33
1266	Study design and methods of the Ansan Geriatric Study (AGE study). <i>BMC Neurology</i> , 2009, 9, 10.	0.8	35
1267	Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil. <i>BMC Neurology</i> , 2009, 9, 7.	0.8	28
1268	Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy. <i>Acta Neurologica Scandinavica</i> , 1993, 88, 16-21.	1.0	29
1269	Tetrahydroaminoacridine (THA) in Alzheimer's disease: An assessment of attentional and mnemonic function using CANTAB. <i>Acta Neurologica Scandinavica</i> , 1993, 88, 29-35.	1.0	34
1270	Transcranial direct current stimulation in severe, drug-resistant major depression. <i>Journal of Affective Disorders</i> , 2009, 118, 215-219.	2.0	190
1271	Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. <i>Lancet Neurology</i> , The, 2009, 8, 334-344.	4.9	226
1272	Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. <i>Annals of Neurology</i> , 2009, 65, 577-585.	2.8	181
1273	Modality of physical exercise and cognitive function in Hong Kong older Chinese community. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 48-53.	1.3	43
1274	Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 479-488.	1.3	64
1275	Prediction of survival in Alzheimer's disease—the LASER-AD longitudinal study. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 739-747.	1.3	18
1276	Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 638-647.	1.3	33
1277	Cholesterol 24-hydroxylase (CYP46A1) polymorphisms are associated with faster cognitive deterioration in Chinese older persons: a two-year follow up study. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 921-926.	1.3	26
1278	Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 532-538.	1.3	65
1279	Three sides of the same coin: measuring global cognitive impairment with the MMSE, ADAS-cog and CAMCOG. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 770-779.	1.3	34

#	ARTICLE	IF	CITATIONS
1280	Serial volumetric MRI in Parkinsonian disorders. <i>Movement Disorders</i> , 2009, 24, S691-8.	2.2	24
1282	Flavonoids and cognitive function: a review of human randomized controlled trial studies and recommendations for future studies. <i>Genes and Nutrition</i> , 2009, 4, 227-242.	1.2	158
1283	Improvement of spontaneous speech in early stage Alzheimer's disease with rivastigmine. <i>Journal of Nutrition, Health and Aging</i> , 2009, 13, 34-38.	1.5	9
1284	What we have learned from the myriad trials. <i>Journal of Nutrition, Health and Aging</i> , 2009, 13, 362-364.	1.5	13
1285	The effect of a nutrient dense drink on mental and physical function in institutionalized elderly people. <i>Journal of Nutrition, Health and Aging</i> , 2009, 13, 760-767.	1.5	43
1286	Galantamine-induced improvements in cognitive function are not related to alterations in $\alpha 4 \beta 2$ nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]Fluoro-A-85380 PET. <i>Psychopharmacology</i> , 2009, 202, 79-91.	1.5	20
1287	Long-term rivastigmine treatment in a routine clinical setting. <i>Acta Neurologica Scandinavica</i> , 2009, 119, 180-185.	1.0	16
1288	Cognitive Decline and Mortality in a Community-Based Cohort: The Monongahela Valley Independent Elders Survey. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 94-100.	1.3	52
1289	HOW TO MANAGE OVERACTIVE BLADDER IN ELDERLY INDIVIDUALS WITH DEMENTIA? A COMBINED USE OF DONEPEZIL, A CENTRAL ACETYLCHOLINESTERASE INHIBITOR, AND PROPIVERINE, A PERIPHERAL MUSCARINE RECEPTOR ANTAGONIST. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 1515-1517.	1.3	51
1290	Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer's disease: A 21-month follow-up "real world" study. <i>Archives of Gerontology and Geriatrics</i> , 2009, 49, e6-e11.	1.4	14
1291	The process and organizational characteristics of memory clinics in Israel in 2007. <i>Archives of Gerontology and Geriatrics</i> , 2009, 49, e115-e120.	1.4	8
1292	Effect of aromatherapy on patients with Alzheimer's disease. <i>Psychogeriatrics</i> , 2009, 9, 173-179.	0.6	169
1293	Reviews: Current Concepts in Alzheimer's Disease: A Multidisciplinary Review. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2009, 24, 95-121.	0.9	245
1294	Conversion of amyloid positive and negative MCI to AD over 3 years. <i>Neurology</i> , 2009, 73, 754-760.	1.5	469
1295	Neuropsychological performance in advanced age: Influences of Demographic factors and Apolipoprotein E: Findings from the Cache County Memory Study. <i>Clinical Neuropsychologist</i> , 2009, 23, 77-99.	1.5	55
1296	Response speed, contingent negative variation and P300 in Alzheimer's disease and MCI. <i>Brain and Cognition</i> , 2009, 69, 592-599.	0.8	75
1297	Diagnostic tools for dementia. <i>Maturitas</i> , 2009, 63, 181-185.	1.0	21
1298	Validation of the Revised Quick Cognitive Screening Test. <i>Archives of Physical Medicine and Rehabilitation</i> , 2009, 90, 1469-1477.	0.5	11

#	ARTICLE	IF	CITATIONS
1299	Cerebral emboli in the genesis of dementia. <i>Journal of the Neurological Sciences</i> , 2009, 283, 17-20.	0.3	22
1300	The value of quantitative EEG in differential diagnosis of Alzheimer's disease and subcortical vascular dementia. <i>Journal of the Neurological Sciences</i> , 2009, 283, 127-133.	0.3	60
1302	A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease. <i>Aging Clinical and Experimental Research</i> , 2009, 21, 102-110.	1.4	140
1303	Special care units for dementia individuals with behavioural problems. <i>The Cochrane Library</i> , 2009, , CD006470.	1.5	50
1304	Ginkgo biloba for cognitive impairment and dementia. <i>The Cochrane Library</i> , 2009, , CD003120.	1.5	290
1306	Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 600-607.	0.9	210
1307	Carotid Intima-Media Thickness as a Predictor of Response to Cholinesterase Inhibitors in Alzheimer's Disease. <i>CNS Drugs</i> , 2009, 23, 253-260.	2.7	9
1308	fMRI Techniques and Protocols. <i>NeuroMethods</i> , 2009, , .	0.2	14
1309	Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2009, 1, 7.	3.0	147
1310	Plasma Urate and Progression of Mild Cognitive Impairment. <i>Neurodegenerative Diseases</i> , 2009, 6, 23-28.	0.8	85
1311	Glial Fibrillary Acidic Protein and Protein S-100B: Different Concentration Pattern of Glial Proteins in Cerebrospinal Fluid of Patients with Alzheimer's Disease and Creutzfeldt-Jakob Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 541-551.	1.2	74
1312	Optimal Dosing of Galantamine in Patients with Mild or Moderate Alzheimer's Disease. <i>Drugs and Aging</i> , 2009, 26, 231-239.	1.3	27
1313	Identifying mild cognitive impairment at baseline in the Ginkgo Evaluation of Memory (GEM) study. <i>Aging and Mental Health</i> , 2009, 13, 171-182.	1.5	18
1314	Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: An ADNI study of 515 subjects. <i>NeuroImage</i> , 2009, 48, 668-681.	2.1	129
1315	Current Alzheimer's disease clinical trials: Methods and placebo outcomes. <i>Alzheimer's and Dementia</i> , 2009, 5, 388-397.	0.4	123
1316	The Effects of Counseling Spouse Caregivers of People With Alzheimer Disease Taking Donepezil and of Country of Residence on Rates of Admission to Nursing Homes and Mortality. <i>American Journal of Geriatric Psychiatry</i> , 2009, 17, 734-743.	0.6	46
1317	Adaptation française d'un outil d'évaluation par téléphone des troubles mnésiques: le French Telephone Interview for Cognitive Status Modified (F-TICS-m). <i>NPG Neurologie - Psychiatrie - Geriatrie</i> , 2009, 9, 17-22.	0.1	8
1318	Influence of the MTHFR C677T Polymorphism on Magnetic Resonance Imaging Hyperintensity Volume and Cognition in Geriatric Depression. <i>American Journal of Geriatric Psychiatry</i> , 2009, 17, 847-855.	0.6	27

#	ARTICLE	IF	CITATIONS
1319	Atomoxetine Augmentation of Cholinesterase Inhibitor Therapy in Patients With Alzheimer Disease: 6-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel-Trial Study. <i>American Journal of Geriatric Psychiatry</i> , 2009, 17, 752-759.	0.6	46
1320	Prevalence of Social Phobia in Non-Demented Elderly From a Swedish Population Study. <i>American Journal of Geriatric Psychiatry</i> , 2009, 17, 127-135.	0.6	41
1321	Efficacy of Rivastigmine for Cognitive Symptoms in Parkinson Disease With Dementia. <i>Neurologist</i> , 2009, 15, 234-237.	0.4	11
1322	A Brief Instrument to Assess Treatment Response in the Patient With Advanced Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 377-383.	0.6	18
1323	Rates of Cognitive Change in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 357-364.	0.6	21
1324	MRI Substudy Participation in Alzheimer Disease (AD) Clinical Trials. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 333-336.	0.6	4
1325	Verbal Repetition in People With Mild-to-Moderate Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 146-151.	0.6	24
1326	An Open-label Study of Memantine Treatment in 3 Subtypes of Frontotemporal Lobar Degeneration. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 211-217.	0.6	110
1327	Increase of BDNF Serum Concentration in Lithium Treated Patients with Early Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 649-656.	1.2	140
1328	Does Cognitive Impairment Influence Burden in Caregivers of Patients with Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 105-114.	1.2	88
1329	Balance Features in Alzheimer's Disease and Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 113-120.	1.2	90
1330	The relationship of excess cognitive impairment in MCI and early Alzheimer's disease to the subsequent emergence of psychosis. <i>International Psychogeriatrics</i> , 2009, 21, 78.	0.6	57
1331	Characteristics and diagnostic profile of patients seeking dementia care in a memory clinic in Hong Kong. <i>International Psychogeriatrics</i> , 2009, 21, 392.	0.6	32
1332	Contextual Thematic Group Treatment for Individuals With Dementia. <i>Perspectives on Neurophysiology and Neurogenic Speech and Language Disorders</i> , 2009, 19, 135-141.	0.4	0
1334	BDNF Variants, Premorbid Educational Attainment, and Disease Characteristics in Alzheimer's Disease: An Exploratory Study. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 887-898.	1.2	13
1335	Application of Repeated-Measures Analysis of Variance and Hierarchical Linear Model in Nursing Research. <i>Nursing Research</i> , 2009, 58, 211-217.	0.8	36
1336	Safety and Tolerability of the Rivastigmine Patch. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 158-164.	0.6	39
1337	Update on the Pharmacological Treatment of Alzheimers Disease. <i>Current Neuropharmacology</i> , 2010, 8, 69-80.	1.4	129



#	ARTICLE	IF	CITATIONS
1338	Clinical and Radiological Differences in Alzheimer's Disease with and without a History of Mild Cognitive Impairment. <i>Neuroradiology Journal</i> , 2010, 23, 659-664.	0.6	1
1339	Antidepressant use in Alzheimer's disease patients: results of the REAL.FR cohort. <i>International Psychogeriatrics</i> , 2010, 22, 120-128.	0.6	25
1340	The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. <i>International Psychogeriatrics</i> , 2010, 22, 984-994.	0.6	195
1341	Inaccuracy in Clinical Trials: Effects and Methods to Control Inaccuracy. <i>Current Alzheimer Research</i> , 2010, 7, 637-641.	0.7	16
1343	A Randomized, Placebo-Controlled Trial of Latrepirdine in Huntington Disease. <i>Archives of Neurology</i> , 2010, 67, 154.	4.9	87
1344	Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. <i>Aids</i> , 2010, 24, 1243-1250.	1.0	592
1345	Effect of Donepezil on Cognition in Severe Alzheimer's Disease: A Pooled Data Analysis. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 843-851.	1.2	32
1346	The effects of aging in delay and trace human eyeblink conditioning.. <i>Psychology and Aging</i> , 2010, 25, 684-690.	1.4	21
1347	Dementia: Continuum or distinct entity?. <i>Psychology and Aging</i> , 2010, 25, 534-544.	1.4	23
1348	Perceptual bias for affective and nonaffective information in asymmetric Parkinson's disease.. <i>Neuropsychology</i> , 2010, 24, 443-456.	1.0	2
1350	Assessing the elderly psychiatric patient. , 0, , 5-22.		0
1351	Effects of Rivastigmine in Alzheimer's Disease Patients with and Without Hallucinations. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 301-311.	1.2	20
1352	Uric Acid as a CNS Antioxidant. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 1331-1336.	1.2	197
1353	Conceptual Evolution in Alzheimer's Disease: Implications for Understanding the Clinical Phenotype of Progressive Neurodegenerative Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 253-272.	1.2	74
1354	Donepezil: A Review of Pharmacological Characteristics and Role in the Management of Alzheimer Disease. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S5410.	0.4	17
1355	Quantitative Pharmacology Approach in Alzheimer's Disease: Efficacy Modeling of Early Clinical Data to Predict Clinical Outcome of Tesofensine. <i>AAPS Journal</i> , 2010, 12, 117-129.	2.2	8
1356	Therapeutic Value of Ginkgo biloba in Reducing Symptoms of Decline in Mental Function. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 51, 535-541.	1.2	90
1357	Volume changes in Alzheimer's disease and mild cognitive impairment: cognitive associations. <i>European Radiology</i> , 2010, 20, 674-682.	2.3	100

#	ARTICLE	IF	CITATIONS
1358	Rivastigmine for the treatment of Parkinson's disease dementia. <i>Aging Health</i> , 2010, 6, 277-284.	0.3	0
1359	A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease. <i>Psychopharmacology</i> , 2010, 207, 637-643.	1.5	202
1360	Validation studies of the Portuguese experimental version of the Montreal Cognitive Assessment (MoCA): confirmatory factor analysis. <i>Journal of Neurology</i> , 2010, 257, 728-734.	1.8	79
1361	Reduced benefit from mnemonic strategies in early-stage Alzheimer's disease: a brief testing-the-limits paradigm for clinical practice. <i>Journal of Neurology</i> , 2010, 257, 1718-1726.	1.8	6
1362	Cortical excitability in very mild Alzheimer's disease: a long-term follow-up study. <i>Journal of Neurology</i> , 2010, 257, 2078-2085.	1.8	31
1363	Lower fluid and fruits / vegetable intake in questionable dementia among older Hong Kong Chinese. <i>Journal of Nutrition, Health and Aging</i> , 2010, 14, 45-49.	1.5	20
1364	The primary care physician and Alzheimer's disease: An international position paper. <i>Journal of Nutrition, Health and Aging</i> , 2010, 14, 110-120.	1.5	83
1365	Follow-up for Alzheimer patients: European Alzheimer disease consortium position paper. <i>Journal of Nutrition, Health and Aging</i> , 2010, 14, 121-130.	1.5	13
1366	Dark side of the town: Depressive symptoms in disadvantaged senior citizens. <i>Journal of Nutrition, Health and Aging</i> , 2010, 14, 483-487.	1.5	6
1367	Predictive factors of hospitalizations in Alzheimer's disease: A two-year prospective study in 686 patients of the REAL.FR study. <i>Journal of Nutrition, Health and Aging</i> , 2010, 14, 288-291.	1.5	38
1369	<sup>11</sup> C-PiB PET assessment of change in fibrillar amyloid- $\beta$ load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. <i>Lancet Neurology</i> , 2010, 9, 363-372.	4.9	674
1370	The dopaminergic basis of cognitive and motor performance in Alzheimer's disease. <i>Neurobiology of Disease</i> , 2010, 37, 477-482.	2.1	28
1371	Promotion of the mind through exercise (PROMoTE): a proof-of-concept randomized controlled trial of aerobic exercise training in older adults with vascular cognitive impairment. <i>BMC Neurology</i> , 2010, 10, 14.	0.8	50
1372	Behavioural symptoms in patients with Alzheimer's disease and their association with cognitive impairment. <i>BMC Neurology</i> , 2010, 10, 87.	0.8	125
1373	Alterations in the red blood cell membrane proteome in Alzheimer's subjects reflect disease-related changes and provide insight into altered cell morphology. <i>Proteome Science</i> , 2010, 8, 11.	0.7	30
1374	Individual differences, aging, and IQ in two-choice tasks. <i>Cognitive Psychology</i> , 2010, 60, 127-157.	0.9	203
1375	The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 191-201.	1.3	46
1376	The Stroud/ADI dementia quality framework: a cross-national population-level framework for assessing the quality of life impacts of services and policies for people with dementia and their family carers. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 249-257.	1.3	13

#	ARTICLE	IF	CITATIONS
1377	Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 1201-1208.	1.3	105
1378	Broad spectrum assessment of psychopathology and adaptive functioning with the Older Adult Behavior Checklist: a validation and diagnostic discrimination study. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 1177-1185.	1.3	17
1379	Cognitive Stimulation Therapy (CST): effects on different areas of cognitive function for people with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 1253-1258.	1.3	119
1380	Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor-based morphometry. <i>Human Brain Mapping</i> , 2010, 31, 499-514.	1.9	66
1381	Split-screen video demonstration of sonography-guided muscle identification and injection of botulinum toxin. <i>Movement Disorders</i> , 2010, 25, 2225-2228.	2.2	11
1382	A comparison of two brief screening measures of cognitive impairment in Huntington's disease. <i>Movement Disorders</i> , 2010, 25, 2229-2233.	2.2	42
1383	Pathological laughter in Gilles de la Tourette syndrome: An unusual phonic tic. <i>Movement Disorders</i> , 2010, 25, 2233-2239.	2.2	21
1384	Long-term effects of coordinative training in degenerative cerebellar disease. <i>Movement Disorders</i> , 2010, 25, 2239-2246.	2.2	148
1385	No increased risk of obstructive sleep apnea in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2246-2249.	2.2	114
1386	Psychiatric symptoms associated with focal hand dystonia. <i>Movement Disorders</i> , 2010, 25, 2249-2252.	2.2	42
1387	Combination of intensive cognitive rehabilitation and donepezil therapy in Alzheimer's disease (AD). <i>Archives of Gerontology and Geriatrics</i> , 2010, 51, 245-249.	1.4	39
1388	Lack of association between antisperm antibodies and language dysfunction in Alzheimer's disease. <i>Archives of Gerontology and Geriatrics</i> , 2010, 50, 338-340.	1.4	6
1389	Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. <i>BMC Geriatrics</i> , 2010, 10, 14.	1.1	225
1390	The fitness for the Ageing Brain Study II (FABS II): protocol for a randomized controlled clinical trial evaluating the effect of physical activity on cognitive function in patients with Alzheimer's disease. <i>Trials</i> , 2010, 11, 120.	0.7	17
1391	Maintenance Cognitive Stimulation Therapy (CST) for dementia: A single-blind, multi-centre, randomized controlled trial of Maintenance CST vs. CST for dementia. <i>Trials</i> , 2010, 11, 46.	0.7	40
1392	Factors associated with persistence of cholinesterase inhibitor treatments in the elderly. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 680-686.	0.9	28
1393	Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy. <i>European Journal of Neurology</i> , 2010, 17, 405-412.	1.7	50
1394	The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 2010, 121, 186-193.	1.0	20

#	ARTICLE	IF	CITATIONS
1395	Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 2010, 122, 270-277.	1.0	14
1396	The prognosis and incidence of social phobia in an elderly population. A 5-year follow-up. <i>Acta Psychiatrica Scandinavica</i> , 2010, 122, 4-10.	2.2	16
1397	Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease. <i>International Journal of Clinical Practice</i> , 2010, 64, 651-660.	0.8	29
1398	ORIGINAL ARTICLE: Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010, 35, 581-588.	0.7	190
1399	Widespread deficits in adult neurogenesis precede plaque and tangle formation in the 3xTg mouse model of Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2010, 32, 905-920.	1.2	98
1401	Old-age psychiatry. , 2010, , 635-692.		1
1402	Seoul Neuropsychological Screening Battery-Dementia Version (SNSB-D): A Useful Tool for Assessing and Monitoring Cognitive Impairments in Dementia Patients. <i>Journal of Korean Medical Science</i> , 2010, 25, 1071.	1.1	375
1403	Effect of APOE $\epsilon$ 4 Allele on Cortical Thicknesses and Volumes: The AddNeuroMed Study. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 947-966.	1.2	82
1404	Measurement of Neuropsychiatric Symptoms in Clinical Trials Targeting Alzheimer's Disease and Related Disorders. <i>Pharmaceuticals</i> , 2010, 3, 2387-2397.	1.7	12
1405	Relationship between Cognitive Impairment and Behavioural Disturbances in Alzheimer's Disease Patients. <i>Behavioural Neurology</i> , 2010, 23, 123-130.	1.1	15
1406	El efecto del formato de intervenci3n individual o grupal en la estimulaci3n cognitivade pacientes con enfermedad de Alzheimer. <i>Revista De Psicopatologia Y Psicologia Clinica</i> , 2010, 15, .	0.1	7
1407	Uncovering Molecular Biomarkers That Correlate Cognitive Decline with the Changes of Hippocampus' Gene Expression Profiles in Alzheimer's Disease. <i>PLoS ONE</i> , 2010, 5, e10153.	1.1	121
1408	Oxidative Damage and Progression to Alzheimer's Disease in Patients with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 1165-1177.	1.2	78
1409	Efficacy and Safety of Galantamine Hydrobromide in the Treatment of Mild to Moderate Dementia. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S5884.	0.4	2
1410	Functional imaging of hippocampal dysfunction among persons with Alzheimer's disease: a proof-of-concept study. <i>Neuropsychiatric Disease and Treatment</i> , 2010, 6, 779.	1.0	0
1411	Regional Variation on the Presentation of Alzheimer's Disease Patients in Memory Clinics within Europe: Data from the ICTUS Study. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 155-165.	1.2	10
1412	Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1903.	3.8	626
1413	The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1363-1368.	0.9	142

#	ARTICLE	IF	CITATIONS
1414	Vitamins B <sub>12</sub> , B <sub>6</sub> , and folic acid for cognition in older men. <i>Neurology</i> , 2010, 75, 1540-1547.	1.5	101
1415	Copper and Ceruloplasmin Abnormalities in Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2010, 25, 490-497.	0.9	86
1416	Level of Executive Function Influences Verbal Memory in Amnesic Mild Cognitive Impairment and Predicts Prefrontal and Posterior Cingulate Thickness. <i>Cerebral Cortex</i> , 2010, 20, 1305-1313.	1.6	104
1417	No effect of donepezil on striatal dopamine release in mild to moderate Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 119-121.	0.9	7
1418	Effects of Oral Rivastigmine on Cognitive Domains in Mild-to-Moderate Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2010, 25, 347-352.	0.9	19
1419	Body Mass Index and Cognitive Decline in Mild Cognitive Impairment. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 126-130.	0.6	90
1420	Neuroimaging Enrichment Strategy for Secondary Prevention Trials in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 269-277.	0.6	42
1421	Performance on the Clock Drawing Task Correlates with fMRI Response to a Visuospatial Task in Alzheimer's Disease. <i>International Journal of Neuroscience</i> , 2010, 120, 335-343.	0.8	11
1422	Treatment Effects of Therapeutic Cholinesterase Inhibitors on Visuospatial Processing in Alzheimer's Disease: A Longitudinal Functional MRI Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 176-188.	0.7	19
1423	Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer's Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 30, 131-146.	0.7	299
1424	APOE ε <sub>2</sub> Allele Is Associated with Larger Regional Cortical Thicknesses and Volumes. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 30, 229-237.	0.7	40
1425	Galantamine for Alzheimer's disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 345-354.	1.5	69
1426	Review: Item Analysis of ADAS-Cog: Effect of Baseline Cognitive Impairment in a Clinical AD Trial. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2010, 25, 119-124.	0.9	22
1427	Review: The Diagnostic Accuracy of Dementia-Screening Instruments With an Administration Time of 10 to 45 Minutes for Use in Secondary Care: A Systematic Review. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2010, 25, 301-316.	0.9	46
1428	Complex environment experience rescues impaired neurogenesis, enhances synaptic plasticity, and attenuates neuropathology in familial Alzheimer's disease-linked APP <sup>swE</sup> /PS1 <sup>E9</sup> mice. <i>FASEB Journal</i> , 2010, 24, 1667-1681.	0.2	162
1429	What the CERAD Battery Can Tell Us about Executive Function as a Higher-Order Cognitive Faculty. <i>Current Gerontology and Geriatrics Research</i> , 2010, 2010, 1-10.	1.6	4
1430	Early detection of Alzheimer's disease with a total score of the German CERAD. <i>Journal of the International Neuropsychological Society</i> , 2010, 16, 910-920.	1.2	79
1431	Diffusion-Weighted Imaging and Cognition in the Leukoariosis and Disability in the Elderly Study. <i>Stroke</i> , 2010, 41, e402-8.	1.0	82

#	ARTICLE	IF	CITATIONS
1432	Insight, cognition and quality of life in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 331-336.	0.9	77
1433	Dementia Syndromes in the Older Adult. , 2010, , 155-178.		18
1434	Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease. <i>Neurology</i> , 2010, 74, 956-964.	1.5	365
1435	Prosocial Capabilities in Alzheimer's Patients. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2010, 65B, 119-128.	2.4	13
1436	Recording care time in nursing homes: development and validation of the "RUD-FOCA" (Resource) Tj ETQq0 0.0 rgBT / Overlock 10	0.6	17
1437	Beyond "OX3": What Temporal and Spatial Orientation Questions Tell Clinicians about Cognitive Dysfunction in Alzheimer's Disease. <i>Clinical Gerontologist</i> , 2010, 34, 45-56.	1.2	7
1438	Pilot Controlled Trial of Mindfulness Meditation and Education for Dementia Caregivers. <i>Journal of Alternative and Complementary Medicine</i> , 2010, 16, 1031-1038.	2.1	168
1439	Predicting time to full-time care in AD: a new model. <i>Journal of Medical Economics</i> , 2010, 13, 362-370.	1.0	6
1441	Reviews: Effects of Transdermal Rivastigmine on ADAS-Cog Items in Mild-to-Moderate Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2010, 25, 627-633.	0.9	19
1442	A comparison of neuropsychiatric and cognitive profiles in delirium, dementia, comorbid delirium-dementia and cognitively intact controls. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 876-881.	0.9	87
1443	The Effect of Spousal Bereavement on Cognitive Functioning in a Sample of Older Adults. <i>Aging, Neuropsychology, and Cognition</i> , 2010, 17, 257-269.	0.7	26
1444	Clinical Psychology and anxiety and depression in dementia. <i>Nordic Psychology</i> , 2010, 62, 44-54.	0.4	10
1445	Cerebrospinal Fluid Abnormalities and Rate of Decline in Everyday Function Across the Dementia Spectrum. <i>Archives of Neurology</i> , 2010, 67, 688.	4.9	69
1446	Serial MRI and CSF biomarkers in normal aging, MCI, and AD. <i>Neurology</i> , 2010, 75, 143-151.	1.5	137
1447	Magnetization transfer ratio may be a surrogate of spongiform change in human prion diseases. <i>Brain</i> , 2010, 133, 3058-3068.	3.7	10
1448	The Predictive Value of Memory Strategies for Alzheimer's Disease in Subjects with Mild Cognitive Impairment. <i>Archives of Clinical Neuropsychology</i> , 2010, 25, 71-77.	0.3	10
1449	Brain-water diffusion coefficients reflect the severity of inherited prion disease. <i>Neurology</i> , 2010, 74, 658-665.	1.5	7
1450	Longitudinal study of carbon monoxide intoxication by diffusion tensor imaging with neuropsychiatric correlation. <i>Journal of Psychiatry and Neuroscience</i> , 2010, 35, 115-125.	1.4	40

#	ARTICLE	IF	CITATIONS
1451	Double-Blind, Controlled Phase II Study of a 5-HT <sub>6</sub> Receptor Antagonist, SB-742457, in Alzheimers Disease. <i>Current Alzheimer Research</i> , 2010, 7, 374-385.	0.7	107
1452	Comparing predictors of conversion and decline in mild cognitive impairment. <i>Neurology</i> , 2010, 75, 230-238.	1.5	533
1453	Randomized, Placebo-Controlled, Clinical Trial of Donepezil in Vascular Dementia. <i>Stroke</i> , 2010, 41, 1213-1221.	1.0	138
1454	Correlation of Longitudinal Cerebrospinal Fluid Biomarkers With Cognitive Decline in Healthy Older Adults. <i>Archives of Neurology</i> , 2010, 67, 217-23.	4.9	99
1456	Total Scores of the CERAD Neuropsychological Assessment Battery: Validation for Mild Cognitive Impairment and Dementia Patients With Diverse Etiologies. <i>American Journal of Geriatric Psychiatry</i> , 2010, 18, 801-809.	0.6	84
1457	Caregiver Burden in Alzheimer Disease: Cross-Sectional and Longitudinal Patient Correlates. <i>American Journal of Geriatric Psychiatry</i> , 2010, 18, 917-927.	0.6	221
1458	Effects of Hormone Therapy on Depressive Symptoms and Cognitive Functions in Women With Alzheimer Disease: A 12 Month Randomized, Double-Blind, Placebo-Controlled Study of Low-Dose Estradiol and Norethisterone. <i>American Journal of Geriatric Psychiatry</i> , 2010, 18, 11-20.	0.6	52
1459	Cognitive tests used in chronic adult human randomised controlled trial micronutrient and phytochemical intervention studies. <i>Nutrition Research Reviews</i> , 2010, 23, 200-229.	2.1	30
1460	Nonpharmacological Therapies in Alzheimer's Disease: A Systematic Review of Efficacy. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 30, 161-178.	0.7	720
1461	Mapping Alzheimer's disease progression in 1309 MRI scans: Power estimates for different inter-scan intervals. <i>NeuroImage</i> , 2010, 51, 63-75.	2.1	79
1462	Twelve-month metabolic declines in probable Alzheimer's disease and amnesic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative. <i>NeuroImage</i> , 2010, 51, 654-664.	2.1	145
1463	Predicting clinical scores from magnetic resonance scans in Alzheimer's disease. <i>NeuroImage</i> , 2010, 51, 1405-1413.	2.1	235
1464	Neuropsychological Predictors of Dementia in a Three-Year Follow-Up Period: Data from the LADIS Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 325-334.	0.7	25
1466	Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease. <i>Neuroscience Letters</i> , 2010, 469, 6-10.	1.0	316
1468	Alterations of cholesterol precursor levels in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010, 1801, 945-950.	1.2	53
1469	Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 104-110.	2.5	51
1470	Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years. <i>Neurobiology of Aging</i> , 2010, 31, 215-223.	1.5	97
1471	Analysis of regional MRI volumes and thicknesses as predictors of conversion from mild cognitive impairment to Alzheimer's disease. <i>Neurobiology of Aging</i> , 2010, 31, 1375-1385.	1.5	104

#	ARTICLE	IF	CITATIONS
1472	The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. <i>Neurobiology of Aging</i> , 2010, 31, 1263-1274.	1.5	126
1473	Subregions of the inferior parietal lobule are affected in the progression to Alzheimer's disease. <i>Neurobiology of Aging</i> , 2010, 31, 1304-1311.	1.5	82
1474	Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans. <i>Neurobiology of Aging</i> , 2010, 31, 1463-1480.	1.5	181
1475	A pilot study of a test for visual recognition memory in adults with moderate to severe intellectual disability. <i>Research in Developmental Disabilities</i> , 2010, 31, 1475-1480.	1.2	5
1476	Efficacy of Rivastigmine on Executive Function in Patients with Parkinson's Disease Dementia. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 330-336.	1.9	26
1477	Alzheimer's Disease Neuroimaging Initiative (ADNI). <i>Neurology</i> , 2010, 74, 201-209.	1.5	1,530
1478	Ginseng for cognition. <i>The Cochrane Library</i> , 2010, , CD007769.	1.5	57
1479	CSF biomarkers predict a more malignant outcome in Alzheimer disease. <i>Neurology</i> , 2010, 74, 1531-1537.	1.5	182
1480	Neurogenesis and Alzheimer's disease: At the crossroads. <i>Experimental Neurology</i> , 2010, 223, 267-281.	2.0	259
1481	Influence of apolipoprotein E $\epsilon$ 4 on rates of cognitive and functional decline in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2010, 6, 412-419.	0.4	63
1482	Predicting cognitive decline in Alzheimer's disease: An integrated analysis. <i>Alzheimer's and Dementia</i> , 2010, 6, 431-439.	0.4	34
1483	Validation of the German Revised Addenbrooke's Cognitive Examination for Detecting Mild Cognitive Impairment, Mild Dementia in Alzheimer's Disease and Frontotemporal Lobar Degeneration. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 448-456.	0.7	53
1484	Subclinical Zinc Deficiency in Alzheimer's Disease and Parkinson's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2010, 25, 572-575.	0.9	117
1485	A Quick Test of cognitive speed is sensitive in detecting early treatment response in alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2010, 2, 29.	3.0	29
1486	Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?. <i>Alzheimer's Research and Therapy</i> , 2010, 2, 24.	3.0	91
1487	Predicting progression of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2010, 2, 2.	3.0	92
1488	Management of Mixed Dementia. <i>Drugs and Aging</i> , 2010, 27, 715-728.	1.3	15
1489	The effects of modified spaced-retrieval training on learning and retention of face-name associations by individuals with dementia. <i>Neuropsychological Rehabilitation</i> , 2010, 20, 81-102.	1.0	20



#	ARTICLE	IF	CITATIONS
1490	Effects of Donepezil, Galantamine and Rivastigmine in 938 Italian Patients with Alzheimer's Disease. CNS Drugs, 2010, 24, 163-176.	2.7	44
1491	Predictive Factors of Discontinuation and Switch of Cholinesterase Inhibitors in Community-Dwelling Patients with Alzheimer's Disease. CNS Drugs, 2010, 24, 431-442.	2.7	29
1492	Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. Current Medical Research and Opinion, 2011, 27, 1375-1383.	0.9	57
1493	Proinflammatory cytokines, sickness behavior, and Alzheimer disease. Neurology, 2011, 77, 212-218.	1.5	189
1494	Power Calculations for Clinical Trials in Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 26, 369-377.	1.2	59
1495	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Alzheimer's disease and other dementias. World Journal of Biological Psychiatry, 2011, 12, 2-32.	1.3	77
1496	Incidence and Subtypes of MCI and Dementia 1 Year after First-Ever Stroke in Patients without Pre-Existing Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2011, 32, 401-407.	0.7	71
1497	Cognitive Skills in the Charitable Giving Decisions of the Elderly. Educational Gerontology, 2011, 37, 559-573.	0.7	2
1498	A Randomized Controlled Trial of High-Dose Vitamin D2 Followed by Intranasal Insulin in Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 26, 477-484.	1.2	133
1499	Long-term Effects of Galantamine on Cognitive Function in Alzheimer's Disease: A Large-Scale International Retrospective Study. Journal of Alzheimer's Disease, 2011, 27, 521-530.	1.2	19
1500	CERAD Neuropsychological Battery Total Score in Multinational Mild Cognitive Impairment and Control Populations: The AddNeuroMed Study. Journal of Alzheimer's Disease, 2011, 22, 1089-1097.	1.2	40
1502	Attention Deficit, Hyperactivity Disorder. , 2011, , 292-295.		0
1503	Alexia Without Agraphia. , 2011, , 83-83.		1
1504	Alexia. , 2011, , 77-83.		0
1505	Arachnoid Cyst. , 2011, , 239-245.		0
1506	24-Month effect of smoking cessation on cognitive function and brain structure in later life. NeuroImage, 2011, 55, 1480-1489.	2.1	79
1507	AddNeuroMed and ADNI: Similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. NeuroImage, 2011, 58, 818-828.	2.1	121
1508	Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls. NeuroImage, 2011, 54, 1178-1187.	2.1	128

#	ARTICLE	IF	CITATIONS
1509	Fractionating verbal episodic memory in Alzheimer's disease. <i>NeuroImage</i> , 2011, 54, 1530-1539.	2.1	164
1510	The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 698-712.	21.5	1,766
1511	Structural Models Describing Placebo Treatment Effects in Schizophrenia and Other Neuropsychiatric Disorders. <i>Clinical Pharmacokinetics</i> , 2011, 50, 429-450.	1.6	34
1512	Antidepressants for agitation and psychosis in dementia. <i>The Cochrane Library</i> , 2011, , CD008191.	1.5	184
1513	Predictors of Family Caregiver Ratings of Patient Quality of Life in Alzheimer Disease: Cross-Sectional Results from the Canadian Alzheimer's Disease Quality of Life Study. <i>American Journal of Geriatric Psychiatry</i> , 2011, 19, 891-901.	0.6	43
1514	Validation of the relevant outcome scale for Alzheimer's disease: a novel multidomain assessment for daily medical practice. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 27.	3.0	21
1515	Predictors of long-term cognitive outcome in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 23.	3.0	72
1516	Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 22.	3.0	20
1517	For debate: substituting placebo controls in long-term Alzheimer's prevention trials. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 9.	3.0	14
1518	Acoustic Neuroma. , 2011, , 20-20.		0
1519	Effects of Socially Stimulating Group Intervention on Lonely, Older People's Cognition: A Randomized, Controlled Trial. <i>American Journal of Geriatric Psychiatry</i> , 2011, 19, 654-663.	0.6	86
1520	Predictors of Patient Self-Ratings of Quality of Life in Alzheimer Disease: Cross-Sectional Results From the Canadian Alzheimer's Disease Quality of Life Study. <i>American Journal of Geriatric Psychiatry</i> , 2011, 19, 881-890.	0.6	46
1521	The relative efficiency of time-to-threshold and rate of change in longitudinal data. <i>Contemporary Clinical Trials</i> , 2011, 32, 685-693.	0.8	25
1522	Regional cerebral blood flow and aberrant motor behaviour in Alzheimer's disease. <i>Behavioural Brain Research</i> , 2011, 222, 375-379.	1.2	13
1523	Changes in cerebral glucose metabolism in patients with mild-to-moderate Alzheimer's disease: A pilot study with the Chinese herbal medicine fuzhisan. <i>Neuroscience Letters</i> , 2011, 501, 35-40.	1.0	26
1524	Cognitive enhancement by drugs in health and disease. <i>Trends in Cognitive Sciences</i> , 2011, 15, 28-36.	4.0	223
1525	40-Hz steady state response in Alzheimer's disease and mild cognitive impairment. <i>Neurobiology of Aging</i> , 2011, 32, 24-30.	1.5	67
1526	Midlife homocysteine and late-life dementia in women. A prospective population study. <i>Neurobiology of Aging</i> , 2011, 32, 380-386.	1.5	68

#	ARTICLE	IF	CITATIONS
1527	Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. <i>Neurobiology of Aging</i> , 2011, 32, 1207-1218.	1.5	611
1528	Combination analysis of neuropsychological tests and structural MRI measures in differentiating AD, MCI and control groupsâ€”The AddNeuroMed study. <i>Neurobiology of Aging</i> , 2011, 32, 1198-1206.	1.5	69
1529	Alzheimer disease biomarkers are associated with body mass index. <i>Neurology</i> , 2011, 77, 1913-1920.	1.5	112
1530	Characterizing Alzheimer's disease using a hypometabolic convergence index. <i>NeuroImage</i> , 2011, 56, 52-60.	2.1	144
1531	Neuropsychological Assessment of the Dementias of Late Life. , 2011, , 339-352.		8
1532	A Multi-Center Randomized Proof-of-Concept Clinical Trial Applying [18F]FDG-PET for Evaluation of Metabolic Therapy with Rosiglitazone XR in Mild to Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1241-1256.	1.2	86
1533	Dimebolin in Dementia. <i>CNS Neuroscience and Therapeutics</i> , 2011, 17, 199-205.	1.9	12
1534	Effects of Cholinesterase Inhibitors in Parkinson's Disease Dementia: A Review of Clinical Data. <i>CNS Neuroscience and Therapeutics</i> , 2011, 17, 428-441.	1.9	61
1535	Should We Listen to People Affected by Dementia?. <i>CNS Neuroscience and Therapeutics</i> , 2011, 17, 1-3.	1.9	4
1536	Costs of care in a mildâ€”toâ€”moderate Alzheimer clinical trial sample: Key resources and their determinants. <i>Alzheimer's and Dementia</i> , 2011, 7, 466-473.	0.4	35
1537	Suitability of the Clinical Dementia Ratingâ€”Sum of Boxes as a single primary endpoint for Alzheimer's disease trials. <i>Alzheimer's and Dementia</i> , 2011, 7, 602.	0.4	79
1538	Longâ€”term progression of Alzheimer's disease in patients under antidementia drugs. <i>Alzheimer's and Dementia</i> , 2011, 7, 579-592.	0.4	60
1539	Assessment of cognition in early dementia. <i>Alzheimer's and Dementia</i> , 2011, 7, e60-e76.	0.4	75
1541	Does Adaptive Cognitive Testing Combine Efficiency with Precision? Prospective Findings. <i>Journal of Alzheimer's Disease</i> , 2011, 25, 595-603.	1.2	15
1543	Effects of Lacunar Infarctions on Cognitive Impairment in Patients with Cerebral Autosomal-Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy. <i>Journal of Clinical Neurology</i>		

#	ARTICLE	IF	CITATIONS
1547	Improved Proper Name Recall in Aging after Electrical Stimulation of the Anterior Temporal Lobes. <i>Frontiers in Aging Neuroscience</i> , 2011, 3, 16.	1.7	79
1548	Cognitive, functional and behavioral assessment: Alzheimer's disease. <i>Dementia E Neuropsychologia</i> , 2011, 5, 153-166.	0.3	22
1549	Sensitivity and Specificity of Medial Temporal Lobe Visual Ratings and Multivariate Regional MRI Classification in Alzheimer's Disease. <i>PLoS ONE</i> , 2011, 6, e22506.	1.1	103
1550	Phenserine Efficacy in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1201-1208.	1.2	62
1551	Effects of AZD3480 on Cognition in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase IIb Dose-Finding Study. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 363-374.	1.2	59
1552	Psychometric Comparison of Standard and Computerized Administration of the Alzheimers Disease Assessment Scale "Cognitive Subscale (ADASCog). <i>Current Alzheimer Research</i> , 2011, 8, 323-328.	0.7	12
1553	Effects of Galantamine in Alzheimers Disease: Double-blind Withdrawal Studies Evaluating Sustained Versus Interrupted Treatment. <i>Current Alzheimer Research</i> , 2011, 8, 771-780.	0.7	21
1554	Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies. <i>Current Alzheimer Research</i> , 2011, 8, 592-606.	0.7	166
1555	Errors in ADAS-Cog Administration and Scoring May Undermine Clinical Trials Results. <i>Current Alzheimer Research</i> , 2011, 8, 373-376.	0.7	10
1556	Patients in Australian Memory Clinics: baseline characteristics and predictors of decline at six months. <i>International Psychogeriatrics</i> , 2011, 23, 1086-1096.	0.6	39
1558	Unawareness of deficits in Alzheimer's disease: role of the cingulate cortex. <i>Brain</i> , 2011, 134, 1061-1076.	3.7	124
1559	Working memory task performance and chunking in early Alzheimer's disease. <i>British Journal of Psychiatry</i> , 2011, 198, 398-403.	1.7	47
1560	Effects of a Newly Developed Cognitive Intervention in Amnesic Mild Cognitive Impairment and mild Alzheimer's disease: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2011, 25, 679-694.	1.2	121
1561	Cost and Care of Patients with Alzheimer's Disease: Clinical Predictors in German Health Care Settings. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 723-736.	1.2	48
1562	Effects of a 6-Month Cognitive Intervention Program on Brain Metabolism in Amnesic Mild Cognitive Impairment and Mild Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 25, 695-706.	1.2	30
1563	Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 225-230.	0.7	62
1564	Effects of a 6-Month Cognitive Intervention on Brain Metabolism in Patients with Amnesic MCI and Mild Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 337-348.	1.2	45
1566	Donepezil treatment in Alzheimer's disease patients with and without cerebrovascular lesions: A preliminary report. <i>Geriatrics and Gerontology International</i> , 2011, 11, 90-97.	0.7	4

#	ARTICLE	IF	CITATIONS
1567	Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. <i>European Journal of Neurology</i> , 2011, 18, 59-68.	1.7	56
1568	The use of neuropsychological tests across Europe: the need for a consensus in the use of assessment tools for dementia. <i>European Journal of Neurology</i> , 2011, 18, 279-285.	1.7	42
1569	Touch Panel-type Dementia Assessment Scale: a new computer-based rating scale for Alzheimer's disease. <i>Psychogeriatrics</i> , 2011, 11, 28-33.	0.6	46
1570	Specific feature of olfactory dysfunction with Alzheimer's disease inspected by the Odor Stick Identification Test. <i>Psychogeriatrics</i> , 2011, 11, 196-204.	0.6	54
1571	REVERSIBLE LIMBIC ENCEPHALITIS IN A PERSON WITH ALZHEIMER'S DISEASE. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 757-759.	1.3	1
1572	REGIONAL MIGRATORY OSTEOPOROSIS IN OLDER ADULTS: A NEW TWIST TO AN OLD DISEASE. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 759-760.	1.3	1
1573	Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease. <i>International Journal of Clinical Practice</i> , 2011, 65, 465-471.	0.8	16
1574	Motor asymmetry and estimation of body-scaled aperture width in Parkinson's disease. <i>Neuropsychologia</i> , 2011, 49, 3002-3010.	0.7	8
1575	Cognitive activity for the treatment of older adults with mild Alzheimer's Disease (AD) - PACE AD: study protocol for a randomised controlled trial. <i>Trials</i> , 2011, 12, 47.	0.7	15
1576	Noninvasive brain stimulation in Alzheimer's disease: Systematic review and perspectives for the future. <i>Experimental Gerontology</i> , 2011, 46, 611-27.	1.2	128
1577	Longitudinal stability of subsyndromal symptoms of depression in individuals with mild cognitive impairment: relationship to conversion to dementia after 3 years. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 355-363.	1.3	22
1578	Galantamine: an update. <i>Neurodegenerative Disease Management</i> , 2011, 1, 227-234.	1.2	2
1579	Factors affecting A $\beta$ plasma levels and their utility as biomarkers in ADNI. <i>Acta Neuropathologica</i> , 2011, 122, 401-13.	3.9	151
1580	Beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer's disease: a proof of concept study. <i>Journal of Neural Transmission</i> , 2011, 118, 463-471.	1.4	188
1581	Entorhinal cortex volume measured with 3T MRI is positively correlated with the Wechsler Memory Scale-Revised logical/verbal memory score for healthy subjects. <i>Neuroradiology</i> , 2011, 53, 617-622.	1.1	18
1582	Do the effects of APOE- E4 on cognitive function and decline depend upon vitamin status? Macarthur studies of successful aging. <i>Journal of Nutrition, Health and Aging</i> , 2011, 15, 196-201.	1.5	18
1583	Incidence and predictive factors of depressive symptoms in Alzheimer's disease: The REAL.FR study. <i>Journal of Nutrition, Health and Aging</i> , 2011, 15, 609-617.	1.5	30
1584	Additive scales in degenerative disease - calculation of effect sizes and clinical judgment. <i>BMC Medical Research Methodology</i> , 2011, 11, 169.	1.4	3

#	ARTICLE	IF	CITATIONS
1585	Study of Mental Activity and Regular Training (SMART) in at risk individuals: A randomised double blind, sham controlled, longitudinal trial. BMC Geriatrics, 2011, 11, 19.	1.1	48
1586	Operationalizing multimorbidity and autonomy for health services research in aging populations - the OMAHA study. BMC Health Services Research, 2011, 11, 47.	0.9	18
1587	Alzheimer's disease - input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial. Trials, 2011, 12, 230.	0.7	42
1588	Cognitive correlates of visual hallucinations in dementia associated with Parkinson's disease. Movement Disorders, 2011, 26, 824-829.	2.2	32
1589	Cognitive impairment in nondemented Parkinson's disease. Movement Disorders, 2011, 26, 2483-2495.	2.2	115
1590	SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. International Journal of Geriatric Psychiatry, 2011, 26, 536-544.	1.3	91
1591	Apathy and cortical atrophy in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2011, 26, 741-748.	1.3	84
1592	Do patients diagnosed with Alzheimer's disease benefit from a psychoeducational programme for family caregivers? A randomised controlled study. International Journal of Geriatric Psychiatry, 2011, 26, 833-842.	1.3	66
1593	Caregivers' estimation of patients' quality of life (QoL) in Alzheimer's disease (AD): An approach using the ADRQL. Archives of Gerontology and Geriatrics, 2011, 53, 13-18.	1.4	29
1594	A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology, 2011, 77, 556-563.	1.5	269
1595	Terminal decline and practice effects in older adults without dementia. Neurology, 2011, 77, 722-730.	1.5	58
1596	A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology, 2011, 76, 1389-1394.	1.5	191
1598	Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. Brain, 2011, 134, 1479-1492.	3.7	118
1599	Influence of Lithium Treatment on GDNF Serum and CSF Concentrations in Patients with Early Alzheimers Disease. Current Alzheimer Research, 2011, 8, 853-859.	0.7	32
1600	Combination Treatment in Alzheimers Disease: Results of a Randomized, Controlled Trial with Cerebrolysin and Donepezil. Current Alzheimer Research, 2011, 8, 583-591.	0.7	53
1601	Neurocognitive Improvement After Carotid Artery Stenting in Patients With Chronic Internal Carotid Artery Occlusion and Cerebral Ischemia. Stroke, 2011, 42, 2850-2854.	1.0	76
1602	A multi-task learning formulation for predicting disease progression. , 2011, , .		171
1603	Effect of Cholinergic Stimulation in Early Alzheimers Disease - Functional Imaging During a Recognition Memory Task. Current Alzheimer Research, 2011, 8, 753-764.	0.7	14

#	ARTICLE	IF	CITATIONS
1604	EHT0202 in Alzheimers Disease: A 3-Month, Randomized, Placebo- Controlled, Double-Blind Study. Current Alzheimer Research, 2011, 8, 203-212.	0.7	108
1605	Mild Cognitive Impairment (MCI) - The Novel Trend of Targeting Alzheimers Disease in Its Early Stages - Methodological Considerations. Current Alzheimer Research, 2011, 8, 798-807.	0.7	11
1606	The importance of multiple assessments of object knowledge in semantic dementia: The case of the familiar objects task. Neurocase, 2011, 17, 57-75.	0.2	5
1607	Learning Characteristics of the CERAD Word List in an Elderly VA Sample. Applied Neuropsychology, 2011, 18, 157-163.	1.5	11
1608	Derivation of a New ADAS-cog Composite Using Tree-based Multivariate Analysis. Alzheimer Disease and Associated Disorders, 2011, 25, 73-84.	0.6	57
1609	Cognitive Effects of Atypical Antipsychotic Medications in Patients With Alzheimer's Disease: Outcomes From CATIE-AD. American Journal of Psychiatry, 2011, 168, 831-839.	4.0	232
1610	Disease-modifying properties of long-term lithium treatment for amnesic mild cognitive impairment: randomised controlled trial. British Journal of Psychiatry, 2011, 198, 351-356.	1.7	319
1611	Treatment With Cholinesterase Inhibitors and Memantine of Patients in the Alzheimer's Disease Neuroimaging Initiative. Archives of Neurology, 2011, 68, 58.	4.9	133
1612	A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology, 2011, 77, 1253-1262.	1.5	222
1613	Rivastigmine in Alzheimer's Disease and Parkinson's Disease Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2011, 26, 443-449.	0.9	37
1614	Erken DÄ¶nem Relapsing-Remitting Multipl Skleroz HastalarÄ±nda BiliÅŸsel Ä°ÅŸlev BozukluklarÄ±. Noropsikiyatri Arsivi, 2011, 48, 1-1.	0.7	0
1615	Relapsing-Remitting Multipl Skleroz HastalarÄ±nda Serum Äœerik Asit DÄ¶zeyinin Kognitif Fonksiyonlar ve Plak SayÄ±sÄ± ile Ä°liÅŸkisi. Noropsikiyatri Arsivi, 2011, 48, 1-1.	0.7	0
1616	Evaluation of a Summary Score of Cognitive Performance for Use in Trials in Perioperative and Critical Care. Dementia and Geriatric Cognitive Disorders, 2011, 31, 451-459.	0.7	11
1617	Efficacy of a cognitive stimulation therapy programme for people with dementia. Irish Journal of Psychological Medicine, 2011, 28, 145-147.	0.7	40
1618	Reliability and Validity of Food Frequency Questionnaire and Nutrient Biomarkers in Elders With and Without Mild Cognitive Impairment. Alzheimer Disease and Associated Disorders, 2011, 25, 49-57.	0.6	43
1619	Adding Delayed Recall to the Alzheimer Disease Assessment Scale is Useful in Studies of Mild Cognitive Impairment But Not Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2011, 25, 122-127.	0.6	51
1620	PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2011, 25, 206-212.	0.6	134
1621	Designing clinical trials to test disease-modifying agents: application to the treatment trials of Alzheimer's disease. Clinical Trials, 2011, 8, 15-26.	0.7	9

#	ARTICLE	IF	CITATIONS
1622	The impact of Cognitive Stimulation Therapy groups on people with dementia: Views from participants, their carers and group facilitators. <i>Aging and Mental Health</i> , 2011, 15, 945-949.	1.5	85
1623	The impact of anticholinergic burden in Alzheimer's Dementia-the Laser-AD study. <i>Age and Ageing</i> , 2011, 40, 730-735.	0.7	80
1624	Effect of Literacy and Education on the Visuoconstructional Ability of Non-demented Elderly Individuals. <i>Journal of the International Neuropsychological Society</i> , 2011, 17, 934-939.	1.2	23
1625	Sustainable Living In Long-term Care: For People with Dementia/Alzheimer's. <i>Educational Gerontology</i> , 2011, 37, 526-547.	0.7	6
1626	Volumes of Lateral Temporal and Parietal Structures Distinguish Between Healthy Aging, Mild Cognitive Impairment, and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 719-734.	1.2	44
1627	The Effect of Vascular Risk Factors on the Efficacy of Rivastigmine Patch and Capsule Treatment in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2011, 1, 150-162.	0.6	8
1628	A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2011, 1, 163-179.	0.6	47
1629	Measuring Therapeutic Efficacy in Patients with Alzheimer's Disease: Role of Instruments. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 233-238.	0.7	8
1630	Spanish Multicenter Normative Studies (Neuronorma Project): Norms for the Abbreviated Barcelona Test. <i>Archives of Clinical Neuropsychology</i> , 2011, 26, 144-157.	0.3	36
1631	Norms for CERAD Constructional Praxis Recall. <i>Clinical Neuropsychologist</i> , 2011, 25, 1345-1358.	1.5	19
1632	A Randomized Pilot Clinical Trial of the Safety of Pioglitazone in Treatment of Patients With Alzheimer Disease. <i>Archives of Neurology</i> , 2011, 68, 45-50.	4.9	183
1633	PRION-1 scales analysis supports use of functional outcome measures in prion disease. <i>Neurology</i> , 2011, 77, 1674-1683.	1.5	33
1634	Cognitive effects of video games on old people. <i>International Journal on Disability and Human Development</i> , 2011, 10, .	0.2	29
1635	Brief Memory and Executive Test: evaluation of a new screening test for cognitive impairment due to small vessel disease. <i>Age and Ageing</i> , 2012, 41, 212-218.	0.7	33
1636	Heat-processed ginseng enhances the cognitive function in patients with moderately severe Alzheimer's disease. <i>Nutritional Neuroscience</i> , 2012, 15, 278-282.	1.5	43
1637	What is the clinically relevant change on the ADAS-Cog?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 171-173.	0.9	117
1638	Cerebrospinal Fluid Cytokine Dynamics Differ Between Alzheimer Disease Patients and Elderly Controls. <i>Alzheimer Disease and Associated Disorders</i> , 2012, 26, 322-328.	0.6	38
1639	Rivastigmine Treatment for the Prevention of Electroconvulsive Therapy-Induced Memory Deficits in Patients With Schizophrenia. <i>Clinical Neuropharmacology</i> , 2012, 35, 161-164.	0.2	14



#	ARTICLE	IF	CITATIONS
1640	Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2012, 69, 29.	4.9	1,073
1641	Symptomatic and Nonamyloid/Tau Based Pharmacologic Treatment for Alzheimer Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006395-a006395.	2.9	57
1642	Randomized, Double-Blind, Parallel-Group, 48-Week Study for Efficacy and Safety of a Higher-Dose Rivastigmine Patch (15 vs. 10 cm <sup>2</sup> ) in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 33, 341-353.	0.7	88
1643	Was Phenserine a Failure or Were Investigators Mislead by Methods?. <i>Current Alzheimer Research</i> , 2012, 9, 1174-1181.	0.7	18
1644	Reviewing the Role of Donepezil in the Treatment of Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2012, 9, 773-781.	0.7	26
1645	Guidelines for the Management of Cognitive and Behavioral Problems in Dementia. <i>Journal of the American Board of Family Medicine</i> , 2012, 25, 350-366.	0.8	107
1646	Association of Cerebral Emboli With Accelerated Cognitive Deterioration in Alzheimer's Disease and Vascular Dementia. <i>American Journal of Psychiatry</i> , 2012, 169, 300-308.	4.0	35
1647	Optimum Design of Disease-Modifying Trials on Alzheimer's Disease. <i>Statistics in Biopharmaceutical Research</i> , 2012, 4, 216-227.	0.6	0
1648	Silicon-Rich Mineral Water as a Non-Invasive Test of the "Aluminum Hypothesis" in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 33, 423-430.	1.2	51
1649	Plasma Transthyretin as a Candidate Marker for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 369-375.	1.2	86
1650	Construct Validity of the Montreal Cognitive Assessment (MoCA). <i>Journal of the International Neuropsychological Society</i> , 2012, 18, 242-250.	1.2	124
1651	Montreal Cognitive Assessment (MoCA): Validation Study for Vascular Dementia. <i>Journal of the International Neuropsychological Society</i> , 2012, 18, 1031-1040.	1.2	108
1652	A Systematic Review of Screening Tools for Predicting the Development of Dementia. <i>Canadian Journal on Aging</i> , 2012, 31, 295-311.	0.6	34
1653	MxA Polymorphisms Are Associated with Risk and Age-at-Onset in Alzheimer Disease and Accelerated Cognitive Decline in Chinese Elders. <i>Rejuvenation Research</i> , 2012, 15, 516-522.	0.9	8
1654	CSF Biomarker and PIB-PET-Derived Beta-Amyloid Signature Predicts Metabolic, Gray Matter, and Cognitive Changes in Nondemented Subjects. <i>Cerebral Cortex</i> , 2012, 22, 1993-2004.	1.6	92
1655	Assessment scales in dementia. <i>Therapeutic Advances in Neurological Disorders</i> , 2012, 5, 349-358.	1.5	244
1656	The Short Cognitive Evaluation Battery in Cognitive Disorders of the Elderly " Italian Version. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 33, 255-265.	0.7	3
1657	Response to Rivastigmine Transdermal Patch or Memantine plus Rivastigmine Patch is affected by Apolipoprotein E Genotype in Alzheimer Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 34, 167-173.	0.7	15

#	ARTICLE	IF	CITATIONS
1658	Systematic Review of Neuropsychological Outcomes in Dementia from Cognition-Based Psychological Interventions. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 34, 244-255.	0.7	34
1659	Blood Pressure Trajectories From Midlife to Late Life in Relation to Dementia in Women Followed for 37 Years. <i>Hypertension</i> , 2012, 59, 796-801.	1.3	129
1660	Efficacy of a Multimodal Cognitive Rehabilitation Including Psychomotor and Endurance Training in Parkinson's Disease. <i>Journal of Aging Research</i> , 2012, 2012, 1-15.	0.4	57
1661	Age and Rate of Cognitive Decline in Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 901-5.	4.9	68
1662	A Lower Prevalence of Self-Reported Fear of Falling Is Associated with Memory Decline among Older Adults. <i>Gerontology</i> , 2012, 58, 413-418.	1.4	35
1663	An Open-Label Exploratory Study with Memantine: Correlation between Proton Magnetic Resonance Spectroscopy and Cognition in Patients with Mild to Moderate Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012, 2, 312-320.	0.6	14
1664	Recommended Measures for the Assessment of Cognitive and Physical Performance in Older Patients with Dementia: A Systematic Review. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012, 2, 589-609.	0.6	90
1665	JO3â€¦The potential of a composite cognitive score for tracking progression in Huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, A36.3-A36.	0.9	0
1666	White Matter Lesion Progression in LADIS. <i>Stroke</i> , 2012, 43, 2643-2647.	1.0	88
1667	Transthyretin Decrease in Plasma of MCI and AD Patients: Investigation of Mechanisms for Disease Modulation. <i>Current Alzheimer Research</i> , 2012, 9, 881-889.	0.7	48
1668	Sulcal Span in Alzheimer's Disease, Amnesic Mild Cognitive Impairment, and Healthy Controls. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 605-613.	1.2	20
1669	Mitochondrial Dysfunction and Immune Activation are Detectable in Early Alzheimer's Disease Blood. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 685-710.	1.2	141
1670	Maternal Family History is Associated with Alzheimer's Disease Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 659-668.	1.2	53
1671	Pilot Randomized Controlled Study of a Histamine Receptor Inverse Agonist in the Symptomatic Treatment of AD. <i>Current Alzheimer Research</i> , 2012, 9, 481-490.	0.7	36
1672	Pilot Study of Granulocyte-Colony Stimulating Factor for Treatment of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 843-855.	1.2	39
1673	Case study in SenseCam use as an intervention technology for early-stage dementia. <i>International Journal of Computers in Healthcare</i> , 2012, 1, 304.	0.5	17
1674	Antipsychotic Use and Mortality Risk in Community-Dwelling Alzheimer's Disease Patients: Evidence for a Role of Dementia Severity. <i>Current Alzheimer Research</i> , 2012, 9, 1106-1116.	0.7	32
1675	CIBIC Plus-J Assessment Using a Videotaped Method in Alzheimer's Disease Patients. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012, 2, 271-277.	0.6	3

#	ARTICLE	IF	CITATIONS
1676	Effect of Homocysteine Lowering Treatment on Cognitive Function: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 133-149.	1.2	114
1677	The Effect of an Aloe Polymannose Multinutrient Complex on Cognitive and Immune Functioning in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 33, 393-406.	1.2	23
1678	Improvement of Semantic Categorization through Procedural Learning in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 121-129.	1.2	10
1679	Memantine and Brain Atrophy in Alzheimer's Disease: A 1-Year Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 459-469.	1.2	35
1680	Capacity to make decisions on medication management in Chinese older persons with mild cognitive impairment and mild Alzheimer's disease. <i>International Psychogeriatrics</i> , 2012, 24, 1103-1111.	0.6	20
1681	Frontotemporal atrophy associated with paranoid delusions in women with Alzheimer's disease. <i>International Psychogeriatrics</i> , 2012, 24, 99-107.	0.6	36
1682	Improving the Accuracy and Precision of Cognitive Testing in Mild Dementia. <i>Journal of the International Neuropsychological Society</i> , 2012, 18, 314-322.	1.2	15
1683	Metal protein attenuating compounds for the treatment of Alzheimer's dementia. , 2012, , CD005380.		21
1684	Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2012, 8, 261-271.	0.4	240
1685	Design of Clinical Development Programs. , 2012, , 571-593.		0
1686	Increased Cerebral Metabolism After 1 Year of Deep Brain Stimulation in Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 1141-8.	4.9	148
1687	Tandem deep brain stimulation – Challenging new structural targets for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S171-S173.	1.1	6
1688	Amyloid deposition, hypometabolism, and longitudinal cognitive decline. <i>Annals of Neurology</i> , 2012, 72, 578-586.	2.8	559
1689	Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort. <i>European Journal of Health Economics</i> , 2012, 13, 561-568.	1.4	5
1690	Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: a beta regression meta-analysis. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2012, 39, 479-498.	0.8	70
1691	Neuropsychology of Alzheimer's Disease. <i>Archives of Medical Research</i> , 2012, 43, 686-693.	1.5	46
1692	Gaining precision on the Alzheimer's Disease Assessment Scale – cognitive: A comparison of item response theory-based scores and total scores. <i>Alzheimer's and Dementia</i> , 2012, 8, 288-294.	0.4	45
1694	Personality Factors Moderate the Associations Between Apolipoprotein Genotype and Cognitive Function as Well as Late Onset Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 1026-1035.	0.6	33

#	ARTICLE	IF	CITATIONS
1695	Cognitive Outcomes After Sertaline Treatment in Patients With Depression of Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 1036-1044.	0.6	41
1696	Normative data of a brief neuropsychological battery for Spanish individuals older than 49. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012, 34, 209-219.	0.8	63
1697	Measuring clinical progression in MCI and pre-MCI populations: enrichment and optimizing clinical outcomes over time. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 24.	3.0	28
1698	Tailored Information and Automated Reminding to Improve Medication Adherence in Spanish- and English-Speaking Elders Treated for Memory Impairment. <i>Clinical Gerontologist</i> , 2012, 35, 221-238.	1.2	29
1699	Weight Loss and Rapid Cognitive Decline in Community-Dwelling Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 647-654.	1.2	113
1700	Tocopherols and tocotrienols plasma levels are associated with cognitive impairment. <i>Neurobiology of Aging</i> , 2012, 33, 2282-2290.	1.5	134
1701	Effects of omega-3 fatty acids on cognitive performance: a meta-analysis. <i>Neurobiology of Aging</i> , 2012, 33, 1482.e17-1482.e29.	1.5	190
1702	A community-based exercise programme to improve functional ability in people with Alzheimer's disease: a randomized controlled trial. <i>Scandinavian Journal of Caring Sciences</i> , 2012, 26, 12-19.	1.0	217
1703	Alzheimer's disease risk factor complement receptor 1 is associated with depression. <i>Neuroscience Letters</i> , 2012, 510, 6-9.	1.0	18
1704	Carotid stenting improves cognitive function in asymptomatic cerebral ischemia. <i>International Journal of Cardiology</i> , 2012, 157, 104-107.	0.8	48
1705	Empirical derivation of the reference region for computing diagnostic sensitive 18fluorodeoxyglucose ratios in Alzheimer's disease based on the ADNI sample. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 457-466.	1.8	23
1706	Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients. <i>Diabetes Research and Clinical Practice</i> , 2012, 98, 68-74.	1.1	47
1707	Donepezil in Parkinson's disease dementia: A randomized, double-blind efficacy and safety study. <i>Movement Disorders</i> , 2012, 27, 1230-1238.	2.2	158
1708	Memory and Executive Screening (MES): a brief cognitive test for detecting mild cognitive impairment. <i>BMC Neurology</i> , 2012, 12, 119.	0.8	50
1709	Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort. <i>BMC Neurology</i> , 2012, 12, 134.	0.8	20
1710	Are the effects of a non-drug multimodal activation therapy of dementia sustainable? Follow-up study 10 months after completion of a randomised controlled trial. <i>BMC Neurology</i> , 2012, 12, 151.	0.8	37
1711	Study protocol: EXERcise and Cognition In Sedentary adults with Early-ONset dementia (EXERCISE-ON). <i>BMC Neurology</i> , 2012, 12, 75.	0.8	14
1712	Rationale and design of a double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of nimodipine in preventing cognitive impairment in ischemic cerebrovascular events (NICE). <i>BMC Neurology</i> , 2012, 12, 88.	0.8	18

#	ARTICLE	IF	CITATIONS
1713	Individual Cognitive Stimulation Therapy for dementia (iCST): study protocol for a randomized controlled trial. <i>Trials</i> , 2012, 13, 172.	0.7	33
1714	Serial position effects in Alzheimer's disease, mild cognitive impairment, and normal aging: Predictive value for conversion to dementia. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012, 34, 841-852.	0.8	35
1715	CSF Biomarkers Correlate with Cerebral Blood Flow on SPECT in Healthy Elderly. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 33, 156-163.	0.7	14
1716	Correlations between atrophy of the entorhinal cortex and cognitive function in patients with Alzheimer's disease and mild cognitive impairment. <i>Psychiatry and Clinical Neurosciences</i> , 2012, 66, 587-593.	1.0	20
1717	Vitamin E for Alzheimer's dementia and mild cognitive impairment. , 2012, 11, CD002854.		110
1718	Non-cognitive outcomes in trials of disease-modifying drugs for Alzheimer's disease. <i>European Geriatric Medicine</i> , 2012, 3, 37-42.	1.2	2
1719	Multi-modal multi-task learning for joint prediction of multiple regression and classification variables in Alzheimer's disease. <i>NeuroImage</i> , 2012, 59, 895-907.	2.1	576
1720	Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer's disease after 12-week donepezil treatment. <i>NeuroImage</i> , 2012, 60, 1083-1091.	2.1	98
1721	Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. <i>The Cochrane Library</i> , 2014, 2014, CD006504.	1.5	224
1722	Longitudinal change in neuropsychological performance using latent growth models: a study of mild cognitive impairment. <i>Brain Imaging and Behavior</i> , 2012, 6, 540-550.	1.1	53
1723	The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI. <i>Brain Imaging and Behavior</i> , 2012, 6, 489-501.	1.1	117
1724	Cortical signatures of cognition and their relationship to Alzheimer's disease. <i>Brain Imaging and Behavior</i> , 2012, 6, 584-598.	1.1	24
1726	The 1-Month Prevalence of Generalized Anxiety Disorder According to DSM-IV, DSM-V, and ICD-10 Among Nondemented 75-Year-Olds in Gothenburg, Sweden. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 963-972.	0.6	13
1727	Montreal Cognitive Assessment (MoCA): Validation study for Frontotemporal Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2012, 25, 146-154.	1.2	66
1728	White-Matter Lesions without Lacunar Infarcts in CADASIL. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 903-911.	1.2	20
1729	Cholinesterase inhibitors for mild cognitive impairment. <i>The Cochrane Library</i> , 2016, 2016, CD009132.	1.5	103
1730	Cognitive stimulation to improve cognitive functioning in people with dementia. <i>The Cochrane Library</i> , 2012, , CD005562.	1.5	443
1731	Activities of daily living in dementia: revalidation of the E-ADL test and suggestions for further development. <i>BMC Psychiatry</i> , 2012, 12, 208.	1.1	27

#	ARTICLE	IF	CITATIONS
1732	Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: The AIBL Active trial. <i>BMC Psychiatry</i> , 2012, 12, 167.	1.1	40
1733	Test-Retest Reliability of a New Medial Temporal Atrophy Morphological Metric. <i>International Journal of Alzheimer's Disease</i> , 2012, 2012, 1-6.	1.1	2
1734	Neuroimaging Studies in Carbon Monoxide Intoxication. , 0, , .		6
1735	Antipsychotics Versus Cholinesterase Inhibitors for the Treatment of Psychosis in Alzheimer's : A Critical Review. , 2012, , .		0
1736	4.5 Literatur. , 2012, , .		0
1737	Relations between cognitive status and medication adherence in patients treated for memory disorders. <i>Ageing Research</i> , 2012, 3, 2.	0.8	4
1738	Evaluaci3n de la cognici3n, la conducta y la funcionalidad de las personas mayores dependientes en los centros residenciales. <i>Comunitania Revista Internacional De Trabajo Social Y Ciencias Sociales</i> , 2012, , 71-91.	0.0	0
1739	Memory loss. <i>Medical Journal of Australia</i> , 2012, 196, 114-117.	0.8	5
1740	Amygdala in Alzheimer's Disease. , 0, , .		4
1741	Amyloid-Î²â€Associated Clinical Decline Occurs Only in the Presence of Elevated P-tau. <i>Archives of Neurology</i> , 2012, 69, 709-13.	4.9	122
1742	Cognitive Assessment. , 2012, , 15-65.		0
1743	A review of the effects of memantine on clinical progression in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 769-776.	1.3	52
1744	Gene by neuroticism interaction and cognitive function among older adults. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 1147-1154.	1.3	14
1746	Specificity of transcranial sonography in parkinson spectrum disorders in comparison to degenerative cognitive syndromes. <i>BMC Neurology</i> , 2012, 12, 12.	0.8	20
1747	Detecting treatment effects with combinations of the ADASâ€cog items in patients with mild and moderate Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 15-21.	1.3	18
1748	Hippocampal Subregions are Differentially Affected in the Progression to Alzheimer's Disease. <i>Anatomical Record</i> , 2012, 295, 132-140.	0.8	34
1749	Dietary protein intake in community-dwelling, frail, and institutionalized elderly people: scope for improvement. <i>European Journal of Nutrition</i> , 2012, 51, 173-179.	1.8	237
1750	Predictors of comprehensive stimulation program efficacy in patients with cognitive impairment. Clinical practice recommendations. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 26-33.	1.3	19

#	ARTICLE	IF	CITATIONS
1751	Memantine effects measured with the Relevant Outcome Scale for Alzheimer's disease in an open-label, single-arm, multicenter clinical study. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 164-172.	1.3	5
1752	Cognitive stimulation therapy (CST) for people with dementia" who benefits most?. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 284-290.	1.3	97
1753	Conclusion: Place of Cognitive Screening Instruments: Test Characteristics and Suspected Diagnosis. , 2013, , 219-238.		3
1754	Factors associated with life-space in older adults with amnesic mild cognitive impairment. <i>Geriatrics and Gerontology International</i> , 2013, 13, 161-166.	0.7	28
1755	Modeling the heterogeneity in risk of progression to Alzheimer's disease across cognitive profiles in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 14.	3.0	28
1756	Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 2.	3.0	16
1758	Potentially inappropriate medication use among patients with Alzheimer disease in the REAL.FR cohort: be aware of atropinic and benzodiazepine drugs!. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1589-1597.	0.8	68
1759	Recommendations for ICT use in Alzheimer's disease assessment: Monaco CTAD expert meeting. <i>Journal of Nutrition, Health and Aging</i> , 2013, 17, 653-660.	1.5	43
1760	Gait variability at fast-pace walking speed: A biomarker of mild cognitive impairment?. <i>Journal of Nutrition, Health and Aging</i> , 2013, 17, 235-239.	1.5	107
1761	Semi-Supervised Multimodal Relevance Vector Regression Improves Cognitive Performance Estimation from Imaging and Biological Biomarkers. <i>Neuroinformatics</i> , 2013, 11, 339-353.	1.5	20
1762	Persistent use of Analgesic Medications in Mild-to-Moderate Alzheimer's Disease. <i>Drugs and Aging</i> , 2013, 30, 439-445.	1.3	9
1763	Repetitive transcranial magnetic stimulation combined with cognitive training is a safe and effective modality for the treatment of Alzheimer's disease: a randomized, double-blind study. <i>Journal of Neural Transmission</i> , 2013, 120, 813-819.	1.4	175
1764	Comparison of the utility of everyday memory test and the Alzheimer's Disease Assessment Scale-Cognitive part for evaluation of mild cognitive impairment and very mild Alzheimer's disease. <i>Psychiatry and Clinical Neurosciences</i> , 2013, 67, 148-153.	1.0	10
1765	Amyloid positron emission tomography with <sup>18</sup> F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2013, 9, 295-301.	0.4	51
1766	The ADAS-Cog revisited: Novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials. <i>Alzheimer's and Dementia</i> , 2013, 9, S21-31.	0.4	69
1767	Mapping creatinine- and cystatin C-related white matter brain deficits in the elderly. <i>Neurobiology of Aging</i> , 2013, 34, 1221-1230.	1.5	19
1768	Sex and ApoE Genotype Differences in Treatment Response to Two Doses of Intranasal Insulin in Adults with Mild Cognitive Impairment or Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 789-797.	1.2	186
1769	Current and Emerging Therapies for Alzheimer's Disease. <i>Clinical Therapeutics</i> , 2013, 35, 1480-1489.	1.1	28

#	ARTICLE	IF	CITATIONS
1770	Premorbid IQ Influence on Screening Testsâ€™ Scores in Healthy Patients and Patients With Cognitive Impairment. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2013, 26, 117-126.	1.2	30
1771	Evidence for the Efficacy of Latrepirdine (Dimebon) Treatment for Improvement of Cognitive Function: A Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2013, 38, 155-164.	1.2	35
1772	Imidafenacin on bladder and cognitive function in neurologic OAB patients. <i>Clinical Autonomic Research</i> , 2013, 23, 189-195.	1.4	21
1773	Testosterone effect on brain metabolism in elderly patients with Alzheimerâ€™s disease: comparing two cases at different disease stages. <i>Aging Clinical and Experimental Research</i> , 2013, 25, 343-347.	1.4	10
1774	Ascertainment bias in dementias: a secondary to tertiary centre analysis in Central Italy and conceptual review. <i>Aging Clinical and Experimental Research</i> , 2013, 25, 265-274.	1.4	5
1775	Association between illness progression measures and total cost in Alzheimer's disease. <i>Journal of Nutrition, Health and Aging</i> , 2013, 17, 745-750.	1.5	13
1776	The Receiver Operational Characteristic for Binary Classification with Multiple Indices and Its Application to the Neuroimaging Study of Alzheimer's Disease. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2013, 10, 173-180.	1.9	20
1777	Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. <i>Neurobiology of Aging</i> , 2013, 34, 62-72.	1.5	49
1778	Association of the Recovery of Objective Abnormal Cerebral Perfusion With Neurocognitive Improvement After Carotid Revascularization. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2503-2509.	1.2	46
1779	Putting the Alzheimer's cognitive test to the test II: Rasch Measurement Theory. , 2013, 9, S10-S20.		41
1780	Effectiveness of regional DTI measures in distinguishing Alzheimer's disease, MCI, and normal aging. <i>NeuroImage: Clinical</i> , 2013, 3, 180-195.	1.4	277
1781	Study design of Aspirin in Reducing Events in the Elderly (ASPREE): A randomized, controlled trial. <i>Contemporary Clinical Trials</i> , 2013, 36, 555-564.	0.8	212
1782	Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: A new approach. <i>Alzheimer's and Dementia</i> , 2013, 9, S56-60.	0.4	12
1783	The Effect of Subsyndromal Symptoms of Depression and White Matter Lesions on Disability for Individuals with Mild Cognitive Impairment. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 906-914.	0.6	45
1784	Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials. <i>Alzheimer's and Dementia</i> , 2013, 9, S45-55.	0.4	96
1785	Neuropsychologic assessment in collaborative Parkinson's disease research: A proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and the University of Washington. <i>Alzheimer's and Dementia</i> . 2013. 9. 609-614.	0.4	24
1786	Cognition and Amyloid Load in Alzheimer Disease Imaged With Flortetapir F 18(AV-45) Positron Emission Tomography. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 272-278.	0.6	44
1787	Deep Brain Stimulation for the Treatment of Alzheimer Disease and Dementias. <i>World Neurosurgery</i> , 2013, 80, S28.e1-S28.e8.	0.7	89



#	ARTICLE	IF	CITATIONS
1788	Wrist actigraphy for measuring sleep in intervention studies with Alzheimer's disease patients: Application, usefulness, and challenges. <i>Sleep Medicine Reviews</i> , 2013, 17, 475-488.	3.8	77
1789	ETNA3, a clinical randomized study assessing three cognitive-oriented therapies in dementia: Rationale and general design. <i>Revue Neurologique</i> , 2013, 169, 752-756.	0.6	9
1790	Fire in the ashes: Can failed Alzheimer's disease drugs succeed with second chances?. <i>Alzheimer's and Dementia</i> , 2013, 9, 50-57.	0.4	32
1791	Modeling disease progression via multi-task learning. <i>NeuroImage</i> , 2013, 78, 233-248.	2.1	174
1792	Impact of behavioral subsyndromes on cognitive decline in Alzheimer's disease: data from the ICTUS study. <i>Journal of Neurology</i> , 2013, 260, 1859-1865.	1.8	35
1793	Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer's disease patients. <i>Clinical Neurophysiology</i> , 2013, 124, 837-850.	0.7	77
1794	Different multivariate techniques for automated classification of MRI data in Alzheimer's disease and mild cognitive impairment. <i>Psychiatry Research - Neuroimaging</i> , 2013, 212, 89-98.	0.9	98
1795	Cognitive Rehabilitation Therapies for Alzheimer's Disease: A Review of Methods to Improve Treatment Engagement and Self-Efficacy. <i>Neuropsychology Review</i> , 2013, 23, 48-62.	2.5	131
1796	Clinical Trials in Predementia Stages of Alzheimer Disease. <i>Medical Clinics of North America</i> , 2013, 97, 439-457.	1.1	46
1797	Florbetapir (F18- <sup>AV</sup> 45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. <i>Alzheimer's and Dementia</i> , 2013, 9, S72-83.	0.4	200
1798	An MRI-based index to measure the severity of Alzheimer's disease-like structural pattern in subjects with mild cognitive impairment. <i>Journal of Internal Medicine</i> , 2013, 273, 396-409.	2.7	53
1799	Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 6.	3.0	98
1800	Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 12.	3.0	11
1801	Rivastigmine for vascular cognitive impairment. <i>The Cochrane Library</i> , 2013, , CD004744.	1.5	57
1802	The Sydney Centenarian Study: methodology and profile of centenarians and near-centenarians. <i>International Psychogeriatrics</i> , 2013, 25, 993-1005.	0.6	49
1803	A Randomized Placebo-Controlled Pilot Trial of Omega-3 Fatty Acids and Alpha Lipoic Acid in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 38, 111-120.	1.2	210
1804	South Asian and Middle Eastern American Older Adults: Dementia, Mood Disorders, and Anxiety Disorders. <i>Clinical Gerontologist</i> , 2013, 36, 216-240.	1.2	9
1805	Patients with hepatitis C infection and normal liver function: an evaluation of cognitive function. <i>Postgraduate Medical Journal</i> , 2013, 89, 433-439.	0.9	27

#	ARTICLE	IF	CITATIONS
1806	A Meta-Analysis of the Efficacy of Donepezil, Rivastigmine, Galantamine, and Memantine in Relation to Severity of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 349-361.	1.2	136
1807	Efficacy of increasing donepezil in mild to moderate Alzheimer's disease patients who show a diminished response to 5 mg donepezil: a preliminary study. <i>Psychogeriatrics</i> , 2013, 13, 88-93.	0.6	13
1808	Higher Rates of Decline for Women and Apolipoprotein E4 Carriers. <i>American Journal of Neuroradiology</i> , 2013, 34, 2287-2293.	1.2	152
1809	Dimensions of physical frailty and cognitive function in older adults with amnesic mild cognitive impairment. <i>Annals of Physical and Rehabilitation Medicine</i> , 2013, 56, 329-341.	1.1	45
1810	The GERAS Study: A Prospective Observational Study of Costs and Resource Use in Community Dwellers with Alzheimer's Disease in Three European Countries – Study Design and Baseline Findings. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 385-399.	1.2	129
1811	Prediction of Alzheimer's disease and mild cognitive impairment using cortical morphological patterns. <i>Human Brain Mapping</i> , 2013, 34, 3411-3425.	1.9	215
1812	Cognitive Interventions in Mild Alzheimer's Disease: A Therapy-Evaluation Study on the Interaction of Medication and Cognitive Treatment. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2013, 3, 301-311.	0.6	16
1813	Impact of behavioral symptoms on patients with Alzheimer's disease. <i>Middle East Current Psychiatry</i> , 2013, 20, 235-241.	0.5	0
1814	Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. <i>BMJ Open</i> , 2013, 3, e002881.	0.8	66
1815	Diagnosing Mild Cognitive Impairment (MCI) in clinical trials: a systematic review. <i>BMJ Open</i> , 2013, 3, e001909.	0.8	115
1817	Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. <i>Cmaj</i> , 2013, 185, 1393-1401.	0.9	158
1818	Rivastigmine for HIV-associated neurocognitive disorders. <i>Neurology</i> , 2013, 80, 553-560.	1.5	32
1819	The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Utility in Detection and Characterization of Mild Cognitive Impairment due to Alzheimer's Disease. <i>Archives of Clinical Neuropsychology</i> , 2013, 28, 837-844.	0.3	86
1820	The Mini-Kingston Standardized Cognitive Assessment. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2013, 28, 239-244.	0.9	2
1821	Cognitive dysfunction: an important extrahepatic manifestation of hepatitis C infection?. <i>Postgraduate Medical Journal</i> , 2013, 89, 431-432.	0.9	6
1822	Implementación de un programa de estimulación cognitiva en personas con demencia tipo Alzheimer: un estudio piloto en chilenos de la tercera edad. <i>Universitas Psychologica</i> , 2013, 12, .	0.6	9
1823	Subgroup of ADNI normal controls characterized by atrophy and cognitive decline associated with vascular damage.. <i>Psychology and Aging</i> , 2013, 28, 191-201.	1.4	32
1824	A Systematic Review and Meta-Analysis of Ginkgo biloba in Neuropsychiatric Disorders: From Ancient Tradition to Modern-Day Medicine. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-11.	0.5	50

#	ARTICLE	IF	CITATIONS
1825	Preserving Cognition, Quality of Life, Physical Health and Functional Ability in Alzheimer's Disease: The Effect of Physical Exercise (ADEX Trial): Rationale and Design. <i>Neuroepidemiology</i> , 2013, 41, 198-207.	1.1	44
1826	Montreal Cognitive Assessment. <i>Alzheimer Disease and Associated Disorders</i> , 2013, 27, 37-43.	0.6	356
1827	Concentration of Donepezil to the Cognitive Response in Alzheimer Disease. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 351-355.	0.7	26
1828	Male Sex Hormones and Systemic Inflammation in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2013, 27, 153-156.	0.6	41
1829	Effects of Memantine on Clinical Ratings, Fluorodeoxyglucose Positron Emission Tomography Measurements, and Cerebrospinal Fluid Assays in Patients With Moderate to Severe Alzheimer Dementia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 636-642.	0.7	29
1830	A Quick Test of Cognitive Speed (AQT): Usefulness in dementia evaluations in primary care. <i>Scandinavian Journal of Primary Health Care</i> , 2013, 31, 13-19.	0.6	18
1831	Longitudinal Progression of Cognitive Decline Correlates with Changes in the Spatial Pattern of Brain <sup>18</sup> F-FDG PET. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1564-1569.	2.8	48
1832	Association between Milder Brain Deformation before a Shunt Operation and Improvement in Cognition and Gait in Idiopathic Normal Pressure Hydrocephalus. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013, 35, 197-207.	0.7	16
1834	Structured Assessment of Mental Capacity to Make Financial Decisions in Chinese Older Persons With Mild Cognitive Impairment and Mild Alzheimer Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2013, 26, 69-77.	1.2	24
1835	A promising rating scale for prion disease clinical research. <i>Nature Reviews Neurology</i> , 2013, 9, 366-367.	4.9	4
1836	Prediction Models for Assessing Long-Term Outcome in Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2013, 28, 440-449.	0.9	5
1837	Affecting Cognition and Quality of Life via Aerobic Exercise in Alzheimer's Disease. <i>Western Journal of Nursing Research</i> , 2013, 35, 24-38.	0.6	40
1838	TeLPI Performance in Subjects With Mild Cognitive Impairment and Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2013, 27, 324-329.	0.6	5
1839	Need for and Challenges Facing Functional Communication as Outcome Parameter in AD Clinical Trials. <i>Alzheimer Disease and Associated Disorders</i> , 2013, 27, 293-301.	0.6	6
1840	Fruits, Vegetables, and Their Components and Mild Cognitive Impairment and Dementia: A Review. <i>Food Reviews International</i> , 2013, 29, 409-440.	4.3	6
1841	Health-Related Resource Use and Costs in Elderly Adults with and without Mild Cognitive Impairment. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 396-402.	1.3	54
1842	Utility of an Effect Size Analysis for Communicating Treatment Effectiveness: A Case Study of Cholinesterase Inhibitors for Alzheimer's Disease. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 1170-1174.	1.3	7
1843	Diagnostic performance of a combination of Mini-Mental State Examination and Clock Drawing Test in detecting Alzheimer's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 581.	1.0	19

#	ARTICLE	IF	CITATIONS
1844	Impaired Awareness of Deficits in Alzheimer's Disease: The Role of Everyday Executive Dysfunction. <i>Journal of the International Neuropsychological Society</i> , 2013, 19, 63-72.	1.2	50
1845	Which part of the Quick mild cognitive impairment screen (Qmci) discriminates between normal cognition, mild cognitive impairment and dementia?. <i>Age and Ageing</i> , 2013, 42, 324-330.	0.7	54
1846	Weight changes in Alzheimer's disease patients with increased aberrant motor behavior. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 998-1004.	1.3	6
1847	Neuropsychological differentiation between <scp>A</scp>lzheimer's disease and dementia with <scp>L</scp>ewy bodies in a memory clinic. <i>Psychogeriatrics</i> , 2013, 13, 157-163.	0.6	19
1848	Cerebral atrophy in elderly with subjective memory complaints. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 38, 358-364.	1.9	9
1849	Classification and prediction of clinical diagnosis of Alzheimer's disease based on <scp>MRI</scp> and plasma measures of Î±â€œtocotrienols and Î³â€œtocopherol. <i>Journal of Internal Medicine</i> , 2013, 273, 602-621.	2.7	67
1850	Effectiveness and Safety of Memantine Treatment for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 445-458.	1.2	51
1851	Explicit (Semantic) Memory for Music in Patients with Mild Cognitive Impairment and Early-Stage Alzheimer's Disease. <i>Experimental Aging Research</i> , 2013, 39, 536-564.	0.6	21
1852	Cognitive Interventions Targeting Subjective Cognitive Complaints. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2013, 28, 560-567.	0.9	19
1853	Histone Deacetylases Enzyme, Copper, and IL-8 Levels in Patients With Alzheimerâ€™s Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2013, 28, 54-61.	0.9	60
1854	An Open-Label, Nonplacebo-Controlled Study on <i>Cistanche tubulosa</i> Glycoside Capsules (Memoregain<sup>Â®</sup>) for Treating Moderate Alzheimerâ€™s Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2013, 28, 363-370.	0.9	40
1855	Deep brain stimulation for cognitive disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2013, 116, 307-311.	1.0	29
1856	Predictors of Progression from Mild Cognitive Impairment to Dementia in the Placebo-Arm of a Clinical Trial Population. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 79-85.	1.2	21
1857	Impact of White Matter Lesions and Cognitive Deficits on Conversion from Mild Cognitive Impairment to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 665-672.	1.2	47
1858	Screening for Cognitive Impairment in Older Adults: A Systematic Review for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2013, 159, 601-12.	2.0	301
1859	Comparing Clinical Profiles in Alzheimer's Disease and Parkinson's Disease Dementia. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2013, 3, 281-290.	0.6	7
1860	Neuropsychological Signs of Alzheimer's Disease 8 Years Prior to Diagnosis. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 537-546.	1.2	43
1861	Progression of mild Alzheimerâ€™s disease: knowledge and prediction models required for future treatment strategies. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 44.	3.0	28

#	ARTICLE	IF	CITATIONS
1862	Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. <i>International Psychogeriatrics</i> , 2013, 25, 707-719.	0.6	43
1863	Cognitive predictors for five-year conversion to dementia in community-dwelling Chinese older adults. <i>International Psychogeriatrics</i> , 2013, 25, 1125-1134.	0.6	23
1864	CERAD practice effects and attrition bias in a dementia prevention trial. <i>International Psychogeriatrics</i> , 2013, 25, 1115-1123.	0.6	30
1865	Cognitive stimulation therapy (CST): neuropsychological mechanisms of change. <i>International Psychogeriatrics</i> , 2013, 25, 479-489.	0.6	55
1866	Aspects of awareness in patients with Alzheimer's disease. <i>International Psychogeriatrics</i> , 2013, 25, 1167-1179.	0.6	9
1867	Effect of CYP2D6*10 and APOE Polymorphisms on the Efficacy of Donepezil in Patients With Alzheimer's Disease. <i>American Journal of the Medical Sciences</i> , 2013, 345, 222-226.	0.4	47
1868	Effect of study partner on the conduct of Alzheimer disease clinical trials. <i>Neurology</i> , 2013, 80, 282-288.	1.5	58
1869	The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 59.	3.0	80
1870	Entorhinal Cortex Thickness Predicts Cognitive Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 755-766.	1.2	105
1871	Symptomatic Treatment of Memory Decline in Alzheimer's Disease by Deep Brain Stimulation: A Feasibility Study. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 315-323.	1.2	88
1873	Serum Adipokine Levels Modified by Donepezil Treatment in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 38, 371-377.	1.2	30
1874	Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors. <i>Clinical Interventions in Aging</i> , 2013, 8, 1007.	1.3	123
1875	CERAD Neuropsychological Total Scores Reflect Cortical Thinning in Prodromal Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2013, 3, 446-458.	0.6	7
1876	Special Care Units and Traditional Care in Dementia: Relationship with Behavior, Cognition, Functional Status and Quality of Life - A Review. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2013, 3, 360-375.	0.6	13,502
1877	Early Enriched Environment Exposure Protects Spatial Memory and Accelerates Amyloid Plaque Formation in APPSwe/PS1L166P Mice. <i>PLoS ONE</i> , 2013, 8, e69381.	1.1	25
1878	Micro-Structural Brain Alterations in Aviremic HIV+ Patients with Minor Neurocognitive Disorders: A Multi-Contrast Study at High Field. <i>PLoS ONE</i> , 2013, 8, e72547.	1.1	19
1880	Cognitive and behavioral assessment of vascular cognitive impairment. , 0, , 410-422.		1
1881	Deep Brain Stimulation as a Tool for Improving Cognitive Functioning in Alzheimer's Dementia: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2013, 4, 159.	1.3	50

#	ARTICLE	IF	CITATIONS
1882	Behavioral symptoms related to cognitive impairment. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 1443.	1.0	86
1883	The Effect of Lipoic Acid Therapy on Cognitive Functioning in Patients with Alzheimer's Disease. <i>Journal of Neurodegenerative Diseases</i> , 2013, 2013, 1-7.	1.1	42
1885	For How Long Should We Use Symptomatic Therapies to Treat People with Alzheimer Disease?. <i>Canadian Journal of Psychiatry</i> , 2014, 59, 615-617.	0.9	8
1886	Efficacy and tolerability of Ginkgo biloba extract EGb 761&reg; in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials. <i>Clinical Interventions in Aging</i> , 2014, 9, 2065.	1.3	126
1887	Cognitive effects of a dietary supplement made from extract of <i>Bacopa monnieri</i> , astaxanthin, phosphatidylserine, and vitamin E in subjects with mild cognitive impairment: a noncomparative, exploratory clinical study. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 225.	1.0	40
1888	Network-Based Biomarkers in Alzheimer's Disease: Review and Future Directions. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 12.	1.7	59
1889	Effects of Caprylic Triglyceride on Cognitive Performance and Cerebral Glucose Metabolism in Mild Alzheimer's Disease: A Single-Case Observation. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 133.	1.7	14
1890	Application of a MRI based index to longitudinal atrophy change in Alzheimer disease, mild cognitive impairment and healthy older individuals in the AddNeuroMed cohort. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 145.	1.7	29
1891	The effects of intracranial volume adjustment approaches on multiple regional MRI volumes in healthy aging and Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 264.	1.7	322
1892	Imaging Brain Metabolism and Pathology in Alzheimer's Disease with Positron Emission Tomography. , 2014, 04, .		17
1893	Effectiveness of weekly cognitive stimulation therapy for people with dementia and the additional impact of enhancing cognitive stimulation therapy with a carer training program. <i>Clinical Interventions in Aging</i> , 2014, 9, 2143.	1.3	44
1894	Cognitive and affective assessment in day care versus institutionalized elderly patients: a 1-year longitudinal study. <i>Clinical Interventions in Aging</i> , 2014, 9, 887.	1.3	12
1895	FOXO1 locus and acetylcholinesterase inhibitors in elderly patients with Alzheimer's disease. <i>Clinical Interventions in Aging</i> , 2014, 9, 1783.	1.3	13
1896	A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H&sub&gt;3&sub&gt; Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2014, 11, 47-58.	0.7	95
1897	Psychological well-being in individuals with mild cognitive impairment. <i>Clinical Interventions in Aging</i> , 2014, 9, 779.	1.3	39
1898	Understanding the Outcomes Measures used in Huntington Disease Pharmacological Trials: A Systematic Review. <i>Journal of Huntington's Disease</i> , 2014, 3, 233-252.	0.9	25
1899	Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study). <i>Arquivos De Neuro-Psiquiatria</i> , 2014, 72, 411-417.	0.3	20
1900	Responsiveness of Magnetic Resonance Imaging and Neuropsychological Assessment in Memory Clinic Patients. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 409-418.	1.2	16

#	ARTICLE	IF	CITATIONS
1901	Validation of an Alzheimer's Disease Assessment Battery in Asian Participants With Mild to Moderate Alzheimer's Disease. <i>Journal of Gerontology &amp; Geriatric Research</i> , 2014, 03, .	0.1	0
1902	Postural Sway, Falls, and Cognitive Status: A Cross-Sectional Study among Older Adults. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 431-439.	1.2	54
1903	Serial Position Effects in Patients with Mild Cognitive Impairment and Early and Moderate Alzheimer's Disease Compared with Healthy Comparison Subjects. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 37, 19-26.	0.7	23
1904	Analysis of burden in caregivers of people with Alzheimer's disease using self-report and supervision hours. <i>Journal of Nutrition, Health and Aging</i> , 2014, 18, 677-684.	1.5	76
1905	Effects of aerobic exercise on cognition and hippocampal volume in Alzheimer's disease: study protocol of a randomized controlled trial (The FIT-AD trial). <i>Trials</i> , 2014, 15, 394.	0.7	37
1906	A Review of "Wandering" Instruments for People With Dementia Who Get Lost. <i>Research on Social Work Practice</i> , 2014, 24, 400-413.	1.1	14
1907	A Quick Test of Cognitive Speed: norm-referenced criteria for 121 Italian adults aged 45 to 90 years. <i>International Psychogeriatrics</i> , 2014, 26, 1493-1500.	0.6	8
1908	Body mass index and mild cognitive impairment-to-dementia progression in 24 months: a prospective study. <i>European Journal of Clinical Nutrition</i> , 2014, 68, 1216-1219.	1.3	41
1909	Memantine in Patients with Moderate to Severe Alzheimer's Disease: Meta-Analyses Using Realistic Definitions of Response. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 37, 71-85.	0.7	45
1910	Effects of Spaced Retrieval Training on Semantic Memory in Alzheimer's Disease: A Systematic Review. <i>Journal of Speech, Language, and Hearing Research</i> , 2014, 57, 247-270.	0.7	21
1911	Prescribing drugs for Alzheimer's disease in primary care: managing cognitive symptoms: Table. <i>Drug and Therapeutics Bulletin</i> , 2014, 52, 69-72.	0.3	1
1912	Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1145-1148.	1.1	73
1913	Reporting standards for studies of diagnostic test accuracy in dementia. <i>Neurology</i> , 2014, 83, 364-373.	1.5	182
1914	Subcortical Atrophy Is Associated with Cognitive Impairment in Mild Parkinson Disease: A Combined Investigation of Volumetric Changes, Cortical Thickness, and Vertex-Based Shape Analysis. <i>American Journal of Neuroradiology</i> , 2014, 35, 2257-2264.	1.2	63
1915	A data-driven model of biomarker changes in sporadic Alzheimer's disease. <i>Brain</i> , 2014, 137, 2564-2577.	3.7	243
1916	Association Between Clinical Measures and Florbetapir F18 PET Neuroimaging in Mild or Moderate Alzheimer's Disease Dementia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2014, 26, 214-220.	0.9	19
1917	Influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cutoffs. <i>Journal of Internal Medicine</i> , 2014, 275, 317-330.	2.7	60
1918	Criteria for validation and selection of cognitive tests for investigating the effects of foods and nutrients. <i>Nutrition Reviews</i> , 2014, 72, 162-179.	2.6	54

#	ARTICLE	IF	CITATIONS
1919	Psychometric evaluation of ADAS-Cog and NTB for measuring drug response. Acta Neurologica Scandinavica, 2014, 129, 114-122.	1.0	32
1920	Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. Journal of Internal Medicine, 2014, 275, 251-283.	2.7	540
1921	Do the Cambridge Neuropsychological Test Automated Battery episodic memory measures discriminate amnesic mild cognitive impairment?. International Journal of Geriatric Psychiatry, 2014, 29, 602-609.	1.3	25
1922	The Study of Mental and Resistance Training (SMART) Study—Resistance Training and/or Cognitive Training in Mild Cognitive Impairment: A Randomized, Double-Blind, Double-Sham Controlled Trial. Journal of the American Medical Directors Association, 2014, 15, 873-880.	1.2	316
1923	The potential effects of meditation on age-related cognitive decline: a systematic review. Annals of the New York Academy of Sciences, 2014, 1307, 89-103.	1.8	286
1924	Cognitive screening for dementia in primary care: a systematic review. International Psychogeriatrics, 2014, 26, 1783-1804.	0.6	73
1925	An updated Alzheimer's disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 581-598.	0.8	29
1927	Establishing robust cognitive dimensions for characterization and differentiation of patients with Alzheimer's disease, mild cognitive impairment, frontotemporal dementia and depression. International Journal of Geriatric Psychiatry, 2014, 29, 624-634.	1.3	20
1928	Item response analysis of Alzheimer's disease assessment scale. , 2014, 2014, 2476-9.		3
1929	Phase II Crossover Trial of Varenicline in Mild-to-Moderate Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2014, 37, 232-245.	0.7	26
1930	Cognitive deficits in mild Parkinson's disease are associated with distinct areas of grey matter atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 576-580.	0.9	58
1931	Neuropsychiatric Symptoms and Regional Neocortical Atrophy in Mild Cognitive Impairment and Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2014, 29, 159-165.	0.9	37
1932	Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC Neurology, 2014, 14, 12.	0.8	101
1933	Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease. BMC Neurology, 2014, 14, 173.	0.8	23
1934	Modeling of Bounded Outcome Scores with Data on the Boundaries: Application to Disability Assessment for Dementia Scores in Alzheimer's Disease. AAPS Journal, 2014, 16, 1271-1281.	2.2	12
1935	A multi-state model for the analysis of changes in cognitive scores over a fixed time interval. Statistical Methods in Medical Research, 2014, 23, 244-256.	0.7	19
1936	Clinical Significance in Dementia Research. American Journal of Alzheimer's Disease and Other Dementias, 2014, 29, 492-497.	0.9	17
1937	Infection Hospitalization Increases Risk of Dementia in the Elderly*. Critical Care Medicine, 2014, 42, 1037-1046.	0.4	62



#	ARTICLE	IF	CITATIONS
1938	Correlational Analysis of 5 Commonly Used Measures of Cognitive Functioning and Mental Status. American Journal of Alzheimer's Disease and Other Dementias, 2014, 29, 718-722.	0.9	20
1939	Clinical Utility of Cognistat in Multiprofessional Team Evaluations of Patients with Cognitive Impairment in Swedish Primary Care. International Journal of Family Medicine, 2014, 2014, 1-10.	1.2	13
1940	Happy and Sad Judgements in Dependence on Mode and Note Density in Patients with Mild Cognitive Impairment and Early-Stage Alzheimer's Disease. Gerontology, 2014, 60, 402-412.	1.4	5
1941	Norms and reliability for the Spanish version of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Form A. Journal of Clinical and Experimental Neuropsychology, 2014, 36, 1023-1030.	0.8	14
1942	A point-based tool to predict conversion from mild cognitive impairment to probable Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 646-655.	0.4	43
1943	Creation of the Argentina-Alzheimer's Disease Neuroimaging Initiative. , 2014, 10, S84-S87.		19
1944	The Quick Mild Cognitive Impairment screen correlated with the Standardized Alzheimer's Disease Assessment Scale's cognitive section in clinical trials. Journal of Clinical Epidemiology, 2014, 67, 87-92.	2.4	32
1945	Does the evidence say a 4-point change in ADAS-cog score is clinically significant?. Alzheimer's and Dementia, 2014, 10, 416-417.	0.4	7
1946	Investigational drugs in Alzheimer's disease: current progress. Expert Opinion on Investigational Drugs, 2014, 23, 837-846.	1.9	48
1947	Effects of Gingko biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: Data from the ICTUS study. Phytomedicine, 2014, 21, 888-892.	2.3	54
1948	Novel Mutations in the Amyloid Precursor Protein Gene within Moroccan Patients with Alzheimer's Disease. Journal of Molecular Neuroscience, 2014, 53, 189-95.	1.1	5
1949	Vitamin E and memantine in Alzheimer's disease: Clinical trial methods and baseline data. Alzheimer's and Dementia, 2014, 10, 36-44.	0.4	46
1950	Benzoate, a D-Amino Acid Oxidase Inhibitor, for the Treatment of Early-Phase Alzheimer Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Biological Psychiatry, 2014, 75, 678-685.	0.7	106
1951	Effects of memantine treatment on language abilities and functional communication: A review of data. Aphasiology, 2014, 28, 236-257.	1.4	12
1952	Dementia in Clinical Practice: A Neurological Perspective. , 2014, , .		24
1953	Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia. International Journal of Geriatric Psychiatry, 2014, 29, 899-905.	1.3	25
1954	Deep Brain Stimulation for Disorders of Memory and Cognition. Neurotherapeutics, 2014, 11, 527-534.	2.1	31
1955	Systematic Review of Clinical Trials Assessing Pharmacological Properties of <i>Salvia</i> Species on Memory, Cognitive Impairment and Alzheimer's Disease. CNS Neuroscience and Therapeutics, 2014, 20, 485-495.	1.9	66

#	ARTICLE	IF	CITATIONS
1956	Galantamine treatment in outpatients with mild Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 2014, 129, 382-392.	1.0	29
1957	Prevalence and Predictors of Burden in Caregivers of People with Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 756-765.	0.6	116
1958	Genome-wide association study of the rate of cognitive decline in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 45-52.	0.4	147
1959	Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2014, 370, 322-333.	13.9	1,613
1960	Brain Stimulation in the Treatment of Late-Life Severe Mental Illness Other than Unipolar Nonpsychotic Depression. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 216-240.	0.6	25
1961	Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 33.	3.8	488
1962	Do changes in specific cognitive functions predict changes in health-related quality of life in people with Alzheimer's disease?. <i>International Journal of Geriatric Psychiatry</i> , 2014, 29, 694-703.	1.3	10
1963	Recognition of facial emotions and identity in patients with mesial temporal lobe and idiopathic generalized epilepsy: An eye-tracking study. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2014, 23, 892-898.	0.9	37
1964	A comparison of neuropsychological performance between US and Russia: Preparing for a global clinical trial. , 2014, 10, 760-768.e1.		17
1965	Orientation and disorientation: Lessons from patients with epilepsy. <i>Epilepsy and Behavior</i> , 2014, 41, 149-157.	0.9	37
1966	An object location memory paradigm for older adults with and without mild cognitive impairment. <i>Journal of Neuroscience Methods</i> , 2014, 237, 16-25.	1.3	13
1967	Safety and efficacy of idalopirdine, a 5-HT <sub>6</sub> receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Neurology</i> , The, 2014, 13, 1092-1099.	4.9	150
1968	Site-independent confirmation of subject selection for CNS trials: dual™ review using audio-digital recordings. <i>Annals of General Psychiatry</i> , 2014, 13, .	1.2	8
1969	Reversal of Metabolic Deficits by Lipoic Acid in a Triple Transgenic Mouse Model of Alzheimer's Disease: A <sup>13</sup> C NMR Study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 288-296.	2.4	53
1970	Prognostic classification of mild cognitive impairment and Alzheimer's disease: MRI independent component analysis. <i>Psychiatry Research - Neuroimaging</i> , 2014, 224, 81-88.	0.9	40
1972	Efficacy and Adverse Effects of Ginkgo Biloba for Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 589-603.	1.2	173
1973	Cognitive and Functional Decline and Their Relationship in Patients with Mild Alzheimer's Dementia. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 949-955.	1.2	63
1974	Global N-Acetylaspartate in Normal Subjects, Mild Cognitive Impairment and Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 939-947.	1.2	27

#	ARTICLE	IF	CITATIONS
1975	"Shall I Compare Thee to a Dose of Donepezil?": Cultural Arts Interventions in Dementia Care Research. <i>Gerontologist</i> , The, 2014, 54, 344-353.	2.3	99
1976	Depressive symptoms in later life: differential impact of social support and motivational processes on depression in individuals with and without cognitive impairment. <i>European Journal of Ageing</i> , 2014, 11, 321-332.	1.2	6
1977	Improved Utilization of ADAS-Cog Assessment Data Through Item Response Theory Based Pharmacometric Modeling. <i>Pharmaceutical Research</i> , 2014, 31, 2152-2165.	1.7	61
1978	Identifying the Neuroanatomical Basis of Cognitive Impairment in Alzheimer's Disease by Correlation- and Nonlinearity-Aware Sparse Bayesian Learning. <i>IEEE Transactions on Medical Imaging</i> , 2014, 33, 1475-1487.	5.4	49
1979	Randomized controlled trials in frontotemporal dementia: cognitive and behavioral outcomes. <i>Translational Neurodegeneration</i> , 2014, 3, 12.	3.6	16
1980	Estrogen Receptor $\pm$ Polymorphisms and the Risk of Cognitive Decline: A 2-Year Follow-Up Study. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 489-498.	0.6	10
1981	Motor imagery of gait: a new way to detect mild cognitive impairment?. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2014, 11, 66.	2.4	25
1982	Clinical trial of an inhibitor of RAGE- $\text{A}\beta^2$ interactions in Alzheimer disease. <i>Neurology</i> , 2014, 82, 1536-1542.	1.5	159
1983	Efficacy of higher-dose 13.3 $\mu\text{g}/24\text{ h}$ (15 $\mu\text{g}/24\text{ h}$ ) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis. <i>International Journal of Geriatric Psychiatry</i> , 2014, 29, 920-927.	1.3	10
1984	Psychosis in Alzheimer's Disease is Associated with Frontal Metabolic Impairment and Accelerated Decline in Working Memory: Findings from the Alzheimer's Disease Neuroimaging Initiative. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 698-707.	0.6	55
1985	Efficacy and safety evaluation of HSD11 $\beta$ inhibitor ABT-384 in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, S364-73.	0.4	32
1986	Optimizing parameters in clinical trials with a randomized start or withdrawal design. <i>Computational Statistics and Data Analysis</i> , 2014, 69, 101-113.	0.7	4
1987	Prevalence of Obsessive-Compulsive Disorder in Relation to Depression and Cognition in an Elderly Population. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 301-308.	0.6	14
1988	Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: A pilot-study. <i>Experimental Gerontology</i> , 2014, 50, 114-121.	1.2	42
1989	Automated algorithm to measure changes in medial temporal lobe volume in Alzheimer disease. <i>Journal of Neuroscience Methods</i> , 2014, 227, 35-46.	1.3	14
1990	The role of human cognitive neuroscience in drug discovery for the dementias. <i>Current Opinion in Pharmacology</i> , 2014, 14, 62-73.	1.7	8
1991	Gait Changes with Anti-Dementia Drugs: A Prospective, Open-Label Study Combining Single and Dual Task Assessments in Patients with Alzheimer's Disease. <i>Drugs and Aging</i> , 2014, 31, 363-372.	1.3	22
1992	Maintenance cognitive stimulation therapy for dementia: single-blind, multicentre, pragmatic randomised controlled trial. <i>British Journal of Psychiatry</i> , 2014, 204, 454-461.	1.7	115

#	ARTICLE	IF	CITATIONS
1993	Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2014, 10, S226-35.	0.4	51
1994	Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. <i>Frontiers in Genetics</i> , 2014, 5, 88.	1.1	562
1995	The Potential of Composite Cognitive Scores for Tracking Progression in Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2014, 3, 197-207.	0.9	8
1996	Renin Angiotensin Aldosterone System Inhibition in Controlling Dementia-Related Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2014, 42, S575-S586.	1.2	30
1997	The Neurosurgical Treatment of Alzheimer's Disease: A Review. <i>Stereotactic and Functional Neurosurgery</i> , 2014, 92, 269-281.	0.8	13
1999	Cognitive consequences of cerebral small vessel disease. , 0, , 236-250.		0
2001	Relationship between Serum Levels of Tau Fragments and Clinical Progression of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 1331-1341.	1.2	25
2002	Effects of Centrally Acting Angiotensin Converting Enzyme Inhibitors on Functional Decline in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 595-603.	1.2	70
2003	A Randomized Study of H3 Antagonist ABT-288 in Mild-To-Moderate Alzheimer's Dementia1. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 959-971.	1.2	59
2004	Therapeutic Development Paths for Cognitive Impairment in Parkinson's Disease: Report of a Regulatory Roundtable. <i>Journal of Parkinson's Disease</i> , 2014, 4, 585-589.	1.5	15
2005	The Extension of the German CERAD Neuropsychological Assessment Battery with Tests Assessing Subcortical, Executive and Frontal Functions Improves Accuracy in Dementia Diagnosis. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 322-334.	0.6	81
2006	CERAD Neuropsychological Compound Scores are Accurate in Detecting Prodromal Alzheimer's Disease: A Prospective AddNeuroMed Study. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 679-690.	1.2	35
2007	P4-193: COMBINATION THERAPY WITH CHOLINESTERASE INHIBITORS AND MEMANTINE FOR ALZHEIMER'S DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS. , 2014, 10, P859-P860.		17
2008	Factors Associated with Cognitive Decline in Transient Ischemic Attack Patients. <i>Canadian Journal of Neurological Sciences</i> , 2014, 41, 303-313.	0.3	4
2009	Caregiver Burden in Alzheimer's Disease: Differential Associations in Adult-Child and Spousal Caregivers in the GERAS Observational Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 51-64.	0.6	77
2010	Alzheimer's disease assessment scaleâ€œcognitive 11â€œitem progression model in mildâ€œtoâ€œmoderate Alzheimer's disease trials of bapineuzumab. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2015, 1, 157-169.	1.8	15
2011	Computer mouse movement patterns: A potential marker of mild cognitive impairment. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 472-480.	1.2	66
2012	Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer's disease. <i>Journal of Pharmacological Sciences</i> , 2015, 129, 188-195.	1.1	19

#	ARTICLE	IF	CITATIONS
2013	Rivastigmine for Alzheimer's disease. The Cochrane Library, 2015, 9, CD001191.	1.5	233
2014	Environmental and behavioural modifications for improving food and fluid intake in people with dementia. The Cochrane Library, 2015, , .	1.5	3
2015	Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2015, 2, 534-547.	1.7	32
2016	Cholesterol, Statins, and Dementia: What the Cardiologist Should Know. Clinical Cardiology, 2015, 38, 243-250.	0.7	47
2017	Moderate-to-High Intensity Physical Exercise in Patients with Alzheimer's Disease: A Randomized Controlled Trial. Journal of Alzheimer's Disease, 2016, 50, 443-453.	1.2	210
2019	BFLCRM: A Bayesian functional linear Cox regression model for predicting time to conversion to Alzheimer's disease. Annals of Applied Statistics, 2015, 9, 2153-2178.	0.5	24
2020	Adding delayed recall to the ADAS-cog improves measurement precision in mild Alzheimer's disease: Implications for predicting instrumental activities of daily living.. Psychological Assessment, 2015, 27, 1234-1240.	1.2	8
2021	Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2015, 48, 403-410.	1.2	138
2022	Magnetic Resonance Spectroscopy in Alzheimer's Disease: Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2015, 46, 1049-1070.	1.2	94
2023	Cognitive-Motor Intervention in Alzheimer's Disease: Long-Term Results from the Maria Wolff Trial. Journal of Alzheimer's Disease, 2015, 45, 295-304.	1.2	15
2024	No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 741-750.	1.2	2
2025	Short and Long-term Effects of rTMS Treatment on Alzheimer's Disease at Different Stages: A Pilot Study. Journal of Experimental Neuroscience, 2015, 9, JEN.S24004.	2.3	90
2026	Neuropsychological Evaluation and Cerebral Blood Flow Effects of Apolipoprotein E4 in Alzheimer's Disease Patients after One Year of Treatment: An Exploratory Study. Dementia and Geriatric Cognitive Disorders Extra, 2015, 5, 414-423.	0.6	7
2027	Alterations in dorsal and ventral posterior cingulate connectivity in APOE4 carriers at risk of Alzheimer's disease. BJPsych Open, 2015, 1, 139-148.	0.3	5
2028	Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. Journal of Alzheimer's Disease, 2015, 46, 1079-1089.	1.2	28
2029	Effects of the Acetylcholine Release Agent ST101 with Donepezil in Alzheimer's Disease: A Randomized Phase 2 Study. Journal of Alzheimer's Disease, 2015, 48, 473-481.	1.2	23
2030	Effect of a Dual-Task Net-Step Exercise on Cognitive and Gait Function in Older Adults. Journal of Geriatric Physical Therapy, 2015, 38, 133-140.	0.6	31
2031	Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 403-411.	1.2	26

#	ARTICLE	IF	CITATIONS
2032	A Longitudinal Study of Transitions Between Informal and Formal Care in Alzheimer Disease Using Multistate Models in the European ICTUS Cohort. Journal of the American Medical Directors Association, 2015, 16, 1104.e1-1104.e7.	1.2	12
2033	Exploring the effects of coexisting amyloid in subcortical vascular cognitive impairment. BMC Neurology, 2015, 15, 197.	0.8	9
2034	Decreased activity with increased background network efficiency in amnesic <scp>MCI</scp> during a visuospatial working memory task. Human Brain Mapping, 2015, 36, 3387-3403.	1.9	22
2035	Motivational processes in mild cognitive impairment and Alzheimer's disease: results from the Motivational Reserve in Alzheimer's (MoReA) study. BMC Psychiatry, 2015, 15, 293.	1.1	23
2036	Cognitive behavioural treatment for mild Alzheimer's patients and their caregivers (CBTAC): study protocol for a randomized controlled trial. Trials, 2015, 16, 526.	0.7	17
2037	Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 205-214.	1.2	57
2038	Frequency and Impact of Informant Replacement in Alzheimer Disease Research. Alzheimer Disease and Associated Disorders, 2015, 29, 242-248.	0.6	10
2039	Multi-arm clinical trials with treatment selection: what can be gained and at what price?. Clinical Investigation, 2015, 5, 393-399.	0.0	26
2040	Non-inferiority margins employed in clinical trials in Japan. Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 289-298.	0.7	3
2041	Associations Between Mild Cognitive Impairment and Hospitalization and Readmission. Journal of the American Geriatrics Society, 2015, 63, 1880-1885.	1.3	40
2042	Adaptive, Dose-finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2015, 29, 192-199.	0.6	23
2043	Enhanced rehabilitation and care models for adults with dementia following hip fracture surgery. The Cochrane Library, 2015, , CD010569.	1.5	44
2044	White Matter Hyperintensities and Mild Cognitive Impairment in Parkinson's Disease. Journal of Neuroimaging, 2015, 25, 754-760.	1.0	38
2045	Improvement of Cerebral Glucose Metabolism in Symptomatic Patients With Carotid Artery Stenosis After Stenting. Clinical Nuclear Medicine, 2015, 40, 701-707.	0.7	8
2046	Welcome Back to Your Future: The Assessment of Dementia by the Latent Variable "c". Journal of Alzheimer's Disease, 2015, 49, 515-519.	1.2	3
2047	Cognitive reserve and A&beta;1-42 in mild cognitive impairment (Argentina-Alzheimer's) Tj ETQq1_1.0.784314 rgBT /O	1.0	13
2048	Neuroprotective Effects of Cistanches Herba Therapy on Patients with Moderate Alzheimer's Disease. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-12.	0.5	20
2049	Deep brain stimulation targeting the fornix for mild Alzheimer dementia: design of the ADVance randomized controlled trial. Open Access Journal of Clinical Trials, 0, , 63.	1.5	1

#	ARTICLE	IF	CITATIONS
2050	The Latent Dementia Phenotype $\hat{\Gamma}$ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 547-560.	1.2	23
2051	Assessment of Dementia. <i>Brain &amp; Neurorehabilitation</i> , 2015, 8, 11.	0.4	7
2052	Longitudinal Associations between Survival in Alzheimer's Disease and Cholinesterase Inhibitor Use, Progression, and Community-Based Services. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 40, 297-310.	0.7	21
2053	The disengagement of visual attention in Alzheimer's disease: a longitudinal eye-tracking study. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 118.	1.7	48
2054	Effect of Tween-20 on Core Biomarkers Measured in Cerebrospinal Fluid from Patients with Alzheimer's Disease, Mild Cognitive Impairment, or Healthy Control Individuals. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 493-502.	1.2	12
2055	Memantine Monotherapy for Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0123289.	1.1	185
2056	Effects of momentum-based dumbbell training on cognitive function in older adults with mild cognitive impairment: a pilot randomized controlled trial. <i>Clinical Interventions in Aging</i> , 2016, 11, 9.	1.3	33
2057	Sex differences in cognitive training effects of patients with amnesic mild cognitive impairment. <i>Aging, Neuropsychology, and Cognition</i> , 2015, 22, 620-638.	0.7	23
2058	The Impact of Sleep on Neuropsychological Performance in Cognitively Intact Older Adults Using a Novel In-Home Sensor-Based Sleep Assessment Approach. <i>Clinical Neuropsychologist</i> , 2015, 29, 53-66.	1.5	38
2059	Trajectories of cognitive decline in different types of dementia. <i>Psychological Medicine</i> , 2015, 45, 1051-1059.	2.7	85
2060	Multiscale entropy analysis of resting-state magnetoencephalogram with tensor factorisations in Alzheimer's disease. <i>Brain Research Bulletin</i> , 2015, 119, 136-144.	1.4	34
2062	Imaging characteristics and safety of florbetapir (18F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease. <i>Annals of Nuclear Medicine</i> , 2015, 29, 570-581.	1.2	10
2063	Reduced N-Acetylaspartate to Creatine Ratio in the Posterior Cingulate Correlates with Cognition in Alzheimer's Disease following Four Months of Rivastigmine Treatment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 39, 68-80.	0.7	3
2064	The promise of futility trials in neurological diseases. <i>Nature Reviews Neurology</i> , 2015, 11, 300-305.	4.9	16
2065	Etanercept in Alzheimer disease. <i>Neurology</i> , 2015, 84, 2161-2168.	1.5	203
2066	Speed versus accuracy in cognitive assessment when using CSIs. <i>Progress in Neurology and Psychiatry</i> , 2015, 19, 21-24.	0.4	23
2067	Souvenaid for Alzheimer's disease. <i>The Cochrane Library</i> , 2015, , .	1.5	2
2068	Raloxifene for women with Alzheimer disease. <i>Neurology</i> , 2015, 85, 1937-1944.	1.5	40

#	ARTICLE	IF	CITATIONS
2069	A phase 2 randomized, controlled trial of the $\beta$ 7 agonist ABT-089 in mild-to-moderate Alzheimer's dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2015, 1, 81-90.	1.8	32
2070	How Do Scores on the ADAS-Cog, MMSE, and CDR-SOB Correspond?. <i>Clinical Neuropsychologist</i> , 2015, 29, 1002-1009.	1.5	87
2071	New scoring methodology improves the sensitivity of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 64.	3.0	63
2072	Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2015, 5, 96-106.	0.6	14
2073	Differential Effects of Acetylcholinesterase Inhibitors on Clinical Responses and Cerebral Blood Flow Changes in Patients with Alzheimer's Disease: A 12-Month, Randomized, and Open-Label Trial. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2015, 5, 135-146.	0.6	25
2074	Cerebral Microbleeds and White Matter Hyperintensities in Cognitively Healthy Elderly: A Cross-Sectional Cohort Study Evaluating the Effect of Arterial Stiffness. <i>Cerebrovascular Diseases Extra</i> , 2015, 5, 41-51.	0.5	33
2075	Balance and Mobility as Predictors of Post-Stroke Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2015, 5, 203-211.	0.6	16
2076	The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 1605.e13-1605.e20.	1.5	27
2077	Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type. <i>Neurobiology of Aging</i> , 2015, 36, 601-607.	1.5	125
2078	Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 511-522.	0.4	55
2079	Maintenance Cognitive Stimulation Therapy: An Economic Evaluation Within a Randomized Controlled Trial. <i>Journal of the American Medical Association</i> , 2015, 308, 63-70.	1.2	51
2080	Quantitative EEG markers relate to Alzheimer's disease severity in the Prospective Dementia Registry Austria (PRODEM). <i>Clinical Neurophysiology</i> , 2015, 126, 505-513.	0.7	43
2081	The diffeomorphometry of regional shape change rates and its relevance to cognitive deterioration in mild cognitive impairment and Alzheimer's disease. <i>Human Brain Mapping</i> , 2015, 36, 2093-2117.	1.9	54
2082	Differences in Alzheimer disease clinical trial outcomes based on age of the participants. <i>Neurology</i> , 2015, 84, 1121-1127.	1.5	34
2083	Melatonin for Sleep Disorders and Cognition in Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2015, 30, 439-447.	0.9	94
2084	<sup>18</sup> F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). <i>The Cochrane Library</i> , 2015, 2015, CD010632.	1.5	128
2086	Low amyloid $\beta$ deposition correlates with high education in cognitively normal older adults: a pilot study. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 919-926.	1.3	22
2087	The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function. <i>NeuroImage</i> , 2015, 105, 357-368.	2.1	38



#	ARTICLE	IF	CITATIONS
2088	Population modelling of patient responses in antidepressant studies: A stochastic approach. <i>Mathematical Biosciences</i> , 2015, 261, 37-47.	0.9	1
2089	Methodological challenges in assessing the impact of comorbidities on costs in Alzheimer's disease clinical trials. <i>European Journal of Health Economics</i> , 2015, 16, 995-1004.	1.4	3
2090	White matter lesions and temporal lobe atrophy related to incidence of both dementia and major depression in 70-year-olds followed over 10 years. <i>European Journal of Neurology</i> , 2015, 22, 781.	1.7	29
2091	Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design. <i>International Psychogeriatrics</i> , 2015, 27, 181-197.	0.6	29
2092	Meta-analysis of the efficacy and safety of Ginkgo biloba extract for the treatment of dementia. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2015, 1, 14.	0.4	78
2093	The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 40, 85-93.	0.7	26
2094	Non-pharmacological interventions for adults with mild cognitive impairment and early stage dementia: An updated scoping review. <i>Molecular Aspects of Medicine</i> , 2015, 43-44, 38-53.	2.7	151
2095	Deep Brain Stimulation Influences Brain Structure in Alzheimer's Disease. <i>Brain Stimulation</i> , 2015, 8, 645-654.	0.7	162
2096	The significance of caudate volume for age-related associative memory decline. <i>Brain Research</i> , 2015, 1622, 137-148.	1.1	34
2097	Bilateral brain reorganization with memantine and constraint-induced aphasia therapy in chronic post-stroke aphasia: An ERP study. <i>Brain and Language</i> , 2015, 145-146, 1-10.	0.8	38
2098	Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease. <i>International Journal of Clinical Practice</i> , 2015, 69, 518-530.	0.8	15
2099	Do cognitive interventions improve general cognition in dementia? A meta-analysis and meta-regression. <i>BMJ Open</i> , 2015, 5, e005247-e005247.	0.8	127
2100	Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 9.	3.0	8
2101	A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 35.	3.0	129
2102	MRI assessment of the effects of acetazolamide and external lumbar drainage in idiopathic Normal Pressure Hydrocephalus. <i>Fluids and Barriers of the CNS</i> , 2015, 12, 9.	2.4	29
2103	Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed. <i>Value in Health</i> , 2015, 18, 638-645.	0.1	21
2104	Effects of Aerobic Training on Cognition and Brain Glucose Metabolism in Subjects with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 747-760.	1.2	24
2105	A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence. <i>Drugs and Aging</i> , 2015, 32, 453-467.	1.3	115

#	ARTICLE	IF	CITATIONS
2106	Predicting Reduction of Cerebrospinal Fluid $\beta$ -Amyloid 42 in Cognitively Healthy Controls. <i>JAMA Neurology</i> , 2015, 72, 554.	4.5	42
2107	Cerebrolysin in Mild-to-Moderate Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Clinical Trials. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 39, 332-347.	0.7	37
2108	Proinflammatory Cytokines and the Clinical Features of Dementia With Lewy Bodies. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 97-99.	0.6	11
2109	Bio-Interface of Conducting Polymer-Based Materials for Neuroregeneration. <i>Advanced Materials Interfaces</i> , 2015, 2, 1500059.	1.9	33
2110	Vascular Disease and Risk Factors are Associated With Cognitive Decline in the Alzheimer Disease Spectrum. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 18-25.	0.6	49
2111	The transitional association between $\beta$ -amyloid pathology and regional brain atrophy. <i>Alzheimer's and Dementia</i> , 2015, 11, 1171-1179.	0.4	37
2112	Determinants of societal costs in Alzheimer's disease: GERAS study baseline results. <i>Alzheimer's and Dementia</i> , 2015, 11, 933-945.	0.4	62
2113	Associations Between Oral Health and Risk of Dementia in a 37-Year Follow-Up Study: The Prospective Population Study of Women in Gothenburg. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 100-105.	1.3	49
2114	Targeting Prodromal Alzheimer Disease With Avagacestat. <i>JAMA Neurology</i> , 2015, 72, 1324.	4.5	179
2115	From Cognitive Science to Dementia Assessment. Policy Insights From the Behavioral and Brain Sciences, 2015, 2, 81-91.	1.4	30
2116	Cerebrospinal fluid $\beta$ 40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease. <i>Journal of the Neurological Sciences</i> , 2015, 358, 308-316.	0.3	25
2117	Long-term effectiveness of rivastigmine patch or capsule for mild-to-severe Alzheimer's disease: a meta-analysis. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 1093-1103.	1.4	7
2118	Effect of Rivastigmine or Memantine Add-on Therapy Is Affected by Butyrylcholinesterase Genotype in Patients with Probable Alzheimer's Disease. <i>European Neurology</i> , 2015, 73, 23-28.	0.6	18
2119	Herbal medicine Davaie Loban in mild to moderate Alzheimer's disease: A 12-week randomized double-blind placebo-controlled clinical trial. <i>Complementary Therapies in Medicine</i> , 2015, 23, 767-772.	1.3	20
2120	Combination Therapy with Cholinesterase Inhibitors and Memantine for Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, .	1.0	67
2121	Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes. <i>JAMA Neurology</i> , 2015, 72, 1183.	4.5	57
2122	Long-Term Response to Cholinesterase Inhibitor Treatment Is Related to Functional MRI Response in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 40, 243-255.	0.7	5
2123	Cerebral Microbleeds, CSF p-Tau, and Cognitive Decline: Significance of Anatomic Distribution. <i>American Journal of Neuroradiology</i> , 2015, 36, 1635-1641.	1.2	45

#	ARTICLE	IF	CITATIONS
2124	Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. <i>Neurology</i> , 2015, 85, 1240-1249.	1.5	288
2125	A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. <i>Neurology</i> , 2015, 85, 1383-1391.	1.5	511
2126	Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. <i>Brain</i> , 2015, 138, 3373-3385.	3.7	200
2127	Suspected non-AD pathology in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2015, 36, 3152-3162.	1.5	63
2128	Evaluation of short cognitive screening tests in 85-year-old men and women. <i>European Geriatric Medicine</i> , 2015, 6, 545-550.	1.2	0
2129	Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 7-17.	1.4	74
2130	Proteomic Analysis of Cerebrospinal Fluid in Alzheimer's Disease: Wanted Dead or Alive. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 1303-1312.	1.2	28
2131	Preventing Loss of Independence through Exercise (PLI <sup>2</sup> ): qualitative analysis of a clinical trial in older adults with dementia. <i>Aging and Mental Health</i> , 2015, 19, 353-362.	1.5	44
2132	Hippocampal volume, early cognitive decline and gait variability: Which association?. <i>Experimental Gerontology</i> , 2015, 61, 98-104.	1.2	57
2133	Apathy as a feature of prodromal Alzheimer's disease: an FDGPET ADNI study. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 470-477.	1.3	53
2134	Multistimulation Group Therapy in Alzheimer's Disease Promotes Changes in Brain Functioning. <i>Neurorehabilitation and Neural Repair</i> , 2015, 29, 13-24.	1.4	37
2135	Impact of 6-Month Aerobic Exercise on Alzheimer's Symptoms. <i>Journal of Applied Gerontology</i> , 2015, 34, 484-500.	1.0	22
2136	Studying ventricular abnormalities in mild cognitive impairment with hyperbolic Ricci flow and tensor-based morphometry. <i>NeuroImage</i> , 2015, 104, 1-20.	2.1	42
2137	Dementia in Taiwan Area. <i>Translational Neuroscience and Clinics</i> , 2016, 2, 38-45.	0.1	1
2138	Within-Individual Variability: An Index for Subtle Change in Neurocognition in Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 325-335.	1.2	24
2139	Brain Atrophy, Anti-Smooth Muscle Antibody and Cognitive Impairment: An Association Study. , 2016, 7, 318.		7
2140	Describing the Sequence of Cognitive Decline in Alzheimer's Disease Patients: Results from an Observational Study. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1065-1080.	1.2	34
2141	Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2016, 13, 809-816.	0.7	5

#	ARTICLE	IF	CITATIONS
2142	Beneficial Effects of an Integrated Psychostimulation Program in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 559-566.	1.2	9
2143	The Effect of Rivastigmine Transdermal Patch on Sleep Apnea in Patients with Probable Alzheimer's Disease. <i>Dementia and Neurocognitive Disorders</i> , 2016, 15, 153.	0.4	3
2144	Foreign Accent Syndrome As a Psychogenic Disorder: A Review. <i>Frontiers in Human Neuroscience</i> , 2016, 10, 168.	1.0	15
2146	Agreement between Patient and Proxy Assessments of Quality of Life among Older Adults with Vascular Cognitive Impairment Using the EQ-5D-3L and ICECAP-O. <i>PLoS ONE</i> , 2016, 11, e0153878.	1.1	13
2147	Recursive Subsystems in Aphasia and Alzheimer's Disease: Case Studies in Syntax and Theory of Mind. <i>Frontiers in Psychology</i> , 2016, 7, 405.	1.1	9
2148	Adjuvant transcranial direct current stimulation for treating Alzheimer's disease: A case study. <i>Dementia E Neuropsychologia</i> , 2016, 10, 156-159.	0.3	22
2149	Treatment of Alzheimer's Disease with Repetitive Transcranial Magnetic Stimulation Combined with Cognitive Training: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study. <i>Journal of</i>		

#	ARTICLE	IF	CITATIONS
2161	Cognitive and Functional Correlates of NPI-Q Scores and Symptom Clusters in Mildly Demented Alzheimer Patients. <i>Alzheimer Disease and Associated Disorders</i> , 2016, 30, 145-151.	0.6	24
2162	Cognitive Profiles on the Severe Impairment Battery Are Similar in Alzheimer Disease and Down Syndrome With Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2016, 30, 251-257.	0.6	19
2163	On the early diagnosis of Alzheimer's Disease from multimodal signals: A survey. <i>Artificial Intelligence in Medicine</i> , 2016, 71, 1-29.	3.8	141
2164	Human behavioral assessments in current research of Parkinson's disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 68, 741-772.	2.9	58
2165	High amyloid $\beta$ deposition related to depressive symptoms in older individuals with normal cognition: a pilot study. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 920-928.	1.3	53
2166	Omega-3 fatty acids for the treatment of dementia. <i>The Cochrane Library</i> , 2016, 2016, CD009002.	1.5	88
2167	Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies. <i>CNS Neuroscience and Therapeutics</i> , 2016, 22, 159-166.	1.9	95
2168	Cognitive Reserve in Alzheimer's Dementia: Diagnostic Accuracy of a Testing-the-Limits Paradigm. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 519-528.	1.2	2
2169	Prediction of Incipient Alzheimer's Disease Dementia in Patients with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 269-281.	1.2	55
2170	Health-Related Quality of Life in Patients with Alzheimer's Disease in Different German Health Care Settings. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 545-561.	1.2	26
2171	Subjective Memory Impairment and Gait Variability in Cognitively Healthy Individuals: Results from a Cross-Sectional Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 965-971.	1.2	11
2172	ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 44.	3.0	27
2173	Low Serum Insulin-Like Growth Factor-I Predicts Cognitive Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 641-649.	1.2	28
2174	Effect of galantamine on attention in patients with Alzheimer's disease combined with cerebrovascular disease. <i>Geriatrics and Gerontology International</i> , 2017, 17, 1661-1666.	0.7	3
2175	Group and individual cognitive therapies in Alzheimer's disease: the ETNA3 randomized trial. <i>International Psychogeriatrics</i> , 2016, 28, 707-717.	0.6	96
2176	Spatial Patterns of Longitudinal Gray Matter Change as Predictors of Concurrent Cognitive Decline in Amyloid Positive Healthy Subjects. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 343-358.	1.2	10
2177	Visual Selective Attention Toward Novel Stimuli Predicts Cognitive Decline in Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1339-1349.	1.2	25
2178	Cognitive Stimulation for People with Dementia in Long-Term Care Facilities: Baseline Cognitive Level Predicts Cognitive Gains, Moderated by Depression. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 253-268.	1.2	24

#	ARTICLE	IF	CITATIONS
2179	How Exercise Influences Cognitive Performance When Mild Cognitive Impairment Exists: A Literature Review. <i>Journal of Psychosocial Nursing and Mental Health Services</i> , 2016, 54, 25-35.	0.3	16
2180	The Effect of Escitalopram on Mood and Cognition in Depressive Alzheimer's Disease Subjects. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 727-735.	1.2	24
2181	Effects of Testosterone Therapy on Cognitive Function in Aging: A Systematic Review. <i>Cognitive and Behavioral Neurology</i> , 2016, 29, 122-138.	0.5	48
2182	Degradation in intrinsic connectivity networks across the Alzheimer's disease spectrum. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 5, 35-42.	1.2	13
2183	The Cognitive Change Index as a Measure of Self and Informant Perception of Cognitive Decline: Relation to Neuropsychological Tests. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 1145-1155.	1.2	93
2184	Function and clinical meaningfulness of treatments for mild Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 2, 105-112.	1.2	13
2185	Accelerating rates of cognitive decline and imaging markers associated with $\beta^2$ -amyloid pathology. <i>Neurology</i> , 2016, 86, 1887-1896.	1.5	42
2186	Utility of the Neurobehavioral Cognitive Status Examination (COGNISTAT) in differentiating between depressive states in late-life depression and late-onset Alzheimer's disease: a preliminary study. <i>Annals of General Psychiatry</i> , 2016, 15, 3.	1.2	11
2187	Reference tissue normalization in longitudinal $^{18}\text{F}$ -florbetapir positron emission tomography of late mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 2.	3.0	37
2188	Structural neuroimaging correlates of cognitive status in older adults: A person-oriented approach. <i>Journal of Clinical Neuroscience</i> , 2016, 30, 77-82.	0.8	4
2189	Large intracranial volume accelerates conversion to dementia in males and APOE4 non-carriers with mild cognitive impairment. <i>International Psychogeriatrics</i> , 2016, 28, 769-778.	0.6	6
2190	Anxiety and depression with neurogenesis defects in exchange protein directly activated by cAMP 2-deficient mice are ameliorated by a selective serotonin reuptake inhibitor, Prozac. <i>Translational Psychiatry</i> , 2016, 6, e881-e881.	2.4	36
2192	The effect of schooling on reported age of onset of cognitive decline: A collaborative study. <i>Journal of Clinical Neuroscience</i> , 2016, 34, 86-88.	0.8	3
2193	Cognitive and functional changes associated with $\text{A}\beta^2$ pathology and the progression to mild cognitive impairment. <i>Neurobiology of Aging</i> , 2016, 48, 172-181.	1.5	28
2194	Refining Mild-to-Moderate Alzheimer Disease Screening: A Tool for Clinicians. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 913-920.	1.2	3
2195	Longitudinal clinical score prediction in Alzheimer's disease with soft-split sparse regression based random forest. <i>Neurobiology of Aging</i> , 2016, 46, 180-191.	1.5	99
2196	REDLetr: Workflow and tools to support the migration of legacy clinical data capture systems to REDCap. <i>International Journal of Medical Informatics</i> , 2016, 93, 103-110.	1.6	13
2197	Mutations in <i>MME</i> cause an autosomal recessive Charcot-Marie-Tooth disease type 2. <i>Annals of Neurology</i> , 2016, 79, 659-672.	2.8	82

#	ARTICLE	IF	CITATIONS
2198	The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 892-904.	1.3	62
2199	Peculiarities of Neurological Disorders and Study Designs. <i>Frontiers of Neurology and Neuroscience</i> , 2016, 39, 8-23.	3.0	1
2200	Cognitive effects of MBSR/MBCT: A systematic review of neuropsychological outcomes. <i>Consciousness and Cognition</i> , 2016, 45, 109-123.	0.8	120
2201	Assessing risk for preclinical $\beta$ -amyloid pathology with <i>APOE</i> , cognitive, and demographic information. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 4, 76-84.	1.2	49
2202	At-home tDCS of the left dorsolateral prefrontal cortex improves visual short-term memory in mild vascular dementia. <i>Journal of the Neurological Sciences</i> , 2016, 369, 185-190.	0.3	77
2203	Clinical Diagnosis of Alzheimer's Disease. , 2016, , 27-48.		14
2204	DSM-IV and DSM-5 Prevalence of Social Anxiety Disorder in a Population Sample of Older People. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 1237-1245.	0.6	11
2205	Brief Screening of Vascular Cognitive Impairment in Patients With Cerebral Autosomal-Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy Without Dementia. <i>Stroke</i> , 2016, 47, 2482-2487.	1.0	15
2206	Musical cognition in Alzheimer's disease: application of the Montreal Battery of Evaluation of Amusia. <i>Annals of the New York Academy of Sciences</i> , 2016, 1375, 28-37.	1.8	12
2207	EL ROL DE LA EVALUACIÓN NEUROPSICOLÓGICA EN EL DIAGNÓSTICO Y EN EL SEGUIMIENTO DE LAS DEMENCIAS. <i>Revista Médica Clínica Las Condes</i> , 2016, 27, 319-331.	0.2	3
2208	An approach for estimating item sensitivity to within-person change over time: An illustration using the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog).. <i>Psychological Assessment</i> , 2016, 28, 1576-1585.	1.2	10
2210	Aerobic exercise and vascular cognitive impairment. <i>Neurology</i> , 2016, 87, 2082-2090.	1.5	104
2211	Assessment of the Incremental Diagnostic Value of Flortetapir F 18 Imaging in Patients With Cognitive Impairment. <i>JAMA Neurology</i> , 2016, 73, 1417.	4.5	84
2212	Deep Brain Stimulation of the Fornix. <i>Neurosurgery</i> , 2016, 63, 1-5.	0.6	10
2213	Disease Progression Modeling: Key Concepts and Recent Developments. <i>Current Pharmacology Reports</i> , 2016, 2, 221-230.	1.5	47
2214	Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study. <i>BMC Geriatrics</i> , 2016, 16, 195.	1.1	20
2215	Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer's disease: a prospective, observational study of factors affecting survival time from admission to death. <i>BMC Neurology</i> , 2016, 16, 156.	0.8	7
2216	Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy controls: a two year follow-up study. <i>BMC Neurology</i> , 2016, 16, 180.	0.8	22

#	ARTICLE	IF	CITATIONS
2217	Elevated mRNA Expression and Low Methylation of SNCA in Japanese Alzheimer's Disease Subjects. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1349-1357.	1.2	33
2218	Symptomatic Cognitive Enhancing Agents. , 2016, , 459-475.		4
2219	Clinical Issues in Alzheimer Drug Development. , 2016, , 503-521.		1
2220	Alzheimer's Disease Assessment Scale's Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 8.	3.0	69
2221	A quasi-experimental study of a reminiscence program focused on autobiographical memory in institutionalized older adults with cognitive impairment. <i>Archives of Gerontology and Geriatrics</i> , 2016, 66, 183-192.	1.4	27
2222	Communicative Coping Behavior Checklist: Observation of Persons With Dementia in the Home Environment. <i>Gerontologist</i> , The, 2016, 56, e63-e69.	2.3	2
2223	Relevance of defensin Î²-2 and Î± defensins (HNP1-3) in Alzheimer's disease. <i>Psychiatry Research</i> , 2016, 239, 342-345.	1.7	12
2224	Florbetapir F18 PET Amyloid Neuroimaging and Characteristics in Patients With Mild and Moderate Alzheimer Dementia. <i>Psychosomatics</i> , 2016, 57, 208-216.	2.5	38
2225	Development and Validation of the Rappel Indicador-24. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016, 29, 160-168.	1.2	3
2226	Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 4.	3.0	134
2227	Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 7.	3.0	44
2228	The efficacy and safety of Fufangdanshen tablets (Radix Salviae miltiorrhizae formula tablets) for mild to moderate vascular dementia: a study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 281.	0.7	13
2229	The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: a meta-analysis. <i>International Journal of Neuroscience</i> , 2016, 126, 299-307.	0.8	59
2230	The roles of apolipoprotein E3 and CYP2D6 (rs1065852) gene polymorphisms in the predictability of responses to individualized therapy with donepezil in Han Chinese patients with Alzheimer's disease. <i>Neuroscience Letters</i> , 2016, 614, 43-48.	1.0	21
2231	Rapidly Versus Slowly Progressing Patients With Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2016, 31, 318-325.	0.9	5
2232	Examining the reliability of ADAS-Cog change scores. <i>Aging, Neuropsychology, and Cognition</i> , 2016, 23, 513-529.	0.7	17
2233	Combined Plasma and Cerebrospinal Fluid Signature for the Prediction of Midterm Progression From Mild Cognitive Impairment to Alzheimer Disease. <i>JAMA Neurology</i> , 2016, 73, 203.	4.5	57
2234	CODEM: an observational communication behavior assessment tool for use in ambulatory dementia care. <i>Aging and Mental Health</i> , 2016, 20, 1286-1296.	1.5	13



#	ARTICLE	IF	CITATIONS
2235	Sparse Multi-Response Tensor Regression for Alzheimer's Disease Study With Multivariate Clinical Assessments. <i>IEEE Transactions on Medical Imaging</i> , 2016, 35, 1927-1936.	5.4	25
2236	The Effects of Cognitive Training for Elderly: Results from <i>My Mind Project</i>. <i>Rejuvenation Research</i> , 2016, 19, 485-494.	0.9	62
2237	No relationship between lipoprotein-associated phospholipase A2, proinflammatory cytokines, and neopterin in Alzheimer's disease. <i>Experimental Gerontology</i> , 2016, 77, 1-6.	1.2	12
2238	Practical Pharmacology for Alzheimer's Disease. , 2016, , .		2
2239	Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease. <i>Neuropharmacology</i> , 2016, 108, 128-135.	2.0	23
2240	Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI. <i>Neurology</i> , 2016, 86, 1377-1385.	1.5	103
2241	Longitudinal decline in mild-to-moderate Alzheimer's disease: Analyses of placebo data from clinical trials. , 2016, 12, 598-603.		26
2242	Attenuation of functional hyperemia to visual stimulation in mild Alzheimer's disease and its sensitivity to cholinesterase inhibition. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 957-965.	1.8	18
2243	Distinguishing between impairments of working memory and inhibitory control in cases of early dementia. <i>Neuropsychologia</i> , 2016, 81, 61-67.	0.7	23
2244	Bilateral deep brain stimulation of the fornix for Alzheimer's disease: surgical safety in the ADvance trial. <i>Journal of Neurosurgery</i> , 2016, 125, 75-84.	0.9	66
2245	Time to Treatment Initiation in People With Alzheimer Disease: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 24-30.	1.2	12
2246	Phone behaviour and its relationship to loneliness in older adults. <i>Aging and Mental Health</i> , 2016, 20, 1084-1091.	1.5	36
2247	Graph-guided joint prediction of class label and clinical scores for the Alzheimer's disease. <i>Brain Structure and Function</i> , 2016, 221, 3787-3801.	1.2	31
2248	Binomial regression with a misclassified covariate and outcome. <i>Statistical Methods in Medical Research</i> , 2016, 25, 101-117.	0.7	8
2249	The rationale for deep brain stimulation in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2016, 123, 775-783.	1.4	30
2250	Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients. <i>Alzheimer's and Dementia</i> , 2016, 12, 110-120.	0.4	310
2251	Towards defining restlessness in individuals with dementia. <i>Aging and Mental Health</i> , 2017, 21, 543-552.	1.5	10
2252	Optimizing Effect Sizes With Imaging Enrichment and Outcome Choices for Mild Alzheimer Disease Clinical Trials. <i>Alzheimer Disease and Associated Disorders</i> , 2017, 31, 19-26.	0.6	1

#	ARTICLE	IF	CITATIONS
2253	My Mind Project: the effects of cognitive training for elderly—the study protocol of a prospective randomized intervention study. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 353-360.	1.4	23
2254	Estudio ROSA: validaci3n de la versi3n espa±ola de la Relevant Outcome Scale for Alzheimer's Disease. <i>NeurologÁa</i> , 2017, 32, 417-423.	0.3	2
2255	Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 312-321.	0.4	34
2256	Assessing quality of life in Alzheimer's disease: Implications for clinicalÁtrials. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 82-90.	1.2	29
2257	The correlation between cerebral arterial pulsatility and cognitive dysfunction in Alzheimer's disease patients. <i>Journal of the Neurological Sciences</i> , 2017, 373, 285-288.	0.3	18
2258	Repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer's disease. <i>Neurophysiologie Clinique</i> , 2017, 47, 47-53.	1.0	64
2259	Face-Name Associative Recognition Deficits in Subjective Cognitive Decline and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1185-1196.	1.2	37
2260	Vitamin E for Alzheimer's dementia and mild cognitive impairment. , 2017, 1, CD002854.		63
2261	Cognitive impairment is correlated with insulin resistance degree: the âœPA-NICO-studyâœ. <i>Metabolic Brain Disease</i> , 2017, 32, 799-810.	1.4	12
2262	Evidence for benefit of statins to modify cognitive decline and risk in Alzheimerâ€™s disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 10.	3.0	145
2263	Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-Î² Concentrations and Cognition Outcomes in Alzheimerâ€™s Disease Patients: AAMulticenter, Randomized, Controlled Clinical Trial. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 129-143.	1.2	67
2264	A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 130-138.	1.8	26
2265	Clinically Meaningful Outcomes in Early Alzheimer Disease: A Consortia-Driven Approach to Identifying What Matters to Patients. <i>Therapeutic Innovation and Regulatory Science</i> , 2017, 51, 380-390.	0.8	14
2266	A Comprehensive Review of the Quality and Feasibility of Dementia Assessment Measures: The Dementia Outcomes Measurement Suite. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 826-837.	1.2	14
2267	Robust Identification of Alzheimerâ€™s Disease subtypes based on cortical atrophy patterns. <i>Scientific Reports</i> , 2017, 7, 43270.	1.6	65
2268	Renal function affects hippocampal volume and cognition: The role of vascular burden and amyloid deposition. <i>Geriatrics and Gerontology International</i> , 2017, 17, 1899-1906.	0.7	10
2269	Association between Mid-Regional Proadrenomedullin Levels and Progression of Deep White Matter Lesions in the Brain Accompanying Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1253-1262.	1.2	11
2270	Dance movement therapy for dementia. <i>The Cochrane Library</i> , 2017, 2017, CD011022.	1.5	56

#	ARTICLE	IF	CITATIONS
2271	Efficacy of Vitamin B Supplementation on Cognition in Elderly Patients With Cognitive-Related Diseases. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2017, 30, 50-59.	1.2	89
2272	Efficacy of Hearing Aids on the Cognitive Status of Patients with Alzheimer's Disease and Hearing Loss: A Multicenter Controlled Randomized Trial. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 123-137.	1.2	55
2273	The Role of Neuropsychology in the Assessment of the Cognitively Impaired Elderly. <i>Neurologic Clinics</i> , 2017, 35, 191-206.	0.8	17
2274	Statistical properties of continuous composite scales and implications for drug development. <i>Journal of Biopharmaceutical Statistics</i> , 2017, 27, 1104-1114.	0.4	23
2275	A brief essay on non-pharmacological treatment of Alzheimer's disease. <i>Reviews in the Neurosciences</i> , 2017, 28, 587-597.	1.4	15
2276	Cortical Atrophy is Associated with Accelerated Cognitive Decline in Mild Cognitive Impairment with Subsyndromal Depression. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 980-991.	0.6	26
2277	Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer's Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 519-528.	1.0	98
2278	Vitamin E for Alzheimer's dementia and mild cognitive impairment. <i>The Cochrane Library</i> , 2017, 4, CD002854.	1.5	176
2279	Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial. <i>Age and Ageing</i> , 2017, 46, 767-773.	0.7	23
2280	Feasibility and baseline findings of a Finnish cognitive training (FINCOG) intervention in a randomised controlled trial among community-dwelling persons with dementia. <i>European Geriatric Medicine</i> , 2017, 8, 245-249.	1.2	3
2281	Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 735-739.	1.9	469
2282	Cognitive Screening Instruments. , 2017, , .		33
2283	Herbal medicine for management of the behavioural and psychological symptoms of dementia (BPSD): A systematic review and meta-analysis. <i>Journal of Psychopharmacology</i> , 2017, 31, 169-183.	2.0	28
2284	Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials. <i>BMC Neurology</i> , 2017, 17, 66.	0.8	60
2285	Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 58, 14-29.	1.5	93
2286	Improving medication adherence among community-dwelling seniors with cognitive impairment: a systematic review of interventions. <i>International Journal of Clinical Pharmacy</i> , 2017, 39, 641-656.	1.0	19
2287	Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer's disease via modulating the expression of miR-106b. <i>Biomedicine and Pharmacotherapy</i> , 2017, 92, 46-57.	2.5	89
2288	An Arabic Version of the Cognitive Subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog): Reliability, Validity, and Normative Data. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 11-21.	1.2	21

#	ARTICLE	IF	CITATIONS
2289	Effects of the Insulin Sensitizer Metformin in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2017, 31, 107-113.	0.6	243
2290	Depressive Symptoms are Associated with Progression to Dementia in Patients with Amyloid-Positive Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 1255-1264.	1.2	31
2291	Relationships between cognitive impairment on ADAS-cog and regional cerebral blood flow using SPECT in late-onset Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2017, 124, 1109-1121.	1.4	7
2292	Economic evaluation of aerobic exercise training in older adults with vascular cognitive impairment: PROMoTE trial. <i>BMJ Open</i> , 2017, 7, e014387.	0.8	8
2293	Olfactory evaluation in Mild Cognitive Impairment: correlation with neurocognitive performance and endothelial function. <i>European Journal of Neuroscience</i> , 2017, 45, 1279-1288.	1.2	20
2294	Patients with Mild Cognitive Impairment Show Lower Visual Short-Term Memory Performance in Feature Binding Tasks. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2017, 7, 74-86.	0.6	11
2295	Cognitive status, fast walking speed and walking speed reserve—the Gait and Alzheimer Interactions Tracking (GAIT) study. <i>GeroScience</i> , 2017, 39, 231-239.	2.1	71
2296	Cross-sectional design with a short-term follow-up for prognostic imaging biomarkers. <i>Computational Statistics and Data Analysis</i> , 2017, 113, 154-176.	0.7	1
2297	Î scores predict mild cognitive impairment and Alzheimer's disease conversions from nondemented states. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 214-221.	1.2	13
2298	Clinical meaningfulness of Alzheimer's Disease Assessment Scale's Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors. <i>Alzheimer's and Dementia</i> , 2017, 13, 1098-1106.	0.4	20
2299	A phase 3 trial of IV immunoglobulin for Alzheimer disease. <i>Neurology</i> , 2017, 88, 1768-1775.	1.5	136
2300	Randomized controlled trials in mild cognitive impairment. <i>Neurology</i> , 2017, 88, 1751-1758.	1.5	35
2301	Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1355-1363.	3.3	9
2302	Acetylcholinesterase inhibitors for electroconvulsive therapy-induced cognitive side effects: a systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 522-531.	1.3	11
2303	What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 797-812.	1.2	23
2304	The Usage of Cognitive Screening Instruments: Test Characteristics and Suspected Diagnosis. , 2017, , 315-339.		4
2305	Severity of Depression Impacts Imminent Conversion from Mild Cognitive Impairment to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1439-1448.	1.2	24
2306	Are sage, rosemary and lemon balm effective interventions in dementia? A narrative review of the clinical evidence. <i>European Journal of Integrative Medicine</i> , 2017, 15, 83-96.	0.8	5

#	ARTICLE	IF	CITATIONS
2307	Cannabinoids for the treatment of dementia. The Cochrane Library, 2017, , .	1.5	7
2308	Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis. Journal of Alzheimer's Disease, 2017, 60, 401-425.	1.2	158
2309	Semantic Memory in the Clinical Progression of Alzheimer Disease. Cognitive and Behavioral Neurology, 2017, 30, 81-89.	0.5	12
2310	TOMM40 and APOE Gene Expression and Cognitive Decline in Japanese Alzheimer's Disease Subjects. Journal of Alzheimer's Disease, 2017, 60, 1107-1117.	1.2	31
2311	A randomized controlled trial of physical activity with individual goal-setting and volunteer mentors to overcome sedentary lifestyle in older adults at risk of cognitive decline: the INDIGO trial protocol. BMC Geriatrics, 2017, 17, 215.	1.1	10
2312	The Stroop-Interference-NoGo-Test (STING): A Fast Screening Tool for the Global Assessment of Neuropsychological Impairments. Neurology International Open, 2017, 1, E98-E106.	0.4	0
2313	Cost-Effectiveness Analysis. , 2017, , 71-87.		0
2314	Cognitive function and walking velocity in people with dementia; a comparison of backward and forward walking. Gait and Posture, 2017, 58, 481-486.	0.6	21
2315	Dementia prevention, intervention, and care. Lancet, The, 2017, 390, 2673-2734.	6.3	4,228
2316	Neuromodulation for Memory. , 2017, , 235-250.		0
2317	Costs and quality of life in community-dwelling patients with Alzheimer's disease in Spain: results from the GERAS II observational study. International Psychogeriatrics, 2017, 29, 2081-2093.	0.6	27
2318	Carotid atherosclerosis promotes the progression of Alzheimer's disease: A three-year prospective study. Experimental and Therapeutic Medicine, 2017, 14, 1321-1326.	0.8	13
2319	Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 393-401.	1.8	47
2320	Everyday cognition scales are related to cognitive function in the early stage of probable Alzheimer's disease and FDG-PET findings. Scientific Reports, 2017, 7, 1719.	1.6	13
2321	Decreasing prevalence of dementia in 85-year olds examined 22 years apart: the influence of education and stroke. Scientific Reports, 2017, 7, 6136.	1.6	63
2322	Cognitive interventions in patients with dementia living in long-term care facilities: Systematic review and meta-analysis. Archives of Gerontology and Geriatrics, 2017, 73, 204-221.	1.4	25
2323	Estandarizaci3n del test de reacci3n cognitiva. Comprobaci3n de su utilidad en el diagn3stico del deterioro cognitivo m3nimo. Neurologia Argentina, 2017, 9, 163-172.	0.1	0
2324	Transdiagnostic Dimensional Assessment of Psychopathology in Later Life. Current Behavioral Neuroscience Reports, 2017, 4, 167-175.	0.6	1

#	ARTICLE	IF	CITATIONS
2325	The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin Targeting (RADAR) Trial. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 803-814.	1.2	28
2326	A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1359-1379.	1.2	65
2327	Validation of the Spanish-language version of the Relevant Outcome Scale for Alzheimer's Disease. <i>Neurología (English Edition)</i> , 2017, 32, 417-423.	0.2	0
2328	An 8-week open label trial of l-Threonic Acid Magnesium Salt in patients with mild to moderate dementia. <i>Personalized Medicine in Psychiatry</i> , 2017, 4-6, 7-12.	0.1	4
2329	The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 513-523.	1.8	17
2330	Detection Test for Language Impairments in Adults and the Aged: A New Screening Test for Language Impairment Associated With Neurodegenerative Diseases: Validation and Normative Data. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2017, 32, 382-392.	0.9	27
2331	Ensemble prediction of longitudinal scores of Alzheimer's disease based on $\ell_{2,1}$ -norm regularized correntropy with spatial-temporal constraint. , 2017, , .		3
2332	The First Frontier: Digital Biomarkers for Neurodegenerative Disorders. <i>Digital Biomarkers</i> , 2017, 1, 6-13.	2.2	100
2333	A six-month longitudinal evaluation significantly improves accuracy of predicting incipient Alzheimer's disease in mild cognitive impairment. <i>Journal of Neuroradiology</i> , 2017, 44, 381-387.	0.6	23
2334	Impact of legumes and plant proteins consumption on cognitive performances in the elderly. <i>Journal of Translational Medicine</i> , 2017, 15, 109.	1.8	28
2336	Executive Dysfunctions Predict Self-Restricted Driving Habits in Elderly People with or without Alzheimer's Dementia. <i>Pharmacopsychiatry</i> , 2017, 50, 203-210.	1.7	11
2337	Sample Size Estimation for Alzheimer's Disease Trials from Japanese ADNI Serial Magnetic Resonance Imaging. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 75-88.	1.2	31
2338	Prevalence of DSM-5 Mild Neurocognitive Disorder in Dementia-Free Older Adults: Results of the Population-Based LIFE-Adult-Study. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 328-339.	0.6	43
2339	The importance of sustained attention in early Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 860-867.	1.3	37
2340	Informal Care Time and Cost in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Change Observed. <i>Neurology and Therapy</i> , 2017, 6, 11-23.	1.4	7
2341	Examining the impact of grape consumption on brain metabolism and cognitive function in patients with mild decline in cognition: A double-blinded placebo controlled pilot study. <i>Experimental Gerontology</i> , 2017, 87, 121-128.	1.2	80
2342	Meta-analysis of randomized, double-blind, placebo-controlled trials of melatonin in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 50-57.	1.3	61
2343	High Caregiver Burden in Young Onset Dementia: What Factors Need Attention?. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 537-543.	1.2	22

#	ARTICLE	IF	CITATIONS
2344	Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 1325-1334.	1.2	247
2345	Effects of Exercise on Cognitive Function in Older People with Dementia: A Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 323-332.	1.2	62
2346	CERAD Neuropsychological Battery's Arabic Version: Regression-Based and Stratified Normative Data and Effects of Demographic Variables on Cognitive Performance in Older Omanis. <i>Cognitive and Behavioral Neurology</i> , 2017, 30, 150-158.	0.5	9
2347	The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease. <i>Medicine (United States)</i> , 2017, 96, e9381.	0.4	7
2348	Medium-Chain Triglycerides in Combination with Leucine and Vitamin D Benefit Cognition in Frail Elderly Adults: A Randomized Controlled Trial. <i>Journal of Nutritional Science and Vitaminology</i> , 2017, 63, 133-140.	0.2	19
2349	Early- versus Late-Onset Alzheimer Disease: Long-Term Functional Outcomes, Nursing Home Placement, and Risk Factors for Rate of Progression. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2017, 7, 172-187.	0.6	20
2350	Accessing morphosyntactic information is preserved at old age, except for irregulars. <i>Mental Lexicon</i> , 2017, 12, 342-372.	0.2	4
2351	Feasibility and first results of a group program to increase the frequency of cognitively stimulating leisure activities in people with mild cognitive impairment (AKTIVA&ndash;MCI). <i>Clinical Interventions in Aging</i> , 2017, Volume 12, 1459-1469.	1.3	2
2352	A new data analysis approach for measuring longitudinal changes of metabolism in cognitively normal elderly adults. <i>Clinical Interventions in Aging</i> , 2017, Volume 12, 2123-2130.	1.3	4
2353	Preliminary Data on the Interaction between Some Biometals and Oxidative Stress Status in Mild Cognitive Impairment and Alzheimer's Disease Patients. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 1-7.	1.9	32
2354	Obesity and Co-morbid Conditions Are Associated with Specific Neuropsychiatric Symptoms in Mild Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 164.	1.7	20
2355	Atrophy of the Posterior Subiculum Is Associated with Memory Impairment, Tau- and A $\beta$ Pathology in Non-demented Individuals. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 306.	1.7	30
2356	Classifying MCI Subtypes in Community-Dwelling Elderly Using Cross-Sectional and Longitudinal MRI-Based Biomarkers. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 309.	1.7	17
2357	Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2017, 11, 281.	1.4	62
2358	Efficacy and Safety of an Herbal Therapy in Patients with Amnesic Mild Cognitive Impairment: A 24-Week Randomized Phase III Trial. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-9.	0.5	4
2359	Efficacy of cognitive stimulation therapy for older adults with vascular dementia. <i>Dementia &amp; Neuropsychologia</i> , 2017, 11, 434-441.	0.3	31
2360	Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnesic Mild Cognitive Impairment-Storage Subtype. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 447-459.	1.2	26
2361	Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations. <i>PLoS ONE</i> , 2017, 12, e0179521.	1.1	48

#	ARTICLE	IF	CITATIONS
2362	Cognitive assessment in Huntington disease clinical drug trials. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 144, 227-244.	1.0	13
2363	The effect of electroacupuncture combined with donepezil on cognitive function in Alzheimer's disease patients: study protocol for a randomized controlled trial. Trials, 2017, 18, 301.	0.7	14
2364	On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimer's Research and Therapy, 2017, 9, 60.	3.0	316
2365	Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years. Alzheimer's Research and Therapy, 2017, 9, 70.	3.0	81
2366	Cognitive Stimulation as a Therapeutic Modality for Dementia: A Meta-Analysis. Psychiatry Investigation, 2017, 14, 626.	0.7	41
2367	Application of Haralick texture features in brain [ <sup>18</sup> F]-florbetapir positron emission tomography without reference region normalization. Clinical Interventions in Aging, 2017, Volume 12, 2077-2086.	1.3	12
2368	INPP5D mRNA Expression and Cognitive Decline in Japanese Alzheimer's Disease Subjects. Journal of Alzheimer's Disease, 2017, 58, 687-694.	1.2	35
2369	COSTS AND RESOURCE USE ASSOCIATED WITH ALZHEIMER'S DISEASE IN ITALY: RESULTS FROM AN OBSERVATIONAL STUDY. Journal of prevention of Alzheimer's disease, The, 2017, 5, 1-10.	1.5	12
2370	Analysis of an incomplete longitudinal composite variable using a marginalized random effects model and multiple imputation. Statistical Methods in Medical Research, 2018, 27, 2200-2215.	0.7	2
2371	Defining SNAP by cross-sectional and longitudinal definitions of neurodegeneration. NeuroImage: Clinical, 2018, 18, 407-412.	1.4	12
2372	The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review. Journal of Alzheimer's Disease, 2018, 63, 423-444.	1.2	214
2373	Study protocol for Vitality: a proof-of-concept randomised controlled trial of exercise training or complex mental and social activities to promote cognition in adults with chronic stroke. BMJ Open, 2018, 8, e021490.	0.8	14
2374	Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future. Journal of Alzheimer's Disease, 2018, 64, S3-S22.	1.2	108
2375	Physical Activity as a Strategy to Promote Cognitive Health Among Older People. , 2018, , 693-711.		0
2376	Voxel-Based Acetylcholinesterase PET Study in Early and Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 62, 1539-1548.	1.2	11
2377	Clinical significance of visually equivocal amyloid PET findings from the Alzheimer's Disease Neuroimaging Initiative cohort. NeuroReport, 2018, 29, 553-558.	0.6	6
2378	Intranasal insulin in Alzheimer's dementia or mild cognitive impairment: a systematic review. Journal of Neurology, 2018, 265, 1497-1510.	1.8	93
2379	Effects of Cognitive Training on Cognition and Quality of Life of Older Persons with Dementia. Journal of the American Geriatrics Society, 2018, 66, 664-670.	1.3	20



#	ARTICLE	IF	CITATIONS
2380	Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2018, 378, 321-330.	13.9	795
2381	Rating scales for cognition in Huntington's disease: Critique and recommendations. <i>Movement Disorders</i> , 2018, 33, 187-195.	2.2	38
2382	A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test-retest reliability and feasibility. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 153-160.	1.2	12
2383	Amyloid pathology in the progression to mild cognitive impairment. <i>Neurobiology of Aging</i> , 2018, 64, 76-84.	1.5	27
2384	Alzheimer's Disease Assessment: A Review and Illustrations Focusing on Item Response Theory Techniques. <i>Assessment</i> , 2018, 25, 360-373.	1.9	16
2385	Limbic and Basal Ganglia Neuroanatomical Correlates of Gait and Executive Function. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2018, 97, 229-235.	0.7	20
2386	Comparing <sup>18</sup> F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. <i>Neurology</i> , 2018, 90, e388-e395.	1.5	83
2387	In Thai Nationals, the ApoE4 Allele Affects Multiple Domains of Neuropsychological, Biobehavioral, and Social Functioning Thereby Contributing to Alzheimer's Disorder, while the ApoE3 Allele Protects Against Neuropsychiatric Symptoms and Psychosocial Deficits. <i>Molecular Neurobiology</i> , 2018, 55, 6449-6462.	1.9	13
2388	Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 130.	3.8	121
2389	Representativeness of European clinical trial populations in mild Alzheimer's disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 36.	3.0	3
2390	Data-driven identification of endophenotypes of Alzheimer's disease progression: implications for clinical trials and therapeutic interventions. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 4.	3.0	29
2391	Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2018, 378, 1691-1703.	13.9	512
2392	Optimal planning of phase II/III programs for clinical trials with multiple endpoints. <i>Pharmaceutical Statistics</i> , 2018, 17, 437-457.	0.7	3
2393	Association between ABCA1 gene polymorphisms and the therapeutic response to donepezil therapy in Han Chinese patients with Alzheimer's disease. <i>Brain Research Bulletin</i> , 2018, 140, 1-4.	1.4	14
2394	Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2018, 75, 834.	4.5	136
2395	Underlying Biological Processes in Mild Cognitive Impairment: Amyloidosis Versus Neurodegeneration. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S647-S657.	1.2	10
2396	π-π Stacking Interaction: A Nondestructive and Facile Means in Material Engineering for Bioapplications. <i>Crystal Growth and Design</i> , 2018, 18, 2765-2783.	1.4	192
2397	18F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies. <i>Scientific Reports</i> , 2018, 8, 4717.	1.6	59

#	ARTICLE	IF	CITATIONS
2398	Validation study of the Alzheimer's disease assessment scale's cognitive subscale (ADAS-Cog) for the Portuguese patients with mild cognitive impairment and Alzheimer's disease. <i>Clinical Neuropsychologist</i> , 2018, 32, 46-59.	1.5	24
2399	The importance of endpoint selection: How effective does a drug need to be for success in a clinical trial of a possible Alzheimer's disease treatment?. <i>European Journal of Epidemiology</i> , 2018, 33, 635-644.	2.5	19
2400	The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical <i>PSEN1</i> E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 150-160.	1.8	107
2402	Cognitive screening in substance users: Diagnostic accuracies of the Mini-Mental State Examination, Addenbrooke's Cognitive Examination-Revised, and Montreal Cognitive Assessment. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2018, 40, 107-122.	0.8	38
2403	Omega-3 fatty acids' supplementation in Alzheimer's disease: A systematic review. <i>Nutritional Neuroscience</i> , 2018, 21, 529-538.	1.5	88
2404	Cultural adaptation of cognitive stimulation therapy (CST) for Chinese people with dementia: multicentre pilot study. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 841-848.	1.3	23
2406	Multiplicity-adjusted semiparametric benefiting subgroup identification in clinical trials. <i>Clinical Trials</i> , 2018, 15, 75-86.	0.7	10
2407	Executive function: Responses to aerobic exercise in Alzheimer's disease. <i>Geriatric Nursing</i> , 2018, 39, 219-224.	0.9	19
2408	Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 21-27.	0.9	7
2409	Art museum-based intervention to promote emotional well-being and improve quality of life in people with dementia: The ARTEMIS project. <i>Dementia</i> , 2018, 17, 728-743.	1.0	46
2410	Anti-Amyloid- $\beta$ Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise. <i>Biological Psychiatry</i> , 2018, 83, 311-319.	0.7	408
2411	Faster progression from MCI to probable AD for carriers of a single-nucleotide polymorphism associated with type 2 diabetes. <i>Neurobiology of Aging</i> , 2018, 64, 157.e11-157.e17.	1.5	18
2412	<i>MEF2C</i> mRNA expression and cognitive function in Japanese patients with Alzheimer's disease. <i>Psychiatry and Clinical Neurosciences</i> , 2018, 72, 160-167.	1.0	36
2413	Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes. <i>Clinical and Translational Science</i> , 2018, 11, 147-152.	1.5	224
2414	DEVELOPMENT OF AZELIRAGON, AN ORAL SMALL MOLECULE ANTAGONIST OF THE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS, FOR THE POTENTIAL SLOWING OF LOSS OF COGNITION IN MILD ALZHEIMER'S DISEASE. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2018, 5, 1-6.	1.5	67
2415	ASSESSMENT OF CLINICAL MEANINGFULNESS OF ENDPOINTS IN THE GENERATION PROGRAM BY THE INSIGHTS TO MODEL ALZHEIMER'S PROGRESSION IN REAL LIFE (IMAP) STUDY. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2018, 6, 1-5.	1.5	8
2416	Early-stage right temporal lobe variant of frontotemporal dementia: 3 years of follow-up observations. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-224431.	0.2	2
2417	DETECTING TREATMENT GROUP DIFFERENCES IN ALZHEIMER'S DISEASE CLINICAL TRIALS: A COMPARISON OF ALZHEIMER'S DISEASE ASSESSMENT SCALE - COGNITIVE SUBSCALE (ADAS-COG) AND THE CLINICAL DEMENTIA RATING - SUM OF BOXES (CDR-SB). <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2018, 5, 1-6.	1.5	8

#	ARTICLE	IF	CITATIONS
2419	WHAT HAVE WE LEARNED FROM EXPEDITION III AND EPOCH TRIALS? PERSPECTIVE OF THE CTAD TASK FORCE. Journal of prevention of Alzheimer's disease, The, 2018, 5, 1-4.	1.5	7
2420	6.Diagnostische Methoden. , 2018, , 187-352.		0
2421	Join and Deep Ensemble Regression of Clinical Scores for Alzheimer's Disease Using Longitudinal and Incomplete Data. , 2018, 2018, 1254-1257.		4
2422	Study protocol on Alzheimer's disease and related disorders: focus on clinical and imaging predictive markers in co-existing lesions. BMC Geriatrics, 2018, 18, 280.	1.1	1
2423	Memantine treatment for Japanese patients with moderate to severe Alzheimer's disease: a meta-analysis of double-blind, randomized, placebo-controlled trials. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2915-2922.	1.0	4
2424	Efficacy, Acceptability, and Safety of Intravenous Immunoglobulin Administration for Mild-To-Moderate Alzheimer's Disease: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2018, 66, 1379-1387.	1.2	7
2425	Exploring Genetic Associations of Alzheimer's Disease Loci With Mild Cognitive Impairment Neurocognitive Endophenotypes. Frontiers in Aging Neuroscience, 2018, 10, 340.	1.7	12
2426	Association between Hippocampal Shape, Neuroinflammation, and Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 66, 1131-1144.	1.2	27
2427	Reliability and validity of a Mediterranean diet and culinary index (MediCul) tool in an older population with mild cognitive impairment. British Journal of Nutrition, 2018, 120, 1189-1200.	1.2	13
2428	Efficacy and safety of Tianmabianchunzhigan in mild to moderate vascular dementia. Medicine (United Tj ETQq1 10,784314 rgBT /Oe 0,4 1		
2429	A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 609-616.	1.8	83
2430	Relationship between Cortical Thickness and Neuropsychological Performance in Normal Older Adults and Those with Mild Cognitive Impairment. , 2018, 9, 1020.		30
2431	Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer's disease clinical program. Alzheimer's Research and Therapy, 2018, 10, 116.	3.0	28
2432	The Multidisciplinary Approach to Alzheimer's Disease and Dementia. A Narrative Review of Non-Pharmacological Treatment. Frontiers in Neurology, 2018, 9, 1058.	1.1	164
2433	The influence of language and culture on cognitive assessment tools in the diagnosis of early cognitive impairment and dementia. Expert Review of Neurotherapeutics, 2018, 18, 859-869.	1.4	29
2434	Oxidative Stress in Elderly with Different Cognitive Status: My Mind Project. Journal of Alzheimer's Disease, 2018, 63, 1405-1414.	1.2	8
2435	Telephone-based Dementia Screening I. , 2018, , .		16
2436	Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLoS Medicine, 2018, 15, e1002660.	3.9	131

#	ARTICLE	IF	CITATIONS
2437	Cognitive Assessment of Patients With Alzheimer's Disease by Telemedicine: Pilot Study. <i>JMIR Mental Health</i> , 2018, 5, e31.	1.7	46
2438	CSF A $\beta$ 1-42, but not p-Tau181, Predicted Progression from Amnesic MCI to Alzheimer's Disease Dementia. <i>NeuroMolecular Medicine</i> , 2018, 20, 491-497.	1.8	4
2439	The conceptual relevance of assessment measures in patients with mild/moderate Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 498-508.	1.2	8
2440	Risk factors for polypharmacy in older adults in a primary care setting: a cross-sectional study. <i>Clinical Interventions in Aging</i> , 2018, Volume 13, 2003-2011.	1.3	23
2441	Ghrelin cascade changes in the peripheral blood of Japanese patients with Alzheimer's disease. <i>Journal of Psychiatric Research</i> , 2018, 107, 79-85.	1.5	10
2442	PSYCHOMETRIC EVALUATION OF THE NEUROPSYCHOLOGICAL TEST BATTERY IN INDIVIDUALS WITH NORMAL COGNITION, MILD COGNITIVE IMPAIRMENT, OR MILD TO MODERATE ALZHEIMER'S DISEASE: RESULTS FROM A LONGITUDINAL STUDY. <i>Journal of prevention of Alzheimer's disease</i> , The, 2018, 5, 1-9.	1.5	8
2443	Hearing Loss Treatment in Older Adults With Cognitive Impairment: A Systematic Review. <i>Journal of Speech, Language, and Hearing Research</i> , 2018, 61, 2589-2603.	0.7	37
2444	Neurostimulation Combined With Cognitive Intervention in Alzheimer's Disease (NeuroAD): Study Protocol of Double-Blind, Randomized, Factorial Clinical Trial. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 334.	1.7	10
2445	Potential Factors Associated with Cognitive Improvement of Individuals Diagnosed with Mild Cognitive Impairment or Dementia in Longitudinal Studies. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 587-600.	1.2	7
2446	Neuropsychological Assessment of Dementia and Cognitive Disorders. <i>Journal of Korean Neuropsychiatric Association</i> , 2018, 57, 2.	0.2	12
2447	Incidence of dementia in patients with adult-onset epilepsy of unknown causes. <i>Journal of the Neurological Sciences</i> , 2018, 395, 71-76.	0.3	24
2448	Therapeutic approaches to Huntington disease: from the bench to the clinic. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 729-750.	21.5	117
2449	Transcranial magnetic stimulation intervention in Alzheimer's disease: a research proposal for a randomized controlled trial. <i>BMC Research Notes</i> , 2018, 11, 648.	0.6	12
2450	The impact of model assumptions in scalar-on-image regression. <i>Statistics in Medicine</i> , 2018, 37, 4298-4317.	0.8	6
2451	Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnesic Mild Cognitive Impairment. <i>JAMA Neurology</i> , 2018, 75, 1114.	4.5	75
2452	Decoupling of Local Metabolic Activity and Functional Connectivity Links to Amyloid in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 405-415.	1.2	21
2453	Neuropsychological correlates of instrumental activities of daily living in neurocognitive disorders: a possible role for executive dysfunction and mood changes. <i>International Psychogeriatrics</i> , 2018, 30, 1871-1881.	0.6	22
2454	Neuropsychiatric Symptoms and Caregiver Burden in Individuals With Alzheimer's Disease: The TEAM-AD VA Cooperative Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2018, 31, 177-185.	1.2	39

#	ARTICLE	IF	CITATIONS
2455	Relationships between Cognition and Activities of Daily Living in Alzheimer's Disease During a 5-Year Follow-Up: ALSOVA Study. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 269-279.	1.2	14
2456	Effect of acupuncture on patients with mild cognitive impairment assessed using functional near-infrared spectroscopy on week 12 (close-out): a pilot study protocol. <i>Integrative Medicine Research</i> , 2018, 7, 287-295.	0.7	12
2457	Escala de Avaliação da Doença de Alzheimer - Subescala Cognitiva (ADAS-Cog): Dados Normativos para a População Portuguesa. <i>Acta Medica Portuguesa</i> , 2018, 31, 94.	0.2	8
2458	Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1305-1311.	1.3	16
2459	New approaches in psychiatric drug development. <i>European Neuropsychopharmacology</i> , 2018, 28, 983-993.	0.3	15
2460	Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer's disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients. <i>BMC Geriatrics</i> , 2018, 18, 168.	1.1	29
2461	Impact of apolipoprotein E genotypes on vitamin E and memantine treatment outcomes in Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 344-349.	1.8	6
2462	Vascular Cognitive Impairment: Epidemiology, Definitions, Stroke-Associated Dementia, and Delirium. , 2018, , 456-474.		0
2463	Informant questionnaire on cognitive decline in the elderly (IQCODE) for assessing the severity of dementia in patients with Alzheimer's disease. <i>BMC Geriatrics</i> , 2018, 18, 146.	1.1	17
2464	A Speech Recognition-based Solution for the Automatic Detection of Mild Cognitive Impairment from Spontaneous Speech. <i>Current Alzheimer Research</i> , 2018, 15, 130-138.	0.7	160
2465	Improving clarity and transparency in cognitive assessment: conversion of the Cambridge Cognition Examination to the International Classification of Functioning, Disability and Health. <i>European Geriatric Medicine</i> , 2018, 9, 455-466.	1.2	1
2466	Opening the debate on deep brain stimulation for Alzheimer disease – a critical evaluation of rationale, shortcomings, and ethical justification. <i>BMC Medical Ethics</i> , 2018, 19, 41.	1.0	15
2467	Resting-State Functional Connectivity Predicts Cognitive Impairment Related to Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 94.	1.7	75
2468	Environmental and behavioural modifications for improving food and fluid intake in people with dementia. <i>The Cochrane Library</i> , 2018, 2018, CD011542.	1.5	31
2469	Screening for dementia with the Vienna Visuo-Constructional Test 3.0 screening (VVT 3.0 screening). <i>Neuropsychiatrie</i> , 2018, 32, 196-203.	1.3	5
2470	TOMMORROW neuropsychological battery: German language validation and normative study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 314-323.	1.8	9
2471	Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 61.	3.0	8
2472	TREM1 mRNA Expression in Leukocytes and Cognitive Function in Japanese Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 1275-1284.	1.2	21

#	ARTICLE	IF	CITATIONS
2473	Addition of the A $\beta$ <sup>42</sup> /40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 33.	3.0	63
2474	Aerobic training modulates salience network and default mode network metabolism in subjects with mild cognitive impairment. <i>NeuroImage: Clinical</i> , 2018, 19, 616-624.	1.4	6
2475	Centre- versus home-based exercise among people with mci and mild dementia: study protocol for a randomized parallel-group trial. <i>BMC Geriatrics</i> , 2018, 18, 27.	1.1	10
2476	Effect of the replacement of dietary vegetable oils with a low dose of extravirgin olive oil in the Mediterranean Diet on cognitive functions in the elderly. <i>Journal of Translational Medicine</i> , 2018, 16, 10.	1.8	52
2477	The Impact of Awareness of and Concern About Memory Performance on the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2018, 26, 896-904.	0.6	23
2478	Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 173-181.	1.8	39
2479	Statistical Model of Dynamic Markers of the Alzheimer's Pathological Cascade. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2018, 73, 964-973.	2.4	8
2480	A Systematic Review and Meta-Analysis of the Effectiveness of Acetylcholinesterase Inhibitors and Memantine in Treating the Cognitive Symptoms of Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 45, 131-151.	0.7	102
2481	The effectiveness of ICT-based neurocognitive and psychosocial rehabilitation programmes in people with mild dementia and mild cognitive impairment using GRADIOR and ehcoBUTLER: study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 100.	0.7	14
2482	A quick test of cognitive speed in older adults with Alzheimer's disease and mild cognitive impairment: A preliminary behavioral and brain imaging study. <i>Psychiatry Research - Neuroimaging</i> , 2018, 280, 30-38.	0.9	5
2483	Real-World, Multinational, Retrospective Observational Survey of the ADAS-Cog and Associations with Healthcare Resource Utilization in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 899-910.	1.2	2
2484	Left lateralized cerebral glucose metabolism declines in amyloid- $\beta$ <sup>2</sup> positive persons with mild cognitive impairment. <i>NeuroImage: Clinical</i> , 2018, 20, 286-296.	1.4	64
2485	Effects of Molecular Hydrogen Assessed by an Animal Model and a Randomized Clinical Study on Mild Cognitive Impairment. <i>Current Alzheimer Research</i> , 2018, 15, 482-492.	0.7	75
2486	Greater tau load and reduced cortical thickness in APOE $\epsilon$ <sup>4</sup> -negative Alzheimer's disease: a cohort study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 77.	3.0	56
2487	Cognitive Stimulation Therapy for Dementia. <i>Clinics in Geriatric Medicine</i> , 2018, 34, 653-665.	1.0	21
2488	A "Comprehensive Visual Rating Scale" for predicting progression to dementia in patients with mild cognitive impairment. <i>PLoS ONE</i> , 2018, 13, e0201852.	1.1	8
2489	Vascular risk factors and the relationships between cognitive impairment and hypoperfusion in late-onset Alzheimer's disease. <i>Acta Neuropsychiatrica</i> , 2018, 30, 350-358.	1.0	8
2490	Deep Brain Stimulation of the Memory Circuit: Improving Cognition in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 337-347.	1.2	11

#	ARTICLE	IF	CITATIONS
2491	Sleep Disturbance and the Risk of Cognitive Decline or Clinical Conversion in the ADNI Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 45, 232-242.	0.7	20
2492	Estudios farmacogenéticos en la enfermedad de Alzheimer. <i>Neurología</i> , 2022, 37, 287-303.	0.3	5
2493	Deep Brain Stimulation Targeting the Fornix for Mild Alzheimer Dementia (the ADvance Trial): A Two Year Follow-up Including Results of Delayed Activation. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 597-606.	1.2	69
2494	Efficacy of antipsychotics in dementia depended on the definition of patients and outcomes: a meta-epidemiological study. <i>Journal of Clinical Epidemiology</i> , 2018, 101, 17-27.	2.4	11
2495	Donepezil for dementia due to Alzheimer's disease. <i>The Cochrane Library</i> , 2018, 2018, CD001190.	1.5	377
2496	Predicting and Tracking Short Term Disease Progression in Amnesic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 3-14.	1.2	18
2497	Effect and Safety of Huannao Yicong Formula (è¸è¸,çŠèæ-1) in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Double-Blinded, Donepezil-Controlled Trial. <i>Chinese Journal of Integrative Medicine</i> , 2019, 25, 574-581.	0.7	16
2498	Cognitive and physical factors affecting daily function in Alzheimer's disease: A cross-sectional analysis. <i>Australian Journal of Cancer Nursing</i> , 2019, 21, 14-20.	0.8	5
2499	Effects of electroacupuncture combined with computer-based cognitive rehabilitation on mild cognitive impairment: study protocol for a pilot randomized controlled trial. <i>Trials</i> , 2019, 20, 478.	0.7	4
2500	Î²-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. <i>Scientific Reports</i> , 2019, 9, 11180.	1.6	28
2502	Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases. <i>CNS Drugs</i> , 2019, 33, 883-904.	2.7	23
2503	Qualitative analysis for the ideational apraxia score from the Alzheimer's disease assessment scale cognitive subscale. <i>Neurology and Clinical Neuroscience</i> , 2019, 7, 180-185.	0.2	1
2504	COMPARING THE STANDARD AND ELECTRONIC VERSIONS OF THE ALZHEIMER'S DISEASE ASSESSMENT SCALE " COGNITIVE SUBSCALE: A VALIDATION STUDY. <i>Journal of prevention of Alzheimer's disease</i> , The, 2019, 6, 1-5.	1.5	2
2505	AgeWell.de " study protocol of a pragmatic multi-center cluster-randomized controlled prevention trial against cognitive decline in older primary care patients. <i>BMC Geriatrics</i> , 2019, 19, 203.	1.1	34
2506	Efficacy and Safety of Cholinesterase Inhibitors for Mild Cognitive Impairment:A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 513-523.	1.2	60
2507	D-glutamate, D-serine, and D-alanine differ in their roles in cognitive decline in patients with Alzheimer's disease or mild cognitive impairment. <i>Pharmacology Biochemistry and Behavior</i> , 2019, 185, 172760.	1.3	50
2508	Plasma Neurofilament Light Chain Levels Are Associated With Cortical Hypometabolism in Alzheimer Disease Signature Regions. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 709-716.	0.9	18
2509	A Novel Ensemble-Based Machine Learning Algorithm to Predict the Conversion From Mild Cognitive Impairment to Alzheimer's Disease Using Socio-Demographic Characteristics, Clinical Information, and Neuropsychological Measures. <i>Frontiers in Neurology</i> , 2019, 10, 756.	1.1	68

#	ARTICLE	IF	CITATIONS
2510	Transcranial Magnetic and Electrical Stimulation in Alzheimer's Disease and Mild Cognitive Impairment: A Review of Randomized Controlled Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 776-780.	2.3	42
2511	Cognitive Functioning and Psychological Well-being in Breast Cancer Patients on Endocrine Therapy. <i>In Vivo</i> , 2019, 33, 1381-1392.	0.6	11
2512	Safety and Efficacy of Edonepic Maleate for Patients With Mild to Moderate Alzheimer Disease. <i>JAMA Neurology</i> , 2019, 76, 1330.	4.5	29
2513	The Assessment of Cognition in Translational Medicine: A Contrast Between the Approaches Used in Alzheimer's Disease and Major Depressive Disorder. <i>Handbook of Behavioral Neuroscience</i> , 2019, 29, 297-308.	0.7	4
2514	Alzheimer's disease drug development pipeline: 2019. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 272-293.	1.8	546
2515	Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease. <i>JAMA Neurology</i> , 2019, 76, 1219.	4.5	107
2516	Validation study of the Alzheimer's Disease Assessment Scale—Cognitive Subscale for people with mild cognitive impairment and Alzheimer's disease in Chinese communities. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1658-1666.	1.3	12
2517	Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 24, 101954.	1.4	42
2518	An artificial neural network model for clinical score prediction in Alzheimer disease using structural neuroimaging measures. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, 246-250.	1.4	35
2519	Impact of Resilience on the Association Between Amyloid- $\beta^2$ and Longitudinal Cognitive Decline in Cognitively Healthy Older Adults. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 361-370.	1.2	11
2520	Blood Pressure Variability and Progression of Clinical Alzheimer Disease. <i>Hypertension</i> , 2019, 74, 1172-1180.	1.3	60
2521	Determining Filipino Normative Data for a Battery of Neuropsychological Tests: The Filipino Norming Project (FNP). <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2019, 9, 260-270.	0.6	3
2522	The impact of leisure activities on older adults' cognitive function, physical function, and mental health. <i>PLoS ONE</i> , 2019, 14, e0225006.	1.1	76
2523	Amyloid PET, FDG-PET or MRI? - the power of different imaging biomarkers to detect progression of early Alzheimer's disease. <i>BMC Neurology</i> , 2019, 19, 264.	0.8	15
2524	Behavioral and psychological symptoms in Alzheimer's dementia and vascular dementia. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 165, 5-32.	1.0	70
2525	Study partner-reported decline identifies cognitive decline and dementia risk. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2448-2459.	1.7	23
2526	A quick test of cognitive speed can predict development of dementia in Parkinson's disease. <i>Scientific Reports</i> , 2019, 9, 15417.	1.6	11
2527	Effects of different acupuncture treatment methods on mild cognitive impairment: a study protocol for a randomized controlled trial. <i>Trials</i> , 2019, 20, 551.	0.7	8



#	ARTICLE	IF	CITATIONS
2528	The "rights" of precision drug development for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 76.	3.0	148
2529	Chinese herbal medicine Qinggongshoutao for the treatment of amnesic mild cognitive impairment: A 52-week randomized controlled trial. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 441-449.	1.8	14
2530	Observation of Patient and Caregiver Burden Associated with Early Alzheimer's Disease in the United States: Design and Baseline Findings of the GERAS-US Cohort Study <sup>1</sup> . <i>Journal of Alzheimer's Disease</i> , 2019, 72, 279-292.	1.2	11
2531	Structural imaging findings on non-enhanced computed tomography are severely underreported in the primary care diagnostic work-up of subjective cognitive decline. <i>Neuroradiology</i> , 2019, 61, 397-404.	1.1	5
2532	Analysis of the relationship between the gut microbiome and dementia: a cross-sectional study conducted in Japan. <i>Scientific Reports</i> , 2019, 9, 1008.	1.6	138
2533	Multi-task exclusive relationship learning for Alzheimer's disease progression prediction with longitudinal data. <i>Medical Image Analysis</i> , 2019, 53, 111-122.	7.0	36
2534	Polyphenol Health Effects on Cardiovascular and Neurodegenerative Disorders: A Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 351.	1.8	177
2535	Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double-blind, placebo-controlled, 6-week trial. <i>Journal of Psychopharmacology</i> , 2019, 33, 1030-1033.	2.0	19
2536	Communicability Characterization of Structural DWI Subcortical Networks in Alzheimer's Disease. <i>Entropy</i> , 2019, 21, 475.	1.1	14
2537	Comparison between physical and cognitive treatment in patients with MCI and Alzheimer's disease. <i>Aging</i> , 2019, 11, 3138-3155.	1.4	33
2538	A Bounded Integer Model for Rating and Composite Scale Data. <i>AAPS Journal</i> , 2019, 21, 74.	2.2	15
2539	Efficacy and Safety of Glycogen Synthase Kinase 3 Inhibitors for Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 1031-1039.	1.2	38
2540	Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 164-174.	1.8	30
2541	Neuropsychiatric Symptoms and Risk of Progression to Alzheimer's Disease Among Mild Cognitive Impairment Subjects. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 25-34.	1.2	42
2542	Medial Temporal Atrophy in Amyloid-Negative Amnesic Type Dementia Is Associated with High Cerebral White Matter Hyperintensity. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 99-106.	1.2	7
2543	Blood Pressure Lowering With Nilvadipine in Patients With Mild-to-Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension. <i>Journal of the American Heart Association</i> , 2019, 8, e011938.	1.6	10
2544	How the Post-Fracture Rehabilitation Choice Affects Brain Function in Older People?. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2019, 9, 34-43.	0.6	0
2545	The Role of S100B in Aerobic Training Efficacy in Older Adults with Mild Vascular Cognitive Impairment: Secondary Analysis of a Randomized Controlled Trial. <i>Neuroscience</i> , 2019, 410, 176-182.	1.1	8

#	ARTICLE	IF	CITATIONS
2546	Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 45.	3.0	19
2547	Behavioural and psychological symptoms in neurocognitive disorders: Specific patterns in dementia subtypes. <i>Open Medicine (Poland)</i> , 2019, 14, 307-316.	0.6	23
2548	Urate and risk of Alzheimer's disease and vascular dementia: A population-based study. <i>Alzheimer's and Dementia</i> , 2019, 15, 754-763.	0.4	58
2549	Can cognitive leisure activity prevent cognitive decline in older adults? A systematic review of intervention studies. <i>Geriatrics and Gerontology International</i> , 2019, 19, 469-482.	0.7	43
2550	Atrial fibrillation increases the risk of dementia amongst older adults even in the absence of stroke. <i>Journal of Internal Medicine</i> , 2019, 286, 101-110.	2.7	23
2551	Is Losing One's Way a Sign of Cognitive Decay? Topographical Memory Deficit as an Early Marker of Pathological Aging. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 679-693.	1.2	22
2552	Diffusion MRI Indices and Their Relation to Cognitive Impairment in Brain Aging: The Updated Multi-protocol Approach in ADNI3. <i>Frontiers in Neuroinformatics</i> , 2019, 13, 2.	1.3	79
2553	Psychological assessment of the elderly. , 2019, , 505-532.		1
2554	Effect of Visit-to-Visit Blood Pressure Variability on Cognitive and Functional Decline in Mild to Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1499-1510.	1.2	7
2555	Sleep-Disordered Breathing in Hospitalized Geriatric Patients with Mild Dementia and Its Association with Cognition, Emotion and Mobility. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 863.	1.2	16
2556	Dynamic <sup>11</sup> C-PiB PET Shows Cerebrospinal Fluid Flow Alterations in Alzheimer Disease and Multiple Sclerosis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1452-1460.	2.8	64
2557	Connectivity and morphology of hubs of the cerebral structural connectome are associated with brain resilience in AD- and age-related pathology. <i>Brain Imaging and Behavior</i> , 2019, 13, 1650-1664.	1.1	10
2558	Extracellular Vesicle Biomarkers Track Cognitive Changes Following Intranasal Insulin in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 489-498.	1.2	51
2559	Neurocognitive Disorders and Neuropsychiatric Symptoms. , 2019, , 39-69.		0
2560	Agreement between self-reports, proxy-reports and the National Patient Register regarding diagnoses of cardiovascular disorders and diabetes mellitus in a population-based sample of 80-year-olds. <i>Age and Ageing</i> , 2019, 48, 513-518.	0.7	13
2561	Sex and genetic differences in postoperative cognitive dysfunction: a longitudinal cohort analysis. <i>Biology of Sex Differences</i> , 2019, 10, 14.	1.8	35
2562	Nanotechnology approaches for enhanced CNS delivery in treating Alzheimer's disease. <i>Journal of Drug Delivery Science and Technology</i> , 2019, 51, 297-309.	1.4	22
2563	Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis. <i>Drugs and Aging</i> , 2019, 36, 435-452.	1.3	36

#	ARTICLE	IF	CITATIONS
2564	Clinical and biological effects of long-term lithium treatment in older adults with amnesic mild cognitive impairment: randomised clinical trial. <i>British Journal of Psychiatry</i> , 2019, 215, 668-674.	1.7	91
2565	Are Older Adults More Willing to Donate? The Roles of Donation Form and Social Relationship. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2019, 74, 440-448.	2.4	12
2566	Dual-phase [ <sup>18</sup> F]florbetapir in frontotemporal dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 304-311.	3.3	18
2567	[ <sup>18</sup> F]Amylovis as a Potential PET Probe for $\beta$ 2-Amyloid Plaque: Synthesis, In Silico, In vitro and In vivo Evaluations. <i>Current Radiopharmaceuticals</i> , 2019, 12, 58-71.	0.3	7
2568	Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. <i>BMC Neurology</i> , 2019, 19, 20.	0.8	92
2569	Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 61-69.	1.8	63
2570	Misidentification Subtype of Alzheimer's Disease Psychosis Predicts a Faster Cognitive Decline. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 308-315.	1.3	8
2571	Efficacy of Cilostazol Administration in Alzheimer's Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study. <i>Neurotherapeutics</i> , 2019, 16, 394-403.	2.1	28
2572	Impact of physical activity in vascular cognitive impairment (AFIVASC): study protocol for a randomised controlled trial. <i>Trials</i> , 2019, 20, 114.	0.7	3
2573	Effects of Home Photobiomodulation Treatments on Cognitive and Behavioral Function, Cerebral Perfusion, and Resting-State Functional Connectivity in Patients with Dementia: A Pilot Trial. <i>Photobiomodulation, Photomedicine, and Laser Surgery</i> , 2019, 37, 133-141.	0.7	77
2574	Methodological considerations in designing and implementing the harmonized diagnostic assessment of dementia for longitudinal aging study in India (LASI-DAD). <i>Biodemography and Social Biology</i> , 2020, 65, 189-213.	0.4	13
2575	EFFECTS OF A GROUP-BASED 8-WEEK MULTICOMPONENT COGNITIVE TRAINING ON COGNITION, MOOD AND ACTIVITIES OF DAILY LIVING AMONG HEALTHY OLDER ADULTS: A ONE-YEAR FOLLOW-UP OF A RANDOMIZED CONTROLLED TRIAL. <i>Journal of prevention of Alzheimer's disease</i> , The, 2020, 7, 1-10.	1.5	5
2576	LASI-DAD study: a protocol for a prospective cohort study of late-life cognition and dementia in India. <i>BMJ Open</i> , 2019, 9, e030300.	0.8	30
2577	Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 871-882.	1.8	79
2578	Translational Difficulties in Querying Rats on "Orientation". <i>BioMed Research International</i> , 2019, 2019, 1-11.	0.9	3
2579	Differences in the Progression from Mild Cognitive Impairment to Alzheimer's Disease between APOE4 Carriers and Non-Carriers. , 2019, , .		1
2580	Mitochondria and Alzheimer's Disease: An Electron Microscopy Study. , 2019, , .		4
2581	Mixed methods implementation research of cognitive stimulation therapy (CST) for dementia in low and middle-income countries: study protocol for Brazil, India and Tanzania (CST-International). <i>BMJ Open</i> , 2019, 9, e030933.	0.8	15

#	ARTICLE	IF	CITATIONS
2582	Feasibility of a 6-month pilot randomised controlled trial of resistance training on cognition and brain health in Canadian older adults at-risk for diabetes: study protocol. <i>BMJ Open</i> , 2019, 9, e032047.	0.8	4
2583	Memantine for dementia. <i>The Cochrane Library</i> , 2019, 3, CD003154.	1.5	166
2584	The Feasibility of Using N-Of-1 Trials to Investigate Deprescribing in Older Adults with Dementia: A Pilot Study. <i>Healthcare (Switzerland)</i> , 2019, 7, 161.	1.0	9
2585	The relationship between the gut microbiome and mild cognitive impairment in patients without dementia: a cross-sectional study conducted in Japan. <i>Scientific Reports</i> , 2019, 9, 19227.	1.6	84
2586	Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 91.	3.0	78
2587	Animal-assisted therapy for dementia. <i>The Cochrane Library</i> , 2019, 2019, .	1.5	31
2588	The evolution of geriatric neurology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 167, 575-584.	1.0	0
2589	Correlation Between Hippocampal Volume and Autobiographical Memory Depending on Retrieval Frequency in Healthy Individuals and Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 1341-1352.	1.2	3
2590	Efficacy and safety of Shenmayizhi decoction as an adjuvant treatment for vascular dementia. <i>Medicine (United States)</i> , 2019, 98, e18326.	0.4	2
2591	Which MCI Patients Should be Included in Prodromal Alzheimer Disease Clinical Trials?. <i>Alzheimer Disease and Associated Disorders</i> , 2019, 33, 104-112.	0.6	12
2592	Cognitively normal women with Alzheimer's disease proteinopathy show relative preservation of memory but not of hippocampal volume. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 109.	3.0	14
2593	The Influence of Physical Exercise on Cognitive Aging. , 2019, , 245-263.		1
2594	Post-fracture Rehabilitation Effects on Brain Function in Older People. <i>Yonago Acta Medica</i> , 2019, 62, 062-066.	0.3	0
2595	The Outcomes of Cognitive Stimulation Therapy (CST) for Community-Dwelling Older Adults With Cognitive Decline in Taiwan. <i>Topics in Geriatric Rehabilitation</i> , 2019, 35, 306-312.	0.2	12
2596	A Meta-Analysis of the Effect of Multisession Transcranial Direct Current Stimulation on Cognition in Dementia and Mild Cognitive Impairment. <i>Clinical EEG and Neuroscience</i> , 2019, 50, 273-282.	0.9	37
2597	The instruments used by the Italian centres for cognitive disorders and dementia to diagnose mild cognitive impairment (MCI). <i>Aging Clinical and Experimental Research</i> , 2019, 31, 101-107.	1.4	18
2598	Dynamic Hyper-Graph Inference Framework for Computer-Assisted Diagnosis of Neurodegenerative Diseases. <i>IEEE Transactions on Medical Imaging</i> , 2019, 38, 608-616.	5.4	14
2599	Meditation on the Soles of the Feet Practice Provides Some Control of Aggression for Individuals with Alzheimer's Disease. <i>Mindfulness</i> , 2019, 10, 1232-1242.	1.6	11

#	ARTICLE	IF	CITATIONS
2600	Neurological Aspects of Foreign Accent Syndrome in Stroke Patients. <i>Journal of Communication Disorders</i> , 2019, 77, 94-113.	0.8	16
2601	Efficacy and safety of idalopirdine for Alzheimer's disease: a systematic review and meta-analysis. <i>International Psychogeriatrics</i> , 2019, 31, 1627-1633.	0.6	10
2602	The Gothenburg H70 Birth cohort study 2014-16: design, methods and study population. <i>European Journal of Epidemiology</i> , 2019, 34, 191-209.	2.5	89
2603	Effects of an animal-assisted intervention on social behaviour, emotions, and behavioural and psychological symptoms in nursing home residents with dementia. <i>Psychogeriatrics</i> , 2019, 19, 219-227.	0.6	32
2604	Association of hippocampal volume with gait variability in pre-dementia and dementia stages of Alzheimer disease: Results from a cross-sectional study. <i>Experimental Gerontology</i> , 2019, 115, 55-61.	1.2	29
2605	Discriminative capacity and construct validity of the Clock Drawing Test in Mild Cognitive Impairment and Alzheimer's disease. <i>Clinical Neuropsychologist</i> , 2019, 33, 1159-1174.	1.5	5
2606	The Adaptation and Validation of an Arabic Version of the Cornell Scale for Depression in Dementia (A-CSDD). <i>Journal of Alzheimer's Disease</i> , 2019, 67, 839-848.	1.2	5
2607	Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 707-713.	1.2	12
2608	A pilot study on the effect of lactoferrin on Alzheimer's disease pathological sequelae: Impact of the p-Akt/PTEN pathway. <i>Biomedicine and Pharmacotherapy</i> , 2019, 111, 714-723.	2.5	50
2609	Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 2.	3.0	19
2610	Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 303-313.	1.2	8
2611	Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease. <i>Human Brain Mapping</i> , 2019, 40, 638-651.	1.9	27
2612	Effect of monosodium L-glutamate (umami substance) on cognitive function in people with dementia. <i>European Journal of Clinical Nutrition</i> , 2019, 73, 266-275.	1.3	14
2613	Accurate risk estimation of $\beta$ -amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms. <i>Alzheimer's and Dementia</i> , 2019, 15, 194-204.	0.4	49
2614	Feasibility and Impact of a Multicomponent Exercise Intervention in Patients With Alzheimer's Disease: A Pilot Study. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2019, 34, 95-103.	0.9	14
2615	Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2019, 137, 279-296.	3.9	128
2616	The efficacy and safety of nimodipine in acute ischemic stroke patients with mild cognitive impairment: a double-blind, randomized, placebo-controlled trial. <i>Science Bulletin</i> , 2019, 64, 101-107.	4.3	9
2617	The ketogenic diet as a potential treatment and prevention strategy for Alzheimer's disease. <i>Nutrition</i> , 2019, 60, 118-121.	1.1	104

#	ARTICLE	IF	CITATIONS
2618	Comparing the effects of clinician and caregiver-administered lexical retrieval training for progressive anomia. <i>Neuropsychological Rehabilitation</i> , 2019, 29, 866-895.	1.0	10
2619	Longitudinal score prediction for Alzheimer's disease based on ensemble correntropy and spatial-temporal constraint. <i>Brain Imaging and Behavior</i> , 2019, 13, 126-137.	1.1	9
2620	Deep brain stimulation for people with Alzheimer's disease: Anticipating potential effects on the tripartite self. <i>Dementia</i> , 2019, 18, 2836-2855.	1.0	10
2621	Screening for cognitive impairment in an Australian aged care assessment team as part of comprehensive geriatric assessment. <i>Aging, Neuropsychology, and Cognition</i> , 2019, 26, 336-347.	0.7	6
2622	Attention Measures of Accuracy, Variability, and Fatigue Detect Early Response to Donepezil in Alzheimer's Disease: A Randomized, Double-blind, Placebo-Controlled Pilot Trial. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 277-289.	0.3	8
2623	“Moon River” Intact Musical Appreciation and Performance in a Man With Semantic Variant Primary Progressive Aphasia. <i>Psychosomatics</i> , 2019, 60, 70-74.	2.5	0
2625	Association of cerebrospinal fluid Neurogranin with Alzheimer's disease. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 185-191.	1.4	21
2626	rCBF and cognitive impairment changes assessed by SPECT and ADAS-cog in late-onset Alzheimer's disease after 18 months of treatment with the cholinesterase inhibitors donepezil or galantamine. <i>Brain Imaging and Behavior</i> , 2019, 13, 75-86.	1.1	7
2627	Monotherapy Is Good Enough for Patients With Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis of 76 Randomized Controlled Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 121-130.	2.3	21
2628	A comparison of self and proxy quality of life ratings for people with dementia and their carers: a European prospective cohort study. <i>Aging and Mental Health</i> , 2020, 24, 162-170.	1.5	29
2629	Neuropsychiatric Symptoms as Risk Factors for Cognitive Decline in Clinically Normal Older Adults: The Cache County Study. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 64-71.	0.6	70
2630	The Health and Retirement Study Harmonized Cognitive Assessment Protocol Project: Study Design and Methods. <i>Neuroepidemiology</i> , 2020, 54, 64-74.	1.1	84
2631	Is Ongoing Anticholinergic Burden Associated With Greater Cognitive Decline and Dementia Severity in Mild to Moderate Alzheimer's Disease?. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 987-994.	1.7	15
2632	Modified ketogenic diet is associated with improved cerebrospinal fluid biomarker profile, cerebral perfusion, and cerebral ketone body uptake in older adults at risk for Alzheimer's disease: a pilot study. <i>Neurobiology of Aging</i> , 2020, 86, 54-63.	1.5	136
2634	Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome. <i>JAMA Neurology</i> , 2020, 77, 215.	4.5	81
2635	Statin Use and Risk of Cognitive Decline in the ADNI Cohort. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 507-517.	0.6	9
2636	Evaluation of the effect of aroma oil as a bath salt on cognitive function. <i>Psychogeriatrics</i> , 2020, 20, 163-171.	0.6	11
2637	A multipredictor model to predict the conversion of mild cognitive impairment to Alzheimer's disease by using a predictive nomogram. <i>Neuropsychopharmacology</i> , 2020, 45, 358-366.	2.8	54

#	ARTICLE	IF	CITATIONS
2638	Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease. <i>BMC Neurology</i> , 2020, 20, 10.	0.8	50
2639	Cerebellar Volume Is Associated with Cognitive Decline in Mild Cognitive Impairment: Results from ADNI. <i>Cerebellum</i> , 2020, 19, 217-225.	1.4	36
2640	Prevalence of obstructive sleep apnea in Alzheimer's disease patients. <i>Journal of Neurology</i> , 2020, 267, 1012-1022.	1.8	23
2641	Waist Circumference and Domain-Specific Cognitive Function Among Non-Demented Japanese Older Adults Stratified by Sex: Results from the Takashima Cognition Study. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 887-896.	1.2	8
2642	Associations of White Matter Hyperintensities with Cognitive Decline: A Longitudinal Study. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 759-768.	1.2	56
2643	Acupuncture and Acupressure for Dementia Behavioral and Psychological Symptoms: A Scoping Review. <i>Western Journal of Nursing Research</i> , 2020, 42, 867-880.	0.6	9
2644	A meta-analysis of the association between caregiver burden and the dependent's illness. <i>Journal of Women and Aging</i> , 2020, 32, 220-235.	0.5	14
2645	Screening for cognitive impairment in older adults with hematological malignancies using the Montreal Cognitive Assessment and neuropsychological testing. <i>Journal of Geriatric Oncology</i> , 2020, 11, 297-303.	0.5	10
2646	Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease. <i>JAMA Neurology</i> , 2020, 77, 199.	4.5	123
2647	A Pilot Study Comparing Effects of Bifrontal Versus Bitemporal Transcranial Direct Current Stimulation in Mild Cognitive Impairment and Mild Alzheimer Disease. <i>Journal of ECT</i> , 2020, 36, 211-215.	0.3	15
2648	Advancing the Use of Mobile Technologies in Clinical Trials: Recommendations from the Clinical Trials Transformation Initiative. <i>Digital Biomarkers</i> , 2020, 3, 145-154.	2.2	47
2649	Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease. <i>Neurology</i> , 2021, 96, e193-e202.	1.5	54
2650	Specific Motor and Cognitive Performances Predict Falls during Ward-Based Geriatric Rehabilitation in Patients with Dementia. <i>Sensors</i> , 2020, 20, 5385.	2.1	7
2651	APOE 4-TOMM40L Haplotype Increases the Risk of Mild Cognitive Impairment Conversion to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 587-601.	1.2	0
2652	Enriching the design of Alzheimer's disease clinical trials: Application of the polygenic hazard score and composite outcome measures. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12071.	1.8	12
2653	Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. <i>Molecular Neurodegeneration</i> , 2020, 15, 57.	4.4	33
2654	Third follow-up of the Cardiovascular Risk Factors, Aging and Dementia (CAIDE) cohort investigating determinants of cognitive, physical, and psychosocial wellbeing among the oldest old: the CAIDE85+ study protocol. <i>BMC Geriatrics</i> , 2020, 20, 238.	1.1	8
2655	Donepezil, a cholinesterase inhibitor used in Alzheimer's disease therapy, is actively exported out of the brain by abcb1ab p-glycoproteins in mice. <i>Journal of Psychiatric Research</i> , 2020, 124, 29-33.	1.5	14

#	ARTICLE	IF	CITATIONS
2656	Weight Loss is a Preclinical Signal of Cerebral Amyloid Deposition and Could Predict Cognitive Impairment in Elderly Adults. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 449-456.	1.2	12
2657	Meta-analysis of Ginkgo biloba Preparation for the Treatment of Alzheimer's Disease. <i>Clinical Neuropharmacology</i> , 2020, 43, 93-99.	0.2	23
2658	Abnormalities of Cortical Sources of Resting State Delta Electroencephalographic Rhythms Are Related to Epileptiform Activity in Patients With Amnesic Mild Cognitive Impairment Not Due to Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 514136.	1.1	8
2659	Associations between Pro- and Anti-Inflammatory Gastro-Intestinal Microbiota, Diet, and Cognitive Functioning in Dutch Healthy Older Adults: The NU-AGE Study. <i>Nutrients</i> , 2020, 12, 3471.	1.7	42
2661	Artificial Intelligence, Speech, and Language Processing Approaches to Monitoring Alzheimer's Disease: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 1547-1574.	1.2	106
2662	The Neuropsychological Correlates of Brain Perfusion and Gray Matter Volume in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 1639-1652.	1.2	3
2663	Association between Structural Connectivity and Generalized Cognitive Spectrum in Alzheimer's Disease. <i>Brain Sciences</i> , 2020, 10, 879.	1.1	11
2664	BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain. <i>Brain</i> , 2020, 143, 3816-3826.	3.7	41
2665	Brief Cognitive Tests for Distinguishing Clinical Alzheimer-Type Dementia From Mild Cognitive Impairment or Normal Cognition in Older Adults With Suspected Cognitive Impairment. <i>Annals of Internal Medicine</i> , 2020, 172, 678-687.	2.0	31
2666	The use of the Hungarian Test Your Memory (TYM-HUN), MMSE, and ADAS-Cog tests for patients with mild cognitive impairment (MCI) in a Hungarian population: a cross-sectional study. <i>BMC Psychiatry</i> , 2020, 20, 571.	1.1	0
2667	Efficacy and Safety of Guilingji Capsules (é3¼ÿé¾,é†èf¶āŠ) for Treating Mild-to-Moderate Cognitive Impairment: Study Protocol for A Randomized, Double-Blind, Positive-Controlled, Multicenter and Noninferiority Trial. <i>Chinese Journal of Integrative Medicine</i> , 2020, 26, 577-582.	0.7	3
2668	The correlation of everyday cognition test scores and the progression of Alzheimer's disease: a data analytics study. <i>Health Information Science and Systems</i> , 2020, 8, 24.	3.4	13
2669	Value of CSF Biomarkers in Predicting Risk of Progression from aMCI to ADD in a 5-Year Follow-Up Cohort. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1543-1550.	0.3	0
2670	&lt;p&gt;MMSE Subscale Scores as Useful Predictors of AD Conversion in Mild Cognitive Impairment&lt;/p&gt;. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 1767-1775.	1.0	24
2671	BHA's CS: A novel cognitive composite for Alzheimer's disease and related disorders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12042.	1.2	12
2672	Assessing what matters most to patients with or at risk for Alzheimer's and care partners: a qualitative study evaluating symptoms, impacts, and outcomes. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 90.	3.0	26
2673	The Amyloid, Tau, and Neurodegeneration (A/T/N) Classification Applied to a Clinical Research Cohort with Long-Term Follow-Up. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 829-837.	1.2	31
2674	Compensating for choroid plexus based off-target signal in the hippocampus using 18F-flortaucipir PET. <i>NeuroImage</i> , 2020, 221, 117193.	2.1	9



#	ARTICLE	IF	CITATIONS
2675	Effects of force level and task difficulty on force control performance in elderly people. <i>Experimental Brain Research</i> , 2020, 238, 2179-2188.	0.7	2
2676	BACE1 and Other Alzheimer's-Related Biomarkers in Cerebrospinal Fluid and Plasma Distinguish Alzheimer's Disease Patients from Cognitively-Impaired Neurosyphilis Patients. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 313-322.	1.2	9
2677	Aromatherapy for dementia. <i>The Cochrane Library</i> , 2020, 2020, CD003150.	1.5	23
2678	Progression of Alzheimer's Disease by Self-Reported Cancer History in the Alzheimer's Disease Neuroimaging Initiative. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 691-701.	1.2	3
2679	A Prospective Longitudinal Study on the Relationship Between Glucose Fluctuation and Cognitive Function in Type 2 Diabetes: PROPOSAL Study Protocol. <i>Diabetes Therapy</i> , 2020, 11, 2729-2737.	1.2	5
2680	Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use. <i>Medicinal Research Reviews</i> , 2021, 41, 2775-2803.	5.0	39
2681	Measurement and Structure of Cognition in the Longitudinal Aging Study in India—Diagnostic Assessment of Dementia. <i>Journal of the American Geriatrics Society</i> , 2020, 68, S11-S19.	1.3	19
2682	Sedative Load in Community-Dwelling Older Adults with Mild-to-Moderate Alzheimer's Disease: Longitudinal Relationships with Adverse Events, Delirium and Falls. <i>Drugs and Aging</i> , 2020, 37, 829-837.	1.3	5
2683	Cognitive stimulation therapy for dementia: Provision in National Health Service settings in England, Scotland and Wales. <i>Dementia</i> , 2021, 20, 1553-1564.	1.0	5
2684	A phase II randomized trial of sodium oligomannate in Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 110.	3.0	54
2685	Lifestyle Risk Factors and Cognitive Outcomes from the Multidomain Dementia Risk Reduction Randomized Controlled Trial, Body Brain Life for Cognitive Decline (BBL-CD). <i>Journal of the American Geriatrics Society</i> , 2020, 68, 2629-2637.	1.3	34
2686	Cognition and motor function: The gait and cognition pooled index. <i>PLoS ONE</i> , 2020, 15, e0238690.	1.1	10
2687	Differentiating Mild Cognitive Impairment, Alzheimer's Disease, and Dementia With Lewy Bodies Using Cingulate Island Sign on Perfusion IMP-SPECT. <i>Frontiers in Neurology</i> , 2020, 11, 568438.	1.1	8
2688	Souvenaid for Alzheimer's disease. <i>The Cochrane Library</i> , 2020, 2020, CD011679.	1.5	4
2689	Overview of Meta-Analyses of Five Non-pharmacological Interventions for Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 594432.	1.7	44
2690	Randomized Controlled Trial of Multi-Component Cognitive Stimulation Therapy (SADEM) in Community-Dwelling Demented Adults. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 1033-1045.	1.2	10
2693	Safety and efficacy of Melissa officinalis extract containing rosmarinic acid in the prevention of Alzheimer's disease progression. <i>Scientific Reports</i> , 2020, 10, 18627.	1.6	27
2694	Correlation Between Hippocampal Enlarged Perivascular Spaces and Cognition in Non-dementic Elderly Population. <i>Frontiers in Neurology</i> , 2020, 11, 542511.	1.1	8

#	ARTICLE	IF	CITATIONS
2695	The Efficacy of COGNITIVE TRAINING in patients with Amnesic mild cognitive impairment (COG-REAGENT): Protocol for a Multi-Center Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 779-787.	1.2	2
2696	Relationship of Established Cardiovascular Risk Factors and Peripheral Biomarkers on Cognitive Function in Adults at Risk of Cognitive Deterioration. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 163-171.	1.2	13
2697	Relationship between dementia and gut microbiome-associated metabolites: a cross-sectional study in Japan. <i>Scientific Reports</i> , 2020, 10, 8088.	1.6	46
2698	Potentially inappropriate medication use in older adults with mild-moderate Alzheimer's disease: prevalence and associations with adverse events. <i>Age and Ageing</i> , 2020, 49, 580-587.	0.7	10
2699	Acupuncture therapy for Alzheimer's disease. <i>Medicine (United States)</i> , 2020, 99, e20244.	0.4	3
2700	Effects of sex, age, and apolipoprotein E genotype on hippocampal parenchymal fraction in cognitively normal older adults. <i>Psychiatry Research - Neuroimaging</i> , 2020, 301, 111107.	0.9	6
2701	A Placebo-Controlled, Parallel-Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 547-557.	1.2	20
2702	Questioning the Meaning of a Change on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Noncomparable Scores and Item-Specific Effects Over Time. <i>Assessment</i> , 2021, 28, 1708-1722.	1.9	5
2703	The meta-memory ratio: a new cohort-independent way to measure cognitive awareness in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 57.	3.0	12
2704	Orthostatic Blood Pressure Recovery Is Associated With the Rate of Cognitive Decline and Mortality in Clinical Alzheimer's Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 2169-2176.	1.7	10
2705	Bupropion for the Treatment of Apathy in Alzheimer Disease. <i>JAMA Network Open</i> , 2020, 3, e206027.	2.8	18
2706	Dynamic association between AT(N) profile and cognition mediated by cortical thickness in Alzheimer's continuum. <i>NeuroImage: Clinical</i> , 2020, 27, 102282.	1.4	2
2707	The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 74.	3.0	53
2708	C-reactive protein as a predictor of mild cognitive impairment conversion into Alzheimer's disease dementia. <i>Experimental Gerontology</i> , 2020, 138, 111004.	1.2	18
2709	Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia. <i>JAMA Neurology</i> , 2020, 77, 1099.	4.5	198
2710	Parametric mode regression for bounded responses. <i>Biometrical Journal</i> , 2020, 62, 1791-1809.	0.6	5
2711	Pharmacogenetic studies in Alzheimer disease. <i>Neurologia (English Edition)</i> , 2022, 37, 287-303.	0.2	4
2712	Management of cognitive decline in Alzheimer's disease using a non-pharmacological intervention program. <i>Medicine (United States)</i> , 2020, 99, e20128.	0.4	11

#	ARTICLE	IF	CITATIONS
2713	Predicting Alzheimer's disease based on survival data and longitudinally measured performance on cognitive and functional scales. <i>Psychiatry Research</i> , 2020, 291, 113201.	1.7	15
2714	Translational Scoring of Candidate Treatments for Alzheimer's Disease: A Systematic Approach. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 22-37.	0.7	5
2715	Clinical Experience in Treatment of Alzheimer's Disease with Jiannao Yizhi Formula (è¸¸, ç¸¸æ¸¸-1) and Routine Western Medicine. <i>Chinese Journal of Integrative Medicine</i> , 2020, 26, 212-218.	0.7	6
2716	NDRG4 Alleviates A $\beta$ 1-40 Induction of SH-SY5Y Cell Injury via Activation of BDNF-Inducing Signalling Pathways. <i>Neurochemical Research</i> , 2020, 45, 1492-1499.	1.6	5
2717	Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease. <i>Neurobiology of Disease</i> , 2020, 139, 104831.	2.1	49
2718	The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 30.	3.0	14
2719	Social networks in mild-to-moderate Alzheimer disease: longitudinal relationships with dementia severity, cognitive function, and adverse events. <i>Aging and Mental Health</i> , 2021, 25, 1923-1929.	1.5	23
2720	&p&gt;MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease&lt;/p&gt;. <i>Open Access Journal of Clinical Trials</i> , 2020, Volume 12, 1-13.	1.5	23
2721	Machine Learning and DWI Brain Communicability Networks for Alzheimer's Disease Detection. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 934.	1.3	20
2722	&p&gt;Comparative Cholinesterase, ð¸¸-Glucosidase Inhibitory, Antioxidant, Molecular Docking, and Kinetic Studies on Potent Succinimide Derivatives&lt;/p&gt;. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 2165-2178.	2.0	30
2723	Immunoabsorption for Treatment of Patients with Suspected Alzheimer Dementia and Agonistic Autoantibodies against Alpha1a-AdrenoceptorâRationale and Design of the IMAD Pilot Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1919.	1.0	4
2724	To Keto or Not to Keto? A Systematic Review of Randomized Controlled Trials Assessing the Effects of Ketogenic Therapy on Alzheimer Disease. <i>Advances in Nutrition</i> , 2020, 11, 1583-1602.	2.9	36
2725	Longitudinal Sensitivity of Alzheimer's Disease Severity Staging. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2020, 35, 153331752091871.	0.9	15
2726	The generalizability of Older Adult Self-Report (OASR) syndromes of psychopathology across 20 societies. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 525-536.	1.3	12
2727	Enhanced rehabilitation and care models for adults with dementia following hip fracture surgery. <i>The Cochrane Library</i> , 2020, 2020, CD010569.	1.5	28
2728	Association Between Cognitive Function and Clustered Cardiovascular Risk of Metabolic Syndrome in Older Adults at Risk of Cognitive Decline. <i>Journal of Nutrition, Health and Aging</i> , 2020, 24, 300-304.	1.5	17
2729	Costs and Resource Use Associated with Community-Dwelling Patients with Alzheimer's Disease in Japan: Baseline Results from the Prospective Observational GERAS-J Study. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 127-138.	1.2	14
2730	A program of exercise, brain training, and lecture to prevent cognitive decline. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 318-328.	1.7	7

#	ARTICLE	IF	CITATIONS
2731	Antiviral therapy: Valacyclovir Treatment of Alzheimer's Disease (VALAD) Trial: protocol for a randomised, double-blind, placebo-controlled, treatment trial. <i>BMJ Open</i> , 2020, 10, e032112.	0.8	43
2732	The role of cerebral microbleeds in the incidence of post-stroke dementia. <i>Journal of the Neurological Sciences</i> , 2020, 412, 116736.	0.3	10
2733	&lt;p&gt;Precision Medicine of Sodium Benzoate for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD)&lt;/p&gt;. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 509-518.	1.0	29
2734	Morphometric network differences in ageing versus Alzheimer's disease dementia. <i>Brain</i> , 2020, 143, 635-649.	3.7	37
2735	Tianzhi granule improves cognition and BPSD of vascular dementia: a randomized controlled trial. <i>Journal of Translational Medicine</i> , 2020, 18, 76.	1.8	12
2736	Hippocampal vascular reserve associated with cognitive performance and hippocampal volume. <i>Brain</i> , 2020, 143, 622-634.	3.7	81
2737	Brain Gray Matter Volume Associations With Abnormal Gait Imagery in Patients With Mild Cognitive Impairment: Results of a Cross-Sectional Study. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 364.	1.7	4
2738	The cognitive footprint of medication: A review of cognitive assessments in clinical trials. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 874-880.	0.7	1
2739	Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach. <i>Alzheimer's and Dementia</i> , 2020, 16, 797-803.	0.4	4
2740	Network topology and machine learning analyses reveal microstructural white matter changes underlying Chinese medicine Dengzhan Shengmai treatment on patients with vascular cognitive impairment. <i>Pharmacological Research</i> , 2020, 156, 104773.	3.1	22
2741	Reliability and concurrent validity of Alzheimer's disease assessment scale - Cognitive subscale, Chinese version (ADAS-Cog-C) among Chinese community-dwelling older people population. <i>Clinical Neuropsychologist</i> , 2020, 34, 43-53.	1.5	11
2742	What works and what does not work in Alzheimer's disease? From interventions on risk factors to anti-amyloid trials. <i>Journal of Neurochemistry</i> , 2020, 155, 120-136.	2.1	26
2743	TRanscranial AlterNating current Stimulation FOR patients with Mild Alzheimer's Disease (TRANSFORM-AD study): Protocol for a randomized controlled clinical trial. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12005.	1.8	8
2744	Brief Assessment of Impaired Cognition Questionnaire (BASIC-Q) - Development and validation of a new tool for identification of cognitive impairment in community settings. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 693-701.	1.3	8
2745	The Cognitive-Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch-Cog study cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12020.	1.8	18
2746	Detection and recognition thresholds for five basic tastes in patients with mild cognitive impairment and Alzheimer's disease dementia. <i>BMC Neurology</i> , 2020, 20, 110.	0.8	20
2747	Contingency awareness, aging, and the parietal lobe. <i>Neurobiology of Aging</i> , 2020, 91, 125-135.	1.5	3
2748	A feasibility randomised control trial of individual cognitive stimulation therapy for dementia: impact on cognition, quality of life and positive psychology. <i>Aging and Mental Health</i> , 2021, 25, 999-1007.	1.5	12

#	ARTICLE	IF	CITATIONS
2749	Neuropsychological outcome of cognitive training in mild to moderate dementia: A randomized controlled trial. <i>Neuropsychological Rehabilitation</i> , 2021, 31, 935-953.	1.0	1
2750	Inter-individual differences in the responses to aerobic exercise in Alzheimer's disease: Findings from the FIT-AD trial. <i>Journal of Sport and Health Science</i> , 2021, 10, 65-72.	3.3	17
2751	Robust estimation in the nested case-control design under a misspecified covariate functional form. <i>Statistics in Medicine</i> , 2021, 40, 299-311.	0.8	2
2752	Antidepressant Use and Progression of Mild to Moderate Alzheimer's Disease: Results from the European ICTUS Cohort. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 433-439.	1.2	2
2753	Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension. <i>Annals of Neurology</i> , 2021, 89, 91-98.	2.8	23
2754	Telltale silence: temporal speech parameters discriminate between prodromal dementia and mild Alzheimer's disease. <i>Clinical Linguistics and Phonetics</i> , 2021, 35, 727-742.	0.5	10
2755	Developing univariate neurodegeneration biomarkers with low-rank and sparse subspace decomposition. <i>Medical Image Analysis</i> , 2021, 67, 101877.	7.0	10
2756	Validation of the cognitive stimulation therapy (CST) program for people with dementia in Portugal. <i>Aging and Mental Health</i> , 2021, 25, 1019-1028.	1.5	5
2757	Untangling the association of amyloid- $\beta^2$ and tau with synaptic and axonal loss in Alzheimer's disease. <i>Brain</i> , 2021, 144, 310-324.	3.7	123
2758	Clinical trials of promising apoptosis modulating drugs. , 2021, , 329-391.		1
2759	The relationship between neurofilament light chain and cognition in neurological disorders: A scoping review. <i>Journal of the Neurological Sciences</i> , 2021, 420, 117229.	0.3	23
2760	Transfer learning for predicting conversion from mild cognitive impairment to dementia of Alzheimer's type based on a three-dimensional convolutional neural network. <i>Neurobiology of Aging</i> , 2021, 99, 53-64.	1.5	34
2761	Reliable change in neuropsychological test scores is associated with brain atrophy in older adults. <i>Journal of Neuropsychology</i> , 2021, 15, 274-299.	0.6	5
2762	Abnormalities of Cortical Sources of Resting State Alpha Electroencephalographic Rhythms are Related to Education Attainment in Cognitively Unimpaired Seniors and Patients with Alzheimer's Disease and Amnesic Mild Cognitive Impairment. <i>Cerebral Cortex</i> , 2021, 31, 2220-2237.	1.6	14
2763	Executive functioning of older adults with bipolar disorder. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 106-115.	1.3	2
2764	Cerebral Small Vessel Disease Influences Hippocampal Subfield Atrophy in Mild Cognitive Impairment. <i>Translational Stroke Research</i> , 2021, 12, 284-292.	2.3	22
2765	Effects of Folic Acid and Vitamin B12 Supplementation on Cognitive Impairment and Inflammation in Patients with Alzheimer's Disease: A Randomized, Single-Blinded, Placebo-Controlled Trial. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2021, 8, 1-8.	1.5	26
2766	Cultural adaptation of Alzheimer's disease assessment scale's cognitive subscale for use in India and validation of the Tamil version for South Indian population. <i>Aging and Mental Health</i> , 2022, 26, 423-430.	1.5	3

#	ARTICLE	IF	CITATIONS
2767	Intranasal Insulin for Alzheimer's Disease. <i>CNS Drugs</i> , 2021, 35, 21-37.	2.7	67
2768	Assessing visuo-constructive functions in patients with subjective cognitive decline, mild cognitive impairment and Alzheimer's disease with the Vienna Visuo-Constructional Test 3.0 (VVT 3.0). <i>Neuropsychiatrie</i> , 2021, 35, 147-155.	1.3	3
2769	Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease. <i>Translational Psychiatry</i> , 2021, 11, 76.	2.4	78
2770	NEUROaid II (MLC901) in cognitively Impaired not demented patients (NEURITES): A pilot double blind, placebo-controlled randomized trial. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12161.	1.8	3
2771	Possibility of Using Quantitative Assessment with the Cube Copying Test for Evaluation of Visuo-spatial Function in Patients with Alzheimer's Disease. <i>Progress in Rehabilitation Medicine</i> , 2021, 6, n/a.	0.3	2
2772	An international, randomized, placebo-controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY-DELTA). <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12171.	1.8	9
2773	New approaches to symptomatic treatments for Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2021, 16, 2.	4.4	96
2774	Recruitment and Baseline Characteristics of Participants in the AgeWell.de Study: A Pragmatic Cluster-Randomized Controlled Lifestyle Trial against Cognitive Decline. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 408.	1.2	15
2775	Aducanumab: Appropriate Use Recommendations. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2021, 8, 1-13.	1.5	115
2776	Brain Activity of Benzoate, a D-Amino Acid Oxidase Inhibitor, in Patients With Mild Cognitive Impairment in a Randomized, Double-Blind, Placebo Controlled Clinical Trial. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 392-399.	1.0	23
2778	Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12123.	1.8	9
2779	Past, Present, and Future of Non-invasive Brain Stimulation Approaches to Treat Cognitive Impairment in Neurodegenerative Diseases: Time for a Comprehensive Critical Review. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 578339.	1.7	51
2780	Research Attitudes Questionnaire scores predict Alzheimer's disease clinical trial dropout. <i>Clinical Trials</i> , 2021, 18, 237-244.	0.7	9
2781	Cognitive Stimulation Therapy for Older Adults With Mild-to-Moderate Dementia in Italy: Effects on Cognitive Functioning, and on Emotional and Neuropsychiatric Symptoms. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2021, 76, 1700-1710.	2.4	22
2782	Neurocognitive effects associated with proprotein convertase subtilisin-kexin type 9 inhibitor use: a narrative review. <i>Therapeutic Advances in Drug Safety</i> , 2021, 12, 204209862095927.	1.0	3
2783	Clinical Dementia Rating Scale. , 2021, , 1-5.		1
2785	Retinal Optical Coherence Tomography Metrics Are Unchanged in Verubecestat Alzheimer's Disease Clinical Trial but Correlate with Baseline Regional Brain Atrophy. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 275-287.	1.2	7
2786	Anti-dementia Medication. , 2021, , 73-104.		0

#	ARTICLE	IF	CITATIONS
2787	Quantification of cognitive impairment to characterize heterogeneity of patients at risk of developing Alzheimer's disease dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12237.	1.2	5
2788	Machine learning identifies novel markers predicting functional decline in older adults. <i>Brain Communications</i> , 2021, 3, fcab140.	1.5	3
2789	Using a distribution-based approach and systematic review methods to derive minimum clinically important differences. <i>BMC Medical Research Methodology</i> , 2021, 21, 41.	1.4	42
2790	Subtle Changes in Medication-taking Are Associated With Incident Mild Cognitive Impairment. <i>Alzheimer Disease and Associated Disorders</i> , 2021, 35, 237-243.	0.6	4
2791	Systematic Assessment of the Impact of DTI Methodology on Fractional Anisotropy Measures in Alzheimer's Disease. <i>Tomography</i> , 2021, 7, 20-38.	0.8	7
2792	Assessment of the DTI-ALPS Parameter Along the Perivascular Space in Older Adults at Risk of Dementia. <i>Journal of Neuroimaging</i> , 2021, 31, 569-578.	1.0	68
2793	REducing SEDENTary Behavior Among Mild to Moderate Cognitively Impaired Assisted Living Residents: A Pilot Randomized Controlled Trial (RESEDENT Study). <i>Journal of Aging and Physical Activity</i> , 2021, 29, 27-35.	0.5	8
2794	Structural Network Efficiency Predicts Resilience to Cognitive Decline in Elderly at Risk for Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 637002.	1.7	10
2796	Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. <i>The Cochrane Library</i> , 2021, 2021, .	1.5	11
2797	Repetitive Transcranial Magnetic Stimulation With H-Coil in Alzheimer's Disease: A Double-Blind, Placebo-Controlled Pilot Study. <i>Frontiers in Neurology</i> , 2020, 11, 614351.	1.1	10
2798	A $\beta$ Accumulation in Vmo Contributes to Masticatory Dysfunction in 5XFAD Mice. <i>Journal of Dental Research</i> , 2021, 100, 002203452110002.	2.5	2
2799	High-Dimensional Spatial Quantile Function-on-Scalar Regression. <i>Journal of the American Statistical Association</i> , 2022, 117, 1563-1578.	1.8	9
2801	"œBody & Brain" effects of a multicomponent exercise intervention on physical and cognitive function of adults with dementia - study protocol for a quasi-experimental controlled trial. <i>BMC Geriatrics</i> , 2021, 21, 156.	1.1	7
2802	A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 62.	3.0	99
2803	Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. <i>Brain</i> , 2021, 144, 2771-2783.	3.7	78
2804	A 4-Year Follow-Up of Subjects with Visually Equivocal Amyloid Positron Emission Tomography Findings from the Alzheimer's Disease Neuroimaging Initiative Cohort. <i>Nuclear Medicine and Molecular Imaging</i> , 2021, 55, 71-78.	0.6	2
2805	Comprehensive Visual Rating Scale on Magnetic Resonance Imaging: Application to Prodromal Alzheimer Disease. <i>Annals of Geriatric Medicine and Research</i> , 2021, 25, 39-44.	0.7	1
2806	Ecological, convergent, and discriminative validities of the cognitive abilities screening instrument in people with dementia. <i>Medicine (United States)</i> , 2021, 100, e25225.	0.4	3

#	ARTICLE	IF	CITATIONS
2807	The Association between Cerebral Small Vessel Disease and the Gut Microbiome: A Cross-Sectional Analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105568.	0.7	18
2808	Relationship Between Alzheimer's Disease and Retinal Choroidal Thickness: A Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 407-419.	1.2	8
2809	Cognitive Effects of Aerobic Exercise in Alzheimer's Disease: A Pilot Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 233-244.	1.2	55
2810	Introducing the tablet-based Oxford Cognitive Screen-Plus (OCS-Plus) as an assessment tool for subtle cognitive impairments. <i>Scientific Reports</i> , 2021, 11, 8000.	1.6	24
2811	Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer's Disease. <i>Pharmaceuticals</i> , 2021, 14, 366.	1.7	6
2812	An Individual Cognitive Stimulation Therapy App for People With Dementia and Their Carers: Protocol for a Feasibility Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2021, 10, e24628.	0.5	8
2813	The Impact of Amyloid Burden and APOE on Rates of Cognitive Impairment in Late Life Depression. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 991-1002.	1.2	9
2814	Influence of COMT polymorphism in cognitive performance on dementia in community-dwelling elderly Mexican (SADEM study). <i>Metabolic Brain Disease</i> , 2021, 36, 1223-1229.	1.4	1
2815	Dementia remains the major predictor of death among octogenarians. A study of two population cohorts of 85-year-olds examined 22 years apart. <i>European Journal of Epidemiology</i> , 2021, 36, 507-517.	2.5	2
2816	Simultaneous modeling of Alzheimer's disease progression via multiple cognitive scales. <i>Statistics in Medicine</i> , 2021, 40, 3251-3266.	0.8	12
2817	AD Course Map charts Alzheimer's disease progression. <i>Scientific Reports</i> , 2021, 11, 8020.	1.6	33
2818	Effects of Morning Blue-Green 500nm Light Therapy on Cognition and Biomarkers in Middle-Aged and Older Adults with Subjective Cognitive Decline and Mild Cognitive Impairment: Study Protocol for a Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1521-1536.	1.2	6
2819	Plasma phosphatidylcholines and vitamin B12/folate levels are possible prognostic biomarkers for progression of Alzheimer's disease. <i>Experimental Gerontology</i> , 2021, 147, 111264.	1.2	13
2820	Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity. <i>Neurology</i> , 2021, 96, e2673-e2684.	1.5	37
2821	Potential Virus Involvement in Alzheimer's Disease: Results from a Phase IIa Trial Evaluating Apovir, an Antiviral Drug Combination. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 1-19.	1.2	6
2822	Clinical and Objective Cognitive Measures for the Diagnosis of Cognitive Frailty Subtypes: A Comparative Study. <i>Frontiers in Psychology</i> , 2021, 12, 603974.	1.1	4
2823	Predicting future cognitive decline with hyperbolic stochastic coding. <i>Medical Image Analysis</i> , 2021, 70, 102009.	7.0	2
2824	Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments: EQ-5D data from the Swedish BioFINDER study. <i>Alzheimer's and Dementia</i> , 2021, 17, 1832-1842.	0.4	5



#	ARTICLE	IF	CITATIONS
2825	Network interdigitations of Tau and amyloid $\beta$ deposits define cognitive levels in aging. <i>Human Brain Mapping</i> , 2021, 42, 2990-3004.	1.9	7
2826	Using historical data to facilitate clinical prevention trials in Alzheimer disease? An analysis of longitudinal MCI (mild cognitive impairment) data sets. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 97.	3.0	7
2827	Learning to play golf for elderly people with subjective memory complaints: feasibility of a single-blind randomized pilot trial. <i>BMC Neurology</i> , 2021, 21, 200.	0.8	3
2828	Effects of Dog-Assisted Therapies on Cognitive Mnemonic Capabilities in People Affected by Alzheimer's Disease. <i>Animals</i> , 2021, 11, 1366.	1.0	6
2829	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. <i>Nature Medicine</i> , 2021, 27, 1034-1042.	15.2	236
2830	Neurotrophins and Neurotrophic Therapy (Based on the Cerebrolysin Model) in the Treatment of Elderly Patients with Cognitive Disorders and Depression. Part 1. <i>Psychiatry</i> , 2021, 19, 87-103.	0.2	2
2831	Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer's disease. <i>Brain</i> , 2021, 144, 3742-3755.	3.7	46
2832	A Digital Twins Machine Learning Model for Forecasting Disease Progression in Stroke Patients. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 5576.	1.3	14
2833	The generalizability of empirically derived syndromes of collateral-reported elder psychopathology across 11 societies. <i>Research in Nursing and Health</i> , 2021, 44, 681-691.	0.8	1
2834	Time trends in the relation between blood pressure and dementia in 85-year-olds. <i>Journal of Hypertension</i> , 2021, 39, 1964-1971.	0.3	2
2835	Multi-Component Intervention Program on Habitual Physical Activity Parameters and Cognitive Function in Patients with Mild Cognitive Impairment: A Randomized Controlled Trial. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6240.	1.2	15
2836	Hippocampal vascularization patterns exert local and distant effects on brain structure but not vascular pathology in old age. <i>Brain Communications</i> , 2021, 3, fcab127.	1.5	9
2837	Cerebrovascular Pathology and Responsiveness to Treatment in Alzheimer's Disease: A Systematic Review. <i>Current Alzheimer Research</i> , 2021, 18, 103-124.	0.7	1
2838	A new deep belief network-based multi-task learning for diagnosis of Alzheimer's disease. <i>Neural Computing and Applications</i> , 2023, 35, 11599-11610.	3.2	31
2839	Correlating natural language processing and automated speech analysis with clinician assessment to quantify speech-language changes in mild cognitive impairment and Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 109.	3.0	37
2840	Effects of ICT-Based Multicomponent Program on Body Composition and Cognitive Function in Older Adults: A Randomized Controlled Clinical Study. <i>Clinical Interventions in Aging</i> , 2021, Volume 16, 1161-1171.	1.3	5
2841	Discriminant Validity of the WAIS-R Digit Symbol Substitution Test in Subjective Cognitive Decline, Mild Cognitive Impairment (Amnesic Subtype) and Alzheimer's Disease Dementia (ADD) in Greece. <i>Brain Sciences</i> , 2021, 11, 881.	1.1	12
2842	Machine Learning Detects Distinct Subtypes of Minimal Cognitive Impairment. <i>Journal of Signal Processing Systems</i> , 2022, 94, 437-443.	1.4	2

#	ARTICLE	IF	CITATIONS
2843	Alzheimer's Dementia Recognition From Spontaneous Speech Using Disfluency and Interactional Features. <i>Frontiers in Computer Science</i> , 2021, 3, .	1.7	14
2844	Long-term antipsychotic use and cognitive decline in community-dwelling older adults with mild-to-moderate Alzheimer disease: Data from NILVAD. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1708-1721.	1.3	3
2845	Longitudinal changes in the control mechanisms for blood pressure and cerebral blood flow in Alzheimer's disease: Secondary results of a randomized controlled trial. <i>Cerebral Circulation - Cognition and Behavior</i> , 2021, 2, 100024.	0.4	2
2846	Signal and Texture Features from T2 Maps for the Prediction of Mild Cognitive Impairment to Alzheimer's Disease Progression. <i>Healthcare (Switzerland)</i> , 2021, 9, 941.	1.0	2
2847	Parkinson disease-associated cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2021, 7, 47.	18.1	391
2848	Development of novel measures for Alzheimer's disease prevention trials (NoMAD). <i>Contemporary Clinical Trials</i> , 2021, 106, 106425.	0.8	4
2849	Multimodal Early Alzheimer's Detection, a Genetic Algorithm Approach with Support Vector Machines. <i>Healthcare (Switzerland)</i> , 2021, 9, 971.	1.0	6
2850	Computer-aided diagnosis of Alzheimer's disease by MRI analysis and evolutionary computing. <i>Research on Biomedical Engineering</i> , 2021, 37, 455-483.	1.5	2
2851	Plasma Neurofilament Light and Future Declines in Cognition and Function in Alzheimer's Disease in the FIT-AD Trial. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 601-611.	1.2	4
2852	Tau-related grey matter network breakdown across the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 138.	3.0	10
2853	Blood CDKN2A Gene Expression in Aging and Neurodegenerative Diseases. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 1737-1744.	1.2	6
2854	Rationale, study design and implementation of the LUCINDA Trial: Leuprolide plus Cholinesterase Inhibition to reduce Neurologic Decline in Alzheimer's. <i>Contemporary Clinical Trials</i> , 2021, 107, 106488.	0.8	7
2855	Combination of white matter hyperintensities and A $\beta$ burden is related to cognitive composites domain scores in subjective cognitive decline: the FACEHBI cohort. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 141.	3.0	7
2856	Changes in Default Mode Network Connectivity in Resting-State fMRI in People with Mild Dementia Receiving Cognitive Stimulation Therapy. <i>Brain Sciences</i> , 2021, 11, 1137.	1.1	12
2857	Designing efficient randomized trials: power and sample size calculation when using semiparametric efficient estimators. <i>International Journal of Biostatistics</i> , 2021, .	0.4	1
2858	Resting State Alpha Electroencephalographic Rhythms Are Differently Related to Aging in Cognitively Unimpaired Seniors and Patients with Alzheimer's Disease and Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 1085-1114.	1.2	8
2859	Memory Clinics and Day Care Centers in Thessaloniki, Northern Greece: 30 Years of Clinical Practice and Experience. <i>Frontiers in Neurology</i> , 2021, 12, 683131.	1.1	1
2860	Preventing Loss of Independence through Exercise (PLI $\text{\AA}$ ): A Pilot Trial in Older Adults with Subjective Memory Decline and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 1543-1557.	1.2	3

#	ARTICLE	IF	CITATIONS
2861	Feasibility of a 26-Week Exercise Program to Improve Brain Health in Older Adults at Risk for Type 2 Diabetes: A Pilot Study. <i>Canadian Journal of Diabetes</i> , 2021, 45, 546-552.	0.4	2
2862	Effect of Age on Clinical Trial Outcome in Participants with Probable Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 1243-1257.	1.2	4
2863	Neurostimulation for cognitive enhancement in Alzheimer's disease (the NICE-AD study): a randomized clinical trial. <i>Neurodegenerative Disease Management</i> , 2021, 11, 277-288.	1.2	4
2864	Evaluation of [18F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies. <i>Brain Communications</i> , 2021, 3, fcab190.	1.5	36
2865	Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase I clinical trial. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 154.	3.0	57
2866	Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria. <i>Alzheimer's and Dementia</i> , 2022, 18, 810-823.	0.4	38
2868	Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity. <i>JAMA Neurology</i> , 2021, 78, 1345.	4.5	109
2869	Apolipoprotein E ε4-related effects on cognition are limited to the Alzheimer's disease spectrum. <i>GeroScience</i> , 2022, 44, 195-209.	2.1	1
2870	Cannabinoids for the treatment of dementia. <i>The Cochrane Library</i> , 2021, 2021, CD012820.	1.5	13
2871	Cognitive Stimulation Therapy. <i>GeroPsych: the Journal of Gerontopsychology and Geriatric Psychiatry</i> , 2021, 34, 117-124.	0.2	3
2872	Social dysfunction is transdiagnostically associated with default mode network dysconnectivity in schizophrenia and Alzheimer's disease. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 264-277.	1.3	8
2873	Analysis the Link between Periodontal Diseases and Alzheimer's Disease: A Systematic Review. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9312.	1.2	37
2874	Personalized prediction of progression in pre-dementia patients based on individual biomarker profile: A development and validation study. <i>Alzheimer's and Dementia</i> , 2021, 17, 1938-1949.	0.4	9
2875	Chinese herbal medicines for mild cognitive impairment. <i>Medicine (United States)</i> , 2021, 100, e27323.	0.4	1
2876	Higher motor cortical excitability linked to greater cognitive dysfunction in Alzheimer's disease: results from two independent cohorts. <i>Neurobiology of Aging</i> , 2021, 108, 24-33.	1.5	15
2877	Clinical trials for Alzheimer's disease in Down syndrome. , 2022, , 307-318.		0
2878	Resting State Alpha Electroencephalographic Rhythms Are Affected by Sex in Cognitively Unimpaired Seniors and Patients with Alzheimer's Disease and Amnesic Mild Cognitive Impairment: A Retrospective and Exploratory Study. <i>Cerebral Cortex</i> , 2022, 32, 2197-2215.	1.6	8
2879	Intranasal insulin. <i>Journal of Neuroendocrinology</i> , 2021, 33, e12934.	1.2	44

#	ARTICLE	IF	CITATIONS
2880	Sex and APOE genotype differences related to statin use in the aging population. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12156.	1.8	6
2881	The Quality of Carerâ€“Patient Relationship Scale: Adaptation and Validation into Portuguese. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1264.	1.2	1
2882	VStore: A Novel Virtual Reality Assessment of Functional Cognition. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2884	Intrinsic motivation in patients with Parkinsonâ€™s disease: a neuropsychological investigation of curiosity using dopamine transporter imaging. <i>Neurological Sciences</i> , 2021, 42, 3349-3356.	0.9	1
2885	Intepirdine as adjunctive therapy to donepezil for mildâ€“toâ€“moderate Alzheimer's disease: A randomized, placeboâ€“controlled, phase 3 clinical trial (MINDSET). <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12136.	1.8	12
2886	Regional Distribution of Neuritic Plaques in the Nondemented Elderly and Subjects With Very Mild Alzheimer Disease. <i>Archives of Neurology</i> , 1998, 55, 1185-1191.	4.9	275
2887	Non-invasive brain stimulation for improving cognitive function in people with dementia and mild cognitive impairment. <i>The Cochrane Library</i> , 0, , .	1.5	2
2889	Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12099.	1.2	16
2890	Reduced parahippocampal volume and psychosis symptoms in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 389-395.	1.3	25
2891	Memory and Learning: The Forgetful Patient. , 2011, , 179-200.		2
2892	Auditory Verbal Learning. , 2011, , 306-309.		2
2893	Consortium to Establish a Registry on Alzheimer's Disease. , 2011, , 690-692.		1
2894	Cholinesterase Inhibitors as Therapy in Alzheimerâ€™s Disease: Benefit to Risk Considerations in Clinical Application. , 1997, , 257-266.		12
2895	The Alzheimerâ€™s Disease Assessment Scale: Modifications That Can Enhance its Use in Future Clinical Trials. , 1997, , 407-411.		4
2896	Brain Disease Classification and Progression Using Machine Learning Techniques. , 2014, , 3-32.		1
2897	Rating Scales. , 1994, , 355-370.		2
2898	Clinical Update of Velnacrine Research. , 1994, , 150-154.		2
2900	Neuropsychiatric Problems in the Elderly. , 1988, , 275-332.		1

#	ARTICLE	IF	CITATIONS
2901	Aluminum Exposure Produces Learning and Memory Deficits. , 1994, , 301-318.		5
2902	Age-Related Change in Cognitive Function. Critical Issues in Neuropsychology, 1997, , 7-14.	0.4	6
2903	Neuropsychological Assessment. Critical Issues in Neuropsychology, 1997, , 360-384.	0.4	3
2904	Brain Imaging and Neuropsychological Identification of Dementia of the Alzheimerâ€™s Type. Critical Issues in Neuropsychology, 1989, , 185-218.	0.4	4
2905	Status of THA as Therapy for Alzheimerâ€™s Disease. , 1991, , 224-230.		4
2906	Alzheimerâ€™s Disease and Speech Background. , 2020, , 107-135.		2
2907	Alzheimerâ€™s Disease and l-Deprenyl: Rationales and Findings. Milestones in Drug Therapy, 1993, , 301-317.	0.1	8
2908	A Hybrid Model for Aiding in Decision Making for the Neuropsychological Diagnosis of Alzheimerâ€™s Disease. Lecture Notes in Computer Science, 2008, , 495-504.	1.0	15
2909	Towards the Neuropsychological Diagnosis of Alzheimerâ€™s Disease: A Hybrid Model in Decision Making. Communications in Computer and Information Science, 2009, , 522-531.	0.4	6
2910	Psychological Methods for the Assessment of Performance and Emotionality in Elderly Patients. , 1989, , 149-163.		2
2911	Assessment of Cognition and Affective Symptoms in Dementia. Advances in Applied Neurological Sciences, 1985, , 38-43.	0.3	4
2912	Evaluation of Psychogeriatric Services: Assessment and Research Methods. , 1988, , 196-204.		1
2913	Molekulare Medizin der Alzheimer-Krankheit. , 1999, , 195-236.		5
2914	Demenz. , 2017, , 1377-1465.		1
2915	Klinische Bewertung der Wirksamkeit von Nootropika. , 1992, , 167-186.		1
2916	Long term treatment of SDAT patients with pyritinol. Key Topics in Brain Research, 1990, , 565-574.	0.2	4
2917	Measuring cognition in advanced Alzheimerâ€™s disease for clinical trials. Journal of Neural Transmission Supplementum, 2002, , 135-148.	0.5	40
2918	Sustained improvement of cognition and global function in patients with moderately severe Alzheimerâ€™s disease:a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin®. Journal of Neural Transmission Supplementum, 2002, , 265-275.	0.5	24

#	ARTICLE	IF	CITATIONS
2919	Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin®. Journal of Neural Transmission Supplementum, 2002, , 277-285.	0.5	19
2920	Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. Journal of Neural Transmission Supplementum, 1998, 54, 301-310.	0.5	137
2921	Rapid cognitive decline in Alzheimer's disease. Consensus paper. Journal of Nutrition, Health and Aging, 2008, 12, 703-713.	1.5	52
2922	Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. Neurotherapeutics, 2005, 2, 348-360.	2.1	1
2923	Analysis of burden in caregivers of people with Alzheimer's disease using self-report and supervision hours. Journal of Nutrition, Health and Aging, 0, , .	1.5	9
2924	Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations. Brain Research, 1988, 472, 371-389.	1.1	80
2925	Memory, Learning, and Attention. , 1992, , 307-337.		12
2926	Neuropsychological Assessment. , 1992, , 643-670.		1
2927	PREFACE: What Do You Mean by "Translational Research"? An Enquiry Through Animal and Translational Models for CNS Drug Discovery: Psychiatric Disorders. , 2008, , xvii-xxxviii.		3
2928	Psychological Assessment of the Elderly. , 2000, , 553-578.		1
2929	Organische psychische Störungen (einschließlich Anfallsleiden). , 2009, , 205-240.		2
2930	Organische psychische Störungen (einschließlich Anfallsleiden). , 2015, , 165-189.		1
2931	Cognitive Mental Status Examinations. Clinics in Geriatric Medicine, 1989, 5, 545-564.	1.0	17
2932	The cholinergic deficit in Alzheimer's disease: impact on cognition, behaviour and function. International Journal of Neuropsychopharmacology, 2000, 3, 3-12.	1.0	30
2935	Psychometrische Schweregradbeurteilung bei dementiellen Erkrankungen: Ein Vergleich von MMST, ADAS, BCRS und SKT. Zeitschrift für Neuropsychologie = Journal of Neuropsychology, 1999, 10, 187-202.	0.2	7
2937	CODEM Instrument. GeroPsych: the Journal of Gerontopsychology and Geriatric Psychiatry, 2014, 27, 23-31.	0.2	14
2938	Cognitive Plasticity in Healthy, Mild Cognitive Impairment (MCI) Subjects and Alzheimer's Disease Patients: A Research Project in Spain. European Psychologist, 2003, 8, 148-159.	1.8	51
2939	The Efficacy of Cognitive Stimulation Therapy (CST) for People With Mild-to-Moderate Dementia. European Psychologist, 2019, 24, 257-277.	1.8	55

#	ARTICLE	IF	CITATIONS
2940	Predictors of cognitive change in older persons: MacArthur studies of successful aging. <i>Psychology and Aging</i> , 1995, 10, 578-89.	1.4	239
2941	Self-efficacy beliefs and change in cognitive performance: MacArthur Studies of Successful Aging. <i>Psychology and Aging</i> , 1996, 11, 538-51.	1.4	53
2942	Assessing changes in Alzheimer's disease: Memory and language.. , 1986, , 149-155.		19
2944	Is subjective memory specific for memory performance or general across cognitive domains? Findings from the Seattle Longitudinal Study.. <i>Psychology and Aging</i> , 2018, 33, 448-460.	1.4	19
2945	How Is Quality of Life Assessed in People With Dementia? A Systematic Literature Review and a Primer for Speech-Language Pathologists. <i>American Journal of Speech-Language Pathology</i> , 2020, 29, 1702-1715.	0.9	7
2946	Actigraphic Predictors of Depressed Mood in a Cohort of Non-Psychiatric Adults. , 0, .		2
2947	Morphological processing in old-age bilinguals. <i>Bilingual Processing and Acquisition</i> , 0, , 217-248.	0.2	7
2948	A narrative review of brain-derived neurotrophic factor (BDNF) on cognitive performance in Alzheimer's disease. <i>Growth Factors</i> , 2020, 38, 210-225.	0.5	8
2949	Clinical trials and therapy. <i>Current Opinion in Neurology</i> , 1998, 11, 435-438.	1.8	3
2950	Nutrients, age and cognitive function. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 1998, 1, 579-585.	1.3	24
2951	Noninvasive brain stimulation for the treatment of neurocognitive disorders: right for prime time?. <i>Current Opinion in Psychiatry</i> , 2021, 34, 129-135.	3.1	3
2952	Ranking diffusion tensor measures of brain aging and Alzheimer's disease. , 2018, , .		4
2953	Linking the Mini-Mental State Examination, the Alzheimer's Disease Assessment Scale's Cognitive Subscale and the Severe Impairment Battery: evidence from individual participant data from five randomised clinical trials of donepezil. <i>Evidence-Based Mental Health</i> , 2021, 24, 56-61.	2.2	14
2954	Predictive Value of Rapid Decline in Mini Mental State Examination in Clinical Practice for Prognosis in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 109-116.	0.7	44
2955	Comparison of Stroke Features and Disability in Daily Life in Patients With Ischemic Stroke Aged 55 to 70 and 71 to 85 Years. <i>Stroke</i> , 1997, 28, 729-735.	1.0	118
2956	Dementia Three Months After Stroke. <i>Stroke</i> , 1997, 28, 785-792.	1.0	263
2957	Empirical evaluation of the global deterioration scale for staging Alzheimer's disease. <i>American Journal of Psychiatry</i> , 1993, 150, 680-2.	4.0	37
2958	The Course of Functional Decline in Geriatric Patients With Schizophrenia: Cognitive-Functional and Clinical Symptoms as Determinants of Change. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 610-619.	0.6	59

#	ARTICLE	IF	CITATIONS
2959	Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. <i>American Journal of Geriatric Psychiatry</i> , 2004, 12, 358-69.	0.6	114
2960	Subjective memory complaints, white-matter lesions, depressive symptoms, and cognition in elderly patients. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 665-71.	0.6	62
2961	Drug Treatments of Dementia. <i>British Journal of Psychiatry</i> , 1989, 155, 595-611.	1.7	27
2963	Neuropsychiatric assessment of patients with dementia. , 2003, , 23-56.		1
2964	Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease. <i>Neurology</i> , 1999, 52, 700-700.	1.5	44
2965	Nursing home placement is related to dementia progression. <i>Neurology</i> , 1999, 52, 714-714.	1.5	77
2966	The staging and assessment of moderate to severe Alzheimer disease. <i>Neurology</i> , 2005, 65, .	1.5	74
2967	Aggressive and impulsive behavior in Alzheimer's disease and progression of dementia. <i>Medical Science Monitor</i> , 2012, 18, CR182-CR189.	0.5	41
2968	Vascular Factors and Cognitive Dysfunction in Alzheimer Disease. <i>Medical Science Monitor</i> , 2015, 21, 3483-3489.	0.5	9
2969	Assessment of outcome in clinical trials in mild Alzheimer's disease: Urgent time for a rethink?. <i>OA Elderly Medicine</i> , 2013, 1, .	0.0	1
2970	The impact of individual Cognitive Stimulation Therapy (iCST) on cognition, quality of life, caregiver health, and family relationships in dementia: A randomised controlled trial. <i>PLoS Medicine</i> , 2017, 14, e1002269.	3.9	95
2971	Fine-mapping of the human leukocyte antigen locus as a risk factor for Alzheimer disease: A case-control study. <i>PLoS Medicine</i> , 2017, 14, e1002272.	3.9	67
2972	A Randomized Controlled Trial of Multicomponent Exercise in Older Adults with Mild Cognitive Impairment. <i>PLoS ONE</i> , 2013, 8, e61483.	1.1	267
2973	Quantified Self and Comprehensive Geriatric Assessment: Older Adults Are Able to Evaluate Their Own Health and Functional Status. <i>PLoS ONE</i> , 2014, 9, e100636.	1.1	32
2974	Preventing Loss of Independence through Exercise (PLI <sup>2</sup> ): A Pilot Clinical Trial in Older Adults with Dementia. <i>PLoS ONE</i> , 2015, 10, e0113367.	1.1	53
2975	Periodontitis and Cognitive Decline in Alzheimer's Disease. <i>PLoS ONE</i> , 2016, 11, e0151081.	1.1	289
2976	Functional connectivity of white matter as a biomarker of cognitive decline in Alzheimer's disease. <i>PLoS ONE</i> , 2020, 15, e0240513.	1.1	33
2977	METHODOLOGICAL ASPECTS OF THE PHASE II STUDY AFF006 EVALUATING AMYLOID-BETA -TARGETING VACCINE AFFITOPE <sup>®</sup> AD02 IN EARLY ALZHEIMER'S DISEASE - PROSPECTIVE USE OF NOVEL COMPOSITE SCALES. <i>Journal of prevention of Alzheimer's disease, The</i> , 2015, 2, 1-12.	1.5	8



#	ARTICLE	IF	CITATIONS
2978	NEUROPSYCHOLOGICAL PROFILE OF "COGNITIVE FRAILTY" SUBJECTS IN MAPT STUDY. <i>Journal of prevention of Alzheimer's disease, The</i> , 2016, 3, 1-9.	1.5	57
2979	Prevalencia de demencia en una poblaci3n urbana de Lima-Per: estudio puerta a puerta. <i>Anales De La Facultad De Medicina</i> , 2013, 69, 233.	0.0	31
2981	Serial position effects differ between Alzheimer's and vascular features in mild cognitive impairment. <i>Aging</i> , 2018, 10, 3866-3880.	1.4	4
2982	Genome-wide association study identifies CD1A associated with rate of increase in plasma neurofilament light in non-demented elders. <i>Aging</i> , 2019, 11, 4521-4535.	1.4	8
2983	Predicting the outcome of non-pharmacological treatment for patients with dementia-related mild cognitive impairment. <i>Aging</i> , 2020, 12, 24101-24116.	1.4	10
2984	Aging is a weak but relentless determinant of dementia severity. <i>Oncotarget</i> , 2016, 7, 13307-13318.	0.8	3
2985	Dementia in Taiwan area. <i>Translational Neuroscience and Clinics</i> , 2016, 2, 38-45.	0.1	4
2986	The effect of anticholinergic medications on cognitive function of patients 80 years and older with essential hypertension. <i>Arterial Hypertension (Russian Federation)</i> , 2019, 25, 246-257.	0.1	5
2987	Overview the effect of statin therapy on dementia risk, cognitive changes and its pathologic change: a systematic review and meta-analysis. <i>Annals of Translational Medicine</i> , 2018, 6, 435-435.	0.7	14
2988	Treatment of Alzheimer's disease across the spectrum of severity. <i>Clinical Interventions in Aging</i> , 2006, 1, 131-142.	1.3	32
2989	Memantine: efficacy and safety in mild-to-severe Alzheimer's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2007, 3, 245-258.	1.0	35
2990	Long-Term Response to Galantamine in Relation to Short-Term Efficacy Data: Pooled Analysis in Patients with Mild to Moderate Alzheimers Disease. <i>Current Alzheimer Research</i> , 2011, 8, 175-186.	0.7	12
2991	Internet Searches and Their Relationship to Cognitive Function in Older Adults: Cross-Sectional Analysis. <i>Journal of Medical Internet Research</i> , 2017, 19, e307.	2.1	23
2992	Neuropsychological Screening and Advanced Neuropsychological Tests. , 2006, , 33-71.		1
2993	Therapeutic approaches to age-associated neurocognitive disorders. <i>Dialogues in Clinical Neuroscience</i> , 2001, 3, 191-213.	1.8	7
2994	Treatment of cognitive impairment in Alzheimer's disease. <i>Dialogues in Clinical Neuroscience</i> , 2003, 5, 35-43.	1.8	13
2995	Pharmacotherapy of mild cognitive impairment. <i>Dialogues in Clinical Neuroscience</i> , 2004, 6, 391-395.	1.8	17
2996	What are we trying to prevent in Alzheimer disease?. <i>Dialogues in Clinical Neuroscience</i> , 2019, 21, 27-34.	1.8	6

#	ARTICLE	IF	CITATIONS
2997	Applications of neuroimaging to disease-modification trials in Alzheimer's disease. <i>Behavioural Neurology</i> , 2009, 21, 129-36.	1.1	14
2998	Relationship between cognitive impairment and behavioural disturbances in Alzheimer's disease patients. <i>Behavioural Neurology</i> , 2010, 23, 123-30.	1.1	6
2999	Dyadic Group Exercises for Persons with Memory Deficits and Care Partners: Mixed-Method Findings from the Paired Preventing Loss of Independence through Exercise (PLI <sup>2</sup> ) Randomized Trial. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 1689-1706.	1.2	8
3000	A randomised controlled trial to evaluate the impact of a human rights based approach to dementia care in inpatient ward and care home settings. <i>Health Services and Delivery Research</i> , 2018, 6, 1-134.	1.4	9
3001	Individual cognitive stimulation therapy for dementia: a clinical effectiveness and cost-effectiveness pragmatic, multicentre, randomised controlled trial. <i>Health Technology Assessment</i> , 2015, 19, 1-108.	1.3	69
3002	Automated tests for diagnosing and monitoring cognitive impairment: a diagnostic accuracy review. <i>Health Technology Assessment</i> , 2016, 20, 1-74.	1.3	6
3003	Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. <i>Health Technology Assessment</i> , 2017, 21, 1-192.	1.3	37
3004	Aerobic and strength training exercise programme for cognitive impairment in people with mild to moderate dementia: the DAPA RCT. <i>Health Technology Assessment</i> , 2018, 22, 1-202.	1.3	37
3005	Support at Home: Interventions to Enhance Life in Dementia (SHIELD) – evidence, development and evaluation of complex interventions. <i>Programme Grants for Applied Research</i> , 2017, 5, 1-184.	0.4	12
3007	Effects of Chinese medicine for tonifying the kidney and resolving phlegm and blood stasis in treating patients with amnesic mild cognitive impairment: a randomized, double-blind and parallel-controlled trial. <i>Zhong Xi Yi Jie He Xue Bao</i> , 2012, 10, 390-397.	0.7	22
3008	Effects of Chinese medicine for promoting blood circulation and removing blood stasis in treating patients with mild to moderate vascular dementia: a randomized, double-blind and parallel-controlled trial. <i>Zhong Xi Yi Jie He Xue Bao</i> , 2012, 10, 1240-1246.	0.7	9
3009	Ginkgo Biloba and Related Compounds in Alzheimer's Disease. <i>Psychiatric Annals</i> , 2002, 32, 13-18.	0.1	4
3010	Use of cholinesterase inhibitors for treatment of Alzheimer disease.. <i>Cleveland Clinic Journal of Medicine</i> , 2001, 68, 608-609.	0.6	19
3011	Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial.. <i>Cleveland Clinic Journal of Medicine</i> , 2008, 75, S87-S87.	0.6	16
3012	Hyperinsulinemia, insulin resistance and cognitive decline in older cohort. <i>Biomedical and Environmental Sciences</i> , 2012, 25, 8-14.	0.2	35
3013	Diagnosis of Dementia: Neuropsychological Test. <i>Korean Journal of Family Medicine</i> , 2010, 31, 253.	0.4	12
3014	Effect of Second-Generation Antipsychotics on Caregiver Burden in Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 121-128.	1.1	20
3015	Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1631-e1638.	1.1	38

#	ARTICLE	IF	CITATIONS
3016	Citalopram Versus Sertraline in Late-Life Nonmajor Clinically Significant Depression. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 360-369.	1.1	45
3017	Rivastigmine From Capsules to Patch. <i>primary care companion for CNS disorders, The</i> , 2014, 16, .	0.2	20
3018	Rivastigmine for Alzheimer's Disease. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2000, 2, 134-138.	0.6	7
3019	Measures to Assess the Noncognitive Symptoms of Dementia in the Primary Care Setting. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2003, 5, 158-163.	0.6	16
3020	Screening for Early Alzheimer's Disease. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2005, 7, 62-69.	0.6	37
3021	A Systematic Review of Assessment and Treatment of Moderate to Severe Alzheimer's Disease. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2006, 8, 158-9.	0.6	40
3022	Adding Memantine to Rivastigmine Therapy in Patients With Mild-to-Moderate Alzheimer's Disease. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2006, 8, 258-63.	0.6	25
3023	Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: systematic review and Bayesian network meta-analysis. <i>Neural Regeneration Research</i> , 2019, 14, 805.	1.6	28
3024	Effect of vinpocetine (cognitolâ„ƒ) on cognitive performances of a Nigerian population. <i>Annals of Medical and Health Sciences Research</i> , 2014, 4, 654.	0.8	18
3025	Deep brain stimulation for treatment of severe Alzheimer's disease: Study protocol for a prospective, self-controlled, phase I trial (case observation). <i>Asia Pacific Journal of Clinical Trials Nervous System Diseases</i> , 2017, 2, 66.	0.3	2
3026	Clinical accuracy of the distinction between Alzheimerâ€™s disease and frontotemporal lobar degeneration. <i>Bratislava Medical Journal</i> , 2014, 115, 161-167.	0.4	3
3027	The Efficacy and Safety of Yokukansankachimpihange for Treating Behavioral and Psychological Symptoms of Dementia in Patients with Alzheimerâ€™s Disease: An Open-Label Pilot Study. <i>Advances in Alzheimer's Disease</i> , 2018, 07, 141-152.	0.3	8
3028	&lt;i>Ratanasampil&lt;i> (Tibetan Medicine, RNSP) Reduces &lt;i>Amyloid Protein (A <sup>2</sup> ) and Pro-Inflammatory Factor Levels and Improves Cognitive Functions in Mild-to-Moderate Alzheimerâ€™s Disease (AD) Patients Living at High Altitude. <i>Journal of Behavioral and Brain Science</i> , 2012, 02, 82-91.	0.2	3
3029	Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil. <i>Psychiatry Investigation</i> , 2016, 13, 341.	0.7	9
3030	Neuropsychiatric symptoms in patients with Alzheimerâ€™s disease with a vascular component. <i>Annals of Agricultural and Environmental Medicine</i> , 2014, 21, 412-415.	0.5	14
3031	Cerebrospinal Fluid A <sup>2</sup> , Tau, and F2-Isoprostane Concentrations in Patients With Alzheimer Disease, Other Dementias, and in Age-Matched Controls. <i>Archives of Pathology and Laboratory Medicine</i> , 2001, 125, 510-512.	1.2	106
3032	Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. <i>ELife</i> , 2019, 8, .	2.8	57
3033	Efficacy and Tolerability of MIC601 in Patients with Mild to Moderate Alzheimer Disease who were Unable to Tolerate or Failed to Benefit from Treatment with Rivastigmine. <i>British Journal of Medicine and Medical Research</i> , 2013, 3, 341-350.	0.2	8

#	ARTICLE	IF	CITATIONS
3034	A Novel Virtual Reality Assessment of Functional Cognition: Validation Study. Journal of Medical Internet Research, 2022, 24, e27641.	2.1	14
3035	Mechanistic Effects of Aerobic Exercise in Alzheimer's Disease: Imaging Findings From the Pilot FIT-AD Trial. Frontiers in Aging Neuroscience, 2021, 13, 703691.	1.7	9
3036	Using Digital Speech Assessments to Detect Early Signs of Cognitive Impairment. Frontiers in Digital Health, 2021, 3, 749758.	1.5	19
3037	BMI1 is associated with CSF amyloid- $\beta^2$ and rates of cognitive decline in Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 164.	3.0	5
3038	Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer's disease. Scientific Reports, 2021, 11, 19853.	1.6	6
3039	Implications of Early Diagnosis for the Development of Therapeutics for Alzheimer's Disease. , 2000, , 297-316.		0
3040	Diagnosis and management of Alzheimer's disease. Dialogues in Clinical Neuroscience, 2000, 2, 129-138.	1.8	3
3041	Dementia: Trial Design and Experience with Large Multicentre Trials. , 2001, , 183-198.		0
3042	Statistical Analysis of Repeated-Measures Data with Drop-outs. , 2001, , 145-156.		0
3043	Anti-inflammatory and Antioxidant Therapies in Alzheimer's Disease. , 2001, , 487-492.		0
3044	Standardised Measurement Instruments in Psychiatry. , 2001, , 497-517.		0
3046	Psychodiagnostische Testverfahren in der klinischen Psychiatrie. , 2002, , 381-419.		0
3048	Patterns of cognitive impairment in Alzheimer's disease assessment and differential diagnosis. Frontiers in Bioscience - Landmark, 2002, 7, e155-184.	3.0	15
3050	Die Aufgaben des Psychologen im multiprofessionellen Team. , 2003, , 257-297.		0
3052	The Principle Syndromes of Dementia. , 2004, , 1216-1233.		0
3053	Die Alzheimer-Krankheit: Molekulare Grundlagen und Therapieansätze. , 2004, , 148-179.		0
3054	The Use, Benefits, and Costs of Cholinesterase Inhibitors for Alzheimer's Dementia in Long-Term Care: Are the Data Relevant and Available?. Journal of the American Medical Directors Association, 2004, 5, 249-255.	1.2	3
3055	Diagnostic Tests: Diagnosing dementia: mental status testing and beyond. Australian Prescriber, 2005, 28, 11-13.	0.5	0

#	ARTICLE	IF	CITATIONS
3057	Computer-assisted stimulating activities for persons with dementia. <i>Gerontechnology</i> , 2005, 3, .	0.0	3
3058	A Randomized, Placebo-Controlled Study of the Efficacy of Cognitive Intervention on Elderly People and on Patientâ€™s with Alzheimerâ€™s Disease. <i>Lecture Notes in Computer Science</i> , 2006, , 759-765.	1.0	0
3059	From Normal to Pathological Ageing - The Spectrum of Mild Cognitive Impairment and Alzheimerâ€™s Disease. <i>European Neurological Review</i> , 2006, , 74.	0.5	0
3060	<i>Progressive Central Nervous System Disorders.</i> , 2007, , 436-472.		1
3061	<i>Trial Designs and Outcomes to Monitor Novel Therapeutics in Alzheimer's Disease.</i> , 2007, , 28-35.		0
3062	<i>Die Aufgaben des Psychologen im multiprofessionellen Team.</i> , 2007, , 197-237.		0
3063	<i>Demenz.</i> , 2008, , 1015-1088.		0
3064	<i>Traitement de la maladie d'Alzheimer.</i> , 2008, , 815-824.		0
3065	fMRI in Neurodegenerative Diseases: From Scientific Insights to Clinical Applications. <i>Neuromethods</i> , 2009, , 657-680.	0.2	0
3066	<i>Imaging CNS Disease States: Alzheimerâ€™s Disease.</i> , 2010, , 303-318.		0
3067	<i>Leitliniensynopse zur S3-Leitlinie Â»DemenzenÂ« (November 2009).</i> , 2010, , 125-226.		0
3068	Knowledge-Based Discrimination in Alzheimerâ€™s Disease. <i>Lecture Notes in Computer Science</i> , 2010, , 89-96.	1.0	0
3072	<i>Clinical Trials in the Treatment of Alzheimer's Disease Based upon Enrichment Designs.</i> Chapman & Hall/CRC Biostatistics Series, 2010, , 283-309.	0.0	0
3073	<i>Demenz.</i> , 2011, , 1240-1319.		0
3074	<i>La communication dans les pathologies neuro-dÃ©gÃ©nÃ©ratives.</i> , 2011, , 21-50.		0
3075	<i>Clinical efficacy of long-term treatment in patients with vascular dementia.</i> <i>Bulletin of Siberian Medicine</i> , 2011, 10, 92-97.	0.1	0
3077	<i>Predictors of Sustained Response to Rivastigmine in Patients With Alzheimerâ€™s Disease.</i> primary care companion for CNS disorders, <i>The</i> , 2011, 13, .	0.2	3
3078	<i>Potential Consequences of Obesity on Cognitive Behavior.</i> , 2011, , 147-166.		0

#	ARTICLE	IF	CITATIONS
3079	Cognitive Rehabilitation in Parkinson's Disease Using Neuropsychological Training, Transfer Training and Sports Therapy. , 0, , .		0
3080	Demenzen (F00â€“F03). , 2012, , 207-223.		0
3081	Consumption of Fish and Omega-3 Polyunsaturated Fatty Acids: Impact on Cognitive Function in Older Age and Dementia. , 2012, , 212-240.		0
3082	The Trend of the Use of Neuropsychological Tests in the Korean Psychiatric Division for the Past 10 Years : Focused on Dementia Research. Journal of Korean Neuropsychiatric Association, 2012, 51, 318.	0.2	0
3083	The Current Status of Alzheimer's Disease Treatment. Frontiers in Neuroscience, 2012, , 117-161.	0.0	0
3084	BendrÅ³jÅ³ kognityviniÅ³ funkcijÅ³ vertinimo skaliÅ³ reikÅ³mÅ— lengvo kognityvinio sutrikimo vertinimui ir alzheimerio ligos prognozei. Health Sciences, 2012, 22, 137-140.	0.0	1
3085	La valutazione in psicologia gerontologica. Ricerche Di Psicologia, 2013, , 225-238.	0.2	0
3086	Physical activity and Management of Alzheimerâ€™s Disease in Tunisian Male Older Adult Patients. IOSR Journal of Dental and Medical Sciences, 2014, 13, 74-78.	0.0	1
3087	Cognitive and Functional Profiles in Mild-to-Moderate Alzheimerâ€™s Disease and Mild Cognitive Impairment Compared to Healthy Elderly. Advances in Alzheimer's Disease, 2014, 03, 168-186.	0.3	2
3088	Assessment with Cognitive Screening Instruments and Comparison of Scales. , 2014, , 71-152.		0
3089	ValidaciÃ³n concurrente de la escala de manifestaciones Å½relevantes para la enfermedad de Alzheimer (ROSA) en pacientes mexicanos. Archivos - Instituto Nacional De NeurologÃa Y NeurocirugÃa, 2014, 19, 3-8.	0.1	0
3090	Clinical Studies of the Cholinergic Deficit in Alzheimerâ€™s Disease. Advances in Behavioral Biology, 1986, , 133-151.	0.2	1
3091	Human and Animal Studies With Cholinergic Agents: How Clinically Exploitable is the Cholinergic Deficiency in Alzheimerâ€™s Disease. Advances in Behavioral Biology, 1986, , 531-537.	0.2	0
3092	Memory Assessment. , 1986, , 41-65.		0
3093	Klinische Beurteilungsebenen hirnorganischer Psychosyndrome: Zum Problem einer differenzierten Befunderhebung. , 1987, , 29-53.		1
3094	Neuropsychological and Computed Tomographic Identification in Dementia. Springer Series in Neuropsychology, 1988, , 61-85.	0.3	3
3095	Treatment of Dementia with Vasoactive Drugs. , 1988, , 425-435.		0
3096	A Clinical Trial of Pentoxifylline in Vascular Dementia. , 1991, , 416-423.		0

#	ARTICLE	IF	CITATIONS
3097	Psychometrie, Rating-Skalen, Evaluation. , 1992, , 131-159.		0
3098	EEG-Mapping bei Alzheimer Patienten unter Behandlung mit Velnacrine (HP-029). , 1993, , 422-425.		0
3099	Psychometrische Testverfahren bei der Demenz vom Alzheimer Typ. , 1993, , 441-446.		0
3100	Rating Scales for Mental Disorders. , 1993, , 107-293.		0
3101	Instruments for Measuring the Efficacy of Treatments for Alzheimerâ€™s Disease. , 1994, , 441-443.		0
3103	Alzheimer's disease.. Japanese Journal of Clinical Pharmacology and Therapeutics, 1994, 25, 323-326.	0.1	0
3104	Trial designs and outcome variables in anti-dementia drug testing. Key Topics in Brain Research, 1994, , 91-103.	0.2	0
3105	Diagnose und Differentialdiagnose der Demenz. , 1996, , 187-210.		0
3106	As time goes by. Nursing Older People, 1996, 8, 20-21.	0.1	0
3107	Clinical Drug Trials in Alzheimer's Disease. , 1996, , .		1
3109	Severe Impairment Battery: A Potential Measure for AD Clinical Trials. , 1997, , 419-423.		1
3110	Tacrine Treatment in Parkinsonâ€™s Disease Dementia. Advances in Behavioral Biology, 1998, , 481-486.	0.2	0
3111	How Can we Improve the Drug Development Process in Alzheimerâ€™s Disease?. Advances in Behavioral Biology, 1998, , 833-839.	0.2	0
3112	Klinische Diagnosekriterien. , 1999, , 109-128.		0
3113	Designing Clinical Trials for Neural Repair. , 1999, , 647-662.		0
3114	Pseudodementia. , 1999, , 173-194.		0
3115	Methods (1): Participants and Test Methods. , 2015, , 19-44.		0
3116	TEMA 5-2015: SÃNDROME DEMENCIAL EN PACIENTES PORTADORES DE VIH/SIDA. Revista ClÃnica De La Escuela De Medicina UCR-HSJD, 2015, 5, .	0.0	1

#	ARTICLE	IF	CITATIONS
3117	The Use of Operant Tasks to Assess Cognition in Persons with Alzheimer's Disease. American Journal of Alzheimer's Disease (Columbia, Mo ), 0, , .	0.3	0
3118	Demenz. , 2016, , 1-89.		0
3119	Neuropsychological Screening and Advanced Neuropsychological Tests. , 2016, , 51-90.		0
3120	Biomarkers in Mild Stages of Alzheimer's disease: Utility in clinical practice and their relation with nutritional and lifestyle factors. Functional Foods in Health and Disease, 2016, 6, 627.	0.3	0
3121	Demenzen (F00 - F03). , 2017, , 231-248.		0
3123	Auditory Verbal Learning. , 2017, , 1-5.		0
3124	Verubecestat. , 2017, , 204-251.		0
3125	Influence of the Silver Rehab Exercise Instructor Training Course on the Physical and Psychological Conditions of the Trainees. Rigakuryoho Kagaku, 2017, 32, 729-735.	0.0	1
3127	Aerobic Fitness and Cognition Changes After Exercise Training in Alzheimer's Disease. Bioengineered, 2017, 6, 22-28.	1.4	2
3128	Three Case Reports of Patients with Secondary Dementia Treated with Korean Traditional Medicine, Especially Boshiniknoe-tang-gami. The Journal of Internal Korean Medicine, 2017, 38, 628-640.	0.0	2
3129	Auditory Verbal Learning. , 2018, , 420-424.		0
3131	Consortium to Establish a Registry on Alzheimer's Disease. , 2018, , 1-5.		0
3133	Consortium to Establish a Registry on Alzheimer's Disease. , 2018, , 940-944.		0
3137	New strategies for diagnosis and treatment of Alzheimer's disease: monoclonal antibodies to beta-amyloid. Medical Alphabet, 2019, 1, 35-42.	0.0	4
3138	Methods (1): Participants and Test Methods. , 2019, , 21-49.		0
3139	A Study on the Status of Psychobehavioral Symptoms in Patients with Alzheimer's Disease. International Journal of Psychiatry and Neurology, 2019, 08, 31-40.	0.1	0
3142	Use of Deep Belief Network Model to Discriminate Mild Cognitive Impairment and Normal Controls Based on EEG, Eye Movement Signals and Neuropsychological Tests. Journal of Medical Imaging and Health Informatics, 2019, 9, 1978-1985.	0.2	4
3143	Dementia and usage of N-methyl-d-aspartate receptor antagonists. , 2020, , 573-584.		0



#	ARTICLE	IF	CITATIONS
3144	Die Demenz. , 2020, , 15-63.		1
3145	Safety and tolerability of GRF6019 in mild-to-moderate Alzheimer's disease dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12115.	1.8	6
3149	for Cognitive Impairment and Dementia in Parkinson's. Neuromethods, 2021, , 193-225.	0.2	0
3150	Neuropsychiatric symptoms, quality of life and caregivers' burden in dementia. Open Medicine (Poland), 2020, 15, 905-914.	0.6	8
3151	Demenzkrankungen. , 2020, , 295-321.		0
3152	Interoperable Multi-Modal Data Analysis Platform for Alzheimer's Disease Management. , 2020, , .		2
3153	Relation of cigarette smoking and mood disorders to cognitive impairment progression. European Journal of Translational and Clinical Medicine, 2020, 3, 29-36.	0.0	0
3154	Psychiatric Disorders in Dementia. , 2021, , 317-385.		0
3155	Psychosocial outcomes of dyadic arts interventions for people with a dementia and their informal caregivers: A systematic review. Health and Social Care in the Community, 2021, 29, 1632-1649.	0.7	12
3156	THE ROSAS COHORT: A PROSPECTIVE, LONGITUDINAL STUDY OF BIOMARKERS FOR ALZHEIMER'S DISEASE. STRATEGY, METHODS AND INITIAL RESULTS. journal of prevention of Alzheimer's disease, The, 2017, 4, 1-11.	1.5	3
3157	Design of clinical development programs. , 2022, , 653-679.		0
3158	Psychometric Properties of the Clinical Dementia Rating " Sum of Boxes and Other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-10.	1.5	12
3159	Safety and Efficacy of Lemborexant in Patients With Irregular Sleep-Wake Rhythm Disorder and Alzheimer's Disease Dementia: Results From a Phase 2 Randomized Clinical Trial. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-12.	1.5	9
3160	Saving cognitive outcome data in Alzheimer's disease clinical trials during the COVID-19 pandemic: Commentary on the virtual administration of the ADAS-Cog. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12081.	1.8	5
3161	Organische psychische Störungen (einschließlich Anfallsleiden). , 2020, , 163-181.		0
3163	Censoring-robust time-dependent receiver operating characteristic curve estimators. Statistics in Medicine, 2021, 40, 6885-6899.	0.8	4
3164	Does Certainty of Genuine Treatment Increase the Drug Response in Alzheimer's Disease Patients: A Meta-Analysis and Critical Discussion1. Journal of Alzheimer's Disease, 2021, 84, 1821-1832.	1.2	2
3165	Losartan to slow the progression of mild-to-moderate Alzheimer's disease through angiotensin targeting: the RADAR RCT. Efficacy and Mechanism Evaluation, 2021, 8, 1-72.	0.9	3

#	ARTICLE	IF	CITATIONS
3166	Tele-neuropsychological assessment tools in Italy: a systematic review on psychometric properties and usability. <i>Neurological Sciences</i> , 2022, 43, 125-138.	0.9	17
3168	Optimizing Cognitive Assessment Outcome Measures for Alzheimer's Disease by Matching Wordlist Memory Test Features to Scoring Methodology. <i>Frontiers in Digital Health</i> , 2021, 3, 750549.	1.5	7
3169	The effect of a nutrient dense drink on mental and physical function in institutionalized elderly people. <i>Journal of Nutrition, Health and Aging</i> , 0, , .	1.5	0
3170	Lower fluid and fruits / vegetable intake in questionable dementia among older Hong Kong Chinese. <i>Journal of Nutrition, Health and Aging</i> , 0, , .	1.5	0
3172	Early onset Alzheimer's disease in a South American pedigree from Argentina. <i>Acta Neurologica Scandinavica</i> , 1995, 91, 6-13.	1.0	1
3173	Practice of Competence Assessment in Dementia: Greece. , 2008, , 121-124.		0
3174	Hirnorganische Störungen. , 2008, , 393-418.		1
3175	Challenges in the Management of Psychotic Symptoms in Long-Term Care. <i>Journal of the American Medical Directors Association</i> , 2003, 4, H17-H20.	1.2	0
3177	Risco para desenvolvimento de transtorno cognitivo em um grupo de idosos ativos. <i>PAJAR - Pan-American Journal of Aging Research</i> , 2020, 8, e37867.	0.1	1
3178	Effects of ICT-based Multicomponent Program on Body Composition and Cognitive Function in Older Adults: A Randomized Controlled Clinical Study (Preprint). <i>JMIR Formative Research</i> , 0, , .	0.7	0
3181	Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. <i>Journal of Psychiatry and Neuroscience</i> , 2003, 28, 13-26.	1.4	39
3182	Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. <i>Cmaj</i> , 2003, 169, 557-64.	0.9	104
3183	The prediction and prevention of Alzheimer's disease--towards a research agenda. <i>Journal of Psychiatry and Neuroscience</i> , 1999, 24, 413-30.	1.4	9
3184	Rivastigmine in Alzheimer's disease: Cognitive function and quality of life. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 1113-23.	0.9	12
3185	Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. <i>Clinical Interventions in Aging</i> , 2008, 3, 211-25.	1.3	319
3189	Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease. <i>Clinical Interventions in Aging</i> , 2010, 5, 1-6.	1.3	18
3190	Drugs for Alzheimer's disease: are they effective?. <i>P and T</i> , 2010, 35, 208-11.	1.0	104
3191	Dementia. <i>Clinical Evidence</i> , 2010, 2010, .	0.2	0

#	ARTICLE	IF	CITATIONS
3192	Dementia. Clinical Evidence, 2012, 2012, .	0.2	4
3193	Medication adherence and cognition. Medical, personal and economic factors influence level of adherence in older adults. Geriatrics, 2006, 61, 30-5.	0.3	14
3194	Amnesic mild cognitive impairment with low myocardial metaiodobenzylguanidine uptake. American Journal of Neurodegenerative Disease, 2012, 1, 146-51.	0.1	13
3195	Advances in designs for Alzheimer's disease clinical trials. American Journal of Neurodegenerative Disease, 2012, 1, 205-16.	0.1	26
3196	Neuropathologic correlates of trial-related instruments for Alzheimer's disease. American Journal of Neurodegenerative Disease, 2014, 3, 45-9.	0.1	2
3197	Effectiveness and safety of generic memantine hydrochloride manufactured in China in the treatment of moderate to severe Alzheimer's disease: a multicenter, double-blind randomized controlled trial. Shanghai Archives of Psychiatry, 2013, 25, 244-53.	0.7	1
3198	Weak central coherence in patients with Alzheimer's disease(â€¢). Neural Regeneration Research, 2013, 8, 760-6.	1.6	1
3199	The association between cardiovascular risk factors and progressive hippocampus volume loss in persons with Alzheimer's disease. Journal of Vascular and Interventional Neurology, 2014, 7, 52-5.	1.1	6
3200	Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's disease. American Journal of Neurodegenerative Disease, 2014, 3, 158-69.	0.1	14
3202	A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS). journal of prevention of Alzheimer's disease, The, 2015, 2, 227-241.	1.5	18
3203	Over-Prescribed Medications, Under-Appreciated Risks: A Review of the Cognitive Effects of Anticholinergic Medications in Older Adults. Missouri Medicine, 2016, 113, 207-14.	0.3	15
3205	Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Ready for Short-term and Long-term Clinical Trial Needs. Innovations in Clinical Neuroscience, 2017, 14, 22-29.	0.1	34
3206	The effect of dietary supplementation on brain-derived neurotrophic factor and cognitive functioning in Alzheimer's dementia. Journal of Clinical and Translational Research, 2018, 3, 337-343.	0.3	4
3207	The effects of twenty-one nutrients and phytonutrients on cognitive function: A narrative review. Journal of Clinical and Translational Research, 2021, 7, 575-620.	0.3	5
3208	A systematic review of language and communication intervention research delivered in groups to older adults living in care homes. International Journal of Language and Communication Disorders, 2021, , .	0.7	1
3209	A Home-Based Individual Cognitive Stimulation Program for Older Adults With Cognitive Impairment: A Randomized Controlled Trial. Frontiers in Psychology, 2021, 12, 741955.	1.1	6
3210	Acupuncture for amnesic mild cognitive impairment. Medicine (United States), 2021, 100, e27686.	0.4	2
3211	Plasma Glutathione Levels Decreased with Cognitive Decline among People with Mild Cognitive Impairment (MCI): A Two-Year Prospective Study. Antioxidants, 2021, 10, 1839.	2.2	15

#	ARTICLE	IF	CITATIONS
3212	The Potential of Naturalistic Eye Movement Tasks in the Diagnosis of Alzheimer's Disease: A Review. <i>Brain Sciences</i> , 2021, 11, 1503.	1.1	13
3213	Effect of N-methyl-d-aspartate receptor enhancing agents on cognition in dementia: an exploratory systematic review and meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , 2021, 11, 22996.	1.6	2
3214	MR Brain Screening using Optimization Techniques – A survey. <i>Current Medical Imaging</i> , 2021, 17, .	0.4	0
3215	Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-Controlled Trial. <i>Movement Disorders</i> , 2022, 37, 513-524.	2.2	21
3216	Dual feature correlation guided multi-task learning for Alzheimer's disease prediction. <i>Computers in Biology and Medicine</i> , 2022, 140, 105090.	3.9	5
3217	Evaluation of plasma amyloid peptides A $\beta$ <sub>1-40</sub> and A $\beta$ <sub>1-42</sub> as diagnostic biomarker of alzheimer's disease, its association with different grades of clinical severity and 18f-fluorodeoxyglucose positron emission tomography Z score in the Indian population: A case-control study. <i>Indian Journal of Nuclear Medicine</i> , 2021, 36, 391.	0.1	1
3218	Prediction and Modeling of Neuropsychological Scores in Alzheimer's Disease Using Multimodal Neuroimaging Data and Artificial Neural Networks. <i>Frontiers in Computational Neuroscience</i> , 2021, 15, 769982.	1.2	9
3219	The Role of Individual Characteristics in Predicting Short- and Long-Term Cognitive and Psychological Benefits of Cognitive Stimulation Therapy for Mild-to-Moderate Dementia. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 811127.	1.7	6
3220	A COMBINED MEASURE OF COGNITION AND FUNCTION FOR CLINICAL TRIALS: THE INTEGRATED ALZHEIMER'S DISEASE RATING SCALE (IADRS). <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2015, 2, 1-15.	1.5	33
3221	CITICOLINE EFFICIENCY ON COGNITIVE FUNCTION: A SYSTEMATIC REVIEW. <i>JAR Life</i> , 0, , 1-12.	0.0	0
3223	Comparative Efficacy and Acceptability of Cholinesterase Inhibitors and Memantine Based on Dosage in Patients with Vascular Cognitive Impairment: A Network Meta-analysis. <i>Current Alzheimer Research</i> , 2022, 19, 133-145.	0.7	11
3224	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 10.	3.0	4
3225	Exploring outcome measures with cognitive stimulation therapies and how these relate to the experiences of people with dementia: A narrative literature review. <i>Dementia</i> , 2022, 21, 1032-1049.	1.0	3
3226	Multi-view prediction of Alzheimer's disease progression with end-to-end integrated framework. <i>Journal of Biomedical Informatics</i> , 2022, 125, 103978.	2.5	6
3227	Informant-based tools for assessment and monitoring of cognition, behavior, and function in neurocognitive disorders: Systematic review and report from a CCCDTD5 Working Group. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	2
3228	Neurological Disorders in an Elderly Cohort Experienced Past Stressful Events: A Retrospective-prospective Study. <i>Current Aging Science</i> , 2022, 15, 163-171.	0.4	0
3229	Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2814-2829.	1.1	7
3230	The Role of Silence in Verbal Fluency Tasks – A New Approach for the Detection of Mild Cognitive Impairment. <i>Journal of the International Neuropsychological Society</i> , 2023, 29, 46-58.	1.2	5

#	ARTICLE	IF	CITATIONS
3231	Predicted Cognitive Conversion in Guiding Early Decision-Tailoring on Patients With Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 813923.	1.7	1
3232	Cross-Sectional Associations of Sarcopenia and Its Components with Neuropsychological Performance among Memory Clinic Patients with Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Frailty &amp; Aging</i> , 2022, 11, 182-189.	0.8	0
3233	Anticholinergic drugs and forebrain magnetic resonance imaging changes in cognitively normal people and those with mild cognitive impairment. <i>European Journal of Neurology</i> , 2022, 29, 1344-1353.	1.7	5
3234	Incorporating historical controls in clinical trials with longitudinal outcomes using the modified power prior. <i>Pharmaceutical Statistics</i> , 2022, , .	0.7	3
3235	The Effectiveness of GRADIOR: A Neuropsychological Rehabilitation Program for People with Mild Cognitive Impairment and Mild Dementia. Results of a Randomized Controlled Trial After 4 and 12 Months of Treatment. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 711-727.	1.2	7
3236	Mitochondrial and Golgi Apparatus Alterations in Alzheimer's Disease: A Study of the Cerebellar Cortex Based on Silver Impregnation Technique and Electron Microscopy. , 2014, , 3-27.		1
3237	Impact of multisession 40Hz tACS on hippocampal perfusion in patients with Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 203.	3.0	32
3238	Fluoxetine May Enhance VEGF, BDNF and Cognition in Patients with Vascular Cognitive Impairment No Dementia: An Open-Label Randomized Clinical Study. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 3819-3825.	1.0	8
3239	Gamma Induction in frontotemporal dementia (GIFTeD) randomized placebo-controlled trial: Rationale, noninvasive brain stimulation protocol, and study design. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12219.	1.8	2
3240	Linguistic Parameters of Spontaneous Speech for Identifying Mild Cognitive Impairment and Alzheimer Disease. <i>Computational Linguistics</i> , 2022, 48, 119-153.	2.5	2
3241	Use of medium chain triglyceride (MCT) oil in subjects with Alzheimer's disease: A randomized, double-blind, placebo-controlled, crossover study, with an open-label extension. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, e12259.	1.8	11
3242	Validation of and Demographically Adjusted Normative Data for the Learning Ratio Derived from the RAVLT in Robustly Intact Older Adults. <i>Archives of Clinical Neuropsychology</i> , 2022, 37, 981-993.	0.3	8
3243	Impact of 40-Hz Transcranial Alternating Current Stimulation on Cerebral Tau Burden in Patients with Alzheimer's Disease: A Case Series. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1667-1676.	1.2	22
3244	Repetitive Transcranial Magnetic Stimulation as a Treatment for Veterans with Cognitive Impairment and Multiple Comorbidities. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1593-1600.	1.2	1
3245	Active music therapy in dementia: results from an open-label trial. <i>Jornal Brasileiro De Psiquiatria</i> , 0, , .	0.2	0
3246	The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 306-318.	21.5	273
3247	Physical Activity Self-Report Is Not Reliable Among Subjects with Mild Vascular Cognitive Impairment: The AFVASC Study. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 405-414.	1.2	1
3248	Determinants of Adherence to a GRADIOR-Computer-Based Cognitive Training Program in People with Mild Cognitive Impairment (MCI) and Mild Dementia. <i>Journal of Clinical Medicine</i> , 2022, 11, 1714.	1.0	4

#	ARTICLE	IF	CITATIONS
3249	Temporal Speech Parameters Indicate Early Cognitive Decline in Elderly Patients With Type 2 Diabetes Mellitus. <i>Alzheimer Disease and Associated Disorders</i> , 2022, 36, 148-155.	0.6	4
3250	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2022, 17, 27.	4.4	30
3251	Effects of multisite anodal transcranial direct current stimulation combined with cognitive stimulation in patients with Alzheimer's disease and its neurophysiological correlates: A double-blind randomized clinical trial. <i>Neurophysiologie Clinique</i> , 2022, 52, 117-127.	1.0	8
3252	Results and insights from a phase I clinical trial of Lomecelin for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 261-273.	0.4	17
3253	Is the Alzheimer's Disease Assessment Scale-Cognitive Subscale Useful in Screening for Mild Cognitive Impairment and Alzheimer's Disease? A Systematic Review. <i>Current Alzheimer Research</i> , 2022, 19, 202-211.	0.7	1
3254	Improved cognitive impairments by silencing DMP1 via enhancing the proliferation of neural progenitor cell in Alzheimer's mice. <i>Aging Cell</i> , 2022, 21, e13601.	3.0	4
3255	Directional DBS of the Fornix in Alzheimer's Disease Achieves Long-Term Benefits: A Case Report. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 809972.	1.7	3
3256	Exploration of salient risk factors involved in mild cognitive impairment. <i>European Journal of Neuroscience</i> , 2022, 56, 5368-5383.	1.2	1
3257	Multi-site rTMS with cognitive training improves apathy in the long term in Alzheimer's disease: A 4-year chart review. <i>Clinical Neurophysiology</i> , 2022, 137, 75-83.	0.7	7
3258	Postural Sway Characteristics Are Affected by Alzheimer's Disease. , 2021, 2021, 7219-7222.		0
3259	Identifying and evaluating clinical subtypes of Alzheimer's disease in care electronic health records using unsupervised machine learning. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 343.	1.5	15
3260	A Multi-modal Data Platform for Diagnosis and Prediction of Alzheimer's Disease Using Machine Learning Methods. <i>Mobile Networks and Applications</i> , 2021, 26, 2341-2352.	2.2	6
3261	An Individual Cognitive Stimulation Therapy App for People with Dementia and Carers: Results from a Feasibility Randomized Controlled Trial (RCT). <i>Clinical Interventions in Aging</i> , 2021, Volume 16, 2079-2094.	1.3	7
3262	Examination of the cognitive function of Japanese community-dwelling older adults in a class for preventing cognitive decline during the COVID-19 pandemic. <i>PLoS ONE</i> , 2021, 16, e0248446.	1.1	6
3264	Protocol for thiamine and folic acid in the treatment of cognitive impairment in maintenance haemodialysis patients: a prospective, randomised, placebo-controlled, double-blind, multicentre study. <i>BMJ Open</i> , 2021, 11, e050605.	0.8	1
3265	A Comparative Study of Structural and Metabolic Brain Networks in Patients With Mild Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 774607.	1.7	4
3266	Increasing the efficiency of randomized trial estimates via linear adjustment for a prognostic score. <i>International Journal of Biostatistics</i> , 2022, 18, 329-356.	0.4	6
3267	Exercise priming with transcranial direct current stimulation: a study protocol for a randomized, parallel-design, sham-controlled trial in mild cognitive impairment and Alzheimer's disease. <i>BMC Geriatrics</i> , 2021, 21, 677.	1.1	5

#	ARTICLE	IF	CITATIONS
3268	Cognitive intervention response is related to habitual physical activity in older adults. <i>Aging Clinical and Experimental Research</i> , 2012, 24, 47-55.	1.4	20
3269	Technology-Enabled Assessment and Improvement of Inclusive Learning and Quality of Life in Higher Education. <i>Computers in Health Care</i> , 2022, , 319-353.	0.2	1
3270	Testâ€“retest reliabilities and minimal detectable changes of 5 versions of the Alzheimerâ€™s Disease Assessment Scale-Cognitive Subscale in people with dementia. <i>Disability and Rehabilitation</i> , 2022, , 1-7.	0.9	1
3271	Cross-disorder and disorder-specific deficits in social functioning among schizophrenia and alzheimerâ€™s disease patients. <i>PLoS ONE</i> , 2022, 17, e0263769.	1.1	3
3272	Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimerâ€™s disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 54.	3.0	24
3274	Blood D-Amino Acid Oxidase Levels Increased With Cognitive Decline Among People With Mild Cognitive Impairment: A Two-Year Prospective Study. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 660-665.	1.0	7
3276	Demenz aus psychologischer Sicht. , 2008, , 141-172.		0
3299	Psychological treatments for depression and anxiety in dementia and mild cognitive impairment. <i>The Cochrane Library</i> , 2022, 2022, CD009125.	1.5	14
3300	Primary CNS lymphoma of the corpus callosum: presentation and neurocognitive outcomes. <i>Journal of Neuro-Oncology</i> , 2022, , 1.	1.4	2
3301	Evaluating the effects of drugs on behavior and quality of life: an alternative strategy for clinical trials. <i>Journal of Consulting and Clinical Psychology</i> , 1992, 60, 225-39.	1.6	2
3302	Alzheimer's disease and depression. <i>Journal of Consulting and Clinical Psychology</i> , 1992, 60, 379-91.	1.6	46
3303	Classical conditioning in patients with Alzheimer's disease: a multiday study. <i>Psychology and Aging</i> , 1995, 10, 248-54.	1.4	12
3306	Disentangling Alzheimerâ€™s disease neurodegeneration from typical brain ageing using machine learning. <i>Brain Communications</i> , 2022, 4, .	1.5	12
3307	What outcome measures are most useful in measuring the effectiveness of anti-dementia medication in people with intellectual disabilities and dementia?. <i>Advances in Mental Health and Intellectual Disabilities</i> , 2022, 16, 87.	0.7	0
3309	Prediction of Medical Conditions Using Machine Learning Approaches: Alzheimerâ€™s Case Study. <i>Mathematics</i> , 2022, 10, 1767.	1.1	3
3310	A Functional Assessment Tool to Distinguish Controls From Alzheimerâ€™s Disease in Lima, Peru. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2022, 37, 153331752211043.	0.9	2
3311	Effect of masupirdine (SUVNâ€“502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, .	1.8	6
3316	Cost-effectiveness Analysis of Combined Physical and Cognitive Exercises Programs Designed for Preventing Dementia among Community-dwelling Healthy Young-old Adults. <i>Physical Therapy Research</i> , 2022, 25, 56-67.	0.3	3

#	ARTICLE	IF	CITATIONS
3317	Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate. <i>Journal of prevention of Alzheimer's disease, The</i> , 0, .	1.5	2
3318	Évaluation et suivi des troubles cognitifs des pathologies neurodégénératives. , 2022, , 149-158.		0
3319	Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimates. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, .	1.8	10
3320	Immunity gene <i>IFITM3</i> variant: Relation to cognition and Alzheimer's disease pathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	1.2	1
3321	Alzheimer's Disease with Epileptiform EEG Activity: Abnormal Cortical Sources of Resting State Delta Rhythms in Patients with Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-29.	1.2	2
3322	Low-rank sparse feature selection with incomplete labels for Alzheimer's disease progression prediction. <i>Computers in Biology and Medicine</i> , 2022, 147, 105705.	3.9	4
3323	The Effectiveness of Dietary-Induced Ketogenesis on Cognition in Older Adults: A Scoping Review of the Literature. <i>SN Comprehensive Clinical Medicine</i> , 2022, 4, .	0.3	0
3324	Clinical Progression of Baseline Risk States for Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-8.	1.2	0
3325	Normative Data of Mini-Mental State Examination, Montreal Cognitive Assessment, and Alzheimer's Disease Assessment Scale-Cognitive Subscale of Community-Dwelling Older Adults in Taiwan. <i>Dementia and Geriatric Cognitive Disorders</i> , 2022, 51, 365-376.	0.7	10
3326	Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer's disease symptoms: a case report. <i>Journal of Medical Case Reports</i> , 2022, 16, .	0.4	5
3327	Serum Levels of Glial Fibrillary Acidic Protein Association with Cognitive Impairment and Type 2 Diabetes. <i>Archives of Medical Research</i> , 2022, 53, 501-507.	1.5	5
3328	Can non-linguistic cognitive stimulation enhance the cognitive and linguistic functions of people with aphasia receiving conversation therapy? Preliminary findings. <i>Aphasiology</i> , 2023, 37, 1456-1483.	1.4	1
3329	A Comparison of Operational Definitions for Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1663-1678.	1.2	4
3330	Modulation of Brain Activity and Functional Connectivity by Acupuncture Combined With Donepezil on Mild-to-Moderate Alzheimer's Disease: A Neuroimaging Pilot Study. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	4
3331	Findings of <sup>18</sup> F-PI-2620 tau PET imaging in patients with Alzheimer's disease and healthy controls in relation to the plasma tau181 levels in a Japanese sample. <i>Neuropsychopharmacology Reports</i> , 0, .	1.1	5
3332	Organized Registration for the Assessment of Dementia by the Nationwide General Consortium Toward Effective Treatment (ORANGE) Registry: Current Status and Perspectives of Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-11.	1.2	0
3333	Decreased sensitivity to loss of options in patients with Parkinson's disease. <i>Neuropsychologia</i> , 2022, 174, 108322.	0.7	0
3336	Psychometric Properties of Alzheimer's Disease Assessment Scale-Cognitive Subscale for Mild Cognitive Impairment and Mild Alzheimer's Disease Patients in an Asian Context. <i>Annals of the Academy of Medicine, Singapore</i> , 2016, 45, 273-283.	0.2	21



#	ARTICLE	IF	CITATIONS
3337	Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 1567-1587.	0.8	22
3338	Association of Pace of Aging Measured by Blood-Based DNA Methylation With Age-Related Cognitive Impairment and Dementia. <i>Neurology</i> , 2022, 99, .	1.5	48
3339	A robust framework to investigate the reliability and stability of explainable artificial intelligence markers of Mild Cognitive Impairment and Alzheimer's Disease. <i>Brain Informatics</i> , 2022, 9, .	1.8	15
3340	Correlations between APOE4 allele and regional amyloid and tau burdens in cognitively normal older individuals. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
3341	An integrated intervention of computerized cognitive training and physical exercise in virtual reality for people with Alzheimer's disease: The jDome study protocol. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	4
3342	Sex specific EEG signatures associated with cerebrospinal fluid biomarkers in mild cognitive impairment. <i>Clinical Neurophysiology</i> , 2022, 142, 190-198.	0.7	2
3343	Serial neurocognitive changes following transcatheter aortic valve replacement: comparison between low and intermediate-high risk groups. <i>Aging</i> , 2022, 14, 6111-6127.	1.4	0
3344	Personalized Prediction of Alzheimer's Disease and Its Treatment Effects by Donepezil: An Individual Participant Data Meta-Analysis of Eight Randomized Controlled Trials. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-15.	1.2	0
3345	Effect of acupuncture with donepezil based on syndrome differentiation on cognitive function in patients with mild-to-moderate Alzheimer's disease: a study protocol for a multicenter randomized controlled trial. <i>Trials</i> , 2022, 23, .	0.7	0
3346	Finger Tapping Test for Assessing the Risk of Mild Cognitive Impairment. <i>Hong Kong Journal of Occupational Therapy</i> , 2022, 35, 137-145.	0.2	4
3347	Predicting progression to dementia with a comprehensive visual rating scale and machine learning algorithms. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	2
3348	Virtual individual cognitive stimulation therapy in Hong Kong: A mixed methods feasibility study. <i>Geriatric Nursing</i> , 2022, 47, 125-134.	0.9	3
3350	Confusion. <i>Nursing Clinics of North America</i> , 1990, 25, 909-918.	0.7	6
3353	Theory of Mind and social functioning among neuropsychiatric disorders: A transdiagnostic study. <i>European Neuropsychopharmacology</i> , 2022, 64, 19-29.	0.3	5
3354	Ketogenic dietary lifestyle intervention effects on sleep, cognition, and behavior in mild cognitive impairment: Study design. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, .	1.8	1
3355	Predicting conversion from mild cognitive impairment to Alzheimer's disease with multimodal latent factors. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2022, 44, 316-335.	0.8	0
3356	Does Resting Motor Threshold correlate with severity of Alzheimer's disease?. , 2022, , .		0
3357	A Randomized, Double-Blind, and Sham-Controlled Trial of an Innovative Brain-Gut Photobiomodulation Therapy: Safety and Patient Compliance. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-12.	1.2	8

#	ARTICLE	IF	CITATIONS
3358	Sensitivity of memory subtests and learning slopes from the ADAS-Cog to distinguish along the continuum of the NIA-AA Research Framework for Alzheimer's Disease. <i>Aging, Neuropsychology, and Cognition</i> , 2023, 30, 866-884.	0.7	7
3359	The Effects of Mindfulness Interventions on Older Adults' Cognition: A Meta-Analysis. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2023, 78, 394-408.	2.4	3
3360	Poor sleep quality is associated with fatigue and depression in early Parkinson's disease: A longitudinal study in the PALS cohort. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	3
3361	Cumulative effect of simvastatin, l-arginine, and tetrahydrobiopterin on cerebral blood flow and cognitive function in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	6
3362	Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 708-720.	0.4	16
3363	A multi-expert ensemble system for predicting Alzheimer transition using clinical features. <i>Brain Informatics</i> , 2022, 9, .	1.8	3
3364	Reduced Olfactory Memory Performance Is Associated with Executive Function Deficits in Older Adults. <i>Experimental Aging Research</i> , 0, , 1-13.	0.6	3
3365	Transcranial alternating current stimulation combined with sound stimulation improves the cognitive function of patients with Alzheimer's disease: A case report and literature review. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	7
3366	Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	8
3367	Creativity and art therapies to promote healthy aging: A scoping review. <i>Frontiers in Psychology</i> , 0, 13, .	1.1	8
3368	Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 1113.	4.5	57
3369	Progression models for repeated measures: Estimating novel treatment effects in progressive diseases. <i>Statistics in Medicine</i> , 2022, 41, 5537-5557.	0.8	8
3370	Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	1
3371	Multi-modal sequence learning for Alzheimer's disease progression prediction with incomplete variable-length longitudinal data. <i>Medical Image Analysis</i> , 2022, 82, 102643.	7.0	5
3372	Sources of Stress Among Families Caring for Relatives With Alzheimer's Disease. <i>Nursing Clinics of North America</i> , 1988, 23, 69-82.	0.7	43
3373	Forecasting Time Series in Healthcare With Gaussian Processes and Dynamic Time Warping Based Subset Selection. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2022, 26, 6126-6137.	3.9	2
3374	Computerized Games versus Crosswords Training in Mild Cognitive Impairment. , 2022, 1, .		9
3375	Disentangling the relationship of subjective cognitive decline and depressive symptoms in the development of cognitive decline and dementia. <i>Alzheimer's and Dementia</i> , 2023, 19, 2056-2068.	0.4	3

#	ARTICLE	IF	CITATIONS
3376	Associations of erythrocyte omega-3 fatty acids with cognition, brain imaging and biomarkers in the Alzheimer's disease neuroimaging initiative: cross-sectional and longitudinal retrospective analyses. American Journal of Clinical Nutrition, 2022, 116, 1492-1506.	2.2	7
3377	Effectiveness and safety of anti-tau drugs for Alzheimer's disease: Systematic review and meta-analysis. Journal of the American Geriatrics Society, 2022, 70, 3281-3292.	1.3	7
3378	The Mediating Role of Inflammation in the Relationship Between $\beta$ -Synuclein and Cognitive Functioning. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2023, 78, 206-212.	1.7	3
3379	Tensor-based Multi-Modality Feature Selection and Regression for Alzheimer's Disease Diagnosis. , 2022, , .		0
3380	Frailty. Medical Clinics of North America, 2023, 107, 183-197.	1.1	17
3381	Examining Cognitive Factors for Alzheimer's Disease Progression Using Computational Intelligence. Healthcare (Switzerland), 2022, 10, 2045.	1.0	6
3382	Prevalence of Alzheimer's disease in rural and urban areas in Cuba and factors influencing on its occurrence: epidemiological cross-sectional protocol. BMJ Open, 2022, 12, e052704.	0.8	3
3383	PROTOCOL: Home-based care for people with dementia: A systematic review. Campbell Systematic Reviews, 2022, 18, .	1.2	2
3386	Anti-dementia Medications: Classification, Indications, and Differential Indications. , 2022, , 2637-2647.		0
3387	An Experimental Study on Evaluating Alzheimer's Disease Features using Data Mining Techniques. Journal of Information and Knowledge Management, 0, , .	0.8	0
3389	Case report: Non-Alzheimer's disease tauopathy with logopenic variant primary progressive aphasia diagnosed using amyloid and tau PET. Frontiers in Neurology, 0, 13, .	1.1	0
3390	Focused ultrasound-mediated blood-brain barrier opening in Alzheimer's disease: long-term safety, imaging, and cognitive outcomes. Journal of Neurosurgery, 2022, , 1-9.	0.9	10
3391	Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2023, 91, 355-362.	1.2	1
3393	Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease. journal of prevention of Alzheimer's disease, The, 0, , .	1.5	12
3394	Data-Driven Disease Progression Modeling. Computers in Health Care, 2022, , 247-276.	0.2	0
3396	Disease progression model using the integrated Alzheimer's Disease Rating Scale. Alzheimer's and Dementia, 2023, 19, 2253-2264.	0.4	2
3397	Self Assessment Memory Scale (SAMS), a new simple method for evaluating memory function. Frontiers in Aging Neuroscience, 0, 14, .	1.7	0
3398	What a Single Electroencephalographic (EEG) Channel Can Tell us About Alzheimer's Disease Patients With Mild Cognitive Impairment. Clinical EEG and Neuroscience, 2023, 54, 21-35.	0.9	3

#	ARTICLE	IF	CITATIONS
3399	Differential impact of body mass index and leptin on baseline and longitudinal positron emission tomography measurements of the cerebral metabolic rate for glucose in amnesic mild cognitive impairment. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	1
3400	Clinical study of acupuncture combined with medication for the elderly with Alzheimer disease. <i>Journal of Acupuncture and Tuina Science</i> , 2022, 20, 464-469.	0.1	0
3401	Blood <i>MAPT</i> expression and methylation status in Alzheimer's disease. , 2022, 1, .		0
3402	The Early Diagnosis of Alzheimer's Disease: A Patient-Centred Conversation with the Care Team. <i>Neurology and Therapy</i> , 0, , .	1.4	1
3403	Polygenic Effect on Tau Pathology Progression in Alzheimer's Disease. <i>Annals of Neurology</i> , 2023, 93, 819-829.	2.8	4
3404	Optimal deep brain stimulation sites and networks for stimulation of the fornix in Alzheimer's disease. <i>Nature Communications</i> , 2022, 13, .	5.8	22
3406	Apathy in patients with Alzheimer's disease is a cost-driving factor. <i>Alzheimer's and Dementia</i> , 2023, 19, 2853-2864.	0.4	2
3407	Transcranial alternating current stimulation combined with sound stimulation improves cognitive function in patients with Alzheimer's disease: Study protocol for a randomized controlled trial. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	3
3408	Hydrocephalus: A neuropsychological and theoretical primer. <i>Cortex</i> , 2023, 160, 67-99.	1.1	1
3409	Visuoconstructional Abilities of Patients With Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 0, , 089198872211355.	1.2	0
3410	Changes in Cognition and Brain Function After 26 Weeks of Progressive Resistance Training in Older Adults at Risk for Diabetes: A Pilot Randomized Controlled Trial. <i>Canadian Journal of Diabetes</i> , 2023, 47, 250-256.	0.4	1
3411	Development and Psychometric Validation of the 27 Item Zarit Caregiver Interview for Alzheimer's Disease (ZCI-AD-27). <i>Current Alzheimer Research</i> , 2022, 20, .	0.7	0
3412	Does Multicomponent Physical Exercise Training Work for Dementia? Exploring the Effects on Cognition, Neuropsychiatric Symptoms, and Quality of Life. <i>Journal of Geriatric Psychiatry and Neurology</i> , 0, , 089198872211491.	1.2	0
3413	Activity of Choline Alfoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2023, 92, 59-70.	1.2	3
3414	Neuropsychiatric symptoms and their neural correlates in individuals with mild cognitive impairment. <i>International Psychogeriatrics</i> , 2023, 35, 623-632.	0.6	2
3416	Cognitive stimulation to improve cognitive functioning in people with dementia. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	14
3417	Analytic Correlation Penalty with Variable Window in Multi-task Learning Disease Progression Model. , 2022, , .		0
3418	Cohort Effects in Alzheimer's Disease Trials: An Empirical Assessment Utilizing Data from the Alzheimer's Disease Cooperative Study. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 0, , .	1.5	0

#	ARTICLE	IF	CITATIONS
3419	Cognitive and behavioral abnormalities in individuals with Alzheimer's disease, mild cognitive impairment, and subjective memory complaints. <i>Current Psychology</i> , 2024, 43, 800-810.	1.7	4
3420	Relationship between homocysteine and cognitive impairment in elderly patients with chronic kidney disease. <i>Electronic Journal of General Medicine</i> , 2023, 20, em476.	0.3	0
3421	Elevated plasma sulfides are associated with cognitive dysfunction and brain atrophy in human Alzheimer's disease and related dementias. <i>Redox Biology</i> , 2023, 62, 102633.	3.9	8
3422	Diagnosis of Alzheimer's disease: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. <i>Dementia E Neuropsychologia</i> , 2022, 16, 25-39.	0.3	2
3423	Post-traumatic stress disorder in Alzheimer's disease. , 2017, 32, 58-69.		5
3424	DNA Methylation as a Biomarker for Monitoring Disease Outcome in Patients with Hypovitaminosis and Neurological Disorders. <i>Genes</i> , 2023, 14, 365.	1.0	3
3425	Recruitment across two decades of NIH-funded Alzheimer's disease clinical trials. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	3.0	1
3426	Effectiveness of an Individualized Exergame-Based Motor-Cognitive Training Concept Targeted to Improve Cognitive Functioning in Older Adults With Mild Neurocognitive Disorder: Study Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 0, 12, e41173.	0.5	2
3427	Alzheimer's Disease – Towards More Patient-centred and Meaningful Clinical Outcomes. <i>Annals of the Academy of Medicine, Singapore</i> , 2008, 37, 535-537.	0.2	2
3428	Forecasting individual progression trajectories in Alzheimer's disease. <i>Nature Communications</i> , 2023, 14, .	5.8	7
3429	Brain Volumes and Metacognitive Deficits in Knowledge of Self, Task and Strategies in Mathematics: A Preliminary Pilot One-Year Longitudinal Study in aMCI Patients Compared to Healthy Controls. <i>Diagnostics</i> , 2023, 13, 680.	1.3	1
3430	Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings. <i>Neurology: Clinical Practice</i> , 2023, 13, .	0.8	9
3431	Predicting conversion of patients with Mild Cognitive Impairment to Alzheimer's disease using bedside cognitive assessments. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2022, 44, 703-712.	0.8	3
3432	Multivariate functional mixed model with MRI data: An Application to Alzheimer's disease. <i>Statistics in Medicine</i> , 0, , .	0.8	0
3433	Efficacy of acupuncture in patients with mild Alzheimer's disease and its impact on gut microbiota: Study protocol for a randomized sham-controlled trial. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	1
3434	Decreasing Incidence and Prevalence of Dementia Among Octogenarians: A Population-Based Study on 3 Cohorts Born 30 Years Apart. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 0, , .	1.7	0
3435	Diagnóstico da doença de Alzheimer: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. <i>Dementia E Neuropsychologia</i> , 2022, 16, 25-39.	0.3	5
3436	Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	3.0	12

#	ARTICLE	IF	CITATIONS
3437	Cognitive trajectories and incident dementia after a cardiovascular event in older adults. <i>Alzheimer's and Dementia</i> , 2023, 19, 3670-3678.	0.4	2
3438	Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia. <i>Neurology</i> , 2023, 100, .	1.5	8
3439	Two Routes to Alzheimer's Disease Based on Differential Structural Changes in Key Brain Regions. <i>Journal of Alzheimer's Disease</i> , 2023, 92, 1399-1412.	1.2	0
3440	Longitudinal changes in surface based brain morphometry measures in amnesic mild cognitive impairment and Alzheimer's Disease. <i>NeuroImage: Clinical</i> , 2023, 38, 103371.	1.4	1
3441	Efficacy and safety of a transdermal donepezil patch in patients with mild-to-moderate Alzheimer's disease: A 24-week, randomized, multicenter, double-blind, parallel group, non-inferiority study. <i>Geriatrics and Gerontology International</i> , 2023, 23, 275-281.	0.7	3
3442	The Application of Intelligent Data Models for Dementia Classification. <i>Applied Sciences (Switzerland)</i> , 2023, 13, 3612.	1.3	6
3443	Therapeutic Inhalation of Hydrogen Gas for Alzheimer's Disease Patients and Subsequent Long-Term Follow-Up as a Disease-Modifying Treatment: An Open Label Pilot Study. <i>Pharmaceuticals</i> , 2023, 16, 434.	1.7	5
3444	CERAD (Consortium to Establish a Registry for Alzheimer's Disease) Neuropsychology Assessment Battery: 35 Years and Counting. <i>Journal of Alzheimer's Disease</i> , 2023, 93, 1-27.	1.2	8
3445	Targeting amyloid $\beta$ in Alzheimer's disease: Meta-analysis of low-dose solanezumab in Alzheimer's disease with mild dementia studies. <i>Alzheimer's and Dementia</i> , 2023, 19, 4619-4628.	0.4	8
3446	Uncovering heterogeneous cognitive trajectories in mild cognitive impairment: a data-driven approach. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	3.0	2
3447	State, trait, and accumulated features of the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) in mild Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2023, 9, .	1.8	1
3448	Mild cognitive impairment is associated with passive suicidal ideation in older adults: A population-based study. <i>Acta Psychiatrica Scandinavica</i> , 2023, 148, 91-101.	2.2	1
3449	Ketogenic Diet as a Promising Non-Drug Intervention for Alzheimer's Disease: Mechanisms and Clinical Implications. <i>Journal of Alzheimer's Disease</i> , 2023, 92, 1173-1198.	1.2	3
3450	Psychometry in Dementia. , 0, , .		0
3451	Identifying prognostic indicators for cognitive stimulation therapy for dementia: protocol for a systematic review and individual participant data meta-analysis. <i>BJPsych Open</i> , 2023, 9, .	0.3	0
3452	Source connectivity patterns in the default mode network differ between elderly golf-novices and non-golfers. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
3453	Higher performance for women than men in MRI-based Alzheimer's disease detection. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	3.0	1
3477	Social participation and risk of developing dementia. <i>Nature Aging</i> , 2023, 3, 532-545.	5.3	11

#	ARTICLE	IF	CITATIONS
3487	Machine Learning for Alzheimer's Disease and Related Dementias. <i>Neuroinformatics</i> , 2023, , 807-846.	0.2	1
3508	Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification. <i>Drugs</i> , 2023, 83, 1387-1408.	4.9	8
3533	A Weakly Supervised Deep Learning Model for Alzheimer's Disease Prognosis Using MRI and Incomplete Labels. <i>Lecture Notes in Computer Science</i> , 2024, , 172-185.	1.0	0
3552	Adaptive Prior Correction in Alzheimer's Disease Spatio-Temporal Modeling via Multi-task Learning. <i>Communications in Computer and Information Science</i> , 2024, , 69-83.	0.4	0
3560	Clinical Dementia Rating Scale. , 2023, , 1058-1063.		0